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Stellingen behorende bij het proefschrift 
CHARGE syndrome: molecular diagnosis, clinical aspects and 
its overlap with Kallmann syndrome 
1. Bij het voorspellen van de pathogeniteit van een missense variant in het CHD7 gen 
is het zinvol om informatie uit verschillende bronnen, o.a. predictieprogamma's, 
structuurmodellen van het gemuteerde eiwit en segregatie van de variant in de 
familie, met elkaar te combineren (dit proefschrift). 
2. MLPA analyse is aan te bevelen bij alle patienten bij wie geen CHD7 mutatie is 
gevonden bij sequentieanalyse, maar die wel worden verdacht van CHARGE syndroom 
(dit proefschrift). 
3. Genetisch identieke muizen met een heterozygote Chdl mutatie laten een grote 
fenotypische variabiliteit zien, hetgeen erop wijst dat de variabiliteit van CHARGE 
syndroom eerder het gevolg is van variaties in de foetale micro-omgeving of 
stochastische gebeurtenissen dan van modifier genen (dit proefschrift). 
4. Met behulp van een reuktest kan voorspeld word en of een kind met CHARGE syndroom 
al dan niet spontaan in de puberteit zal komen (dit proefschrift). 
5. Als bij een patient met Kallmann syndroom een CHD7 mutatie gevonden wordt, dan 
zullen bij uitvoerige klinische evaluatie vrijwel altijd andere kenmerken van CHARGE 
syndroom worden gevonden (dit proefschrift). 
6. CHARGE syndroom is voornamelijk een klinische diagnose, maar CHD7 analyse draagt 
bij aan het stellen van de diagnose in patienten met een mild fenotype (dit proefschrift). 
7. De verbeterde genetische diagnostiek en de daaraan gekoppelde toename in 
prenatale screeningsmogelijkheden zou nooit mogen leiden tot een verminderde 
maatschappelijke acceptatie van mensen met een erfelijke ziekte. 
8. Patientenzorg en onderzoek zijn soms lastig te combineren; in dat geval verdient het 
aanbeveling om in een onderzoeksgroep onder te duiken. 
9. "Yesterday is history. Tomorrow is a mystery. Today is a gift. That's why we call it the 
present:' Babatunde Olatunji. 
10. "Remember that not getting what you want is sometimes a wonderful stroke of luck:' 
Dalai Lama. 
11. "Never mistake knowledge for wisdom. One helps you make a living; the other helps 
you make a life:' Sandra Carey. 
12. "The Hof CHARGE stands for humorogenius:' Noam Raphael, 17-year-old with CHARGE 
syndrome. 
Jorieke van Kammen-Bergman 
Groningen, 2 november 2011 
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In this thesis we discuss the clinical effects of mutations in the CHDl gene in the context of two 
rare heritable syndromes: CHARGE syndrome and Kallmann syndrome. CHARGE syndrome is a 
multiple congenital anomaly syndrome, predominantly caused by mutations in the CHDl geneY A 
subset of patients has hypogonadotropic hypogonadism (delayed or absent puberty) and anosmia 
(an inability to smell).3 5 This combination of features is also seen in Kallmann syndrome,6 which is 
genetically heterogeneous: mutations in six different genes account for less than 30% of patients.7 
Because of the clinical overlap between CHARGE and Kallmann syndromes, the CHDl gene was 
thought to play a role in Kallmann syndrome as well. 
1.1 CHD7 
Discovery of the CHD7 gene 
The CHDl gene was identified as the causative gene in CHARGE syndrome in 2004.2 Because 
CHARGE syndrome was expected to be a microdeletion syndrome at that time, two patients with 
CHARGE syndrome were analysed with array-based comparative genomic hybridisation (array CGH) 
in order to detect copy number alterations. In one patient, a de novo microdeletion of 4.8 Mb was 
Identified on chromosomal band 8q12. Previously, a patient with CHARGE syndrome was reported 
with an apparently balanced translocation between chromosomes 6 and 8.8 Array CGH analysis in 
this patient identified a complex microdeletion that partially overlapped with the deletion of the 
first patient. The shortest region of deletion overlap encompassed 2.3 Mb and contained nine genes. 
Seventeen additional patients with CHARGE syndrome were screened for deletions in this region, 
but no copy number changes were found.2 Next, all the genes in the region were sequenced and 
ten heterozygous mutations were found in the CHDl gene. Optimisation of the sequence analysis 
technique led to six additional CHDl mutations being found in the cohort of 17 patients, indicating 
that CHDl was the major gene involved in CHARGE syndrome.4 
The CHD7 gene and its expression 
The CHDl gene consists of 37 coding exons and one non-coding exon. Expression of CHDl is 
tissue- and developmental stage-dependent and correlates with the congenital anomalies found in 
CHARGE syndrome. In human embryos, CHDl is ubiquitously expressed during early development.9 
At later stages, CHDl is expressed in undifferentiated neuroepithelium and in the neural crest 
containing mesenchyme of the pharyngeal arches. CHDl expression then appears in the otic vesicle, 
the limb bud mesenchyme, dorsal root ganglia, and cranial nerves, and subsequently in the neural 
retina, semicircular canals, pituitary gland, nasal epithelia, and olfactory bulb and nerves.9 In human 
adults, CHDl was detected at equal levels in different tissues (retina, cornea, brain, skeletal muscle, 
heart, kidney and lung).2 
The CHD7 protein and function 
The CHDl gene encodes for the CHD7 protein, a highly conserved protein of 2997 amino acids. 
10 
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CHD7 is a member of the s;;hromodomain helicase QNA binding protein family that consists of nine 
members.10•11 CHD7 belongs to CHO subfamily Ill, which is characterised by the presence of two 
chromodomains (Qiromatin grganisation .!I!.Qdifier), two SWl2/SNF2-like ATPase/helicase domains, 
a SANT DNA binding domain, and two BRK domains (see Figure 1, page 29). Based on the functions 
of these domains, CHD7 is thought to function as an ATP-dependent chromatin remodeler,10 which 
mainly acts during embryonic development. CHD7 binds to histone H3 methylated at lysine 4 in 
the enhancer regions of numerous genes in different cell types.12 CHD7 can form complexes with 
different proteins, thereby ensuring specific binding to different enhancer regions, and leading to 
time- and tissue-specific regulation of gene expression. 13 One example is the association of CHD7 
with PBAF (Qolybromo- and .6.RG 1-2ssociated factor containing complex) that is essential for neural 
crest gene expression and cell migration.14 CHD7 was also shown to interact both directly and 
indirectly with another CHO protein, CHD8. 15 In addition, Chdl was shown to cooperate with Sox2 
in regulating genes of the Notch pathway (Jag 1, Rbpj and Hes5) and Sonic Hedgehog pathway (Gli2, 
G/i3, Mycn and Tulp3) in mouse neural stem cells.16 Another study reported association of CHD7 with 
rDNA and it was suggested that CHD7 plays a role as a positive regulator of rRNA synthesis.17 
Chd7 animal models 
Several Chdl animal models have been generated, of which the mouse models have been studied 
most extensively. In the past, mouse lines were generated by subjecting male mice to a highly 
potent mutagen, N-ethyl-N-nitroso-urea (ENU). The progeny of these mice were then assessed for 
congenital anomalies or behavioural changes. Positional cloning and sequence analysis of candidate 
genes can ultimately lead to identification of the causative mutation. The first Chdl mutant mouse 
was generated by such an ENU mutagenesis programme in 1995 18•19 and showed circling behaviour 
(due to balance disturbance) and altered circadian activity. Ten years later, it was discovered that 
the causative mutation had occurred in the Chdl gene.20 Mice with homozygous Chdl mutations 
die in utero (around El 0.5 - El 1.5) and half of the mice with a heterozygous Chdl mutation die 
before weaning.20•21 The phenotype of the Whirligig mouse, which carries a heterozygous nonsense 
mutation in exon 11 of the Chdl gene, was studied in detail. Whirligig mice have several features 
in common with human CHARGE syndrome: fully penetrant semicircular canal anomalies and 
occasional congenital heart defects, cleft palate, choanal atresia, and reduced body weight.20 
Recently, a Drosophila model of CHARGE syndrome was described.22 Fruit flies with reduced 
expression of kismet (the Drosophila homologue of Chdl) have neuronal migration defects and 
reduced motor function and memory. 22 Another study showed that kismet mutants had ectopic 
expression of hedgehog in Drosophila wings leading to abnormal wings and it was concluded that 
hedgehog expression is regulated by Kismet.23 
Chdl-deficient Xenopus (tadpole) embryos showed absent or malformed otolith (part of the 




1.2 CHARGE SYNDROME 
History 
Reports of patients with CHARGE-like anomalies date back to 1961, when Angel man described a girl 
with unilateral coloboma, cleft palate, pulmonary stenosis, severe growth failure, and developmental 
delay.2' Edwards and colleagues reported a boy with bilateral posterior staphylomata (protrusion of 
the sclera with deformation of the eye leading to myopia), unilateral facial palsy, a congenital heart 
defect (patent ductus arteriosus, right-sided aorta) and unilateral renal agenesis.25 It was noted 
that the earlobes were poorly formed (later recognized as typical CHARGE ears). This boy had an 
abnormal EEG and developmental delay. He died at three months of age. 
Almost twenty years later, in 1979, Hall and Hittner recognized clustering of certain congenital 
anomalies.26,27 Bryan Hall investigated a cohort of 17 patients with choanal atresia and recognized 
that several features were regularly associated, including ocular coloboma, heart defects, mental 
and growth retardation, micropenis, small ears, micrognathia and microcephaly.26 In some of his 
patients, cleft palate, facial palsy, tracheo-oesophageal fistula, feeding problems and seizures were 
present. Helen Hittner and colleagues described ten patients with colobomatous microphthalmia 
and associated heart disease, mental retardation, ear anomalies and hearing loss.27 In addition, they 
saw facial palsy in six patients, whereas severe feeding difficulties, renal and skeletal anomalies only 
occurred in a minority. 
In 1981, Roberta Pagon and colleagues examined 21 patients and reviewed the cases (n=41) 
described in the literature.26 She proposed the acronym CHARGE; ocular i;;oloboma, heart defects, 
choanal f!.tresia, retardation of growth and development, genital hypoplasia and gar anomalies or 
deafness. In 2004, CHDl was identified as the causative gene and CHARGE association was changed 
to CHARGE syndrome.2 
Prevalence 
Different estimates of the incidence of CHARGE syndrome can be found in the literature and range 
from 1 :8,500 in Canada29 to 1 :51,000 in Alberta.30 Most frequently, an incidence of 1:10,000 is cited.3' 
Unfortunately, the incidence estimates in the literature are based on a clinical diagnosis of CHARGE 
syndrome and DNA analysis was not used for establishing the diagnosis. In more than 90% of 
patients who fulfil the clinical criteria, a CHDl mutation can be identified. In addition, an increasing 
number of patients who do not fulfil the clinical criteria are found to have a CHDl mutation and 
can be diagnosed with CHARGE syndrome.4 Because CHARGE syndrome is well known among 
clinical geneticists and has a very recognizable phenotype, we think that CHDl analysis will now be 
performed in all children suspected of having CHARGE syndrome. We therefore used the number of 
CHO7mutations found in the two DNA diagnostic laboratories in the Netherlands that perform CHDl 
analysis (Radboud University Nijmegen Medical Centre and Erasmus Medical Centre) to estimate the 
incidence of CHARGE syndrome in the Dutch population. Forty CHDl mutations were identified in 
735,942 children born in the Netherlands in the four-year period 2006-2009 inclusive. We estimate 
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that the frequency of CHDl mutations is 1/18,399 in newborn children in the Netherlands. The birth 
incidence of CHARGE syndrome will be higher, because CHDl analysis will not have been performed 
in some of the very mildly affected children with CHARGE syndrome (e.g. without coloboma and 
choanal atresia) and we think we will have missed 10% of the typical CHARGE patients who do not 
have a detectable CHDl mutation. We therefore estimate the incidence of CHARGE syndrome in 
the Netherlands at 1:15, 000 to 1 :17, 000. This is only a rough estimate, because random fluctuations 
could have distorted the numbers in this relatively short period of study. 
Clinical features and clinical diagnosis 
CHARGE syndrome has a very variable clinical presentation.32 Some patients are severely affected 
with profound mental retardation or life-threatening congenital anomalies, whereas others are 
mildly affected and may be unaware that they have CHARGE syndrome. Multi-sensory impairment 
is a main feature of CHARGE syndrome.1 Patients can suffer from hearing loss, blindness, balance 
disturbance and anosmia. The majority of patients with CHARGE syndrome have hypogonadotropic 
hypogonadism and anosmia, which means that these patients might also be diagnosed with 
Kallmann syndrome.3·5 The most frequently occurring features in CHARGE syndrome are external 
ear anomalies (triangular conchae, absent ear lobes), cranial nerve dysfunction (e.g. facial palsy, 
sensorineural hearing loss, swallowing problems and anosmia) and semicircular canal anomalies 
(leading to balance disturbance). For an overview of the features occurring in CHARGE syndrome 
see Figure 1 on page 178 and Table 2 on page 181. 
At present, there are two different sets of clinical criteria used for diagnosing CHARGE syndrome. 
The Blake criteria were compiled in 1998 and were updated by a consortium in 2006 and 2 009.31•33 
The other set of criteria was drawn up by Verloes in 2005.34 Both sets are composed of several major 
and minor criteria. Choanal atresia and coloboma are major criteria in both sets. The other major 
criteria are cranial nerve dysfunction and the characteristic ears in the Blake set of criteria and 
semicircular canal anomalies in the Verloes set. The two sets of diagnostic criteria are summarized 
in Table 1 on page 179. 
Molecular diagnosis 
Since 2004, CHARGE syndrome can also be diagnosed molecularly.2 Sequence analysis of the 
CHDl gene detects mutations in more than 90% of patients who fulfil the clinical criteria for 
CHARGE syndrome.4 Most CHDl mutations are nonsense or frameshift mutations and lead to 
haploinsufficiency, while missense mutations and deletions are found in only a minority of 
patients4•35-41 (see Figure 2, page 30). Most mutations occur de novo and are predominantly of paternal 
origin.42 However, familial recurrence of CHARGE syndrome has also been described4•32•36•3 9.43-4s (see 





Little is known about the pathogenesis of CHARGE syndrome. The current hypothesis is that 
decreased expression of CHD7 during embryogenesis leads to altered expression of other, as yet 
mainly unidentified, target genes that are important in the development of the eye, inner ear, heart, 
choanae, brain and kidney (see also the section on "CHD7 protein and function" in this introduction). 
If CHD7 expression is below a critical threshold (which is developmental stage- and tissue-specific), 
congenital anomalies will occur.13.4° This theory can explain the discordant phenotypes seen in 
monozygotic twins with CHARGE syndrome.•,l639 
Surveillance and genetic counselling 
The complexity of CHARGE syndrome requires surveillance by an expertteam. In 2005, an outpatient 
clinic for CHARGE syndrome was started in the Radboud University Nijmegen Medical Centre; it was 
moved to the University Medical Centre Groningen in 2007. More than 70 patients with CHARGE 
syndrome have visited this multidisciplinary outpatient clinic, in which 12 different specialists are 
involved. In the clinic, the patients are screened for congenital anomalies that can occur in CHARGE 
syndrome (e.g. heart defects and kidney anomalies), growth and development are recorded, and 
advice is given to the local doctors, parents and other caregivers (see Table 4 on pages 188-189). 
In addition, genetic counselling for the patients and their families is important. When the 
CHD7 mutation has occurred de novo in the patient, the recurrence risk for the parents is 2-3% 
due to somatic and germline mosaicism.4·32·36·44 Patients with CHARGE syndrome have a 50% chance 
of transmitting the CHD7 mutation to their offspring. Thus, reproductive options, like prenatal 
diagnosis and pre-implantation genetic diagnosis, should be discussed at an early stage. 
1.3 KALLMANN SYNDROME 
History 
As long ago as 1856, a Spanish doctor named Aureliano Maestre de San Juan described a deceased 
male patient with features of Kallmann syndrome.47 This patient had testicular atrophy, absence 
of olfactory neurons in the brain, and had no sense of smell. In 1944, in Germany, Dr. Frans Joseph 
Kallmann described three families with one female and 11 male patients, who had primary 
hypogonadism, colour blindness, anosmia, synkinesia (mirror movements of the upper limbs) and 
mental defects.• He established the hereditary nature of the disease, which was later named after 
him. The association between hypogonadism and anosmia due to olfactory bulb agenesis was 
termed olfacto-genital dysplasia by a Swiss anatomist, Dr. de Morsier, in 1954.48 
Prevalence 
Kallmann syndrome is a rare syndrome of which the true incidence is hard to ascertain. Different 
studies have estimated the incidence at 1:10,000 to 1 :86,000 males.49 The male to female ratio was 
estimated at 4:1. The reason for the male preponderance is currently unknown. Under-diagnosis in 
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female patients or sex-dependent penetrance of mutations in KS genes could play a role. 
Clinical features and clinical diagnosis 
Kallmann syndrome is characterized by the combination of hypogonadotropic hypogonadism 
(HH) and anosmia or hyposmia and is therefore a clinical diagnosis.6 HH is defined as the absence 
of pubertal development at 18 years of age, prepubertal levels of sex steroid hormones, and l ow 
levels of gonadotropic hormones. Boys with Kallmann syndrome often have a micropenis and 
cryptorchidism, but many Kallmann patients are only recognized when puberty fails t o  occur 
spontaneously.so Adult male Kallmann pat ients have small testes, absence of fac ial and axillary ha ir 
growth, a high pitched voice, decreased muscle mass, diminished libido and erectile dysfunction. 
Adult female Kallmann patients have primary amenorrhea and have little or no breast development. 
Patients with Kallmann syndrome are infertile and may develop osteoporosis if untreated.51 •52 
Patients are not always aware of their smell deficit and it is therefore recommended that formal 
smell testing be performed (e.g. the University of Pennsylvania Smell Identification Test53•54). 
Other clinical features that can occur in Kallmann syndrome are bimanual synkinesia (mirror 
movements of the upper limbs), unilateral renal agenesis, cleft lip and/or palate, hypodontia, 
sensor ineural hear ing loss, l oss of nasal cartilage, and occas ional ly hand or feet anomal ies.50• 55 The 
phenotypes of Kallmann patients within the same family can be variable : some have only anosmia, 
while others have only HH or both features. 
Molecular diagnosis 
Kallmann syndrome is genetically heterogeneous and a genetic defect can at present be identified 
in less than 30% of patients. 7 At present, diagnostic testing is possible for five Kallmann genes 
in the Netherlands; KAL7, FGFR7, PROK2, PROKR2 and FGFB (www.dnadiagnostiek.nl). Kallmann 
syndrome can be inherited in different ways: X-lin ked recessive (KAL 756.57), autosomal dominant 
with inc omplete penetrance (FGFR7, 58 FGF8 59), and autosomal recessive (PROK2, PROKR2"°) (Table 1 ) .  
Mutations in all these genes, except for KAL 7 ,  have also been found in patients with normosmic HH. 
Digenic inheritance has also been described, which means that mutations in two dif ferent Kallmann 
or HH genes are found in the same patient (a combination of mutations in PROKR2 and PROK2, 60•61 
KAL1 and PROKR2,60 FGFR1 and FGFB,59 PROKR2 and GNRH1,62 FGFR1 and GNRHR7, 63 PROKR2 and 
KISS7R, 62 and FGFR1 and NELF.63 It was suggested that a significant proportion ( 11.3%) of patients 
with Kallmann syndrome or normosmic HH can be attributed to oligogenic inheritance.64.64 Recently, 
three more genes ( WDR7 7, NELF and CHD7) were associated with Kallmann syndrome ( Table 1 ). 
In 2010, heterozygous mutations in the WDR71 gene were identified in patients with Kallmann 
syndrome or HH.65 In 2011, three patients were reported with NELF mutations: one was compound 
heterozygous for two NELF mutations, whereas the other patients had a heterozygous NELF 
mutation in combination with an FGFR7 mutation or a TACR3 mutation, respectively.66 In 2 008, the 
CHDl gene was described as playing a role in HH and/or Kallmann syndrome. Two studies identified 
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CHDl mutations in patients with Kallmann syndrome.67•68 The first study found that heterozygous 
CHDl mutations could lead to isolated HH or Kallmann syndrome without other CHARGE features,68 
and the second study concluded that Kallmann patients with a CHDl mutation always have other 
features of CHARGE syndrome (chapter 4.1 ).67 This thesis will further discuss the role of the CHDl 
gene in Kallmann syndrome in chapter 4. 
Table 1 Molecular diagnosis in Kallmann.syndrome 
Gene Inheritance Frequency in 
pattern Kallmann patients 
KALI'•·" XLR/digenic 5-1 0% 
FGFR/ 58 AD/digenic -10% 
PRQK:z,;> AR/digenic <5% 
PROKR2'° AR/digenic -5% 
FGFB'9 AD/digenic <5% 
WDR/ 165 AD <5% 
NELF"6 AR/digenic <<5% 
CHD7"7 68  AD -5% 
Additional clinical features 
Unilateral renal agenesis, bimanual synkinesia, hearing 
loss, high arched palate, nystagmus, hypodontia" 
Cleft lip and/or palate (CLP), loss of nasal cartilage, 
hand/feet anomalies, synkinesia, hearing loss, 
hypodontia, agenesis of corpus callosum" 
Sleep disorder, pectus excavatum, obesity""· .. " 
Sleep disorder, synkinesia, high arched palate, obesity, 
pes planus, pectus excavatum".69 71 
CLP, hearing loss, camptodactyly, hypertelorism�• 
No additional features reported65 
Unilateral renal agenesis (NELF/KAL 1)66, CLP and 
clinodactyly (NELF/FGFR 7)61 
Additional features of CHARGE syndrome, e.g. CLP, 
hearing loss, external ear anomalies, coloboma, 
semicircular canal hypoplasia•'611 
AD, autosomal dominant; AR, autosomal recessive; XLR, X-linked recessive 
Pathogenesis 
HH and anosmia in Kallmann syndrome are the result of hypothalamic gonadotropin releasing 
hormone (GnRH) deficiency and olfactory bulb agenesis, respectively.n.73 In normal embryogenesis, 
the olfactory neurons extend their axons through the cribriform plate of the ethmoid bone and 
synapse in the olfactory bulb (Figure 1).73 75 GnRH neurons originate in the nasal placode and migrate 
alongside the olfactory neurons into the brain until they eventually reach the hypothalamus. 
Hypothalamic GnRH neurons secrete GnRH into the portal blood circulation in a pulsatile manner, 
which leads to the production of gonadotropins in the pituitary; follicle stimulating hormone (FSH) 
and luteinising hormone (LH). FSH and LH are necessary for normal fertility and activate the testes 
in males and ovaries in females to produce testosterone and estrogens, respectively. The rising 
levels of sex steroids induce puberty development. In Kallmann syndrome, the neuronal migration 
of olfactory nerves and GnRH neurons is disturbed. There is some evidence from the description of 
a human foetus with X-linked Kallmann syndrome in 1989.76 In this foetus, the olfactory nerves and 
GnRH neurons were found in a tangle beneath the forebrain. The olfactory bulb had not formed and 
the GnRH neurons had never reached the hypothalamus. These findings were confirmed in 2010, 
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when another human foetus with a KAL 7 nonsense mutation was described with an absence of 








Figure 1 .  Schematic representation of normal (a) and defective (b) migration of olfactory neurons and GnRH 
neurons. (a) Normal migration. The olfactory and the vomeronasal neurons extend their axons through the 
cribriform plate of the ethmoid bone and the olfactory bulb is formed. GnRH neurons migrate alongside these 
axons and further into the brain towards their destination in the hypothalamus. (b) Defective migration in 
Kallmann syndrome. The olfactory and vomeronasal neurons extend their axons through the cribriform plate, 
but do not connect with the forebrain. The olfactory bulb is not formed. The GnRH neurons do not enter the 
brain but form a tangle with the olfactory and vomeronasal neurons beneath the forebrain. Reprinted with 
permission from the Nederlands Tijdschrift voor de Geneeskunde.75 (see color image on page 234) 
Surveillance and genetic counselling 
HH can be treated with sex steroids, gonadotropins or pulsatile GnRH therapy. Sex steroid 
treatment (testosterone in males and estrogens/progestins in females) will induce secondary 
sexual characteristics, but testes volume in boys will not increase and patients will not be fertile.si 
Recombinant FSH or pulsatile GnRH therapy are used to restore fertility in patients with HH. Timely 
induction of puberty is important, because this will reduce the risk of osteoporosis. Bone mineral 
density studies can be considered, especially in patients with other risk factors for osteoporosis. 
Patients should be screened for additional (non-reproductive) features of Kallmann syndrome, 
for example a smell deficit and unilateral renal agenesis (Table 1 ). Anosmia cannot be cured, but it is 
important that patients are aware of their smell deficit. Olfaction is important for detecting warning 
odours (e.g. gas, smoke and rotten food), is linked to memory (through the limbic system), plays a 
role in personal hygiene (detection of body odour), and determines the flavour of food and drinks.15" 
Genetic counselling in Kallmann syndrome is hampered by the high percentage (65-75%) of 
1 7  
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patients in whom no genetic defect can be identified and by the possibility of digenic inheritance. 
DNA analysis can sometimes give an indication of the recurrence risk of Kallmann syndrome for 
offspring. One should discuss the reasons for DNA analysis, as Kallmann syndrome is generally not 
a reason for terminating a pregnancy (after prenatal diagnosis) or a reason to refrain from having 
children. 
1 .4 CLINICAL COMPARISON OF CHARGE AND KALLMANN SYNDROMES 
In order to study the Kallmann features that can be part of CHARGE syndrome, standardised clinical 
phenotyping is important. Therefore, the quantitative clinical description of puberty development, 
the University of Pennsylvania Smell Identification Test and radiologic evaluation of the olfactory 
bulbs will be discussed below. 
Clinical description of puberty development 
Puberty development can best be evaluated by a paediatric endocrinologist. The Tanner stages are 
used to determine the stage of pubertal maturation (Table 2).78 In boys, stretched penile length and 
testes volume can be measured. A micropenis is present when the stretched penile length is below 
-2.5 SD for a given age (reference values for the Dutch population can be found in Massa et a/).79 In 
both boys and girls, serum concentrations of gonadotropins and sex steroids should be determined. 
HH is diagnosed when no sexual maturation has occurred at 1 8  years of age and when endocrine 
studies show prepubertal levels of sex steroids and gonadotropins. HH is invariably present in 
Kallmann syndrome and is also seen in approximately 85% of boys and 60% of girls with CHARGE 
syndrome.4•6 







Pubic hair (males and 
females) 
No pubic hair 
Sparse, long and slightly 
pigmented pubic hair 
Darker, coarser and curlier 
hair 
Adult hair covering pubis 
Adult hair extending 
laterally 
TV, testes volume 
1 8  
Male genitalia 
Prepubertal 
Growth of testes, reddening 
of scrotum 
Further growth of testes, 
growth of penis 
Further growth of testes 
and penis, darkening of 
scrotum 
Adult scrotum and penis 
(TV �20 ml) 
Female breast development 
Prepubertal 
Breast buds form, enlargement 
of areola 
Further growth of breast buds 
and areola, areola confluent with 
breast contour 
Further growth of breasts and 
areola, papilla and areola project 
above breast contour 
Adult breasts, areola confluent 
with breast contour 
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The University of Pennsylvania Smell Identification Test (UPSIT} 
The UPSIT is a widely used smell test and was developed in the USA in 1 984 (UPSIT, Sensonics 
Inc, Haddon Heights, New Jersey,53 www.sensonics.com). The test consists of 40 scratch-and-sniff 
odorants and is forced-choice (with four options for each odour). The UPSIT can be used in children 
of five years or older. The UPSIT score varies between O and 40 (with 1 point for each correct answer) 
and age- and sex-specific reference scores are available. Anosmia is a key feature of Kallmann 
syndrome, while in CHARGE syndrome a smell deficit is present in the majority of patients_l.s,so 
Radiological evaluation of the olfactory bulbs 
A high resolution MRI scan with slices of 3 mm or less in the coronal plane is required for olfactory 
bulb analysis. Analysis should be done by an experienced neuroradiologist. Olfactory bulb 
hypoplasia or aplasia is frequently present in both Kallmann and CHARGE syndromes.5•9•81 83 
1 .5 SCOPE AND OUTLINE OF THIS THESIS 
Chapter 1 provides background information on the CHD7 gene and we discuss the history, clinical 
features, clinical and molecular diagnosis, pathogenesis, surveillance and genetic counselling 
aspects of CHARGE syndrome and Kallmann syndrome. However, several issues still remain to 
be elucidated. My general goal was to gain more insight into CHARGE syndrome and Kal lmann 
syndrome, with a special focus on the CHD7 gene. I have divided the results of my research into four 
chapters. 
Chapter 2: CHD7 
Many patients with CHD7 mutations have been reported in the literature. Several patients have 
been reported more than once, but this is not always clearly indicated. Especially in review articles, 
this can lead to confounding data. Moreover, an increasing number of mutations are not being 
published. We therefore created an online CHD7 mutation database that contains all the CHD7 
variants identified by the DNA diagnostic laboratories of the Radboud University Nijmegen Medical 
Centre, the Netherlands and the Department of Cellular and Molecular Medicine, the Panum 
Institute, University of Copenhagen, Denmark and all the CHD7 variants that have been reported in 
the literature, in combination with the relevant clinical data. This database is presented in chapter 
2.1 . We also give an overview of the CHD7 mutation spectrum and review the current knowledge on 
the function of the CHO? protein. 
CHD7 variants can be either pathogenic (disease-causing), benign (non-disease causing) or the 
effect of a variant can be unknown (unclassified variant). It can be difficult to distinguish between 
the different categories, especially in the case of variants that lead to an amino acid substitution 
(missense mutations). We have therefore created a classification system in chapter 2.2 that reflects 
the chance that a given missense variant in the CHD7 gene is pathogenic. To test the hypothesis that 
missense mutations are associated with a milder phenotype than truncating mutations (nonsense 
1 9  
I 
Chapter 1 
and frameshift mutations and deletions), we also compared the clinical features of patients with 
missense mutations with those of patients with truncating mutations. 
Only a few patients with partial or complete deletions of the CHDl gene have been reported 
in the literature. The frequency of CHDl deletions is therefore considered to be low. We have 
performed multiplex ligation-dependent probe ampl ification (MLPA) in 54 patients suspected of 
CHARGE syndrome but without an identified CHDl mutation upon sequence analysis and present 
the results in chapter 2.3. 
Chapter 3: CHARGE syndrome 
Mouse models have been helpful in gaining insight into the pathogenesis of human disease. The 
Whirligig mouse seemed to be an excellent model for studying CHARGE syndrome, because many 
CHARGE features are present in these mice. We hypothesised that the Whirligig mouse could be 
a good model to study the pathogenesis of anosmia and HH in CHARGE syndrome. We therefore 
analysed sense of smell, olfactory bulb anatomy, gonads, GnRH neuron migration and reproductive 
performance in these mice. The results are presented in chapter 3.1 .  
Anosmia and HH often occur in  association, for example in Kallmann syndrome. We hypothesised 
that anosmia and HH would also be associated in CHARGE syndrome. If this proved to be the case, 
an easily administered smell test could be used to predict the occurrence of HH in patients with 
CHARGE syndrome. This would offer the opportunity to start hormone replacement therapy at a 
more appropriate age in these patients. In chapter 3.2, we present the results of our study of smell 
and pubertal development in a cohort of 35 adolescent patients with CHARGE syndrome who were 
seen at our outpatient clinic. 
The meticulous follow-up of patients with CHARGE syndrome at our outpatient clinic has 
resulted in a valuable source of cl inical information. This helps to improve the survei l lance of these 
patients, who often have a complex combination of impairments and medical complications. Via 
the outpatient clinic, we heard that three patients had died unexpectedly after the neonatal period. 
We were able to collect clinical data on four additional patients (from the Netherlands and Canada) 
who also died after the neonatal period and we investigated the causes of death and risk factors 
that could identify those children at risk for sudden death. The results are summarised in chapter 
3.3. 
Chapter 4: Kallmann syndrome 
Because of the considerable cl inical overlap between CHARGE and Kallmann syndromes, we 
hypothesised that CHDl mutations might be present in patients with Kallmann syndrome. We 
therefore analysed the CHDl gene in  36 patients with Kallmann syndrome and 20 patients with 
normosmic HH from North America and Japan in whom mutations in KAL1, FGFR1, PROK2 and 
PROKR2 had been excluded. The results are presented in chapter 4.1 .  
A concurrent study also performed CHDl analysis i n  patients with Kal lmann syndrome or 
20 
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normosmic HH, but their results partly conflicted with our results. We therefore repeated our study 
in a Dutch cohort with clinically well-characterised patients with Kallmann syndrome and present 
the results in chapter 4.2. 
Chapter 5: Implications and general discussion 
During the follow-up of our patients in the presented studies, we were impressed by the clinical 
variability of CHARGE syndrome. Especially in those patients who initially presented as Kallmann 
syndrome, the clinical presentation was sometimes extremely mild. We therefore decided to explore 
the complete phenotypic spectrum with a special focus on the mild end of the spectrum and to 
discuss the implications of the expanding phenotypic spectrum for CHD7 analysis and clinical 
surveillance. In chapter 5.1, we evaluate the clinical characteristics of our own cohort of 280 CH07-
positive patients and of previously reported patients with CH07 mutations, and compare these with 
previously reported patients with CHARGE syndrome but an unknown CHD7 status. In addition, 
we propose guidelines for CHD7 analysis and present updated recommendations for the clinical 
surveillance of patients with a CHD7 mutation. 
In chapter 5.2, I further explore the implications of the results of my studies and give 
recommendations for ongoing and future studies. 
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ABSTRACT 
CHD7 is a member of the chromodomain helicase DNA-binding (CHD) protein family that plays 
a role in transcription regulation by chromatin remodelling. Loss-of-function mutations in CHDl 
are known to cause CHARGE syndrome, an autosomal dominant malformation syndrome in which 
several organ systems, for exam pie the central nervous system, eye, ear, nose and mediastinal organs, 
are variably involved. In this paper, we review all the currently described CHD l variants, including 
1 84 new pathogenic mutations found by our laboratories. In total, we compiled 531 different 
pathogenic CHDl alterations from 515 previously published patients with CHARGE syndrome and 
296 unpublished patients analysed by our laboratories. The mutations are equally distributed along 
the coding region of CHDl and most are nonsense or frameshift mutations. Most mutations are 
unique, but we identified 96 recurrent mutations, predominantly arginine to stop codon mutations. 
We built a locus-specific database listing all the variants that is easily accessible at www.CHD7.org. In 
addition, we summarize the latest data on CHD7 expression studies, animal models and functional 
studies, and we discuss the latest clinical insights into CHARGE syndrome. 
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INTRODUCTION 
bhromodomain helicase QNA-binding (CHO) proteins play a role in transcription activation and 
repression by chromatin remodelling. For this function, all members of the CHO protein family 
possess two chromodomains (l;hromatin Qrganisation modifier domains) located on the N-terminal 
and a centrally located SNF-like helicase motif. The human CHO family consists of nine members that 
can be subdivided into three subfamilies based on dif ferences in their structure and sequence.1-2 
Members of subfamily I contain a DNA-binding domain located in the (-terminal region. Subfamily 
II members harbour paired N-terminal PHO (g_lant homeo g_omain) Zinc-finger-like domains. 
Members of subfamily Ill are characterised by (-terminal paired BRK (fuahma and Kismet) domains 
and a SANT-like domain �witching-defective protein 3, 2.daptor 2, nuclear receptor co-repressor, 
transcription factor 1 1 18). CHD7 is one of the CHO proteins of subfamily 1 1 1.1-2 
CHDl is located at chromosome 8 (Sq 12) starting 61 .59 Mb from the p-arm telomere. CHDl has 
a genomic size of 188 kb and consists of 38 exons, of which the first is non-coding. The encoded 
protein (2997 amino acids, Figure 1) is localized in both the nucleoplasm and nucleolus.3 CHD7 is 
highly conserved across species and orthologs have been identified in Xenopus, zebrafish, mouse 
and chicken, amongst others.4.,; This, in combination with the observation that homozygous Chdl 
mutant mice do not survive beyond an early embryonic stage, suggests strong selective pressure 
and a high functional importance of CHD7.7•8 Indeed, recent reports about CHD7 function suggest 
a role in controlling gene expression programs by ATP-dependent chromatin remodelling in 
embryonic stem cells and other cell types.u 
Heterozygous mutations and deletions of CHDl (OM IM *608892) result in CHARGE syndrome 
(OMIM #2 14800), a complex of multiple congenital malformations involving the central nervous 
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Figure 1 .  Overview of the CHDl gene and protein 
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Overview of CHO7with its 38 exons and introns. The sizes of the exons and introns are drawn to scale. The cDNA 
of CHDl consists of 37 exons: the first exon and also part of genomic exon 2 and 38 are non-coding. The CHD7 
protein consists of 2997 amino acids and has several conserved domains which are drawn to scale. 
Chromodomain, chromatin organisation modifier domain; Helicase N, helicase N-lobe; DEXDc, DEAD-like 
helicase superfamily including an ATP-binding domain; Helicase C, helicase C-lobe; SANT domain, switching­
defective protein 3, adaptor 2, nuclear receptor co-repressor, transcription factor 1 1 1B  domain; BRK domain, 
Brahma and Kismet domain. 
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system, eye, ear, nose and mediastinal organs.9 CHARGE syndrome has been estimated to occur in 
1/10,000 births worldwide and has a broad clinical variability.10,1 1  Clinical features include ocular 
i;_oloboma, heart defects, choanal .i!_tresia, retarded growth and development, genital hypoplasia, 
�ar anomalies, deafness and semicircular canal hypoplasia.12•14 Based on these characteristics, 
clinical criteria for CHARGE syndrome have been defined by Blake et a/15 and Verloes.16 CHDl analysis 
is a major contributor to the diagnosis today, although not all clinically diagnosed patients with 
CHARGE syndrome carry a mutation in this gene.12•13•17 CHDl mutations have also been found in 
patients initially diagnosed with Kallmann syndrome, which supports the well-known observation 
that Kallmann syndrome is part of the phenotypic spectrum of CHARGE syndrome.18·20 
In this study, we provide an overview of all CHDl sequence variants, submicroscopic genomic 
rearrangements and translocations that were published before June 15th 2011. In addition, we 
present all the unpublished CHDl variants that have been identified in the DNA diagnostic 
laboratories of the Radboud University Nijmegen Medical Centre (RUN MC) and the Department of 
Cellular and Molecular Medicine (ICMM), University of Copenhagen (Supplementary Methods). All 
CHDl variants, including relevant clinical data, were entered into the new locus-specific database 
at www.CHD7.org. Furthermore, we summarize the latest data on the function of CHD7 and discus 
the clinical implications of identifying a CHDl mutation. The interpretation of missense variants is 
discussed in another paper (Bergman et al, submitted). 
MUTATION SPECTRUM 
lntragenic CHD7 mutations in CHARGE syndrome 
Per June 15th 2011, a total of 531 pathogenic and unique CHDl alterations had been identified in 
811 index patients with CHARGE syndrome, including 184 new mutations identified by the DNA 
diagnostic laboratories of the RUNMC and ICMM.8•9·'1·13·1Hs The majority of the pathogenic CHDl 
variants are intragenic mutations (Figure 2). A schematic presentation of CHDl and the locations of 
Complete or partial deletion/ 





Figure 2. Distribution of mutation 
types in the CHDl gene 
An overview of the distribution of 
Nonsense the different pathogenic mutation 
types found in CHDl. Nonsense and 
frameshift mutations occur in over 
75% of the patients. Missense and 
splice site mutations comprise an 
additional 20%, while complete and 
partial deletions/duplications and 
chromosomal re-arrangements are 
rare. 
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the unique pathogenic mutations within the gene are presented in Figure 3, grouped by mutation 
type. In addition to the pathogenic mutations, 89 unique unclassified variants have been described 
in 1 08 patients in the literature and from our laboratories; these are mostly missense variants and 
intronic variants near the splice sites. In Supplementary Table S1, we provide a complete overview 
of all the CHDl variants (pathogenic mutations and unclassified variants) found by our laboratories 
in patients that have not been reported before, including their phenotypic information. Detailed 
information on all the CHDl mutations, including the unclassified variants, can also be accessed at 
the online locus-specific database (www.CHD7.org). 
The mutations are distributed along the entire coding region and splice sites of CHDl and all 
types of mutations are found (Figures 2 and 3). The most prevalent types are nonsense mutations 
(43%), and frameshift mutations (34%). Splice site and missense mutations are found in 1 1  % and 
9%, respectively, while small in-frame deletions rarely occur (<1%). The remainder comprises the 
larger deletions and duplication (2%) and translocations (<1%), which will be discussed in the next 
sections. No mutations were found in exon 7 and only one mutation each was found in exons 9 
and 28. This is probably due to the small genomic sizes of these exons, which are 56, 84 and 58 
nucleotides, respectively (2.2% of the coding genomic size). 
Approximately 28-32% of the mutations are found in the regions of CHDl that encode for the 
functional domains. The encoded region of these domains is approximately 20-25% of CHDl, so 
the frequency of mutations within these domains is only slightly higher than would be expected if 
the mutations were distributed equally (Supplementary Table S2). This observation could be due to 
a predilection of missense mutations for the functional domains. Pathogenic missense mutations 
were predominantly found in the highly conserved middle exons of the gene, while they were not 
found in the first seven or last five exons of the gene. In contrast, benign missense variants occurred 
more often in the first and last exons, which are non-conserved regions (Bergman et al, submitted). 
Nonsense and frameshift mutations were found scattered throughout the whole gene. 
Most mutations are unique for a patient or family, but de novo recurrent mutations do occur. In 
total, 96 different recurrent mutations were found in 363 index patients. The two most frequently 
reported mutations to date (both n=1 2) are the c.1480C> T in exon 2 and the c.7879C> T in exon 36. 
They both result in the substitution of an arginine by a stop codon, at codon 494 and codon 2627, 
respectively. Of all the recurrent mutations, a remarkable number involves an arginine transition to 
a stop codon (27 different mutations in 1 87 patients). This was also observed by Bartels et aP6 and is 
in agreement with previous observations that the CG-nucleotide pair is hyper-mutable to TG.69 This 
makes the arginine CGA codon, which occurs 27 times in CHDl, uniquely vulnerable to mutating 
into a stop codon. 
Whole gene deletions and exon deletions or duplications of CHD7 
Chromosomal microdeletions including CHDl have been described in only eight index cases in the 
literature.8•9•24•26•44•55•63 In addition, we recently identified two whole gene deletions of CHDl. A loss of 
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Figure 3. Overview of pathogenic CHDl mutations and copy number variants in index patients 
The location of CHDl mutations in 81 1 index patients. A. Overview of the location of nonsense, frameshift, 
missense and splice site mutations. The mutations are spread over the CHDl gene, but missense mutations occur 
more often in the middle of the gene. The first spl ice site mutation is located in intron 3 and the last splice site 
mutation in intron 37. Several recurrent mutations occur. B. The deletions and duplication found in CHDl. Arrow 
= deletion extends further, dashed line = the exact size of deletion is unknown. 
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exons 2 to 38 was identified by MLPA (not further defined by whole-genome array) in a patient with 
bilateral choanal atresia, semicircular canal hypoplasia and a heart defect, and a 7.7 Mb deletion 
including CHDl was found in a patient with bilateral coloboma, external ear anomalies and a heart 
defect. 
Wholeexon deletions and dupl ications were found in seven index cases in the l iterature.22•26•29•58•63,64 
Therefore, aberrations of CHDl detected by MLPA or whole genome array comprise only 2% of the 
defects in patients with molecularly confirmed CHARGE syndrome ( 1 7  of 81 1 patients). In contrast, 
in cohorts of CHARGE or CHARGE-like patients without a CHDl mutation these aberrations are 
detected in 0-22%. However, the analytical method, number of exons screened, and clinical inclusion 
criteria differed between the studies. Compiling al l  the studies, six whole exon deletions, one whole 
exon duplication, and two whole gene deletions were identified in  1 52 patients who showed no 
CHDl mutation upon sequencing (6%).22,26,29,ss,60,63.64 
Although typical CHARGE patients without a CHDl mutation are more likely to have a deletion 
of CHDl than mildly affected patients, deletions have also been demonstrated in four atypical 
patients.8•64 Therefore, MLPA analysis of CHDl is advisable in all patients suspected of CHARGE 
syndrome in whom no CHDl mutation is found by sequencing. 
Translocations 
Translocations involving chromosome 8q1 2  have been described in two cases in the l iterature. 
The first patient with an apparently balanced translocation t(6;8)(6p8p;6q8q) was later found to 
have a cryptic deletion including CHDl.9•44 The second de novo translocation t(8; 1 3) (q 1 1 .2;q22) was 
reported in monozygotic twins and disrupted CHDl.46 We report here an additional translocation 
t(2;8)(q 1 1 .2;q1 1 .2) in a typical CHARGE patient. The breakpoint was defined at 8q1 2.2 between FISH 
probes RP1 1 -414L 17 at 61 .40 Mb and RP3-491 L6 at 61 .83 Mb (CH07 is located at 61 .59 - 6 1 .77 Mb). 
Thus, it is highly l ikely that CHDl is disrupted by the translocation. Unfortunately, MLPA a nd array 
CGH could not be performed due to insufficient DNA, so a deletion of CHDl could not be excluded. 
CHD7 mutation detection rate 
The mean mutation detection rate reported so far for patients suspected of CHARGE syndrome in a 
research setting is 58%, with a range of 33-1 00%, depending on the selection criteria and molecular 
techniques used.9•13•17•22•25•37.49•57•60•62•63 Most studies also included atypical CHARGE patients and whole 
exon or whole gene deletions were not always excluded in the patients. 
In a diagnostic setting, the mutation detection rate is lower because CHDl analysis is a lso 
commonly used to exclude CHARGE syndrome in patients with an atypical presentation. GeneDx 
(Gaithersburg, Maryland, USA) reported a mutation detection rate of 32% in the patients referred 
to them (n=203/642),26 while in the RUN MC laboratory the mutation detection rate is 41 % 
(n=382/922). As pointed out by Jongmans et a/,13 the mutation detection rate rises above 90% if 
only those CHARGE patients who meet the clinical diagnostic criteria of Blake et a/15 and/orVerloes16 
33 
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are taken into account. On the other hand, CHD7 mutations have been identified in atypical CHARGE 
patients_ 1 2, 1J,22,2s.49.62,63 
Benign CHD7 variants 
Many benign variants have been described in CHD7, mostly in intronic regions. In the NCBI 
Single Nucleotide Polymorphism database (http://www.ncbi.nlm.nih.gpv/SNP, dbSNP build 
132), over 1 500 variants are reported in the CHD7 region. In the literature, 72 unique benign 
variants have been described in patients with CHARGE syndrome, their unaffected parents and 
controls.17•20•23•26·3M3.s4.60·63·70 Occasionally, benign variants were initially misclassified as pathogenic 
mutations in the literature. For example, c.6103+8C> T had occurred de novo and was classified 
as pathogenic,'7·26 but later proved to be a benign variant.10 In Supplementary Table 53 we give 
an overview of the benign variants in the coding region and in the first or last 50 nucleotides of 
an intron that have either been published, or found by the RUNMC or ICMM, or published with 
frequency data in the NCBI SNP database. 
Familial CHARGE syndrome and somatic and germ line mosaicism 
CHARGE syndrome is typically a sporadic condition. Familial recurrence is rare and almost all CHD7 
mutations occur de novo. Seventeen families with multiple affected members due to a segregating 
CHD7 mutation have been reported to date.12·1 3·1 7•34.47•53·61·63 In addition, we identified a presumed 
pathogenic missense mutation (c.6221 T>C; p.Leu2074Pro) in two sisters with Kallmann syndrome, 
whose clinical features were previously reported by Levy and Knudtzon.71 In all CHARGE families, a 
remarkable clinical variability is seen. Especially the parents are relatively mildly affected, and do 
not fulfil the clinical diagnostic criteria.1 2The type of mutations seen in familial CHARGE syndrome 
varies: mainly nonsense mutations are found in monozygotic twins and affected sibs with unaffected 
parents (germline mosaicism), whereas a preponderance of missense and splice site mutations is 
seen in the two-generation families.12 A likely explanation is that missense and splice site mutations 
give rise to a milder phenotype (Bergman eta/, submitted). 
Germline and somatic mosaicism have been suggested in some families in the literature. '3·'7·26.47·63 
More recently, germline mosaicism was proven in a father who had a CHD7 truncating mutation 
(c.7302dupA) in his spermatozoa, but not In his peripheral blood cells and who had two children 
with CHARGE syndrome.53 Somatic mosaicism could be demonstrated in three families: in an 
unaffected mother who had two sons with CHARGE syndrome (c.5982G>A; p.Trp1994X);13 in an 
unaffected father who had a son and daughter with CHARGE syndrome (c.2520G>A; p.Trp840X);47 
and in a father whose child had CHARGE syndrome (c.7636G> T; p.Glu2546X).26 We identified an 
even more complicated case of somatic mosaicism in a child affected with CHARGE syndrome. CHD7 
sequence analysis in a blood sample showed 3 alleles at the c.5534+ 1 position (intron 26); the wild­
type allele was present in half of the sequence, while two mutations were also found at that same 
position (c.5534+ 1 G>A and c.5534+ 1 G> T). MLPA analysis showed no exon copy number variations. 
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CHD7 analysi s  in b lood samples f rom both parents was normal. The most like ly explanation is that 
two somatic mutations occurred on one allele, creating two mutant ce l l  lines. 
Disease-causing CHD7 variants in non-CHARGE syndrome patients 
CHD7 mutations have been identified in patients with Kallmann syndrome (KS), which is a 
syndrome that partially over laps with CHARGE syndrome. KS is characterised by the c ombination 
of hypogonadot ropic hypogonadism (HH) and a sme l l deficit. Occasiona lly, othe r  features, like renal 
anomalies, denta l agenesis, cleft lip/palate and hea ring loss can occur in Ks.12.73 Two groups have 
analysed CHD7 in pat ients with normosmic idiopathic hypogonadotropic hypogonadism (nlHH) or 
KS. The first study analysed 197 patients and identified seven CHD7 mutations.20 Four patients with 
a CHD7 mutation were diagnosed with nlHH and the other three patients had KS. No additional 
anomalies were reported in three patients, while two patients had a facial cleft in combination 
with cryptorchidism or hearing loss, one patient had myopia, and another had c ryptorchidism. It 
should be noted, however, that the authors did not report whether the patients had undergone 
a formal smell test or if they we re clinically re-evaluated after the CHD7 mutation was identified.20 
The second study identified three CHD7 mutations in 56 patients with nlHH or KS. 19 All three CHD7-
positive patients we re proven to be anosmic by formal smell tests and therefore had received 
the diagnosis KS. All patients had additional CHARGE featu res, and two could be re -diagnosed 
as CHARGE syndrome after clinical re-evaluation. 1 9  All nlHH/KS cases with a CHD7 mutation were 
sporadic in both studies. The chance of finding a CHD7 mutation in patients with HH seems highest 
if at least anosmia and one other featu re of CHARGE syndrome is pre sent, especially since HH and 
anosmia have been proven to be highly corre lated in CHARGE syndrome patients with a proven 
CHD7 mutation. 18 At least two mutations found in the studies described above were also found in 
CHARGE patients. The combined resu lts of the two studies suggest that Kallmann syndrome can be 
seen as a mild clinical p resentation of CHARGE syndrome. Recent ly, CHD7 analysis was performed in 
a third cohort of 30 Finnish patients with Kallmann syndrome, but no pathogenic mutations were 
identified. 74 
Studies of CHD7 have also been done in several cohorts of patients with one feature of CHARGE 
syndrome, e.g . scoliosis, cleft lip/palate or congenital hea rt defect s. Scoliosi s  develops in late 
childhood in more than 60% of patients with CHARGE syndrome .7s In 53 families with isolated  
scoliosi s, a genome-wide scan showed linkage and association with Sq 12  loci .7° Further analysis 
revealed a potentially functional polymorphism in CHD7 (IVS2-3238A>G), which is hypothesized to 
disrupt normal spinal growth patterns and predispose to spinal deformity. So far, this a ssociation 
has not been confirmed by a second independent study and the polymorphism has not been 
described in other patients or controls. 
C left lip/palate occurs in 30-48%of patients with CHARGE syndrome with a CHD7mutation. 12•1 3• 1 7•76 
In 184 cases with non-syndromic cleft lip/palate, a role for CHD7 could not be proven, a lthough 
some variants were found.37 
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Congenital heart disease occurs in approximately 75% of CHARGE patients.12•1 1.17·76 Analysis 
of CHDl in 67 patients with a congenital heart defect and in 1 00 controls revealed seven intronic 
variants.77 Remarkably, one variant was detected in patients only (IVS1 4-35C>G), while another 
variant (IVSl 2-5T>C) had a lower frequency in the patient group, suggesting it has a protective effect. 
No CHDl mutations were found in the coding region and it was concluded that CHDl mutations do 
not contribute substantially to non-syndromic congenital heart defects. 
Other causes of CHARGE syndrome 
The cause of CHARGE syndrome remains unclear in 5-1 0% of typical CHARGE patients and in 40-
60% of patients suspected of CHARGE syndrome. Non-detectable rearrangements in CHDl (e.g. 
deep intronic mutations that affect splicing, intragenic rearrangements or mutations in regulatory 
regions), and whole gene or exon deletions/duplications (which are not a lways screened for) might 
explain CHARGE syndrome in some of these patients. It is also possible that there are other genes 
involved in CHARGE syndrome. 
The only other gene that was shown to be implicated in CHARGE syndrome, the SEMA3E gene, 
was found to be mutated in one CHARGE patient and disrupted in another patient with a de nova 
chromosomal translocation between chromosomes 2 and 7.78 No mutation in CHDl was found in 
these patients." Thus far, no additional SEMA3E mutations have been reported in CHARGE patients. 
Other candidate genes have also been tested without revealing any pathogenic mutations, e.g. 
PITX2 and PAX in 29 and 34 patients with CHARGE syndrome, respectively.79·8° CHDl results are not 
known for these patients. It is further worth noting that analysis of CHDB, whose protein product 
interacts with CHD7, revealed no mutations in 25 CHO7-negative CHARGE patients.27 
Phenocopies of CHARGE syndrome due to chromosomal imbalances have been reported. 
Unfortunately, most cases were published before 2004 so that CHDl analysis was not performed. 
Chromosomal imbalances reported in patients with a CHARGE-like phenotype are shown in Table 
1 .  Some chromosomal aberrations, for example duplication 1 (q25q32) and deletion 4(q31 qter), 
have been reported as causes of CHARGE syndrome.8 ' -82 However, our review of the clinical features 
revealed that these patients had neither choanal atresia nor coloboma, and thus did not fulfil the 
clinical diagnostic criteria for CHARGE syndrome.5·'6 
In contrast to the unique chromosomal cases mentioned in Table 1 ,  a recurrent clinical overlap 
has been reported for 22ql 1 .2 deletion syndrome and CHARGE syndrome.8•11.4°.45•56•66•83•84 The 
overlapping clinical features include cleft palate, cardiac malformations, ear abnormalities, hearing 
loss, growth deficiency, developmental delay, renal abnormal ities, hearing loss, hypocalcaemia and 
immune deficiency.s.4s,s6·66•83·85·116 CHDl mutations are more often, but not exclusively, associated with 
coloboma, choanal atresia, facial nerve palsy, tracheo-oesophageal fistula and micropenis compared 
to 22ql 1 .2 deletions.86 Hypoplastic semicircular canals are suggestive for CHARGE syndrome, as 
they are present in almost al l patients with CHARGE syndrome.12•16•87•88 However, semicircular canal 
abnormalities cannot exclude 22ql 1 .2 deletion syndrome, since this feature has been described in 
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patients with a 22ql 1 deletion, albeit very rarely.'2•89 Defects of the lateral semicircular canals were 
also noted in a mouse model for 22ql 1.2 deletion syndrome, the Tbx1•1• mouse.8 
In conclusion, CHDl is the major causative gene in CHARGE syndrome. If sequence analysis does 
not reveal a CHDl mutation, M LPA and genome-wide array studies should be performed in patients 
suspected of CHARGE syndrome. In the future this will probably be extended with who le genome 
sequencing. 
Table 1 .  Unique chromosomal imbalances mimicking CHARGE syndrome 
Chromosomal imbalance 
der(2)t(2;21 )(q37;qter) 
der(3)t(3;22)(p25.1 ;q 1 1 . 1 )  
del(3)(p1 2p21 .2) 
der(4)t(4;8)(q34,3;q22, 1 )  
der(6)t(4;6)(q34;q25) 
der(9)t(9;1 3)(p23;q33) 
inv dup(1 4)(q22q24.3) 
der(l B)t(2;1 B)(q37.3;q22.3) 
trisomy 1 8  
der(21 )t(l 9;21 )(ql 3.1 q22.3) 
der(X)t(X;2)(p22.1 ;q33) 
THE CHD7 MUTATION DATABASE 
Reference 
1 1 4  
1 1 5  
1 1 6  
1 1 7  
1 1 8  
1 1 8  
1 1 9  




We have established a web-based, locus-specific database which gives a complete overview of 
the variants identified in CHDl. This CHDl mutation database has been constructed to aid both 
clinicians and scientists. The database contains all the CHDl mutations, unclassified variants and 
benign variants, which have been published in the medical literature, including those presented in 
this article. The database is patient-based and contains information about the clinical phenotype of 
the patient, if provided. For missense variants a prediction of pathogenicity is given (Bergman et a l, 
submitted). 
The database software was constructed by the Genomics Coordination Centre, a joint venture 
of the Department of Genetics, UMCG, and the Groningen Bioinformatics Centre, University of 
Groningen, the Netherlands. The software is based on the online patient registry for dystrophic 
epidermolysis bullosa.90 All the software has been built using the open-source MOLGEN IS  
framework9M3 and is freely available to others working on locus-specific databases at http://www. 
molgenis.org. 
Mutations are numbered according to the current reference sequence (RefSeq NM_0l 7780.2), 
and the mutation nomenclature is according to the Human Genome Variation Society (HGVS) 
recommendations (http://www.hgvs.org/rec.html). The database will be freely accessible online at 
www.CHD7.org. It can be updated with any reported variant from any team, worldwide. It is highly 
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recommended that new as well as previously reported variants are submitted to the database, 
because additional data will improve its value, e.g. for the interpretation of unclassified variants and 
phenotype-genotype correlations. 
NOVEL INSIGHTS INTO CHD7 FUNCTION 
Expression patterns of CHD7 
The expression of CHD7 has been studied in human, mouse and chicken embryos, amongst 
others.6·7·1 7•57•94 97 In all species, Chd7 expression patterns correlate with the developmental 
abnormalities observed in CHARGE syndrome.4•6•1 7•57 The expression of Chd7 is tissue- and 
embryonic stage-dependent. Neural crest derived cells express CHD7 in different tissues in all the 
studied species, while no major differences in expression pattern are observed across species.4-7•17•57 
Expression has been observed in several areas of the brain, including the pituitary, olfactory bulb, 
and ganglia of the cranial nerves, and has also been demonstrated in the otic and optic pits, 
developing inner ear, nasal and oral epithelium.4•6•7•1 7•57•94•95 CHD7 expression was also noted in the 
vascular plexus of the yolk sac, cardiac outflow tract, pharyngeal and brachia I arches, and the heart, 
although not in all studies.4"'·7•1 7•97 It was also seen in the enteric neurons, kidneys and epithelium of 
the stomach, gut and lungs.6.7 
Animal models for CHARGE syndrome 
Different models exist, of which the mouse models have been studied most extensively.6 8-94•95·98 100 
The mouse Chdl gene sequence is 97% similar to the human sequence. The first nine Chdl mutant 
mice, including the most-studied Whirligig mouse (ChdJWhll+) with a heterozygous nonsense 
mutation in exon 1 1 ,  were identified in a large-scale ENU mutagenesis program by their dominantly 
inherited head bobbing and circling behaviour due to inner ear defects.6 Later, Chd7-deficient mice 
were generated using gene-trap technology, where a beta-galactosidase expression vector was 
introduced between exons 1 and 2 of the gene (ChdJG"+).7 
Mice with homozygous Chdl mutations die in utero and in heterozygous mice a reduced survival 
at weaning is seen.6·7 Most abnormalities frequently observed in human CHARGE syndrome have 
been found in mice as well. All mutant mice show a balance disturbance due to semicircular canal 
defects consistent with the phenotype in humans.6-8•98 In addition, in most heterozygous mice, low 
postnata I bodyweight or reduced growth was found. 6•7 Gen ita I defects in ChdJWMI+ mice include vu I val 
hypoplasia, clitoral abnormalities, and abnormal uterine horns in females, and hypoplastic testes in 
males.0•94 In Chdl611• mice, delayed puberty, erratic oestrus cycles, decreased levels of circulating LH 
and FSH, and a reduced GnRH neuron count in the hypothalamus were observed.100 Furthermore, 
hyposmia and olfactory bulb anomalies were observed in Chd7-deficient mice.94·95 Heart defects in 
mice include interventricular septum defects and pharyngeal arch anomalies, like interrupted aortic 
arch,6,. while choanal atresia and cleft palate have also been observed in some mice.6 Remarkably, 
optic coloboma has not been reported in mice, but some do have a keratoconjunctivitis sicca.6 
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External ear anomalies and trachea-oesophageal defects have also not been described previously 
in Chd7-deficient mice. Why mice with Chd7 mutations display some, but not all CHARGE features is 
unclear, but may indicate species-specific differences in the developmental requirement for Chd7 or 
differences in genetic background.76 
The effect of Chd7 deficiency has also been studied in Xenopus and Drosophila. In Chd7-
deficient Xenopus embryos, otolith malformations, ocular coloboma, microphthalmia, craniofacial 
malformations and heart defects were observed.5 Null mutations in Kismet, the homologue of Chdl 
and ChdB in Drosophila, were found to be embryonically lethal. Decreased Kismet expression was 
associated with abnormal wings, neuro-anatomical defects, and defects in memory and motor 
function.101• 102 
The combination of a heterozygous Chd7 mutation with a heterozygous mutation in another 
gene might cause more severe defects. These double heterozygous effects have been studied 
in mouse models for Kallmann syndrome (ChdJWhll•;fgfr1Hspyl+) and 22ql 1 .2 deletion syndrome 
(Chdl";Tbx1•1 ).8•94 Double heterozygous Chd7Whll+;fgfr1Hspyt+ mice showed reduced survival, but 
their anatomical abnormalities were the same as in the ChdJWhV+ mice.94 In double heterozygous 
ChdJ+1· ;Tbx1•1· mice, the heart, inner ear and thymus were found to be more frequently and/or more 
severely affected. In addition, the postnatal viability of double heterozygotes was significantly 
reduced.8 Thus, the double heterozygous models studied so far were indeed less viable and thus 
more severely affected. 
Function of the CHD7 protein 
Before the discovery of CHD7 mutations as the cause of CHARGE syndrome, already several theories 
had been proposed to explain the pathogenesis of the various malformations seen in CHARGE 
syndrome. The postulated pathogenic mechanisms included maldevelopment of the neural crest 
cells, 103 disruption of the interaction between mesoderm and neural crest cells, 104 and disruption of 
mesenchymal-epithelial interaction.105 Upon the discovery of CHD7 as the major actor in CHARGE 
syndrome, a critical role in chromatin remodelling during development was suggested, based on 
the domains of CHD7 and the known function of CHD family members.9 Recently, more insight into 
the function of CHD7 has been obtained. 
Several studies have focused on CHD7 binding sites and function. Schnetz et al showed that 
CHD7 binds in a cell type- and stage-specific manner to methylated histone H3 lysine 4 in enhancer 
regions (i.e. regions associated with transcriptional activation) of numerous genes.3 They concluded 
that CHD7 may have a function in enhancer-mediated transcription based on four observations: 
the CHD7 binding sites are predominantly located distal to transcription start sites, most often 
contain DNase hypersensitive sites, are frequently conserved, and are located near genes expressed 
in relatively high levels similar to gene enhancer elements. In mouse embryonic stem (ES) cells, 
Chd7 was shown to co-localize at suspected gene enhancer elements together with a known gene­
enhancer binding protein element, p300, and other proteins which are core components of the 
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transcriptual circuitry of ES cells, for example Oct4, Sox2, Nanog, Smadl and Stat3.106 The expression 
profiles of Chd7 wild-type, heterozygous and null ES cells from mice indicate that Chd7 modulates or 
fine tunes the levels of genes that are specifically expressed in mouse ES cells in both a positive and 
negative direction, but it has no effect on ES cell pluripotency, self-renewal or reprogramming.106 A 
study of the CHD7 Drosophila ortholog, Kismet, showed that Kismet also regulates the transcription 
of genes by promoting early elongation by RNA polymerase II and by recruiting the ASHl and TRX 
histone methyltransferases to chromatin to counteract the epigenetic silencing of genes by the 
Polycomb group proteins. 107 
In addition to a role in the transcription regulation of nuclear genes, CHD7 was also reported to be 
involved in the regulation of ribosomal RNA (rRNA) biogenesis in the nucleolus.108The involvement of 
CHD7 in rRNA regulation was suspected because chromatin immunoprecipitation followed by next­
generation sequencing (ChlP-seq) showed a high enrichment of CHD7 at the rDNA. Results from 
further tests, including analysis of pre-rRNA levels in wild-type, heterozygous and null ES cells from 
mouse embryos, as well as the effect on cell proliferation and protein synthesis in CHDl knockdown 
cells, supported the idea that CHD7 functions as a positive regulator of rRNA synthesis. It was also 
shown that the role of Chd7 is tissue-specific by comparing pre-rRNA expression between wild-type 
and heterozygous cells of different tissues. In addition, it was noticed that Chd7 co-associates with 
treacle, the protein involved in Treacher Collins syndrome, and that the binding of treacle with rDNA 
partly depends on the presence of Chd?.108 
A tissue-specific effect of CHD7 was demonstrated in a study in Xenopus and human neural 
crest cells, which showed that CHD7 is essential for the formation of multipotent migratory neural 
crest cells.5 The transcription factors Sox9, Twist and Slug, which are critical for the formation of 
multipotent migratory neural crest cells, were diminished after knockdown of Chd7 in Xenopus 
embryos. Among others, PBAF (Qolybromo- and �RGl -gssociated factor containing complex) is a 
molecular partner for CHD7 in human neural crest cells: CHD7 and PBAF bind together to the neural 
crest cell-specific regulatory elements of TWIST/ and SOX9. The cooperation of CHD7 with PBAF 
promotes neural crest gene expression and cell migration. 
Other tissue-specific studies show that Chd7 is required for the proliferation and differentiation 
of neural stem cells in the basal olfactory epithelium of Chdl6'1+ mice.95 Chd7-haploinsufficiency was 
associated with decreased expression of Fgfr1, Bmp4 and Otx2 in the embryonic olfactory placode 
of Chdl6'1+ mice, whereas in the adult hypothalamus Otx2 and GnRHI expression were diminished. 100 
These results suggest that Chd7 affects GnRH neurogenesis and signalling by influencing the 
transcriptional regulation of target genes involved in the BMP and FGF pathways. In the inner ear 
of mice, Chd7 is necessary for proliferation of neuroblasts and the expression of genes known to 
be involved in inner ear morphogenesis, like Ngn1, ltx2 and Fgf10.96 In mesenchymal stem cells of 
bone marrow, Chd7 forms a complex with Nik, Setdbl ,  and Ppar-gamma that promotes osteoblast 
formation in preference to adipogenesis.109 In the mouse pharyngeal arch, Chd7 and Tbxl are 
both required in ectoderm during embryogenesis for normal great vessel development.8 In the 
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wing development of Drosophila, Kismet is a component of the hedgehog transcriptual repression 
mechanism in anterior compartment cells.102 In mouse neural stem cells, it was shown that Chd7 
cooperates with Sox2 (an HMG-box transcription factor) in activating the expression of common 
target genes, which include effectors of the Sonic Hedgehog ( Gli2, Gli3, Mycn and Tulp3) and Notch 
pathway (Jag 1, Rbpj and HesS) .110-1 1 1  CHARGE syndrome and SOX2 anophthalmia syndrome show 
considerable clinical overlap and also the phenotypes of the diseases caused by mutations in the 
common target genes overlap with CHARGE syndrome and SOX2 anophthalmia syndrome: pituitary 
and genital anomalies occur in Pallister Hall syndrome (GL/3), trachea-oesophageal anomalies 
are seen in Feingold syndrome (MYCN), and semicircular canal anomalies are present in Alagille 
syndrome (JAG7). 
We conclude from all recent studies on the function of CHD7 that its haploinsufficiency alters 
the transcription of tissue-specific target genes that are normally regulated by CHD7 or complexes 
in which CHD7 is involved.3 •106-1O0,1 1O Since the effect of CHD7 is tissue- and developmental stage­
dependent due to different binding sites, protein complexes and target genes, 3·'08 the current 
hypothesis is that the broad clinical variability of congenital anomalies seen in CHARGE syndrome 
may be explained by subtle alterations of the CHD7 level in time and place. In this respect, frequently 
affected organs, like the inner ear, may be more sensitive to CHD7-dosage than, for example, the 
palate which is more variably af fected. 1O6•1 12 However, the precise gene targets and complexes for 
each tissue are still unknown, and the common factors, targets, and molecular genetic pathways are 
only slowly starting to emerge.1 12.m Further studies are needed to identify the genetic, epigenetic 
and environmental factors that modify the phenotype in CHARGE syndrome. 
Reviewing the theories on the pathogenesis of CHARGE syndrome postulated before the 
identification of CHDl, we conclude that the role of the neural crest has been confirmed by recent 
studies.5•1O3 CHD7 may also indirectly influence the interaction between the neural crest and other 
tissues, or have an additional direct effect on other cell types, so the theories on mesenchymal ­
epithelial and mesoderm-neural crest cell interaction might be correct as well.'°'· 105 These theories 
deserve further study since not all the defects seen in CHARGE syndrome can be explained by 
neural crest cell involvement.105 Furthermore, a recent study in heterozygous Chdl mice showed 
that rescue of Chd7 in neural crest cells did not improve the phenotype of pharyngeal arch defects, 
while rescue of Chd7 in pharyngeal ectoderm did.0 
LATEST CLINICAL INSIGHTS 
We estimated a new incidence of CHARGE syndrome, which is lower than the previous estimate of 
1 in 10, 000 live births worldwide.'0• 1 1 Our estimate was based on the number of CHDl mutations 
that were identified in chi ldren born in the Netherlands between 2006 and 2009 and the overall 
birth prevalence in those years. This gives a good estimate of the incidence of CHARGE syndrome, 
because most children who are suspected of CHARGE syndrome will undergo CHDl analysis (DNA 
testing is insurance covered in the Netherlands). Forty CHDl mutations were found in 735,942 live-
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born children, which gives a birth incidence of 1 in 1 8,400. However, because we based our estimate 
on the number of CHD7mutations, the patients with CHARGE syndrome who had not yet undergone 
CHDl analysis because of a very mild phenotype ( 14-1 7% of all patients with a CHO? mutation) and 
the patients with typical CHARGE syndrome but without a mutation in CHDl (a maximum of 1 0%) 
were not included.12·13 If we take this into account, we estimate the incidence of CHARGE syndrome 
in the Netherlands at 1 in 1 5,000 to 1 in 1 7,000 live births. 
Now that CHARGE syndrome can be diagnosed molecularly, it is possible to delineate the 
phenotypic consequences of CHDl mutations. The penetrance of CHDl mutations is generally 
complete, but their expression is highly variable.12 This is underscored by the observation of 
discordant features in monozygotic twins, and by the occurrence of identical mutations in patients 
with Kallmann and CHARGE syndromes.1 3•1 7•63 The most consistent clinical features in patients with 
a CHDl mutation are semicircular canal hypoplasia, external ear abnormalities and cranial nerve 
dysfunction, which are present in over 90% of the patients.1 2•76 In addition, most patients have some 
degree of developmental delay, but their cognitive function can be normal.12•76 Coloboma and 
choanal atresia are found in 75-81 % and 38-55% of patients with a CHDl mutation, respectively.1 2•76 
Minor features of CHARGE syndrome vary in their incidence: congenital heart defects occur in 76-
77%, genital hypoplasia in 62-81 %, cleft lip and/or palate in 33-48%, and trachea-oesophageal 
anomalies in 1 9-29%.12•76 No clear genotype-phenotype correlations have been found for CHDl 
mutations, although missense mutations can be associated with a milder phenotype (Bergman et 
al , submitted).12•1 3• 18 With the rapidly growing information on the cl in ical effects of CHDl mutations, 
it is l ikely that the clinical spectrum of CHARGE syndrome will expand further and the definition of 
CHARGE syndrome may need to be redefined. CHARGE syndrome remains a clinical diagnosis, as 
long as no mutations can be found in 5-1 0% of the clinical typical CHARGE patients. Nonetheless, 
a pathogenic mutation in CHDl confirms the diagnosis and gives tools for counselling about 
reproductive options. In patients who do not completely fulfil the clinical CHARGE diagnostic 
criteria, identifying a CHD7mutation is important in order to guarantee accurate clinical surveillance, 
which can possibly lead to the identification of additional CHARGE features (e.g. balance problems, 
endocrine dysfunction, and anosmia).12 Recently, a guideline for CHDl analysis was publ ished, 
which will help clinicians to decide if CHDl analysis or imaging of the semicircular canals should 
be performed in the diagnostic work-up of the patients that are suspected of CHARGE syndrome.12 
For counselling of recurrence risks, it is important to know the genetic status of the parents. 
Most CHDl mutations occur de novo and are predominantly located on the paternal a l lele of the 
patient.54 In these cases, the recurrence risk for the parents is 2-3%, as both germline and somatic 
mosaicism have been described.13·47·53 In a minority of cases, however, one of the parents carries the 
CHDl mutation and the recurrence risk is 50%.12 Reproductive options should be discussed with 
the parents of patients with CHARGE syndrome and with the patients themselves at an appropriate 
age. The severity and diversity of CHARGE syndrome features cannot be predicted in the offspring 
by molecular diagnosis. Foetal ultrasound has an additional value, but the full clinical presentation, 
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may only become evident after birth. 
CONCLUSIONS 
Loss-of-function mutations in CHD7 cause CHARGE syndrome, a highly variable multiple congenital 
anomaly syndrome. We have established a web-based database (www.CHD7.org) which gives an 
up-to-date overview of all the described CHD7 mutations and clinical phenotype of patients, and 
includes 184 new mutations and 296 patients presented in this paper. Our database will al so allow 
inclusion of new cases. In this paper we have summarized the latest data on expression studies, 
animal models and molecular studies of CHD7. The function of CHD7 and its interaction with other 
genes is emerging, indicating that it regulates the expression of genes in a cell type- and embryonic 
stage-dependent manner. 
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u, Supplementary Table S1.  CHDl mutations and unclassified variants found in unpublished patients 1 9 
A. All pathogenic CHDl mutations found by our laboratories in previously unpublished patients, including their phenotypic information I � 
CHD7 c CHD7 p Mutation Segregation Phenotyplc Information 
type C H A R R G E sec C(L)P HL FD VII TE 
G D 
del del u no yes yes u u u u yes u u u u u 
del del de novo yes yes u u u u yes u u u u u u 
transloc transloc de novo no yes yes yes u yes yes u yes yes yes yes no 
1 60del Leu54fs fs u yes yes u yes u yes yes yes u yes u no u 
191_1 94del Thr64fs fs u yes yes u u u u u u u yes u u u 
232C>T Gln7BX non u u no u u poss yes yes u yes yes poss yes u 
257del Pro86fs fs de novo no no no u yes No yes u yes yes yes yes no 
282del Asn96fs fs de novo u no yes u poss yes u u u yes u u u 
31 7delA His1 06fs fs de novo u u u u u u u u u u u u u 
334C>T Gln 1 1 2X non u yes yes yes yes u yes u no u yes u yes u 
388C>T Gln1 30X non not maternal yes u no yes u yes u yes u yes yes u u 
406C>T Gln1 36X non u u u u u yes u u u u u u u u 
469C>T Arg1 57X non u yes yes yes u u yes yes yes u u u u yes 
469C>T Arg1 57X non u yes u u u u u yes u yes u u u u 
550C>T Gln1 84X non u no yes yes u u u u u u u u u yes 
601 C>T Gln201 X non u yes yes no yes yes u yes u no yes u u u 
604C>T Gln202X non de novo yes yes yes u u u yes u u u u u no 
608dup His203fs fs u yes yes yes u u u yes yes u u u u yes 
61 9C>T Gln207X non de novo yes yes u u yes u yes u u yes yes yes u 
61 9C>T Gln207X non u u u u u u u u u u u u u u 
627del Met21 0X fs u yes yes yes u yes yes yes u u yes u yes u 
635delA Gln21 2fs fs u yes yes u no yes yes yes u u yes poss yes no 
674del Pro225fs fs u yes yes yes u u u yes u u u u u u 
689C>G Ser230X non de novo yes no u u u yes yes u yes u u u u 
71 8del Gln240fs fs u no yes yes no u yes yes yes no yes u u yes 
781del Ser261 fs fs de novo u yes u u u yes yes u yes u u u u 
791_792del Leu264fs fs u u yes yes u u u yes u u u u u u 
844C>T Gln282X non u u yes u u u u yes u yes yes u u yes 
921_922del Gly308fs fs u u yes yes u u u yes u u yes u yes u 
934C>T Arg312X non u yes yes yes yes u u yes u u u u u u 
934C>T Arg312X non u u u u u u u yes u u yes yes u u 
995T>G Leu332X non de novo yes yes u u poss yes yes u u yes poss yes u 
1 066_1069 dup Ser357fs fs u yes no no yes yes yes yes yes u yes u yes no 
1 093C>T Gln365X non u yes no u u poss yes yes u yes yes poss u yes 
1 1 23C>T Gln375X non de novo yes no u yes yes yes yes yes yes yes yes u u 
1 1 35C>T Gln379X non u yes yes u u u yes u yes u yes u yes u 
1 1 59C>T Gln387X non u u u u u u u u u u u u u u 
1 1 70T>G Tyr390X non u u yes yes u u u yes u u u u u u 
1 247InsG Ser417fs fs u yes yes yes u u u yes u u u u u no 
1 31 2C>T Gln438X non u u u u u u u u u u u u u u 
1480C>T Arg494X non u yes yes no no u yes yes yes no yes yes u no r! 
5· 1 480C>T Arg494X non u yes yes yes no yes yes yes yes u yes u u yes ::, 
1 480C>T Arg494X non u u yes yes u u u yes u u u yes u u 
1 480C>T Arg494X non de novo yes yes yes yes u u yes yes u yes u u no Cl 
1480C>T Arg494X non not maternal u yes no u u No yes u no u u u u 0 ::, 
1 528del Gln51 0fs fs u yes yes u u u yes u u yes yes u u u s-
It> 
1645C>T Gln549X non u yes yes u yes yes u u u u u u u u 
1678delG Glu560fs fs u yes yes u u yes yes u u yes yes u u u CJ " 
1 683_ 1 684 delCT Phe562fs fs u u u u u u u <Cl yes yes yes yes yes yes yes 
1 735C>T Gln579X non u yes yes yes u u u yes u u u u yes u It> :5· 
1 735C>T Gln579X non u yes u no u u yes yes u u u poss u yes 0 
1 740del Val581 fs fs u u u u u u u ;;-yes yes yes yes yes poss yes 
1 926_1929 del Lys643fs fs u poss u u no yes yes yes u no yes yes yes u :5· 
1 932_1935 
delGAAA Lys645fs fs not maternal yes no yes u yes yes yes u yes no yes u yes 
r, 
� "" 1 953dup Asp652fs fs de novo yes yes no yes u u yes u no yes yes no yes 
1 953dup Asp652fs fs u u yes u no yes yes yes u u yes yes u u 
1 953dup Asp652fs fs u yes no u yes yes yes yes u u yes poss u u a" 
V, 1 953dup Asp652fs fs de novo yes yes no no u no yes yes yes yes no yes no 
-
V, 
1972G>T Glu658X u u u u 9 1-.J non yes yes yes yes yes yes yes yes yes yes 
1 983dup Lys662fs fs u yes yes u u yes u yes u u yes u u u 
1 988-1 989dup Glu664fs fs de novo u u u u u u u u u u u u yes !'-> 
1 989dup Glu664fs fs u yes no u u yes yes yes yes u yes u u u 
1 990G>T Glu664X non u yes no u u yes u u yes yes yes yes u u 
2019_2023 
Pro674fs fs u yes yes no u yes u yes u u yes yes u yes delinsGGG 
2096+2T>A ? splice de novo yes yes no yes u yes yes yes u u u yes no 
2097-lG>A ? splice u yes yes u u yes u yes yes u u yes yes u 
21 18del Ala707fs fs de novo no yes yes u poss u yes u u u u u u 
21 57del Glu1 720fs fs de novo yes yes yes yes yes u u u u yes yes u u 
218l dup Asp728fs fs de novo u yes u u poss u u yes u u u yes yes 
21 96dup Pro733fs fs de novo u yes u u u u u u yes u u u yes 
2236delC Gln746fs fs de novo u u u u u u u u u u u u u 
2238+1G>T ? splice u yes no no no yes no yes yes no yes no yes no 
2238+2T>G ? splice u u u u u u u u u u u u u u 
2238+1G>A ? splice u u yes yes u u u yes u u u u u u 
2247 _2260 del 5er750fs fs u yes yes yes u u u u yes u u u u u 
2374C>T Gln792X non u u u u u u u u u u u u u u 
2443-2A>T ? splice de novo no yes no yes yes yes yes u no yes u yes no 
2443-lG>A ? splice u u u u u u u u u u u u u u 
2498+2T>C ? splice u yes yes u yes poss u yes u yes yes u u u 
2498+1 G>T ? splice de novo u yes yes u u u u u u yes u u u 
2498+2dup ? splice u u yes u u u u yes u yes u u u poss 
2504_2508 del Tyr835fs fs de novo u yes yes u u no yes yes u yes poss u u 
2504 2508 del Leu836fs fs u yes yes u u u u yes u u u u u u 
2504_2508 del Tyr835fs fs u u yes u u u u u u yes u u u no 
2520G>C Trp840Cys mis de novo yes no no no yes yes yes u no no u no u 
2571 insA Arg858fs fs de novo yes yes no yes u yes u yes u yes u u yes 
2572C>T Arg858X non de novo u yes yes u u yes yes u u u u u yes 
2577dup Lys860X fs u yes yes no u yes u yes u u yes u yes u 
2601 -2605del Lys867fs fs u u yes u u u u yes u u u u u u 
2620delG Asp874fs fs u yes yes u yes yes yes yes u no yes yes yes no 
2707_2710 
His903fs fs de nova yes yes u u delCACT u u u u u u u u u 
281 5G>T Glu939X non u no yes no u yes yes yes yes yes yes yes yes no 
2829del glu943fs fs u yes yes yes u u u yes u u u u u u 
2839C>T Arg947X non u u no yes u u u u yes u u u u u 
2859del Trp953X fs u yes yes no yes yes u yes yes u yes yes u no 
2887A>T Lys963X non not maternal u u u u u u u u u u u u u 
2905_2906 def Arg969fs fs u u u u u u u u u u u u u u 
2957+2T>C 7 splice u yes yes no u yes u yes u u yes poss u u 
2957+5G>A ? splice de nova yes yes no yes no yes yes u yes yes u yes no 
2959C>T Arg987X non not maternal yes yes u u u yes yes u u u poss u u 
3023_3024 del Tyrl OOBX fs de nova yes yes no yes u yes yes u u yes poss u no 
3024T>A Tyrl OOBX non u u u u u u u u u u u u u u 
3059T>C Leu1 020Ser mis u u yes yes u u u u u u u u u yes 
3082A>G lle1 028Val mis de novo yes no u u yes yes yes u yes yes u u u C: 
3082A>G lle1 028Val mis de novo u u u u u u u u ci yes yes no yes yes g. 3082A>G lle1 028Val mis u no yes u u no yes u yes yes yes yes u no ::, 
C: 
3091T>C Trp1031 Arg mis de nova yes yes u u u yes yes u u u u yes u Q. 
31 06C>T Arg1 036X non de nova yes yes yes u yes u yes yes yes u u u yes ril' 
31 06C>T Arg1 036X de nova u u u u u u u u u u 0 non yes yes yes ::, 
3 1 1 7dup Glu1040fs fs u yes u u u u u u u u u u poss yes n, 
31 65del lle1 056fs fs u u u u u u u u u u u u u u � 
de nova CJ 31 73T>A Leul 0SBX non yes yes no no u yes yes yes no yes yes yes no " 
IQ 3205C>T Arg1069X non u u u u u u u u u u u u u u n, ::, 
3205C>T Arg1069X non u no yes u u poss n, yes yes u yes yes u u u 5· 
Tyr1 075fs fs de nova < 3222_3223 insS no yes yes no u u yes u u u u u u 0 
3245C>A Thr1082Asn mis de nova u u u u u u u u u u u u u Q. 
3301T>C Cysl 1 01 Arg mis de nova u u u u u u yes u u yes u u u 5· 
f""\ 
331 8del Ala l 1 07fs fs de nova u yes u u u u u u yes u u u u i; 
3322delC Hlsl 1 08fs fs de nova u u yes u u yes u u u yes u u u :,:, 




3379-3C>G ? splice u u u u u yes poss u u 9 .i:,. yes yes yes yes yes 
3514_3515 del Glu1 1 72fs fs de nova yes no u yes poss yes yes u yes yes yes u u 
3522+2T>G ? splice u u u u u u u u u u yes yes yes yes t-,J 
3522+2T>C ? splice de nova u no u u u u u u u yes u u u 
3523-lG>C ? splice u yes yes no yes yes yes yes u no yes u yes no 
3573dup Glul 1 92fs fs u yes yes yes u yes u u u u yes u u u 
3616dup llel 206fs fs de nova yes yes u u u yes yes yes yes yes u u u 
3641A>G Gln1214Arg mis de nova yes no no yes yes yes yes u u yes u u no 
3641A>G Gln1214Arg mis de nova u u u u yes u yes u u yes u u u 
3655C>T Arg1219X non de nova yes yes u u u u u u u u u u u 
3655C>T Arg1219X non u yes yes u yes u u u u u yes u u u 
3734del Met1 245fs fs de nova yes yes yes no yes yes yes yes yes yes yes u no 
3807del Phe1 269fs fs u yes no no yes yes yes yes u no yes u poss no 
3847C>T Gln1283X non u u u yes u u yes yes u u yes u u u 
3875T>C Leu1 292Pro mis de novo u yes u u u u u u u u u u u 
3937del Ser1 31 3fs fs de novo yes no no no yes u yes u yes yes poss u no 
3952T>C Cys1 318Arg mis de novo yes yes no u poss yes yes u no u yes yes no 
3990-2G>A ? splice de nova yes yes no no u yes yes yes u yes yes yes no 
3993C>G Tyr1 331 X non de nova u u u u u u u u u u u u u 
401 5C>T Arg1 339X non de novo u yes u u u u u u u u u u u 
4034G>A Arg1 345His mis de novo no no u u yes no yes u yes yes poss u yes 
41 13-41 1 4  insCA Gly1372fs fs de nova yes yes no yes yes u yes u no yes u yes u 
421 3C>T Gln1 405X non u yes no yes u u u yes no u yes poss u u 
421 3C>T Gln1 405X non de nova yes no u yes yes u yes u u yes poss u u 
4253del Asn141 8fs fs not maternal yes no u u yes u yes u yes yes yes u u 
4257del Tyr1420fs fs u yes yes u u u u yes u yes u poss u u 
4270del Met1 424fs fs u yes yes yes u u yes yes yes u u u u yes 
4295_ 4296 del Leu1 432fs fs u u u u u u u u u u u u u u 
4353+2T>C ? splice u u yes yes u u u u u u yes u u u 
4357_4358 Gln1453fs fs not maternal u no u u yes yes yes u u yes yes yes u dupCA 
4375G>T Glu1459X non de nova yes yes yes u u yes u u no u u no no 
4393del Arg1465fs fs not maternal yes yes yes yes yes u yes u u u u u no 
4393C>T Arg1465X non u yes yes no no yes no yes yes yes yes yes u no 
4393C>T Arg1465X non u u u u u u u u u u u u u u 
4393C>T Arg1 465X non u u u u u u u u u u u u u u 
4424del Glu1475fs fs u u u u u u u u u u u u u u 
4480C>T Arg1494X non de novo yes yes u yes yes u yes u u yes yes yes u 
4480C>T Arg1 494X non u u u u u u u u yes u u u u u 
4644+5G>A ? splice de novo no no yes no yes u no yes u yes no no no 
4665del Pro1 556fs fs u u yes u u u yes yes u yes u u yes u 
4731 del Asp1578fs fs de novo no no yes u u yes yes yes no yes yes u u 
4783C>T Gln1 595X non u no no yes u u yes yes yes no yes yes yes no 
4850+1 dup Trp161 8fs fs u no yes yes u u u yes no no u u yes no 
4850+2T>A ? splice de nova u u u u u u u u u u u yes u 
4850+1 G>A ? splice not maternal u u u u u u u u u u u u u 
4851 -2A>G ? splice u yes no no yes yes yes yes yes u yes yes yes poss 
4851 -2A>T ? splice u yes yes no yes u yes yes yes u yes yes yes u 
4854G>A Trp1618X non de novo yes yes u u no u yes u yes yes u yes u s 
501 2_5018 del Thr1671fs fs u u yes u u u u u u u u u u u g. ::, 
5050G>A Gly1 684Ser mis de nova no yes no yes yes u u yes yes yes u u no 
Q. 
5069dup Arg1691fs fs de novo yes yes yes u u u yes yes no yes no yes u 
51 36G>A Trp1712X non not maternal u yes u u u u u u u u u u u 
5205_5206 insT Asn1 736X non u yes poss yes yes yes u u u u yes yes u u 
11) 
521 1- lG>C ? splice u yes yes yes u u yes yes u u yes yes u no 2 
5241 -5244del Tyr1 747X fs de nova no yes u no yes yes yes yes no yes yes yes no 
5297C>G Ser1 766X de nova u u u 10 non yes yes yes yes yes yes yes yes yes no 11) 
::, 
5316G>A Trp1 772X non u u u u u u u u u u u u u u 11) s· 
5390G>T Gly1 797Val mis de nova yes no u no yes yes yes yes u yes yes yes u 
5405-1 7G>A ? splice de nova no no no yes u u :c-yes yes yes yes yes yes yes 11) 
Q. 
5405-7G>A ? splice u yes no prob yes yes No yes yes u yes u yes u s· 
5405-1 7G>A ? splice u no no no no yes u yes yes no yes yes u u � 5405-7G>A ? splice de nova no no no u u yes no yes yes yes u u no 
5405-1 7G>A ? splice u yes no no u u u yes u yes yes u u no .,, 




5428C>T Arg 181 0X de novo u u u u u u u u u u u u u 9 Q\ non 
5434G>C Asp181 2His mis de novo no no yes no poss u yes yes no yes yes u no 
5435A>G Asp1 81 2Gly mis de novo u u u u u yes yes no no yes yes poss yes t,.J 
5444T>C Leu181 5Pro mis u yes yes u u u u yes u yes u u yes u 
5453dup Glu181 9fs fs de novo u u yes u u u u u u u u u u 
5458C>T Arg1 820X non de novo yes yes yes u yes u yes u u yes u u yes 
5458C>T Arg1 820X non de novo u u u u u u u u u u u u u 
5534+1 G>T ? splice de novo yes yes no u u u yes u yes u u u u 
5534+ 1 G>A/T ? splice de novo u yes prob u u u yes u u u u u u 
5539G>T Glu1 847X non de novo u yes u u yes yes u u u yes u u u 
5592del Phe1 864fs fs u yes yes u yes yes yes yes u yes yes u u u 
5597A>G Asp1 866Gly mis de novo yes yes u u u u u u u u u u u 
5607+1 G>A ? splice de novo yes yes no u u u yes u no u yes yes u 
5706C>A Tyr1 902X non u yes yes u u yes u u u u yes u u u 
5709G>A Trp1903X non u u yes yes u yes u u u u yes u yes yes 
5866dup Glu1 956fs fs u u u u u u u u u u u u u u 
5898G>A Trp1 966X non u yes yes yes yes yes yes yes yes u yes u yes no 
5908G>T Glu1 970X non de novo yes yes yes u u u u u u u u u u 
591 0dup Glu1971fs fs not maternal yes yes no yes yes u yes yes u yes u u yes 
5944_5989 dup Phe1 997fs fs de novo u u u u u u u u u u u u u 
5968C>T Gln1 990X non de novo yes yes no u yes yes yes u yes yes yes u u 
601 8-601 9insG Ser2007fs fs u no yes yes yes yes u yes u no yes poss u no 
6018dup Ser2007fs fs u yes no no yes yes yes yes u no u u yes no 
6070del Arg2024fs fs u yes yes u u yes u u yes yes yes poss u u 
6070C>T Arg2024X non u yes no yes yes yes u u u no u poss yes no 
6070C>T Arg2024X non u yes yes yes u yes u yes u u u u u yes 
6070C>T Arg2024X non u yes yes u u yes u yes u u yes u poss u 
6070C>T Arg2024X non de novo u u u u u u u u u u u u u 
6079C>T Arg2027X non de novo yes no no u yes u yes yes no yes yes yes u 
6079C>T Arg2027X non u yes yes yes no yes u yes u u yes poss yes no 
6079C>T Arg2027X non u yes yes u u u u yes u yes u u yes u 
6079C>T Arg2027X non u yes yes yes u yes yes yes no no yes u yes no 
6079C>T Arg2027X non de novo u u u u u u u u u u u u u 
6103+1G>A 7 splice u yes u yes u u u yes yes u u u u u 
6104-2A>T 7 splice u yes yes u u u yes u u yes u poss yes u 
61 48C>T Arg2050X non u yes yes u u yes yes yes u no yes yes u poss 
61 48C>T Arg2050X non de novo yes yes yes u u u yes u yes yes u yes u 
6148C>T Arg2050X non u u u u u u u u u u u u u u 
61 57C>T Arg2053X non u no yes no yes yes u yes u no yes yes u no 
61 57C>T Arg2053X non u yes u u u u u yes u u u yes yes yes 
61 57C>T Arg2053X non u yes yes yes yes yes u yes yes u yes u yes no 
61 65_6166 delGT Tyr2056fs fs de novo yes yes u u u u yes u u yes u yes u 
61 65_6166 delGT Tyr2056fs fs de novo u yes u u u u u u u yes yes u u 
61 79del Leu2060fs fs u yes yes u u u u yes u u u u yes u 
61 96G>T Glu2066X non u u u u u u u u u u u u u u 
6221T>C' Leu2074Pro mis not matemar no u u u u yes u u u yes u u u 
6221T>C' Leu2074Pro mis not maternal" yes u u u u yes u u u yes u u u Q 
6224del Gly2075fs fs u yes yes yes u u u yes yes u yes u u u g. ::, 
6271T>C Trp2091 Arg mis de novo u u u ,: yes no no yes poss yes no yes yes no 
Cl.. 6292C>T Arg2098X non u u u u u u u u u u u u u u 
631 6A>T Lys21 06X non u yes yes no u yes u yes yes u yes u u no 
6322G>A Gly21 08Arg mis de novo yes no u u no yes yes u yes yes poss u u "' 
6473C>G Ser2158X non u yes yes u u yes u u u u yes u u u 
6520A>T Lys21 74X non u u u u u u u u u u u u u u 
6526G>T Glu21 76X non u yes yes u u yes u yes u IQ yes yes yes yes no "' 
6620dup Cys2207fs fs u yes yes u u u u yes u no yes poss u no "' 
5· 6651del Glu221 7fs fs de novo u u u u u u u u u u u u u � 
6652_6656 del Leu2218fs fs u u u u u u yes u u u u u u < yes 
Cl.. 
6667del Val2223fs fs u u yes u u u u yes yes yes u u u u 5· 
6681_6685 dup Ser2229fs fs de novo u u u u u u u n yes yes yes yes yes yes � 6688delA Lys2230fs fs de novo u u u u u u u u u u u u u 
6705del Gly2236fs fs u yes yes yes u u u u u u yes u u u rn � 6857dup Phe2287fs fs de novo no no yes u yes yes yes yes yes yes yes yes no ::, 
6857G>C Gly2286Ala mis de novo yes yes no no yes u yes no u yes u yes no a" V, 3 '-I "' 
-
V, 
6888_6889 lnsT Ala2297fs fs u u ,.., 00 yes yes u yes u u u u yes u u u 
6935A>C Lys231 2Thr mis Not maternal no u yes u yes u yes u u yes u yes u 
6937-1G>C ? splice de novo yes yes no yes yes u yes u no u no poss yes t,., 
6937-2A>G ? splice u yes yes no yes u yes yes u u no u yes u 
6937-2A>G ? splice u yes no no yes yes yes u yes yes u u u no 
7075C>T Gln2359X non u no yes yes no u yes yes yes no yes yes u no 
71 06del Val2369fs fs u yes yes no yes u No yes yes no yes yes yes no 
71 60C>A Ser2387X non de novo yes yes yes no u No yes yes no yes yes yes yes 
7164+1G>A ? splice de novo u yes yes no no No yes yes u yes u u no 
7252C>T Arg241BX non de novo yes yes no u yes u yes u yes yes u yes u 
7252C>T Arg241BX non not maternal" yes u u u u u u yes u u u u u 
7252C>T Arg2418X non de novo u yes u u u yes yes u u yes u u u 
7252C>T Arg2418X non de novo yes yes no yes yes yes yes u yes yes u u no 
7276C>T Gln2426X non de novo yes u u u u u u u u yes u u u 
7282C>T Arg2428X non u yes yes u u poss u yes u yes yes poss u u 
7282C>T Arg2428X non de novo u u u u u u u u u u u u u 
7282C>T Arg2428X non u yes u u u u u yes yes yes u u u u 
7320del Val2441 fs fs u yes no no u u u no yes u yes u u u 
7344_7345 del Glu2450fs fs u yes yes yes u u u yes yes u u u yes u 
7400del Leu2467fs fs u u u u u u u u u u u u u u 
7441 C>T Gln2481 X non de novo yes yes yes u yes yes yes u u yes u u u 
7451 dupT Leu2485fs fs u no yes no yes yes yes yes yes no yes yes u no 
7454dup Asn2486fs fs u u u u u u u u u u u u u u 
7577del Phe2526fs fs u yes yes u u u u u u u u u yes u 
7593dup Thr2532fs fs u no yes no yes yes yes yes yes yes yes yes u u 
771 7-7720 del Asn2573fs fs u yes no u yes yes yes u u u u yes u u 
7879C>T Arg2627X non u u no u u yes yes yes u u u yes yes u 
7879C>T Arg2627X non de novo yes yes u yes yes u yes u no u u u yes 
7879C>T Arg2627X non u yes yes yes u u yes u u yes u u u yes 
7879C>T Arg2627X non de novo u yes u u u u yes yes u yes u u u 
7879C>T Arg2627X non de novo yes no yes u u yes yes yes no yes no u no 
7879C>T Arg2627X non u yes u yes no no u yes u u no u yes u 
7879C>T Arg2627X non u u yes u u poss u yes yes yes yes poss yes u 
7879C>T Arg2627X non u yes yes yes u u u yes u u u u u u 
7891C>T Arg2631X  non u yes yes u u yes No u no yes yes u yes no 
7895del Asn2632fs fs u u u u u u u u u u u u u u 
7933G>T Glu2645X non u yes yes u yes u u yes u yes yes u u u 
7957C>T Arg2653X non u yes yes yes yes yes No yes yes no yes yes u no 
7957C>T Arg2653X non u u yes u u u yes yes u yes u u u u 
7957C>T Arg2653X non u yes yes u u yes u u u u yes u u u 
8077-lG>A ? splice de novo no yes no no yes u yes u u yes yes yes u 
8356G>T Gly2786X non u yes yes no no yes yes no u no yes u yes yes 
861 3_8622 Asn2871fs fs de novo delins14 yes yes no u u u yes yes yes yes u u u 
8630_8634 del Ala2877fs fs u yes yes yes u u yes yes u no u yes u yes 
B737dup Leu2913fs fs u yes u yes u poss yes yes no u yes poss u u 





















u, I � IO 
-
B. All u nclassified variants (UVs) found by our laboratories in previously u npublished patients, including their phenotypic information 
°' � 
Phenotyplc Information 
C H G 
iii 
CHD7 c CHD7 p Domain Segregation A R R E sec C(L)P HL FD VII TE ... 
D G !',J 
-380C>T' ? u u yes yes u u u yes u u u u u u 
-360C>T ? u u yes u u u u u u u yes u u u 
21 5A>G Tyr72Cys u yes yes no yes yes u yes u no no u u u 
295G>C Ala99Pro paternal u yes no yes u yes yes u no yes u poss u 
760C>G Gln254Glu u u yes yes yes u u yes yes u yes u u yes 
131 5C>T Pro439Ser u u yes u u u u u u u u u u u 
1672C>G Pro558Ala u u u u u u u u u u u u u u 
2095A>G Ser699Gly u yes yes yes yes u u u u u u u u u 
2436A>T Lys81 2Asn u u yes yes yes u u yes yes u yes u u yes 
2436A>T Lys81 2Asn CDl maternal u yes u yes u u u u u u u u u 
2824A>G Thr942Ala CD2 paternal yes no u u no yes yes u yes yes u u u 
2923G>A Gly975Arg HD u u u yes yes u u u yes u yes u u u 
3242T>G lle1 081 Ser u u u u u u u u u u u u u u 
3751T>C Cys1251 Arg HD u yes yes u u u u yes yes u yes u yes u 
3949C>T Arg131 7Cys yes u u u u u u u u u u u u 
4850G>A Gly161 7Asp u u yes yes u u u u u u u u yes u 
4850G>A Gly161 7Asp not maternal yes yes u yes yes yes yes u u yes poss yes u 
4856G>T Gly1 619Val u no yes yes yes yes u yes yes u u u u u 
5894+5G>A ? u u u u u u u u u u u u u u 
591 5C>G Ala1 972Giy SANT paternal no yes no u yes u u no no u yes u u 
6290A>G Asp2097Gly u u u u u u u u u u u u u u 
6775G>A Aia2259Thr u u u u u u u u u u u u u u 
6777A>G Aia2259Ala not maternal yes u u no u yes yes u yes yes u u u 
7097T>G Leu5066Arg u u u no yes u u u yes u yes u u u 
7390A>G Lys2464Glu maternal u u u no u yes yes u yes yes no u no 
7463G>A Gly2488Asp paternal u u u u u u u u u u u u u 
841 6C>G Leu2806Val maternal no no yes u u u yes u u u poss u u 
841 6C>G Leu2806Val u u yes u u u u u u u u u u u 
6777A>G Ala2259Aia not maternal yes yes yes u u yes no u u yes yes u u 
VII, facial palsy; A, atresia of choanae; C, coloboma; CD, chromodomain; C(L)P, cleft lip and/or palate; del, deletion; E, ear anomaly; FD, feeding d ifficulties necessitating 
tube feeding; fs, frameshift mutation; G, genital hypoplasia; H, heart defect; HD, helicase domain; HL, hearing loss; mis, missense mutation; non, nonsense mutation; poss, 
possibly; prob, probably; RG, retarded growth; RD, retarded development; SANT, SANT domain; splice, splice site mutation; SCC, semicircu lar canal hypoplasia; TE, tracheo· 
oesophageal anomaly; U, unknown; -, sib with features of CHARGE syndrome but unknown CH07 status; •, sibs with CHD7 mutation; 1, UV found together with a frameshift 
mutation (c.791 _792del; p.Leu264fs). 
Supplementary Table S2. The domains of CHD7: localisation, sizes and mutations 



















971 -1 258 
964-1 1 65 
1 294-1 464 
1 962-2021 
2564-. . .  
. . .  -2686 
NCBI EMBL-EBI 1 
Amino acids Amino ocids 
801 -862 801 -861 
883-935 883-934 
971 -1 256 971 -1 256 
987-1 1 36 964-1 1 65 
1 290-1 412 1 325-1 404 
1 962-2021 
2562-2604 2562-2606 





1 294-1 464 
2564-261 3 
2642-2686 









971- 1 256 
987-1 1 36 








971 -1 258 
964-1 1 65 
1 290-1 464 
1 962-2021 
2562-261 3  
2641 -2686 
'This table shows the predicted size of CHD7 domains from Uniprot (www.uniprot.org/uniprot/Q9P2D1 ), Alamut (mutation interpretation software, version 1 .5), NCBI 
Protein (reference sequence NP _060250.2) and EMBL-EBI (European Bioinformatics Institute, www.ebi.ac.uk/interpro/, protein accession: Q9p2d1 ). The EMBL-EBI database 
gives more than one prediction for several domains, these additional predictions are depicted in the columns EMBL-EBI 2 and 3. The smallest region of overlap and largest 


















(1\ "" B. The number and percentage of mutations per domain 
Domain Percentage of CHD7" Number of mutations 
Smallest region - Largest region (%) Smallest region-Largest region (N) 
CDl 2.0 -2.3 38 -39 
CO2 1 .7 -2.3 9 -1 3  
Helicase N and DEXDc 9.5 -9.6 1 00 - 1 01 
Helicase C 2.7 -5.8 33 -55 
SANT 2.0 -2.0 1 8  - 1 8  
BRK1 1 .4 • 1 .7 4 -6 
BRK2 1 .5 - 1 .5 20 ·21 
Total 20.9 -25.5 222 -253 
b Percentage of CHD7 = the number of amino acids in each domain / the total number of amino acids of CHD7 (N=2997) 
Percentage of mutations' 
Smallest region- Largest region (%) 
4.8 -4.9 
1 . 1  -1 .6 





28.0 -3 1 .9 
' Percentage of mutations = the number of pathogenic mutation in each domain / the total number of pathogenic mutations in CHDl (excluding whole or partial gene 
deletion and translocation, N=792). 
CD = chromodomain (chromatin organisation modifier domain); Helicase N = helicase N-lobe; DEXDc = DEAD-like helicase superfamily including an ATP-binding domain; 




Supplementary Table S3. Benign variants detected in CHD7' 
CHD7 variant Exon NCBI SNP MAP Inherited' Other Phenotype of Number of Reference database mutation• Index' controls' 
c.1 09A>T p.Met37Leu 2 + CH 
c.21 6T>C p.Tyr72Tyr 2 rs1 6926453 0.0048 u fs CH ,. 
c.277A>G p.Thr93Ala 2 + CH 
c.307T>A p.Serl 03Thr 2 rs41 272435 0.0155 + fs, mis, horn CH 1 2  lll.26,63 
c.309G>A p.Serl 03Ser 2 rsl 1 5293759 0.0055 u CH ,. 
c.350G>A p.Glyl l 7 Asp 2 + CH 6J 
c.363T>G p.Gly121 Gly 2 rs791 58412 u CH 
c.500C>T p.Pro 1 67Leu 2 rs61 742851 u CH 
C: 
c.657C>T p.Gly21 9Gly 2 rsl 1 3483301 0.0201 u CH ,. s g. 
c.71 2G>A p.Val238Met ,. ::, 2 u CH C: 
c.71 2G>C p.Val238Leu 2 u fs CH Cl.. 
c.715C>G p.Leu239Ala 2 u fs CH 0 ::, 
c.856A>G p.Arg286Gly 2 rs6199571 3 u CH lb 
c.101 8A>G p.Met340Val 2 rs41 305525 0.0053 + non CH, SC 3, 2/69 SC 20,26,.60,70 
c.1 1 05C>G p.Pro369Ala 2 + CH ,. lb 
c.1 1 79A>G p.Pro393Pro 2 rsl 1 1 238892 u CH lb 5· 
<:: 
c.1 323T>G p.Gly441Gly 2 u CLP 2 37 0 
c.1 397C>T p.Ser466Leu 2 rs71 640285 u CH 6 20.26.37 Cl.. 
5· 
c.1 467A>G p.Gln489Gln 2 rs71640286 u C 1 20 
� 
c.1 536A>G p.Pro51 2Pro 2 u CH ,. 
c.1 565G>T p.Gly522Val 2 + hom CLP, CH 1 2  26,37 '§ 
c.1571A>C p.Hls524Pro 2 rs78962949 u CH a" a, 3 l,oJ c.1579T>G p.Ser527 Ala 2 u CLP 2, 1 /92 CLP V lb 
-
(I\ f"\ .;. c.1 632C>G p.Pro544Pro 2 rs45536935 u SC 4/69 SC 70 
c.1 665+34G>A p.? intron 2 rs7836586 0.2 1 14  + fs, non, del SC, CH 13/69 SC 17,S.4.70.77 
c.1 786C>A p.Gln596Lys 3 rs75653665 u CH !'J 
c.1 803G>A p.Lys601 Lys 3 rs74999330 u CH 
c.1 907G>T p.Gly636Val 3 + non CH " 
c.2049G>A p.Lys683Lys 3 rs781 07494 u CH 
c.2050_2055dupAAAGCA p.Lys684_ 3 + del CH 3 Ala685dup 
c.2053_2058dupGCAAAA p.Ala685_ 3 + del, non CH 3 Lys686dup 
c.2067G>A p.Thr689Thr 3 rs34979623 0,0024 u CH 
c.2096+ 1 SinsA p.? intron 3 rsl 1 1577577 u u 
c.21 24T>C p.Ser708Ser 4 rs79302359 0.0127 u CH "' 
c.2230G>A p.Gly7445er 4 u mis CH 26,60 
c.2238+39G>A p.? mtron 4 rs4540437 0.1351 u SC, CH 1 3/69 SC 17,70,71 
c.2361 C>A p.Ser787Ser 5 u CH " 
c.2376+49insTGGACT p.? lntron 5 rs33909822 u CH 
c.2376+41G>A p.? intron 5 rs74407310 u u 
c.2376+42insTGGACT p.? intron 5 rsl l 2021443 u u 
c.2376+43insTGGACT p.? lntron 5 rs35504039 + fs CH ... 
c.2376+48insTGGACT p.? intron 5 rs5891 777 + non, fs CH 
c.2376+49A> T p.? intron 5 rs77952475 u u 
c.2377-3dupT p.7 lntron 5 u u .. 
c.2436A>T p.Lys81 2Asn 6 rs61978638 0.0060 u CH 
c.2442+38A> T p.? mtron 6 rs41272438 0.0163 u CH 1 7  O.lO 
c.2443-43C> T p.? mtron 6 rs74693288 0.0052 u u 
c.2614-48C>G p.? intron 8 rs79276682 0.0690 u u 
c.2614-45G>A p.? intron 8 rs6471902 0.1852 u CH " 
c.2831 G>A p.Arg944Hls 1 0  rsl 1 7506164 0.0077 + CH ,. 
c.2957+20C>T p.7 intron u CH 1 1  
c.3201 +21T>G p.7 intron 0,0075 u CH 1 2  
c.3202-5T>C p.? intron 0,1505 u CH " 1 2  
c.3379-33A>G p.7 intron rs45461 501 u CH ,. 1 3  
c.3522+ 1 3T>A p.7 intron u fs CH 1 4  
c.3523-39C>G p.? intron 0,01 1 u CH " 1 4  
c.3523-35C>G p.7 intron rs41 272442 0.0588 CHO 1 4  + non 
c.3778+ 1 7C> T p.7 intron rs 1 1 1 863846 0.0044 u u 1 5  
c.3879G>A p.Val1 293Val 16 u CH 
c.4533+34T>C p.7 intron u fs CH 19  s: 
intron C: c.4533+46A>G p.7 rs7844902 0.1987 u non, fs, del CH " Q 19  
g. c.4534-13G> T p.7 intron rsl 14996731 u u 19  ::, 
C: 
c.4614T>C p.Ala 1 535Ala 20 u mis CH D 0.. 
c.4644+26C> T p.? intron rs1 1 5999896 u u 20 0 
intron ::, c.4644+36C> T p.? rs71 640287 u CH 1 ,. s-20 "' 
c.4780C>T p.Pro1 5945er 21 u fs CH 
c.5015C>T p.Ala1672Val 22 rs61737194 u CH " 
IQ 
intron "' c.5051 -4C>A p.? u CH 00 ::, 22 "' 
intron 5· c.5051 -4C> T p.? rs71640288 + mis CH 2 20.26.60 "' 22 0 
c.5147insGCCAGCTG p. 23 u fs CH ,. 
0.. 
c.5307C>T p.Ala 1 769Ala 25 rs1 6926499 0.0246 u CH ,. 5· 
I"'\ 
c.5404+41 C> T p.7 lntron rsl 1 5544727 u u s; 25 
intron (;) c.5607+27A>T p.? rs779881 97 u u n, 27 
c.5754T>C p.Thr1 918Thr 29 rs61 746542 u CH ::, 0.. 
°' c.5757C>G p.Ala19 19Ala 29 rs79203206 0.0086 u CH 3 V, "' 
-
CJ\ intron 9 OI c.5894+32C>G/T p.? rs41 265252 0.0100 u u 29 
intron c.5895-23A>G p.? u CH .. ;. 29 .... 
c.61 03+8C> T p.? 
lntron 
rs3763592 0.1391 fs CH 17,20,26 30 + 
c.61 1 1 C>T p.Pro2037Pro 31 rs41312170 0.0053 u CH 2 20,26 
c.6135G>A p.Pro2045Pro 31 rs6999971 0.0304 + non, fs CH B 20,26,63 
c.61 67C>A p.Arg2062Arg 31 u non CH " 
c.61 84C>T p.Arg2062Trp 31 u non CH 
c.6276G>A p.Glu2092Glu 31 rs2068096 0.1 1 84 + non,fs CH 1 2  17,20,26 
c.6282A>G p.Gly2094Gly 31 rs41 312172 0.0032 u non CH , 20,26 
c.6304G>A p.Val21 02lle 31 u CH 37 
c.6335C>T p.Thr21 1 2Met 31 + CLP 37 
c.6352A>G p.Asn21 1 BAsp 31 + CH 
c.6478G>A p.Ala21 60Thr 31 rs61 753399 0.0014 u mis CH ,. .. 
c.651 3C>T p.Ala21 71Ala 31 u CH 
c.6672C>T p.Gly2224Gly 31 u CLP 1 37 
c.6673G>A p.Ala2225Thr 31 u CH ,. 
c.6738G>A p.Glu2246Glu 31 rs61 729627 0.0632 u CH ,. .. 
c.6822T>C p.Ala2274Ala 32 rs61 743849 u CH " 
c.6843C>G p.Asp2281 Glu 32 u CH .. 
c.6924G>A p.Ser2308Ser 32 rs61 733338 0.0086 + non CH .. 
c.6936+29G>T p.? 
lntron 
rs78582735 u u 
32 
c.6936+35C> T p.? intron rsl l 2592072 u u 32 
c.6989G>C p.Gly2330Ala 33 rs77704609 u CH ,. 
c.6990C>T p.Gly2330Gly 33 rsl 1 6523071 u CH 
c.71 07C>T p.Val2369Val 33 u C 1 " 
c.7209G>A p.Arg2403Arg 34 rs61 74651 8  u u 
c.7243G>T p.Als241 5Ser 34 rs41315633 u u 
c.7278G>A p.Gln2426Gln 34 rsl 15546145 u u 
c.7356A>G p.Thr2452Thr 34 rs2272727 0.0382 + non, fs, del CH 17,JQ.M 
c.7471C>T p.Arg2491Cys 34 u spl CH 
c.7579A>C p.Met2527Leu 34 + CH ,. 
c.7590A>G p.Lys2530Lys 34 rs61 742801 0.0086 u CH ,. 
c.7830+44A>G p.? intron rsl l 54281 54 0.0143 u u 35 
c.7958G>A p.Arg2653Gln 36 + fs CH 
c.81 73A>G p.lfe2725Val 38 rsl 1 3877656 u u 
c.8199T>G p.Ala2733Ala 38 u CH 
c.8250T>G p.Phe2750Leu 38 rs3750308 u u 
c.8339C>T p.Ala2780Val 38 + CH 
c.8355C>T p.Ala2785Ala 38 u mis CH ,. 
c.8365G>A p.Ala2789Thr 38 u IHH 20 
c.8416C>G p.Leu2806Val 38 rs45521933 0.0045 + CH '6,00 
c.8569T>G p.Ser2857 Ala 38 u CH ,. 
c.8661G>A p.Pro2887Pro 38 u fs CH 6J 
c.8790C>T p.Ala2930Ala 38 rs61 736186 u CH 
c.8950C>T p.Leu2984Phe 38 + fs CH ,,.,. 
• Benign variants in the coding region and in the first or last SO nucleotides of an intron of CHD7 that have either been publ ished, or found by the RUNMC or ICMM, or 
published with frequency data in the NCBI SNP database 
b Minor allele frequency from NCBI SNP database (May 251h 201 1 )  or the literature 
' U, unknown;+, found in the parent or in one or more unaffected sibs of at least one index patient 
dThe type of pathogenic mutation that was found in combination with the benign variant in at least one index patient: fs, frameshift mutation; mis, missense mutation; 
horn, variant present in homozygous state; non, nonsense mutation; spl, splice site mutation 
• C, control; CH, CHARGE syndrome; CHD, congenital heart defect; CLP, cleft lip and/or palate; IHH, idiopathic hypogonadotropic hypogonadism; SC, scoliosis patient or 
parent; U, unknown 



















Chapter 2. 1 
Supplementary Methods 
DNA was isolated according to standard procedures. The 37 coding exons of CHDl (exons 2-38, 
RefSeq NM_0l 7780.02) and their flanking intron sequences were amplified by PCR and sequenced 
as described before. 1 3 Whole gene deletions and duplications were excluded by multiplex ligation­
dependent probe amplification (MLPA) using a commercially available set of probes, the SALSA 
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CHARGE syndrome is characterized by the variable occurrence of multi-sensory impairment, 
congenital anomalies and developmental delay, and is caused by heterozygous mutations in the 
CHDl gene. Correct interpretation of CHDl variants is essential for genetic counselling. This is 
particularly difficult for missense variants, because most variants in the CHDl gene are private and 
a functional assay is not yet available. We have therefore developed a novel classification system 
to predict the pathogenic effects of CHDl missense variants that can be used in a diagnostic 
setting. Our classification system combines the results from three computational algorithms (SIFT, 
PolyPhen-2 and Align-GVGD) with segregation and phenotypic data. The combination of different 
variables will lead to a more confident prediction of pathogenicity than was previously possible. 
Our classification was confirmed by studies using a structural model of the chromo- and helicase 
domains of CHD7. We have used our system to classify 145 CHDl missense variants. Our data show 
that pathogenic mutations are mainly present in the middle of the CHDl gene, whereas benign 
variants are clustered in the 5' and 3' regions. Finally, we show that CHDl missense mutations are in 
general associated with a milder phenotype than truncating mutations. 
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INTRODUCTION 
CHARGE syndrome is a clinically heterogeneous syndrome that is characterized by the occurrence 
of ocular t.oloboma, heart defects, 9tresia of choanae, retardation of growth and/or development, 
genital anomalies, and _gar anomalies often combined with deafness.' ... It is inherited in an autosomal 
dominant fashion (OMIM #214800). Most cases are sporadic due to de nova mutations but familial 
recurrence has also been described.' Previous studies have estimated that CHARGE syndrome has 
an incidence of 1/1 0,000 newborns,5·6 but we estimate that the incidence is lower, between 1/15,000 
and 1 /1 7,000, based on the number of CHDl mutations found in the Netherlands between 2006 
and 2009 (Janssen et al ., submitted). The major gene involved in CHARGE syndrome is CHDl and 
heterozygous CHDl mutations are found in more than 90% of the patients with typical CHARGE 
syndrome based on the clinical diagnostic criteria.5•7·9 Nonsense and frameshift mutations are the 
most prevalent variants in this syndrome with a frequency of 43% and 34%, respectively (Janssen 
et al ., submitted). Splice site mutations are found in 11 % of patients, while missense mutations are 
present in 9% of patients. Deletions and genomic rearrangements are rare events (3%). Although 
missense mutations in the CHDl gene are found in only a minority of patients, they can cause 
serious problems in genetic counselling. 
Variants that are expected to lead to a truncated protein (nonsense and frameshift mutations 
and deletions) are considered to be pathogenic (disease causing), because they are highly likely to 
result in haploinsufficiency. The interpretation of missense variants, however, can be difficult, as they 
can be either pathogenic or benign. The interpretation of the consequences of a missense variant is 
especially difficult in rare diseases, like CHARGE syndrome, in which most mutations are private. A 
functional assay would be very helpful in the classification of missense variants, but is not available 
for CHD7. In order to analyze the consequences of missense variants, computational algorithms 
have been developed.10These are mostly based on multiple sequence alignments of a protein across 
species, with mutations at conserved positions being more likely to disrupt protein function, and/ 
or on the nature of the specific amino acids involved. Each algorithm has its unique strengths and 
weaknesses. Therefore, it is worthwhile to combine different algorithms to increase the accuracy of 
the prediction. 1 1 • 12 In addition, structural models, when available, can help in predicting the effect of 
a certain variant on the structural and binding properties of the protein.'1•11 Apart from these tools, 
segregation analysis can supply crucial information for classifying missense variants.18•19 
In this study, we present a novel classification system for CHDl missense variants that combines 
the results of three computational algorithms; SIFT,2°·21 PolyPhen-2,22•23 and Align-GVGD24•25 with 
segregation and phenotypic data. We have classified all the CHDl missense variants known to us 
(n=l 45). To study the reliability of our classification, we constructed a structural model of the CHD7 
chroma- and helicase domains and studied the effects of mis sense variants located in these domains 
on protein stability. Furthermore, we compared the clinical features of patients with a missense 
variant that we classified as 'probably pathogenic' with the features of patients with a truncating 
mutation in order to test our hypothesis that missense mutations are associated with a less severe 




PATIENTS AND METHODS 
Patients and CHD7 analysis 
For the classification, we included all CHDl missense variants reported in the l iterature before June 
1 5th 201 1 1 •7•9·'4•26-43 and the variants that were reported in the NCBI Single Nucleotide Polymorphism 
database (http://www.ncbi.nlm.niv.gov/SNP, dbSNP build 1 32) with frequency data (n=1 04, 
Supplementary Table 51 ). I n  addition, we included al l  unpublished missense variants that were 
found in the DNA diagnostic laboratories of the Radboud University Nijmegen Medical Centre 
(RUNMC), Nijmegen, the Netherlands and the Department of Cellular and Molecular Medicine 
(ICMM), the Panum Institute, University of Copenhagen, Denmark (n=41 ). CHDl analysis was 
performed as previously described7 and multiplex l igation-dependent probe amplification (MLPA) 
was performed if CHDl sequence analysis did not identify a mutation.44 Segregation of the CHDl 
variant was studied whenever possible. 
Genotype-phenotype correlation 
For the phenotypic comparison of patients with a CHDl missense mutation with those carrying 
a truncating mutation, we only included the patients who were analyzed at the RUNMC and the 
ICMM. In total, we compared the clinical features of 39 patients with a missense variant that we had 
classified as 'probably pathogenic' with the features of 3 1 5  patients with a truncating mutation (5 
patients with a deletion, 1 45 patients with a frameshift mutation and 1 65 patients with a nonsense 
mutation). Clinical data were gathered through questionnaires and/or retrospective chart review. 
x2-test and Fisher's exact test were performed to identify significant differences between the two 
groups of patients (significance level p<0.05). 
Assessment of possible splice effects 
We first screened al l  CHDl missense variants for possible splice effects using the splicing module of 
Alamut version 1 .5. This module contains four splice prediction programs; SpliceSiteFinder-Like,45 
MaxEntScan,46 NNSPLICE,47 and GeneSplicer.48 
Classification system for CHD7 missense variants 
Missense variants in the CHDl gene were analyzed with three computational algorithms that 
predict whether a variant is deleterious; SIFT, PolyPhen-2 and Align-GVGD (for further description, 
see below). The outcome of each of these three algorithms was scored as 0 (benign), +0.5 (possibly 
pathogenic), or + 1 (probably pathogenic). The scores of the three algorithms were then summed as 
previously suggested by McGee et a/.12 
In addition to the score of the algorithms (varying between 0 and +3), we integrated data from 
segregation analysis in our classification system (Table 1 ). If the variant of interest had occurred de 
novo in one patient with features of CHARGE syndrome, 3 points were added. If a certain variant 
had occurred de novo twice, or more often, in  patients with features of CHARGE syndrome, 4 points 
were added. If the variant was found in a first-degree relative of the index patient who also had 
features of CHARGE syndrome, 1 extra point was added. In contrast, 2 points were subtracted if the 
variant was found in one or more clinically well characterized persons without features of CHARGE 
syndrome, or if the variant was found in two or more persons reported to be normal, but for whom 
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Table 1 .  Novel classification system for CHDl missense variants 
Computational algorithms (summed score between O and +3) 
SIFT: tolerated = 0, not tolerated = + 1 
Polyphen: benign = 0, possibly damaging = +0.S, probably damaging = + 1 
Align-GVGD: CO = 0, Cl 5/C25/C35 = +0.5 and C45/C55/C65 = + 1 
Segregation analysis (summed score between -10 and +SJ 
Variant occurred de novo in one patient with features of CHARGE syndrome = +3 
Variant occurred de novo twice, or more often, in patients with features of CHARGE syndrome = +4 
Variant present in a first-degree relative with features of CHARGE syndrome = + 1 
Asymptomatic carrier of the varianf = -2 
Variant found in a homozygous state = -5 
Variant found in combination with a pathogenic CHDl mutation' = -3 
Prediction based on total summed score (total score between -10 and +8) 
Probably benign: total score 0 or less 
Unknown: total score between 0 and +4 
Probably pathogenic: total score +4 or more 
• this category includes variants that are present in one or more clinically well characterized persons without 
features of CHARGE syndrome, or variants that are found in two or more persons reported to be normal, but 
for whom no detailed clinical information was available (e.g. controls reported in the NCBI SNP database or not 
thoroughly investigated family members) 
• a pathogenic CHDl mutation is defined as a truncating, missense or splice site mutation in the CHDl gene that 
is clearly pathogenic (this category does not include unclassified variants or benign variants) 
no detailed clinical information was available (e.g. controls reported in the NCB I  SNP database or not 
thoroughly investigated family members). Five points were subtracted if the variant was found in a 
homozygous state (th is because homozygous mutations are presumed to be lethal). Three points 
were subtracted if the missense variant was found in combination with a clearly pathogenic CHDl 
mutation, i.e. a truncating, missense or splice site mutation. 
Total scores could vary between -10 and +8. Variants with a negative score or 0 were classified as 
'probably benign; those with a score between 0 and +4 were classified as 'unclassified variants (UV); 
and those with scores of +4 and higher were classified as 'probably pathogenic ' ( Table 1 ). 
In our classification system, absence of the missense variant of interest in control chromosomes 
is not integrated because the variant should be absent in a very large number of controls ( >  1000), 
before the variant can be classified as probably pathogenic. This is an effect of the individual rarity 
of CHDl missense variations.18 
SIFT 
The S IFT algorithm, �orting Intolerant .Erom Tolerant, is available at http://sift.jcvi.org. S IF T  uses 
the PS I-BLAST algorithm to find functionally related protein sequences and then creates a protein 
sequence alignment of multiple species.20-11 Prediction is based on the evolutionary conservation 
of the affected residue and the type of amino acid substitution. The S IFT score is calculated with 
position-specific scoring matrices with Dirichlet priors and ranges between 0 and 1. S IFT scores less 
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than 0.05 are predicted to be deleterious and scores greater or equal to 0.05 are predicted to be 
tolerated. For our classification system, we scored an output of'tolerated' as O and an output of'not 
tolerated' as + 1 .  
PolyPhen 
PolyPhen-2, Polymorphism Phenotyping program version 2, is available at http://genetics.bwh. 
harvard.edu/pph2/. PolyPhen-2 is an update from PolyPhen23 and relies on sequence-based and 
structure-based features.22 For this study, version 2.2.0 (r364) of PolyPhen-2 was used. The source 
of the sequence and structure information were UniProtKB/UniRef100 release April 5th 201 1 and 
PDB/DSSP Snapshot April 6th 201 1 ,  respectively. HumVar-trained PolyPhen-2 was developed for 
diagnostic work in Mendelian diseases. PolyPhen-2 calculates the Naive Bayes posterior probability 
that a certain variant is damaging and gives estimations of the false-positive and true-positive rates. 
Based on the model's false-positive rate, a quantitative classification (benign, possibly damaging, or 
probably damaging) is given. If data are lacking, the PolyPhen-2 outcome is reported as 'unknown'. 
For our classification system, we assigned a score of O to variants that were predicted to be 'benign; 
a score of +0.5 for variants that were 'possibly damaging' and a score of + 1 for variants that were 
'probably damaging'. None of the CHDl missense variants that we entered in PolyPhen-2 had 
'unknown' as an outcome. 
Align-GVGD 
Align-GVGD is avai lable at http://agvgd.iarc.fr/agvgd_input.php. Align-GVGD combines protein 
sequence alignments of multiple species with the biophysical characteristics of amino acids to 
calculate the range of biochemical variation among amino acids found at a given position in the 
al ignment (Grantham variation). In addition, the biochemical distance of the mutant amino acid 
from the observed amino acids at a particular position in different species is calculated (Grantham 
deviation).24•25 A grade, varying from CO to C65, is given to estimate the probability that a certain 
variant is pathogenic. For our classification system, CO was scored as 0, Cl 5, C25 and C35 were 
scored as +0.5, and C45, CSS and C65 were scored as + 1 .  
Structural model of the CHD7 chromo- and helicase domains 
No experimentally derived structures of the CHD7 chroma- and helicase domains are available 
as yet and we therefore constructed a structural model for these domains. We did not perform 
structural analysis of the SANT a nd BRK domains of CHD7, because only three of the 1 45 missense 
variants were identified in these domains. Template structures for the homology modelling of 
the CHD7 chroma- and helicase domains were selected from the protein database using BLAST 
(Supplementary Table 52).49 54 We used the X-ray structure of the yeast chromatin remodeler Chd1 
(3MWY) as a basis for our structural model and for a l l  subsequent analyses, because it shows the 
chroma- and helicase domains in  a single structure.52 Multiple sequence al ignments and structura l  
a lignments of the CHD7 target structure and the template structures were performed using 
Expresso/T-Coffee.55•56 The homology models of the CHD7 protein were constructed using YASARA 
Structure version 1 1 .4 . 18 using standard settings. A short combined steepest descent and simulated 
annealing minimization using constraints on aligned backbone atoms was performed, followed by 
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a full unrestrained simulated annealing minimization for the entire model using the YASARA2 force 
field.57-59 Modelling of the CHDl variants and the assessment of the effect on CHD7 stability was 
performed using the FoldX protein design a lgorithm,60•61 (Stricher F et a/., manuscript in preparation) 
as described previously. 13•15·17 
RESULTS 
Classification of CHD7 missense variants 
A complete overview of all 145 missense variants in the CHDl gene is supplied in Supplementary 
Table S 1. As a first screen, we ran the splice prediction programs and determined that 1 2  of the 145 
missense variants might have an effect on splicing. However, as we were unable to confirm the splice 
prediction with RNA studies, we classified these variants with our scoring system to see whether the 
amino acid substitution had a pathogenic effect. Using our scoring system (see methods section 
and Table 1 ), 43 variants had a score <?4 and were classified as 'probably pathogenic' (30%, with five 
variants possibly affecting splicing), 69 variants had a score between O and 4 and were classified 
as 'UV' (48%, with seven variants possibly affecting splicing), and 33 variants had a score so and 
were classified as 'probably benign' (23%) (Supplementary Table S 1 ). Our classification agreed well 
with most of the classifications of the 1 04 previously reported variants (Table 2). In fact, it was 
only discordant for two variants, p.Val21 02lle and p.Ala2789Thr. We had classified both variants as 
'probably benign; but they had previously been reported as pathogenic14•32 (Supplementary Table 
5 1 ). 
Table 2. Our classification of 1 04 CHDl missense variants versus the classification as reported in the literature 
Classification as reported in the literature 
Pathogenic UV dbSNP Benign Total 
Our classification Pathogenic 30 1 0 0 31 
UV 1 0  29 7 4 50 
Benign 2 5 2 14  23 
Total 42 35 9 1 8  1 04 
dbSNP, variant solely reported in the NCBI SNP database; UV, unclassified variant 
Most CHDl missense variants were identified in only one person, but 38 variants were recurrent 
(26%). Of these recurrent variants, 15/38 were classified as 'probably pathogenic' (including four 
variants possibly affecting splicing), 9/38 as 'UV' (including two variants possibly affecting splicing) 
and 1 4/38 as 'probably benign'. Four benign variants (p.Ser103Thr, p.Met340Val, p.Gly522Val 
and p.Phe2750Leu) were found in many persons (n> 15). Two of these variants (p.Ser103Thr 
and p.Gly522Val) were found in homozygous states and are therefore surely benign (mice with 
homozygous Chdl mutations die in early embryogenesis62). The four most frequently occurring 
pathogenic missense mutations were each found in more than three index patients (p.lle1028Val, 
p.Gln1214Arg, p.Gly2108Arg, and p.Arg2319Cys). Five pathogenic missense mutations were 
possibly implicated in familial CHARGE syndrome: p.Ser834Phe,31 p.Leu2074Pro (the CHDl mutation 
was identified in the current study, but the clinical features of the affected siblings were previously 




The 1 45 CHDl missense variants were distributed throughout the entire coding region of 
the CHD7 gene, as shown in Figure 1 .  The variants that we classified as 'probably benign' were 
predominantly located in the 5' and 3' regions of the CHDl gene and those classified as 'probably 
pathogenic' were found in the middle of the gene. Forty-five variants were located In, or were in 
very close proximity to, functional domains of CHD7; 1 1  in the chromodomains, 31 in the hel icase 
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Figure 1. The distribution of 1 45 different missense variants over the coding region of the CHDl gene (the 
variants were found in 322 index patients or controls). The missense variants are divided into five categories: 
'probably pathogenic; 'probably pathogenic with a possible effect on splicing; 'UV; 'UV with a possible effect 
on splicing' and 'probably benign'. The variants are scattered over the entire CHDl gene, but the 'probably 
pathogenic'variants are located in the middle, whereas the'probably benign'variants are predominantly present 
in the 5' and 3' regions of the CHDl gene. 
n, number of times that a variant was found in an index patient or control; ·, variant possibly affecting splicing. 
Structural modelling of CHD7 variants 
Modelling of the CHD7 chromo- and helicase domains 
We constructed a structural model of the CHD7 chromo- and helicase domains using the template 
structures that are shown in Supplementary Table 52. One X-ray structure of the yeast chromatin 
remodeler Chd1 (3MWY) contains both chromo- and helicase domains in a single structure.52 We 
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used this X-ray structure as the basis for our structural model and for al l subsequent analyses (Figure 
2). Additional models were built using the other templates mentioned in Supplementary Table 52 
to aid or confirm the sequence alignment, to aid in side chain placement, and to explore possible 
structural variants. Our structural model shows the two chromodomains capping the DNA-binding 
cleft between the N-terminal and (-terminal lobe of the helicase domain and has the two helicase 
lobes relatively spaced far apart with residues of the (-terminal lobe not making any direct contact 
with AT P (Figure 2). Like the yeast Chdl structure, the CHD7 model shows an acidic helix connecting 
chromodomain 1 and 2 that interacts with a basic patch on the (-terminal helicase lobe. This 
suggests that CHD7 might employ a similar mechanism to discriminate between nucleosome-DNA 
substrates as that proposed for the yeast Chdl structure.52 
CD1 TrpMoey. 
Figure 2. Structural model of the CHD7 chrome- and helicase domains {amino acids 799 - 1 464) based on the 
3MWY X-ray structure of yeast chromatin remodeler Chdl S.l and additional template structures {Supplementary 
Table 52). Our structural model shows the two chromodomains capping the DNA-binding cleft between the 
N-terminal and (-terminal lobe of the helicase domain and has the two helicase lobes relatively spaced far apart 
with residues of the (-terminal lobe not making any direct contact with ATP. Chromodomain 1 {CDl ) is blue, 
chromodomain 2 {CO2) is green, the helicase N-lobe {HD N) is yellow, the helicase C-lobe {HD C) is red and 
the linkers between the domains are grey. The ATP-binding domain is depicted in cyan (located in the helicase 
N-lobe) and the missense variants are shown in purple. A: Missense variants that were predicted to have a 
deleterious effect on protein stabil ity. Many are located in the core of the protein. B: Missense variants that were 
predicted to have a minor effect on protein stability. Many are located at the surface of the protein or in the 
linker between chromodomain 2 and the helicase N-lobe. C: p.Asn1 0305er and p.Glnl 395His: possible effect on 
ATP-binding; p.Glu871 Asp, p.lle1 028Val and p.Arg 13 1 7Cys: undetermined effect on protein stability. {see color 
image on page 234-235) 
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Structural assessment of the effect of CHD7 variants 
Based on the "wild-type" model described above, FoldX was used to create structural models of the 
different CHDl variants and estimate their effect on the structural stability of the CHD7 chromo­
and helicase domains. The effect of the different missense variants was classified either as l ikely to 
have a minor effect, or likely to have a detrimental effect on the structural stabi lity of the protein. 
Mutations increasing the calculated Gibbs free energy with more than 1 kcal/mol were considered 
to be potentially 'detrimental'. For the calculation, the main focus was on the terms that describe 
increases in energy due to Van derWaals clashes (mutation to a larger residue in the protein core), or 
to a loss in Van derWaals energy (mutation to a smaller residue in the protein core), or unfavourable 
salvation (mutation from a hydrophobic residue to a hydrophilic residue in the protein  core). An 
increase in energy due to the loss of a hydrogen bond was ignored, due to the high dependence on 
accurate atom positions of the hydrogen-bond donor and acceptor. Apart from effects on structural 
stability, the position of the mutation in the structure was also taken into account: was it in close 
proximity to the ATP binding site or was a known interaction motive a ltered? 
The prediction based on our classification system was largely confirmed by the predicted 
effects ofthe CHO7variants on protein stabil ity in our structural model. Of the 42 CHDl variants that 
were located in the chromo- or helicase domains, 21 were labelled as 'probably pathogenic' by our 
classification system (Supplementary Table 51, Figure 2). Of these 21  variants, 19 were found to have 
a likely detrimental effect; on protein stability (n=1 7) or on ATP binding (n=2, p.Asn1 030Ser and 
p.Gln 1 395His). p.Asn1 030Ser was found to be in close proximity to the ATP binding site in the N-lobe 
of the hel icase domain and p.Gln1 395His was found on the opposite side in the C-lobe (Figure 2). 
Although not in direct contact with ATP, the latter variant is located next to p.Arg1 399, which in 
homologous structures is considered to function as one of the Arginine finger residues involved 
in stabilizing the transition state of ATP. Therefore, these two variants could Influence the ATPase 
activity of the helicase domain and are predicted to be 'detrimental'. The effect on protein stabil ity 
of the remaining two variants that we classified as 'probably pathogenic' could not be determined 
(p.l le1 028Val and p.Glu871 Asp). No direct effects on phosphorylation or interaction motives were 
found for any of the variants. The variants that we classified as 'probably pathogenic' were very often 
located in the core of the CHD7 protein ( 1 7/21 variants). We classified only one variant (p.Arg944His), 
located in  the chromodomaln, as 'probably benign' and our structural model also predicted it would 
have a minor effect on protein stabil ity. The remaining twenty variants in the chroma- and helicase 
domains were classified as 'UV; because they lacked segregation or phenotypic data. Structural 
modelling showed that nine of these variants were possibly detrimental, 1 0  variants had only 
a minor effect (4 of these variants were located in  the l inker between chromodomain 2 and the 
helicase N-lobe) and one variant had an undetermined effect on protein stability. 
Genotype-phenotype correlation 
The clinical data of the patients who had CHDl analysis done at the RUNMC or ICMM were used 
to compare the phenotype of patients with a missense variant that we classified as 'probably 
pathogenic' (n=39) with that of patients with a truncating mutation in the CHDl gene (n=31 S) 
(Table 3). The patients with a truncating mutation more often fulfilled the clinical criteria of Blake et 
a/5 and Verloes8 (p=0.01 7 and p=0.03 1 ,  respectively). In addition, cleft lip and/or palate (p=0.041 ), 
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choanal anomalies (p=0.009) and congenital heart defects (p<0.001) were present significantly 
more often in patients with a truncating mutation compared to those with a missense mutation. 
Furthermore, trachea-oesophageal anomalies were borderline significant (p=0.052), with more 
frequent occurrence in the patients with a truncating mutation. The other clinical features were not 
significantly different between the two groups. In conclusion, missense mutations were in general 
found to be associated with a milder phenotype compared to truncating mutations. 
Table 3. Phenotypic comparison of patients carrying a CHDl missense mutation with patients carrying a CHDl 
truncating mutation 
Patients with a CHDl Patients with a CHD7 Comparison 
missense mutation truncating mutation p-value 
(n=39)" (n=315)" 
Blake criteria 57. 1% 85.5% 0.0 17  
(8/14)' (1 06/124)' 
Verloes criteria 71 .4% 92.5% 0.03 1 
( 1 0/14) (1 1 1/1 20) 
Cleft lip and/or palate 30.4% 55.6% 0.04 1 
(7/23) (80/1 44) 
Choanal anomaly 28.6% 60.4% 0.009 
(6/21 )  ( 1 1 0/1 82) 
Heart defect 50.0% 82.5% <0.001 
(1 6/32) (21 2/257) 
Tracheo-oesophageal anomaly 1 3.0% 33.6% 0.052 
(3/23) (43/1 28) 
Coloboma and/or microphthalmia 75.8% 86.9% 0.1 1 0  
(25/33) (1 99/229) 
Cranial nerve dysfunction 81 .0% 90.8% 0.240 
( 1 7/21 )  (1 1 9/1 3 1 )  
Semicircular canal anomaly and/ 95.0% 1 00% 0.142 
or balance disturbance (1 9/20) ( 12 1/ 12 1 )  
External ear anomaly 96.6% 98.2% 0.463 
(28/29) (21 7/22 1 )  
Kidney anomaly 26. 1 %  37.6% 0.348 
(6/23) (44/1 1 7) 
• 39 missense variants that were classified as 'probably pathogenic' 
• 3 1 5  truncating mutations; 5 deletions, 1 45 frameshift mutations, 1 65 nonsense mutations 
• Due to lacking clinical data, the number of patients is lower than the total number of patients 
DISCUSSION 
A novel classification system for CHD7 missense variants 
It is important to classify missense variants accurately as either benign or pathogenic, because of 
the clinical implications. Patients harbouring a pathogenic CHDl mutation should be screened for 
additional features of CHARGE syndrome, for example, hypogonadotropic hypogonadism, heart and 
kidney defects (see surveillance scheme in 1) . Early detection and treatment of hypogonadotropic 
hypogonadism is important, because this will reduce the risk of osteoporosis.29 In addition, 
genetic counselling is indicated to inform the patient and the parents about reproductive options. 




about CHD7 function. A good classification of CHDl missense variants, however, is difficult. The 
absence of a particular missense variant in the control population is often used for confirmation 
of pathogenicity. However, most CHDl missense variants are found only once, even in cohorts of 
more than 1 000 patients, and therefore very large numbers of controls should be screened before 
the missense variant can be classified as 'probably pathogenic'.18 A control group of that size is 
currently not available, but the 1 000 genome project a nd the Dutch genome project will l ikely 
supply useful data. In addition, a val idated functional model can be very helpful in  the classification, 
but such a model is currently not available, due to the complexity of CHD7 function. To overcome 
these problems, we have developed a novel classification system that can be used in a diagnostic 
setting. Our system combines different variables: the results of three computational algorithms, 
segregation and phenotypic data (Table 1 ). It wil l  therefore increase the reliability of predictions. We 
used our system to classify a l l  known missense variants (n=l 45) and were able to classify 43 variants 
as 'probably pathogenic; 69 as 'unknown; and 33 as 'probably benign'. The specificity and sensitivity 
of our classification is not known, because a gold standard does not exist. However, combining the 
output of different algorithms is known to increase the predictive value64 and segregation data are 
widely accepted as a valuable source of information for the classification of missense variants.18 In 
addition, our classification was largely in agreement with the predicted effects on protein stabil ity in  
the structural model of the CHD7 chroma- and helicase domains that we constructed and was also 
frequently in agreement with predictions from the literature (Table 2). 
According to our classification system, a variant is considered 'probably pathogenic'when it has 
occurred de nova twice, or more often, in  patients with features of CHARGE syndrome, or when the 
variant has occurred de nova in  one patient with features of CHARGE syndrome and is predicted to be 
deleterious according to at least one computational algorithm. A variant that has a deleterious effect 
according to all three computational algorithms and is present in a patient and a first-degree relative 
with features of CHARGE syndrome is also predicted to be 'probably pathogenic'. Considering that 
many diagnostic laboratories conclude that every de nova variant is pathogenic, we are confident 
that a variant classified as 'probably pathogenic' with our more conservative approach is very likely 
to be a true pathogenic mutation. We classify a variant as 'probably benign'when there are no clues 
to suggest pathogenicity from either the computational algorithms or segregation data or when the 
segregation data suggest that the variant is probably benign. This means that there is a chance that 
a variant that we classified as 'probably benign; might later receive the label 'probably pathogenic; 
if future studies show that the variant has occurred de novo twice, or more often, in patients with 
features of CHARGE syndrome. Two variants that we classified as 'probably benign; p.Val2 1 02lle 
and p.Ala2789Thr, were previously reported as pathogenic missense mutations.14·32 Both variants 
were found in an index patient with few features of CHARGE syndrome; p.Val2 1 02l le was found in 
a patient with a cleft palate a nd a congenital heart defect, and p.Ala2789Thr was found in a patient 
with hypogonadotropic hypogonadism and myopia. Because both variants were predicted to be 
'benign' by the three computational algorithms and segregation data were not available, the total 
summed score was 0, leading to our classification of'probably benign'. Neither variant was located 
in the chromo- or helicase domain and therefore structural modell ing was not performed by us. 
However, Ala2789Thr was predicted to be deleterious according to a structural model of CHD7 that 
was constructed by Kim et a/.14 
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Unfortunately, we had to classify many variants as'UV' (69/145=48%), due to a lack of segregation 
data (n=41) or of phenotypic data of the carrier parent (n=23). For five variants, these data were 
available, but we still had to classify the variant as 'UV'. Four of these five variants were predicted 
to be pathogenic according to the computational algorithms, but segregation data suggested 
that the variants were benign. Additional segregation and phenotypic data from patients and/or 
controls can ultimately lead to a correct classification of all missense variants. The locus-specific 
CHDl mutation database (available at www.CHD7.org65) provides a valuable source of information, 
as it contains both segregation and clinical data. Clinical data are very important, because the 
phenotype of patients who undergo CHDl analysis in a clinical diagnostic laboratory is not always 
highly suggestive of CHARGE syndrome.28 On the contrary, many patients have only a few features 
of CHARGE syndrome and CHDl analysis is performed to exclude a diagnosis of CHARGE syndrome. 
The prior chance of finding a pathogenic CHDl mutation in this group is therefore much lower than 
in the group of patients with typical CHARGE syndrome. 
The computational algorithms gave discordant predictions in 34% (50/145 variants, 
Supplementary Table 5 1 ). However, when all three computational algorithms gave the same 
prediction, this is usually, but not always, in agreement with our classification: 1 1  variants were 
predicted to be 'benign' by the three algorithms and also by our classification, but of the 58 variants 
that were considered 'probably pathogenic' by the three algorithms, we classified 32 as 'probably 
pathogenic; 25 as 'UV' and one as 'probably benign'. The variant that we classified as 'probably 
benign; p.Arg2062Trp, was found in combination with a nonsense mutation. It is possible that the 
missense variant and the nonsense mutation had both occurred on the same allele and therefore 
both could be pathogenic, although this is highly unlikely. Unfortunately, segregation data were not 
available for this patient and we could therefore not establish whether the missense variant was in 
trans with the pathogenic mutation. Based on our findings, complete reliance on the computational 
algorithms seems unadvisable. 
Segregation data in combination with phenotypic data are reasonably reliable, but one should 
be aware that a variant that segregates with the disease is not always pathogenic, because the 
missense variant may be in linkage disequilibrium with an unidentified pathogenic mutation. 
When interpreting segregation data, the possibility of phenocopies, variable expressivity and non­
paternity should be considered. The presence of a CHDl variant in the NCBI SNP database does not 
necessarily mean that the variant is benign, because there is always a chance that a mildly affected 
patient with CHARGE syndrome could have been included in the NCBI SNP cohorts.18 
Our system mainly classifies missense variants according to the predicted effect of the amino 
acid substitution. However, missense variants, as wel l as synonymous changes, can also have a 
deleterious effect on splicing, because the variant can be located in, or close to, a splice site, or 
it can create a novel splice site. Of the 145 missense variants that were assessed in this study, 12 
were predicted to have a possible effect on splicing according to the splice prediction programs 
(12/145=8%). RNA studies should be performed to confirm the splice effects. As CHDl is hardly 
expressed in leucocytes or fibroblasts, confirmation of the splice prediction can best be performed 




Distribution of CHD7 missense variants 
The CHDl missense variants were present in the entire coding region of the CHDl gene (Figure 1 ,  
Supplementary Table S 1 ). The variants that we classified a s  'probably pathogenic' were all located 
in the middle of the CHDl gene. Those that we classified as 'probably benign' were predominantly 
located at the 5' and 3' ends of the CHDl gene: 25/33 'probably benign'variants were found in amino 
acids 1 -750 and 2320-2997 (Figure 1 ). The 5' end of the CHDl gene is only weakly to moderately 
conserved among species and both the 5'and 3'ends ofthe CHD7 protein do not contain functionally 
important domains. 
Structural model of chromo- and helicase domains 
We constructed a structural model of the chroma- and helicase domains of the CHD7 protein, based 
on d ifferent template structures (Figure 2, Supplementary Table 52). Unfortunately, there was a low 
percentage sequence identity (approximately 30%) between the target sequence and most of the 
template sequences. This increases the risk of alignment errors, resulting in the construction of 
faulty structural models. However, a structural superposition of structures of several chroma- or 
helicase domains derived from distantly related organisms showed that many structural features of 
these domains are particularly well conserved despite remote ancestry and divergent functionality. 
For example, the N- and (-terminal lobe of the zebra fish Rad54 SWI2/SNF2 chromatin-remodelling 
domain can be superimposed with less than 2-2.5 A root mean square deviation over 1 20-200 
(-alpha atoms on the equivalent domains of yeast chromatin remodeler Chd l and on the SWl2/ 
SNF2 ATPase core domain of the Archaea Su/folobus solfataricus. For the chromodomains, the same 
trends were observed upon structural superimposition. This indicates that sufficiently accurate 
models can be constructed of the conserved regions and that the location of many of the CHDl 
variants can be predicted with reasonable accuracy. FoldX was used to create structural models of 
the d ifferent CHD7variants and estimate their effect on the structural stabil ity of the CHD7 chromo­
and helicase domains. Because the accuracy of the energy prediction by FoldX depends on the 
exact position of the amino acid atoms in a structure, the accuracy of our prediction is more l imited 
than in previous works,13•15•1 6  due to the use of models based on low sequence identity between 
target and template, and the low resolution of the available template structures. 
Because of the somewhat l imited predictive accuracy of our structural model, we used it 
solely for confirming the predictions made by our classification system. The predictions from 
the structural model were largely in agreement with our classification. The variants that we had 
classified as 'probably pathogenic' had a l ikely detrimental effect on protein stabil ity and were 
frequently located in the core of the CHD7 protein. In addition, the variants that were predicted to 
have a minor effect on protein stability were frequently located at the surface of the CHD7 protein. 
A previous study constructed a structural model of the (-terminal part of the CHD7 protein and 
concluded that variants in the loop regions were likely detrimental, because of their possible effects 
on the structural and binding properties of the CHD7 protein.14 This is in contrast to our model, 
where five CHDl missense variants located in loop regions were all predicted to have a likely minor 
effect on protein stabi l ity (Supplementary Table 5 1 ). No direct effects on interaction motives or 
phosphorylation could be identified. 
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Genotype-phenotype correlation 
CHARGE syndrome is extremely variable and the phenotype cannot be predicted from the genotype. 
However, when comparing the clinical features of patients with a CHDl missense mutation with 
patients with a truncating mutation, we have shown that missense mutations are, in general, 
associated with a milder phenotype (Table 3). This association is also seen in other syndromes, e.g., 
Rett syndrome.66Three features were found significantly more often in the patients with a truncating 
mutation: cleft lip/palate, choanal anomalies, and congenital heart defects. The features that are 
almost always present in CHARGE syndrome (external ear anomalies, cranial nerve dysfunction 
and balance disturbance caused by semicircular canal anomalies 1), do not occur significantly more 
often in patients with a truncating mutation. This was to be expected, because these features are 
frequently seen in very mildly affected patients.1 •31,37,39,67 
CONCLUSION 
We have developed a novel classification system to predict the pathogenic effects of CHDl missense 
variants that can be used in a diagnostic setting. In our classification system we have combined the 
outcome of SIFT, PolyPhen-2 and Align-GVGD with segregation data and phenotypic data of carriers 
of a CHDl missense variant. The combination of different variables will lead to a more confident 
prediction of pathogenicity than was previously possible. Our classification was confirmed by 
studies in a structural model of the chromo- and helicase domains, which showed that pathogenic 
mutations were frequently located in the protein core and were predicted to reduce the stability 
of the CHD7 protein. We have used our system to classify 145 CHDl missense variants and have 
made our data available in the locus-specific CHDl mutation database (www.CHD7.org). Ongoing 
submission of new segregation and phenotypic data will contribute to a better classification, in 
particular for those CHDl missense variants that we have classified as UV. CHDl missense variants 
were found scattered throughout the entire coding region of the CHDl gene, with pathogenic 
mutations found in the middle of the CHDl gene and the benign variants clustered in the 5' and 3' 
regions. Finally, we showed that CHDl missense mutations are, in general, associated with a milder 
phenotype than truncating mutations. 
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Supplementary Table 5 1 .  Classification of 1 45 missense variants in the CHDl gene 
00 
00 
CHD7variant Domain' SIFT" Poly Align Score # controls• # index 
Phen-2' GVGD algorithms• patients' 
c.1 09A>T tolerated/0.23 benign co 0 0 1 CH 
p.Met37Leu /0.001 
c.123G>A not tolerated benign co 1 0 1 CH 
p.Met41 lle /0.002 
c.1 64A>G not tolerated benign co 1 0 1 KS 
p.HisSSArg /0.023 
c.215A>G not tolerated benign co 1 0 1 CH 
p.Tyr72Cys /0.247 
c.257C>G not tolerated poss co 1 .5 0 1 CH 
p.Pro86Arg /0.253 
c.277A>G tolerated/1.0 benign co 0 0 1 CH 
p.Thr93Ala /0 
c.295G>C not tolerated benign co 1 0 1 CH 
p.Ala99Pro /0. 156 
c.307T>A not tolerated benign co 1 1 5  10 CH, 
p.Serl 03Thr /0.013 3 KS/HH 
c.350G>A not tolerated poss co 1 .5 0 1 CH 
p.Glyl l 7 Asp /0.545 
c.SOOC>T not tolerated benign co 1 1 0 
p.Prol67Leu /0 
c.602A>G not tolerated benign co 1 0 4 CH 
p.Gln201 Arg /0 
c.71 2G>A tolerated/0.25 benign co 0 0 1 CH 
p.Val238Met /0.002 
c.71 2G>C tolerated/0.16 benign co 0 0 1 CH 
p.Val238Leu /0 
c.71 5C>G not tolerated benign co 1 0 1 CH 
p.Pro239Ala /0.066 
c.760C>G not tolerated benign co 1 0 1 CH 
p.Gln254Glu /0.004 
c.856A>G not tolerated benign co 1 1 0 
p.Arg286Gly /0.043 
c.101 8A>G not tolerated benign co 1 5 1 1  CH, 




























Total summed Effect on the 
score ; stability of 
classification' the CHD7 
protein' 
-2 ;  benign 
1 ; UV 
1 ; UV 
1 ; UV 
l .5 ; UV 
0 ;  benign 
1 ; UV 
-9 ; benign 
-3.5 ; benign 
1 ; UV 
1 ; UV 
O ;  benign 
-3 ; benign 
-2 ; benign 
1 ; UV 
1 ; UV 






















c.1 1 05C>G tolerated/0.1 3 benign co 0 0 1 CH 3 family -2 ; benign ,. 
p.Pro369Ala /0.066 members 
carrier ):, 
c.13 1 5C>T not tolerated benign co 1 0 1 CH u 1 ; UV cs ::, 0 
p.Pro439Ser /0.1 1 2  i 
c.1 397C>T not tolerated benign co 1 4 3 CH, 1 CLP, parent carrier -1 ; benign ,,. xn, cs 
p.Ser466Leu /0.001 1 KS/HH "' "' 
c.1 531T>G not tolerated benign co 1 1 1 CLP u 1 ; UV n " 
p.Leu51 1 Val /0.052 Q 5· 
c.1 565G>T not tolerated poss co 1 .5 1 3  3 CH, u -, homo -5.5 ; benign , .. ,. cs ::, 
p.Gly522Val /0.622 1 3 CLP � "' 




c.1 579T>G not tolerated benign co 1 2 1 CLP u -1 ; benign " -0 
p.Ser527 Ala /0.008 lb 
c.1 672C>G not tolerated benign co 1 0 2 CH u 1 ; UV ". CS �-
p.Pro558Ala /0.066 s-
lb 
c.1 786C>A not tolerated benign co 1 6 0 u -1 ; benign dbSNP -0 Q 
p.Gln596Lys /0.008 s-
c.1 907G>T tolerated/0.40 co 1 CH -2.5 ; benign " 0 poss 0.5 0 u + 
p.Gly636Val /0.622 ::, ;:;· 
c.2095A>G not tolerated benign co 1 0 2 CH u 1 ; UV cs lb 
p.Ser699Gly /0.013 " 
c.2096G>C not tolerated benign co 1 0 1 CH u 1 ; UV ,. ct 0 
p.Ser699Thr /0.013 .... 
c.21 82G>A not tolerated benign co 1 0 1 CH u 1 ; UV ,. 
p.Asp 728Asn /0.139 ..... 
c.21 94C>G not tolerated benign co 1 0 1 CH parent carrier 1 ; UV ' 3 j;;• 
p.Pro732Ala /0.1 36 lb ::, 
c.2230G>A not tolerated prob co 2 0 4 CH poss poss 0 or-1 ; benign 111. 41 "' lb 
p.Gly7445er /0.968 unaffected i§ 
parent carrier ::!. Q 
c.2436A>T C01 loop not tolerated prob C65 3 2 4 CH unaffected 1 ; UV minor dbSNP, CS ::, 
p.Lys81 2Asn /0.988 parent carrier 3· 
c.2501C>T COl core not tolerated prob C65 3 0 1 CH, 1 HH de novo in 6 ;  pathogenic detrimental 101 n 
p.Ser834Phe /0.998 affected parent � 
:,:, 
c.2520G>C C01 core not tolerated prob C65 3 0 1 CH de novo 6 ; pathogenic detrimental cs 
p.Trp840Cys /0.999 � 
c.261 3G>T co, not tolerated poss C35 2 0 1 CH de novo 5 ;  pathogenic undeterm 7ll ::, 
p.Glu871Asp surface• /0.560 a" 
00 3 
\I) c.2680A>G CO2 not tolerated poss C55 2.5 0 1 CH parent carrier 2.S ; UV minor ,. lb 
,.Thr894Ala surface /0.850 
-
c.2720A>C CD2 not tolerated prob C65 3 0 1 CH u 3 ; UV minor JI 
p.Lys907Thr surface* /0.999 
9 0 c.2750C>T CD2 core not tolerated prob C65 3 0 1 CH parent carrier 3 ; UV minor 
p.Thr91 7Met /1 .000 
c,281 3G>A CD2 not tolerated benign C25 1 . 5  0 1 CH u 1 .5 ; UV minor " 
p.Arg938Lys linker /0.21 1  "' 
surface* 
c.2824A>G CD2 not tolerated benign co 1 0 1 CH parent carrier 1 ; UV minor cs 
p.Thr942Ala linker /0.04 /0.021 
loop 
surface 
c.2831 G>A CD2 not tolerated benign C25 1 .5 2 1 CH parent carrier -0.5 ; benign minor ", dbSNP 
p.Arg944His linker /0.185 
loop 
surface 
c.2840G>A CD2 not tolerated prob C35 2.5 0 1 CH parent carrier 2.5 ; UV minor ,. 
p.Arg947Gln linker /0.986 
loop 
surface 
c.2923G>A HD N not tolerated prob C65 3 0 1 CH u 3 ; UV detrimental cs 
p.Gly975Arg core /1 .000 
c.2936T>C HD N not tolerated prob C65 3 0 1 CH de novo 6 ;  pathogenic detrimental " 
p.Leu979Pro core /0.994 
c.2947T>G HD N not tolerated prob C65 3 0 1 CH u 3 ; UV detrimental ., 
p.Trp983Gly core /0.968 
c.3005A>G HD N not tolerated prob C35 2.5 0 1 CH de novo 5.5 ; pathogenic detrimental " 
p.Gln1 002Arg core /0.990 
c.3059T>C HD N not tolerated prob C65 3 0 2 CH de novo 6 ; pathogenic detrimental ••, cs 
p.Leu 1 020Ser core /0.991 
c.3082A>G HD N not tolerated prob C25 2.5 0 7 CH >1 de novo 6.5 ; pathogenic undeterm "·41•719129 (same patient), 
p.lle1028Val core /0.981 cs 
c.3089A>G HD N ATP not tolerated prob C45 3 0 1 CH de novo 6 ;  pathogenic ATP binding 30 
p.Asn 1 030Ser binding /0.995 
cleft 
c.3091T>C HD N not tolerated prob C65 3 0 1 CH de novo 6 ; pathogenic detrimental cs 
p.Trp1 031 Arg core /0.999 
c.3091T>G HD N not tolerated prob C65 3 0 1 CH de novo 6 ; pathogenic detrimental 39 
p.Trp1031Gly core /0.998 
c.3242T>G HD N not tolerated prob C65 3 0 1 CH u 3 ; UV detrimental cs 
p.lle1081Ser core /0.998 
c.3245C>A HD N not tolerated prob C55 3 0 1 CH de novo 6 ;  pathogenic detrimental cs 
p.Thrl 082Asn core /0.999 
c.3301T>C HD N not tolerated prob C65 3 0 2 CH >1 de novo 7 ; pathogenic detrimental ,. 
p.Cys 1 1 01 Arg core /0.998 
c.3302G>A HO N not tolerated prob C65 3 0 1 CH u 3 ; UV detrimental ,,,. (same patient) 
p.Cys 1 101Tyr core /0.998 
c.3340A>T HO N not tolerated prob C65 3 0 1 CH u 3 ; UV minor 29 :i,. 
p.Asn1 1 1 4Tyr loop /0.999 0 
surface i 
c.3607G>C HO C not tolerated prob C25 2.5 0 1 CH u 2.5 ; UV minor ,. 6:" 
p.Glu1 203Gln core /0.998 "' "' 
c.3623T>A HO C not tolerated prob C65 3 0 1 CH u 3 ; UV detrimental ,. 
p.Val1 208Asp /0.995 core iS· 
c.3641A>G HO C not tolerated prob C35 2.5 0 4 CH >1 de novo 6.5 ; pathogenic detrimental 29·", cs ::, 
p.Gln1214Arg core /0.959 � "' 
c.3751T>C HOC not tolerated prob C65 3 0 1 CH u 3 ; UV detrimental cs 3 
p.Cys1251 Arg core /0.998 0 
c.3770T>G HO C not tolerated prob C65 3 0 1 CH de novo 6 ;  pathogenic detrimental ,,.,,. (same patient) 
p.Leu 1 257 Arg core /0.997 "' 
c.3875T>C HO C not tolerated prob C65 3 0 1 CH de novo 6 ;  pathogenic detrimental cs � 
p.Leu 1 292Pro core /0.997 
c.3881T>C HO C not tolerated prob C65 3 0 2 CH de novo 6 ;  pathogenic detrimental "'" 
p.Leu 1 294Pro core /0.997 
c.3905T>C HO C not tolerated prob C65 3 0 1 CH de novo 6 ;  pathogenic detrimental " "' 
p.Leu 1 302Pro core /0.962 ::, ;:;· 
c.3949C>T HO C not tolerated prob C65 3 0 1 CH parent carrier 3 ; UV undeterm cs "' 
p.Arg 13 1 7Cys surface /0.978 
c.3952T>C HO C not tolerated prob C65 3 0 1 CH de novo 6 ;  pathogenic detrimental cs � 0 
p.Cys1318Arg core /0.951 .... n 
c.3965T>C HO C not tolerated prob C65 3 0 1 CH u 3 ; UV detrimental " 
p.Leu 1 322Pro core /0.976 " 
3 
c.3973T>G HO C not tolerated prob C65 3 0 1 CH de novo 6 ;  pathogenic detrimental ,. .;;· "' 
p.Tyrl 325Asp core /0.942 "' 
c.4033C>T HO C not tolerated prob C65 3 0 1 CH parent carrier 3 ; UV detrimental ,. "' 
p.Arg 1 345Cys surface* /0.999 cl 
c.4034G>A HO C not tolerated prob C25 2.5 0 1 CH de novo 5.5 ; pathogenic detrimental cs �-
p.Arg1345His surface* /0.999 � 
c.4185G>C HD C ATP not tolerated prob C15  2.5 0 2 CH >1 de novo 6.5 ; pathogenic ATP binding ,.,., 5· n 
p.Glnl 395Hls binding /0.997 ::i:: 
cleft :i,. ::0 
c.4247C>G HO C not tolerated prob C65 3 0 1 CH u 3 ; UV detrimental ,. Cl n, 
p.Thr141 6Arg core /0.965 � 
c.4369A>C HO C not tolerated prob C45 3 0 1 CH parent carrier 3 ; UV minor 11 
p.Lysl 457Gln surface /0.993 0 
� 3 c.4406A>G not tolerated prob C65 3 0 1 CH de novo 6 ;  pathogenic ,,,. (same patient) "' 
,.Tyrl 469Cys /0.996 
.. 
c.4529C>G not tolerated poss C55 2.5 0 1 CH u 2.5 ; UV " 
p.Alal510Gly /0.901 
c.4727T>G not tolerated benign C65 2 0 1 CH u 2 ; UV ,. 9 
p.Phe 1 576Cys /0.1 06 
c.4774C>T not tolerated prob C65 3 0 1 CH parent carrier 3 ; UV .., � 
p.Arg 1 592Trp /0.974 
c.4780C>T not tolerated poss C65 2.5 0 1 CH u + -0.5 ; benign cs 
p.Pro 1 594Ser /0.757 
c.4787A>G not tolerated prob C65 3 0 3 CH de nova 6 ; pathogenic 26.41•7129 (same patient) 
p.Asp 1 596Gly /0.941 
c.4849G>A not tolerated prob C55 3 0 1 CH u 3 ; UV ,. 
p.Glyl 61 75er /0.969 
c.4850G>A not tolerated prob C65 3 0 2 CH u 3 ; UV cs 
p.Glyl 61 7 Asp /0.992 
c.4856G>T not tolerated prob C65 3 0 1 CH u 3 ; UV cs 
p.Gly161 9Val /0.972 
c.4929C>G not tolerated prob C65 3 0 1 CH u 3 ; UV ., 
p.Cysl 643Trp /0.992 
c.501 5C>T not tolerated benign C65 2 1 0 u 2 ; UV dbSNP 
p.Ala1 672Val /0.004 
c.5050G>A not tolerated prob C55 3 0 3 CH >1 de novo 7 ;  pathogenic ""', CS 
p.Glyl 684Ser /0.969 
c.521 6T>G not tolerated benign C65 2 0 1 CH de nova 5 ;  pathogenic " 
p.Leu 1 73gArg /0.463 
c.5222G>C not tolerated prob C65 3 0 1 CH de nova 6; pathogenic ,. 
p.Arg1 741 Pro /0.972 
c.5225T>A not tolerated prob C65 3 0 1 CH de nova 6 ;  pathogenic 41 
p.Val1 742Asp /0.962 
c.5234T>C not tolerated prob C65 3 0 1 CH de nova 6 ;  pathogenic " 
p.Leul 745Pro /0.960 
c.5373C>A not tolerated prob C35 2.5 0 1 CH parent carrier 2.5 ; UV ,. 
p.Aspl 791Glu /0.969 
c.5390G>T not tolerated prob C65 3 0 1 CH de nova 6 ;  pathogenic cs 
p.Glyl 797Val /0.998 
c.5402A>C not tolerated prob C65 3 0 1 CH de nova 6 ;  pathogenic "" (same patient) 
p.Hisl 801 Pro /0.935 
c.5405G>A not tolerated prob C65 3 0 1 CH de nova 6 ;  pathogenic 40 
p.Glyl 802Asp /0.990 
c.5434G>C not tolerated prob C65 3 0 1 CH de nova 6 ;  pathogenic cs 
p.Aspl812His /0.997 
c.5435A>G not tolerated prob C65 3 0 1 CH de nova 6 ;  pathogenic cs 
p.Asp 181 2Gly /0.992 
c.5436C>A not tolerated prob OS 2.5 0 1 CH de novo 5.5 ; pathogenic 
p.Aspl 81 2Glu /0.978 
c.5444T>C not tolerated prob C65 3 0 2 CH de novo 6 ; pathogenic ", CS ):,, 
p.Leul81 5Pro /0.984 ::, 0 
<: 
c.5597A>G not tolerated poss co 1 .5 0 3 CH de novo 4.5 ; pathogenic ", cs !t 
p.Asp1866Gly /0.856 " "' 
c.5848G>A not tolerated benign css 2 0 1 CH parent carrier 2 ; UV ,. "' 
5, 
p.Ala 1 950Thr /0233 " 
C, 
c.591 5C>G SANT not tolerated poss C55 2.5 0 1 CH unaffected O.S ; UV cs 5· 
p.Ala 1 972Gly /0.840 parent carrier ::, 
c.61 84C>T not tolerated prob C65 3 0 1 CH u + 0 ;  benign cs � lb p.Arg2062Trp /0.990 3 
c.61 94G>A not tolerated prob C25 2.5 0 2 CH parent carrier 2.S ; UV ,. 0 
p.Arg2065His /0.995 '1J � 
c.6221T>C not tolerated prob C65 3 0 1 KS/CH affected sib 4 ; pathogenic 61, cs ;::;· 
p.Leu2074Pro /0.997 carrier � s-
c.6230G>A not tolerated poss C25 2 0 1 CLP parent carrier 2 ; UV JI .. 
p.Arg2077Lys /0.794 '1J C, 
c.6250A>G not tolerated benign css 2 0 1 CH u 2 ; UV " s-0 
p.Ser2084Gly /0.032 IQ .. 
c.6271T>C not tolerated prob C65 3 0 1 CH de novo 6 ; pathogenic cs ;::;· 
p.Trp2091 Arg /0.997 .. � 
c.6287A>G not tolerated prob C25 2.5 0 2 CH de novo 5.5 ; pathogenic ..... " ;;:-
p.His2096Arg /0.982 0 .... 
c.6290A>G not tolerated prob C65 3 0 1 CH u 3 ; UV cs 
p.Asp2097Gly /0.992 0 
'-l 
c.6304G>A tolerated/0.18  benign co 0 0 1 CH u O ;  benign " 3 
p.Val2102lle /0.005 i;;· "' 
not tolerated ,. .. c.6308G>A prob C65 3 0 2 CH u 3 ; UV ::, "' 
p.Gly21 03Asp /0.992 11> <: 
c.6322G>A not tolerated prob C65 3 0 4 CH >1 de novo 7 ; pathogenic "·"", (same patient), CS C, =:!. 
p.Gly21 08Arg /0.999 C, ::, 
c.6335C>T not tolerated prob C65 3 0 1 CLP parent carrier 3 ; UV " ;;:-5· 
p.Thr21 1 2Met /0.998 I"\ 
c.6347T>A not tolerated prob C65 3 0 1 KS/CH, >1 de novo 7 ; pathogenic ,..,. � 
p.lle21 16Asn /0.993 2 CH :ti C) 
c.6352A>G not tolerated Cl5 2 0 1 CH 2 family 0 ;  benign cs n, poss 
� p.Asn21 1 8Asp /0.560 members 
Q.. carrier ... 0 "° c.6478G>A tolerated/0.48 benign co 0 1 3 CH poss poss, -7 or -8 ; benign ,.,.,, dbSNP 3 
1,,1 
p.Ala21 60Thr /0.003 unaffected homo 11> 
parent carrier 
c.6673G>A tolerated/0.33 benign /0 co 0 0 1 CH u O ;  benign " 
':C.. 
p.Ala2225Thr 
c.6775G>A not tolerated benign co 1 0 1 CH parent earner 1 ; UV cs 
p.Ala2259Thr /0.02 /0.001 
c.6843T>G not tolerated benign C35 1 .5 0 1 CH poss poss -0.5 or- 1 .5 ; .. !-J 
p.Asp2281 Glu /0.106 unaffected benign 
"' 
parent earner 
c.6857G>C not tolerated benign C55 2 0 1 CH de novo 5 ;  pathogenic cs 
p.Gly2286Ala /0.095 
c.6935A>C not tolerated poss C65 2.5 0 1 CH u 2.5 ; UV C5 
p.Lys231 2Thr /0.826 
c.6955C>A not tolerated poss C65 2.5 0 1 CH affected parent - 3.S ; UV 39 
p.Arg231 9Ser /0.794 carrier 
c.6955C>T not tolerated prob C65 3 0 6 CH affected parent - 4 ;  pathogenic 7,28,32.33,38,-41 
p.Arg231 9Cys /0.930 and sib carrier 
c.6989G>C tolerated/0.09 prob co 1 6 1 CH u -1 ; benign 28, dbSNP 
p.Gly2330Ala /0.935 
c.7097T>G not tolerated prob C65 3 0 1 CH u 3 ; UV cs 
p.Leu2366Arg /0.923 
c.7243G>T not tolerated poss C65 2.5 2 0 u 0.5 ; UV dbSNP 
p.Ala241 5Ser /0.645 
c.7390A>G not tolerated benign C55 2 0 1 CH parent carrier 2 ; UV cs 
p.Lys2464Glu /0.01 5 
c.7463G>A not tolerated poss C65 2.5 0 1 CH 2 family 0.5 ; UV cs 
p.Gly2488Asp /0.61 1 members 
carrier 
c.7471 C>T not tolerated benign /0 C65 2 0 1 CH u + -1 ; benign cs 
p.Arg2491 Cys 
c.7485G>T not tolerated benign C65 2 0 1 CH parent carrier 2 ; UV 28 
p.Arg2495Ser /0.108 
c.7579A>C tolerated/0.1 5 benign co 0 0 7 CH parent carrier O ;  benign ",CS 
p.Met2527Leu /0.064 
c.7958G>A BRK2 not tolerated prob C35 2.5 0 1 CH parent carrier + -0.5 ; benign cs 
p.Arg2653Gln /0.946 
c.8047C>T BRK2 not tolerated prob co 2 0 1 CH parent carrier 2 ; UV " 
p.Pro2683Ser /0.985 
c.81 04C>T not tolerated prob C65 3 0 1 CH parent carrier 3 ; UV " 
p.Arg2702Cys /0.951 
c.8173A>G not tolerated benign co 1 1 0 u 1 ; UV dbSNP 
p.lle2725Val /0.421 
c.81 97G>A not tolerated poss co 1 .5 0 1 CH u 1 .5 ; UV " 
p_.Ala2733Thr /0.824 
� 
c.8250T>G not tolerated poss C15 2 1 8  0 u 0 ;  benign dbSNP 
p.Phe2750Leu /0.623 
c.8339C>T not tolerated benign C65 2 0 1 CH 3 family 0; benign cs 
p.Ala2780Val /0.095 members 
carrier 
c.8365G>A tolerated/0.26 benign co 0 0 1 HH u 0 ;  benign ,. 
p.Ala2789Thr /0.082 
c.8416C>G not tolerated poss C25 2 0 S CH poss poss 0 or-1 ; benign ll4\ C5 
p.Leu2806Val /0.726 unaffected 
parent carrier 
c.8569T>G tolerated/0.13 benign co 0 0 1 CH u 0 ;  benign " 
p.Ser2857 Ala /0.014  
c.8639C>T not tolerated benign C15  1 .5 0 1 HH u 1 .5 ; UV 
p.Pro2880Leu /0.02 /0.D15  
c.8791 G>A not tolerated benign co 1 0 1 CH parent carrier 1 ; UV " 
p.Val2931 Met /0.342 
c.8842A>G not tolerated benign co 1 0 1 KS u 1 ; UV ,. 
p.Lys2948Glu /0.05 /0.004 
c.8950C>T not tolerated benign co 1 0 4 CH unaffected + -4 ; benign ,.,,,. (same patient) 
p.Leu2984Phe /0.314 parent carrier 
Gray rows, possible effect on splicing 
• -, not in domain; CD, chromodomain; *, interface between chromo- and helicase domain; HD N, helicase domain N-lobe; HD C, helicase domain C-lobe 
b SIFT output: tolerated, SIFT score 2:0.0S; not tolerated, SIFT score <0.05; 'not tolerated' is 0, unless otherwise indicated 
' Polymorphism Phenotyping (PolyPhen) output: benign; poss, possibly damaging; prob, probably damaging; na·ive Bayes posterior probability that a certain variant is 
damaging 
d summed score of computational algorithms (Table 1 )  
• # controls, number of controls carrying the missense variant 
' #  index patients, number of index patients carrying the missense variant; CH, CHARGE syndrome; KS, Kallmann syndrome; HH, hypogonadotropic hypogonadism; SC/C, 
scoliosis or control (variants published by Gao et al"); CLP, cleft lip and/or palate 
9 U, unknown; parent carrier, unknown whether the carrier parent has features of CHARGE syndrome; poss u naffected parent carrier, the missense variant was found in the 
unaffected parent OR the missense variant was found in combination with a pathogenic CHDl mutation in the index patient (variants published by Vuorela eta/'') 
• -, no other CHDl mutation found in the index patient; +, missense variant found in combination with a clearly pathogenic CHDl mutation in the index patient; homo, 
missense variant found in the homozygous state 
' total summed score and classification according to our classification system (Table 1 )  
' undeterm, undetermined 
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I i  Supplementary Table S2. Template structures that were used for homology modeling of the CHD7 chrome- and helicase domains 
Template structure Domain PDB ID %Seq ID Resolution (A) Reference I i-...  
Human CHD6 chromodomain 2 CO2 2EPB 68% NMR 1 0.221 0/pdb2epb/pdb 
Yeast Chdl tandem chromodomains C01 &2 2H1 E 26% 2.2 " 
Human CHD1 tandem chromodomains C01 &2 2B2T 28% 2.45 50 
Yeast Chdl chromodomain CO2 2DY8 36% NMR " 
Human CHD4 chromodomain CO2 2EE1 32% NMR 1 0.221 0/pdb2ee1/pdb 
Zebrafish Rad54 SWl2/SNF2 chromatin-remodeling domain helicase 1 Z3I 30% 3 S4 
Sulfolobus solfataricus SWl2/SNF2 ATPase domain helicase 1 Z6A 29% 3 •• 
Yeast Chdl chromatin remodeler CD1 &2, helicase 3MWY 39% 3.7 n 
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CHARGE syndrome is a multiple congenital anomaly syndrome caused by mutations in the CHDl 
gene. Mutations in this gene are found in 60-70% of patients suspected of having CHARGE syndrome. 
However, if only typical CHARGE patients are taken into account, mutations in the CHDl gene are 
found in over 90% of cases. The remaining 10% might be caused by hitherto undetected alterations 
of the CHDl gene, including whole exon duplications and deletions that are missed by the currently 
used diagnostic procedures. Therefore we looked for these kinds of alterations by multiplex ligation­
dependent probe amplification in 54 patients suspected of having CHARGE syndrome without a 
CHDl mutation. In one patient a partial deletion of the CHDl gene (exon 13-38) was identified, 
while in the other patients no abnormalities were found. The frequency of exon deletions in our 
cohort was 1.9% (1 /54) and 5.6% (1 /18) in all patients and in typical CHARGE patients, respectively. 
We conclude that exon copy number alterations of the CHDl gene are not a major cause of CHARGE 
and CHARGE-like syndrome. 
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INTRODUCTION 
In 2004 the underlying gene defect for CHARGE syndrome (the CHDl gene, O MIM #214800) was 
identified on chromosome 8 (8q12.1).1 This multiple congenital anomaly syndrome was originally 
described as a combination of �oloboma, heart defects, �tresia of choanae, retardation of growth 
and/or development, genital hypoplasia and �ar anomalies and/or deafness.2 Later, additional 
congenital malformations were recognised, of which agenesis  of the semicircular canals and 
arhinencephaly were found to be present in nearly all patients.3 5 The prevalence is approximately 
1 in 10 ,000. CHARGE syndrome is diagnosed on clinical grounds according to two dif ferent sets of 
criteria as proposed by Blake eta/6 and Verloes,7 and/or analysis of the CHDl �hromodomain helicase 
QNA binding protein 7) gene. Three large, independent studies found heterozygous mutations in 
the CHDl gene in 60-70% of patients suspected of having CHARGE syndrome.8- 10 However, if the 
clinical criteria for CHARGE syndrome6•7 are strictly applied, mutations in CHDl are present in over 
90% of the typical CHARGE patients. 
The two sets of criteria used for diagnosing CHARGE syndrome, consist of phenotypic features 
that do not fully overlap (Table 1 ). Blake et al consider a patient as having typical CHARGE syndrome 
if four major, or three major and three minor, criteria are present.6 Based on new diagnostic insights, 
Verloes refined the criteria and included abnormalities of the semicircular canals! Besides, Verloes 
distinguished three categories of CHARGE syndrome patients: typical, partial and atypical. Verloes 
considered typical CHARGE patients to present with three major, or two major and two minor, 
criteria . Patients were considered to have partial CHARGE syndrome when two major and one minor 
criteria were present , while atypical CHARGE patients have two major and no minor criteria, or one 
major and three minor criteria. 
Most of the CHDl mutations that have been described in CHARGE syndrome are truncating 
(nonsense and frameshift), but missense mutations have also been found. Most mutations are 
unique, although some recurrent de novo mutations have been found. There seem to be no real 
mutation hot spots, but some exons (2 , 3, 31 and 34) are more frequently mutated than others (own 
unpublished data). The higher mutation frequency of these exons appears to be related to their 
size, with the largest exon 2 most frequently mutated. Until now, only one intragenic deletion has 
been reported in a CHARGE patient.' 1 Whole gene deletions of CHDl, although present in the two 
patients who contributed to the discovery of the CHDl gene, 1 were not found in two large cohorts 
of CHARGE patients.9·1 0 However, single exon deletions or duplications would have been missed 
with the techniques used in these studies. Since the underlying defect in the remaining 10% of 
typical CHARGE patients has not yet been discovered, we hypothesised that exon copy number 
alterations of the CHDl gene might contribute to CHARGE syndrome. We identified a cohort of 54 
patient s suspected of having CHARGE syndrome who did not have a CHD7 mutation. We screened 
for single exon deletions or duplications in the CHDl gene using multiplex ligation-dependent 




Table 1 .  Clinical criteria for identifying CHARGE syndrome patients 
Major criteria Minor criteria Inclusion rule 
Blake eta/6 1 .  Ocular coloboma or 1 .  Congenital cardiovascular Typical CHARGE: 
microphthalmia malformations 4 majors, OR 
2. Choanal atresia or stenosis 2. Tracheo-oesophageal 3 majors + 3 minors 
3. Characteristic external ear defect 
anomaly, or middle ear 3. Genita l hypoplasia 
malformations or mixed or delayed pubertal 
deafness development 
4. Cranial nerve dysfunction 4. Cleft lip and/or palate 
5. Developmental delay 
6. Growth retardation 
7. Characteristic face 
Verloes' 1 .  Ocular coloboma 1 .  Heart or oesophagus Typical CHARGE: 
2. Choanal atresia or stenosis malformation 3 majors, OR 
3. Hypoplasia of semicircular 2. Malformation of the inner 2 majors + 2 minors 
canals or external ear 
3. Rhombencephalic Partial CHARGE: 
dysfunction including 2 majors + 1 minor 
sensorineural deafness 
4. Hypothalamo- Atypical CHARGE: 
hypophyseal dysfunction 2 majors, but no 
5. Mental retardation minors, OR 
1 major + 3 minors 
MATERIALS AND METHODS 
Fifty-four patients were selected from a group of patients who were referred for mutation analysis of 
CHD7 because of clinical features suggestive of CHARGE syndrome. Mutation screening performed 
by polymerase chain reaction (PCR) followed by direct sequencing had not revealed any CHD7 
alterations in these patients.9The DNA samples were subsequently screened for exon deletions and/ 
or duplications of the CHD7 gene by MLPA analysis. Half of the patients (see Table 2) were analysed 
using home-designed synthetic oligonucleotides, covering all the coding exons of the CHD7 gene 
in four probe sets as described before.12 The other patients were screened with a commercially 
available set of probes, the SALSA P201 kit (MRC-Holland,Amsterdam, the Netherlands; http://www. 
mrc-holland.com). This set includes the usual control probes located on different chromosomes, 
together with probes for most exons of the CHD7 gene (27 of 38 exons). When exons were located 
closely together, one representative exon was chosen for the region. Because probes for both the 
first non-coding exon (exon 1 )  and the last exon (exon 38, containing the stopcodon) were included, 
both kits would also have detected whole gene deletions. 
The MLPA analysis as well as the statistical analysis was performed as described previously.12 A 
patient with a known heterozygous deletion of the whole gene was used as a positive control and 
we included two negative controls in each analysis. 
Clinical information on the 54 index patients was obtained from our investigations at the 
outpatient clinic for children with CHARGE syndrome or through the referring cl inicians, by means 
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of a written questionnaire submitted prior to DNA analysis. Additional information was requested 
when necessary. We scored patients for CHARGE features according to the two sets of criteria (Blake 
et a/6 and Verloes7) as summarised in Table 1. Patients were classified as typical CHARGE syndrome 
when they fulfilled the criteria for typical CHARGE of at least one of the two scoring sets. 
RESULTS 
In our cohort of 54 patients we found a deletion of exon 13-38 in patient no. 1 (Figure 1 ). In all other 
patients no exon copy number changes in the CHDl gene were found. 
An overview of the clinical features of patient no. 1 is given in Table 2 (see also Figure 2). The 
patient was born at 42 weeks of gestation with a birth weight of 3.685 kg. At birth right facial nerve 
palsy and dysmorphic ears were noted. In addition he had partial palsy of cranial nerves IX and X, for 
which he required tube feeding for one year. Choroid colobomas, hypoplasia of the pons and vermis 
of the cerebellum, severe bilateral mixed hearing loss, undescended testes and micropenis were 
present as well. At age 12 years, his height was 141.5 cm (-2 SD). He had a square and asymmetric 
face and proved to be anosmic by the University of Pennsylvania Smell Identification Test.13 
Unfortunately, imaging of the semicircular canals was not performed, but vestibular dysfunction 
was noted on physical examination. 
Our cohort proved to be phenotypically heterogeneous, varying from typical CHARGE patients 
to partial and atypical patients and patients only suspected of having CHARGE syndrome. Table 2 
gives an overview of their clinical features and scores according to Blake et al's and Verloes' criteria. 
Eighteen patients had typical CHARGE syndrome (according to Blake et al (n=5), Verloes (n=7) or 
both (n=6)). Four patients had partial CHARGE, 26 had atypical CHARGE syndrome according to 










Figure 1 .  Example of an MLPA analysis (SALSA P201 kit) with 1 3  different DNA samples from (suspected) CHARGE 
patients. On the X-axis the probes of the different exons are named (01 - ti l l  28-, representing exon 1 till 38 ofthe 
CHDl gene, and 29- till 36-, control probes that have two genomic copies in the normal population). On the 
Y-axis are the normalised values (see Koolen et al for details12), 1 means that two copies are present, 0.5 means 
that only one copy is present. The sample marked with triangles is patient no. 1 with the partial deletion of the 




Table 2. Clinical features of 54 patients suspected of having CHARGE syndrome but with no mutation in the 
CHDl gene 
Case Sex• Age• Diagnostic Major criteria Minor criteriah 
criteria 
yr Blake Verloes' Eye Atresia of Cranial nerve Ear SCC9 
anomaly<' choanae• dysfunction' anomaly 
1 M 1 2  + C Vll, Vlll, IX, X + + AN, B, CF, GH 
2 M 2 + + C, Mi - (CLP) VIII + + MR, S 
3 *  F 10  + + C s VIII H, MR, RG, S 
4 *  F 21 + + C A Vll,VIII + B, H, HHD, GH, MR, R 
5 *  M 2 d  + + C, Mi - (CLP) u + u CF, H, S,TE 
6 F 3 + + C s VI II + u MR 
7 F + + - (CP) VIII + + CF, H, RG 
B M 1 0  + a C VII I  + u B, CF, GH, MR 
9 F 7 + a Mi A VIII + u B, CF, MR, S 
1 0 *  F 14  + a A VIII + u H, MR, RG, S 
1 1  * M 3 + a A (CP) VIII + u B, H, MR 
12 * F 4 + a C VI, VII, VIII, IX, XII + u CF, GH, H, MR 
13 * F 29 + C, Mi A + u MR 
1 4 *  F 6 + C + + H, MR, R, S 
1 5  M + C A u + u H 
16  F 2B + C, Mi A VIII u u H, MR, 5  
1 7  F ½ + C, Mi - (CP) u + u TE 
1 8  * M 3 + C, Mi - (CP) VIII u GH, MR 
1 9  M 7 p C, M i  - (CP) + u 
20 F 4 p Mi s VIII + B 
21 F 1 6  p C, Mi - (CP) u u u H, RG 
22 F 1 3  p C, Mi A u u u MR, RG 
23 * M 46 a C VII I  + u MR 
24 * M 1 a A + u B, GH, H, R, S 
25 * F 3 a A VI II + u B, CF, MR 
26 * M ½ a A VIII + u H, S 
27 * M 2 a C + u H, MR, RG 
28 * M 36 a C vm u B, GH, H, HHD 
29 * F 1 1  a C u H, MR, R, 5 
30 M 39 a C, Mi u H, MR, RG, S 
31 M 1 1  d - a A + u B, CF, H 
32 * F 2 a Mi - (CLP) + u B, H 
33 * F 1 2  a C, Mi + u B, MR, RG 
34 * M ¼ a A + u B, H, R 
35 * F 29 a A VII.VIII S,TE 
36 F 4 a A + u B, MR, RG 
37 * M 2 a C H, MR 
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38 * F 3 a A H, MR 
39 M 4 a A + u H, MR, RG 
40 M 3 a C, Mi VIII u B, CF, H, R, RG 
41 F 5 a C, Mi  VIII u GH, H, MR, 5  
42 F a C VIII u H, MR, 5 
43 F 1 1  a C, Mi  + u GH, H, R, RG 
44 F 8 a C u H, MR 
45 F 3 a A VIII + H, MR, S  
46 F 4 a A (CP) + u CF, H, MR, S 
47 F 1 1  a C + u MR, RG 
48 F 3 a - (CPJ + u H 
49 * F 22 VIII + u H, HHD, S 
so * F 6 Vll, VIII + B, H, MR,TE 
51  * M 8 C, Mi u H, R, RG 
52 * M 9 A u H 
53 F 1 0  VI II + u CF, MR, R, 5, TE 
54 M 4 - (CLP) u H, R 
The patient with the partial CH07 deletion is depicted in bold. 
*The patients that were screened with home-designed synthetic oligonucleotides are indicated with an asterisk. 
The other patients were analysed with the SALSA P201 MLPA kit. 
• F, female; M, male. b d, day; yr, year. ' a, atypical; p, partial. d C, coloboma; Mi, microphthalmia. • A, atresia of 
choanae; CLP, cleft lip and palate; CP, cleft palate; 5, stenosis of choanae. Presence of CLP or CP was counted as 
a major criterion, because this rarely occurs together with atresia of choanae. ' U, unknown. 0 SCC, semicircu lar 
canal hypoplasia or vestibular dysfunction h AN, anosmia; B, brain abnormalities; CF, characteristic face; H, heart 
defect; GH, genital hypoplasia; HHD, hypothalamo-hypophyseal dysfunction; MR, mental retardation; R, renal 
abnormality; RG, retarded growth; 5, skeletal abnormality; TE, trachea-oesophageal abnormalities. 
Figure 2. Photographs of patient no. 1 with a partial deletion of the CHD7 gene at 1 2  years and 3 months of 
age. Note square face with facial palsy and microcornea (both right-sided), dysplastic ear with typical triangular 





A defect in  the CHDl gene is found in 60-70% of all patients suspected of having CHARGE syndrome 
and in over 90% of typical CHARGE patients.9 In the remaining 1 0% of typical patients the cause of 
CHARGE syndrome remains elusive. Genetic heterogeneity could be present, but the only other 
gene that has been implicated in CHARGE syndrome, the SEMA3E gene, was found to be mutated in 
only one CHARGE patient.14 So far, mutations in this gene have not been reported in other CHARGE 
patients. It seems therefore more plausible to assume that CHDl is the major causative gene, 
considering the small percentage of typical patients in  whom no mutation is found. 
CHARGE patients normally u ndergo only a routine sequence analysis, which would miss any 
mutations located deep in the intrans or in the promotor region of the CHDl gene. In addition, whole 
exon deletions or duplications would not be detected. Hitherto, only three CHARGE patients have 
been described with a genomic rearrangement leading to a deletion of the whole CHDl gene.1•15·16 
Whole gene duplications are not likely to cause CHARGE syndrome. Based on the mutations found 
so far (predominantly leading to a truncated protein) and on the presumed function of CHDl, the 
identified mutations most l ikely have a loss-of-function effect. This, however, does not rule out 
single exon dupl ications, which would result in a distortion of the reading frame, as a cause of 
CHARGE syndrome. 
So far no intragenic duplications and only one patient with an intragenic deletion of exons 
8-1 2 has been reported. 11 The described intragenic deletion was detected by multiplex PCR/liquid 
chromatography assay and appeared to have arisen through an Alu-mediated replacement event. 
This patient was one of a cohort of 1 3  typical CHARGE patients studied by Udaka et al, which leads 
to an exon deletion frequency of 7.7% ( 1/1 3). Another study, by Vuorela et al, did not find CHDl 
deletions with quantitative real-time PCR and MLPA analysis in 44 CHDl mutation negative patients.'7 
Unfortunately they did not supply the clinical characteristics of their patients and therefore it is not 
known how many typical CHARGE patients were included in their cohort. 
In our cohort of 54 patients suspected of having CHARGE syndrome without CHDl alterations 
on routine sequencing, we found one patient with a deletion of exons 1 3-38. In the other patients 
no exon copy number changes of the CHDl gene were found by MLPA analysis. Our patient with 
the partial CHDl deletion could clinically not be distinguished from the patients with normal MLPA 
results. One of the used MLPA kits (SALSA P201 ) did not cover al l  exons of the CHDl gene directly. 
However, exons missing in this MLPA kit are located close to exons that are represented in the kit. 
Very small deletions or dupl ications (within exons) will be missed using MLPA analysis in general, 
but bigger copy number variations are detectable with both MLPA kits. 
The frequency of exon deletions in our cohort was 1 .9% ( 1 /54) and 5.6% ( 1 /1 8) in al l  patients 
and in typical CHARGE patients, respectively. The latter figure is in accordance with the finding of 
Udaka et al . However, it should be noted that the classification of our CHARGE patients is based on 
the ava i lable cl inical information. Unfortunately in 42 patients imaging of the semicircular canals 
has not been performed. This means that the 25 patients who satisfied the Verloes' criteria for 
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atypical or partial CHARGE could in theory have typical CHARGE in the presence of semicircular 
canal anomalies. If we take this precaution into account, the frequency of partial CHD7 deletions in 
typical CHARGE patients without a mutation in CHD7 is 2.3-5.6% (1 /43-1 /18) according to our study. 
Since we did not detect any exon copy number alterations in the 36 non-typical patients, it 
seems that M LPA analysis of the CHD7 gene does not significantly improve the mutation analysis for 
this group of patients. In typical CHARGE patients however, we do recommend MLPA analysis of the 
CHD7 gene, even though the frequency of partial CHD7 deletions is low. A thorough clinical work-up 
is essentia l (e.g. imaging of semicircular canals) in order to classify patients as typical or non-typical 
CHARGE patients . 
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ABSTRACT 
CHARGE syndrome is a multiple congenital anomaly syndrome characterised by s;oloboma, heart 
defects, f!_tresia of choanae, retardation of growth and/or development, genital hypoplasia, and gar 
anomal ies often associated with deafness. It is caused by heterozygous mutations in the CHDl gene 
and shows a highly variable phenotype. Anosmia and hypogonadotropic hypogonadism occur 
in the majority of CHARGE patients, but the underlying pathogenesis is unknown. Therefore, we 
studied the ability to smell and aspects of the reproductive system (reproductive performance, 
gonadotropin-releasing hormone (Gn RH) neurons and anatomy of testes and uteri) in a mouse 
model for CHARGE syndrome, the whirligig mouse (Chd?Vh11•). We showed that s;hromodomain 
helicase QNA-binding protein 7 (Chd7) is expressed in brain areas involved in olfaction and 
reproduction during embryonic development. We observed poorer performance in the smell 
test in  adult Chd?Vh"+ mice, secondary either to olfactory dysfunction or to balance disturbances. 
Olfactory bulb and reproductive organ abnormalities were observed in a proportion of Chdrv"v+ 
mice. Hypothalamic GnRH neurons were sl ightly reduced in  Chdrvhv+ females and reproductive 
performance was slightly less in Chd?V1"1+ mice. This study shows that the penetrance of anosmia and 
hypogonadotropic hypogonadism is lower in Chd?VhJ'+ mice than in  CHARGE patients. Interestingly, 
many phenotypic features of the Chdl mutation showed incomplete penetrance in  our model mice, 
despite the use of inbred, genetically identical mice. This supports the theory that the extreme 
variability of the CHARGE phenotype in both humans and mice might be attributed to variations in 
the foetal microenvironment or to purely stochastic events. 
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INTRODUCTION 
CHARGE syndrome is a multiple congenital anomaly syndrome with variable occurrence of 
s;;oloboma, heart defects, .il_tresia of choanae, retardation of growth and/or development, genital 
hypoplasia, gar abnormalities and deafness. 1 More recently, semicircular canal hypoplasia and 
anosmia due to olfactory bulb aplasia were found to be part of the CHARGE spectrum.H Since the 
discovery that heterozygous mutations in the CHD7 gene (OM IM *608892) are the major cause of 
CHARGE syndrome, the phenotypic spectrum has broadened.6•7 Some very mild cases of CHARGE 
syndrome have been identified, some of which were originally diagnosed as Kallmann syndrome.8 A 
recent study claimed that Kallmann syndrome m ight be a mild allel ic var iant of CHARGE syndrome.9 
However, it might also be that CHD7 mutations can have a very mild presentation mimicking 
Kallmann syndrome.8 Kallmann syndrome and CHARGE syndrome share many features, including 
not only anosmia and hypogonadotropic hypogonadism (owing to gonadotropin-releasing 
hormone (GnRH) deficiency), but also hearing impairment, cleft lip/palate and renal agenesis.8 The 
underlying cause of this phenotypic overlap is uncertain. It might be that thromodomain helicase 
QNA-binding protein 7 (CHD7), a putative chromatin remodelling protein, could affect express ion of 
one or several Kallmann syndrome genes (e .g. KAL7, FGFRI, PROK2, PROKR2 and FGFB). 10 If suitable 
mouse models are available, mouse studies can provide insights into the underlying pathogenic 
pathways of anosmia and hypogonadotropic hypogonadism in CHARGE syndrome. 
The whirligig mouse (ChdJNhlf•) carries an ENU (N-ethyl-N-nitroso-urea)-induced nonsense 
mutation in the Chd7 gene and shows a phenotype that is very similar to that of humans with 
CHARGE syndrome.11 Features that are present in both mouse and human include fully penetrant 
semicircular canal defects and occasional heart defects, choanal atresia, cleft palate and eye 
defects.11 However, olfaction and reproductive organs have not been extensively studied so far. 
We performed a smell test and analysed olfactory bulb and reproductive organ anatomy in 
ChdJNhil•mice. We also studied GnRH neurons in the hypothalamus of embryonic and adult Chd7Nhv+ 
mice and analysed the expression of Chd7 during olfactory and GnRH neuron development. The 
overlap between CHARGE and Kallmann syndromes was further explored by crossing ChdJNhil+ 
mice with Fgfr7Hsprl• mice. Fgfr7H,,,,,i+ mice have a missense mutation (W691 R) in the conserved 
kinase domain of the Fgfrl gene (one of the genes involved in Kallmann syndrome).11 This missense 
mutation causes a loss-of-receptor-function (Calvert J, Dedos S, Hawker K and Steel KP, manuscript 
in preparation). 
METHODS 
Mice and genotyping 
Mutant mice were maintained as heterozygote by wild-type matings on a C3HeB/FeJ background .11•13 
Additional matings were set up between Fgfr7Hspr1• females and Chdlwhll• males to create double 
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Genomic DNA from ear clips was purified'4 and genotyping of FgfrJH,pyJ+ (supplementary 
methods) and ChdJWl'u+ mice was performed.11 Wild-type littermates were used as controls. 
Olfaction test 
In the olfaction tests, we determined the ability of wild-type C3HeB/FeJ mice to discriminate 
between urine from various mouse strains (adapted from Brown et a/1s and Lee et a/16). Urine samples 
from five adult BALB/c and five adult 129/55 male mice was pooled, diluted with distilled water ([1 o· 
2], [l O 3) and [10-4)), aliquoted and frozen at -B0°C until use. C3HeB/FeJ mice (8 males and 5 females) 
aged between 8 and 12 weeks were used for the habituation-dishabituation experiment. Clean 
plastic mouse cages (- 31 x 12 x 13 cm) with a gridded lid were placed in a separate room away 
from the colony. The experiments were conducted in normal light, as C3HeB/FeJ mice are blind 
because of retinal degeneration from age three weeks onwards.1 7 On day 1, the mice were allowed 
to become familiar with the test situation by placing them in a clean cage with bedding for 3 min, 
followed by a 2-min presentation of water (100 µI) on a cotton bud inserted through the lid. On 
day 2, seven mice were presented with 100 µI water, 3 x 100 µI of 129/55 urine [10-4] and 1 x 100 
µI of BALB/c urine [10-4] on cotton buds for 2 min each with 2 min between each presentation. The 
other six mice received 2-min sessions of 1 00 µI water, 3 x 1 00 µI of BALB/c urine [ 10-4) and 1 x 1 00 
µI of 129/55 urine [10-4]. On day 3 all urine concentrations were raised to [10·3] and on day 4 to [10 2). 
During each 2-min session, the number of sniff bouts and their cumulative duration were recorded. 
For the olfaction test, we used 21 ChdJW1>11• mice aged between 11 and 15 weeks (9 females and 
12  males), and 19 age· and sex-matched wild-type littermates (8 females and 11 males). On day 1, all 
mice became familiar with the test situation as described above. On day 2, all mice were presented 
with 100 µI water followed by 100 µI of BALB/c urine [10·2] for 2 min each, with 2 min between the 
presentations. During each 2-min session, the number of sniff bouts and their cumulative duration 
were recorded. The data of ChdJWW• and wild-type mice were compared using the Wilcoxon signed­
rank test (as in Lee et a/16). 
Histopathological examination 
Mice used for the smell test (n=40) were weighed, injected with pentobarbital sodium BP 
(Lethobarb, Fort Dodge Animal Health, Southhampton, UK) and transcardially perfused with ice­
cold 1 0% formalin (Sigma, Gillingham, UK). Brain, testes, ovaries and uteri were dissected, weighed 
and preserved in 10% neutral buffered formalin (Sigma). Gross anatomy was viewed using a Leica 
stereomicroscope and digital photographs were taken with a Leica Dfc490 camera. The olfactory 
bulb and brain length, used to establish the olfactory bulb/brain ratio, were measured as depicted 
in Figure 3A. Testes were weighed and their length was measured. Uterine horns and ovaries were 
weighed together. Measurements of the ChdJW1111• and wild-type brains and reproductive organs 
were analysed using the Student's t-test (or the Mann-Whitney test for small sample sizes, n<l 5). 
Brains were processed for paraffin embedding and cut in 8 µm coronal sections with every tenth 
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section mounted on a SuperFrost (VWR, Lutterworth, UK) glass slide. Olfactory bulb organisation 
was analysed in Nissl-stained sections.18 
El 2.5 and El 6.5 wild-type, ChdJWhlt+ and Hspy/+;Whi/+ embryos were obtained from timed 
pregnancies, with E0.5 at noon on the day the vaginal plug was found. The embryos (n=28) were 
dissected in ice -cold PBS and yolk sacs were taken for genotyping.1 1  Heads were fixed in 10% 
neutral-buffered formalin, dehydrated and embedded in paraffin. Sections of 8 µm thickness were 
stained for haematoxylin/eosin or processed for immunohistochemistry, for which the Ventana 
Discovery System (Ventana, Tucson, AZ, USA) and Ventana reagents (Ezprep, cat. no. 950- 100), CC1 
(cat. no. 950-124), LCS (cat. no. 50-010), Reaction buffer (cat. no. 950 -300), DABMap Kit (cat. no. 760-
124), and haematoxylin counterstain (cat. no. 760-202 1) were used according to the manufacturer 's 
instructions. Antibodies against GnRH1 (Chemicon, Watford, UK, cat. no. MAB5456) and CHD7 (a gift 
from Abeam, Cambridge, UK, cat. no. ab31824) were diluted 1:500 in Ventana buffer (cat. no. 251-
018, Ventana). The respective secondary antibodies, biotinylated rabbit anti-mouse, and biotinylated 
donkey anti-rabbit, were diluted 1:100 in PBS containing 10% heat-inactivated foetal calf serum, 2% 
BSA, 0. 1 % Triton X-1 00 and 1 0mM sodiumazide. The sections were examined with a Zeiss Axioscope 
(Welwyn Garden City, UK) and digital images were taken using a Zeiss Axioscope HRc. 
Breeding data analysis 
The re productive function of adult wild-type (mean age 2.2 months, SD 0.77) and ChdJWh11+ (mean 
age 3.2 months, SD 1.76) mice was assessed by the number of days required for production of the 
first litter after placing the test mutant with a wild-type mate. Differences were analysed with the 
Student 's t-test (or the Mann-Whitney test for small samples). 
RESULTS 
Chd7 is present in brain areas involved in olfaction and reproduction 
lmmunohistochemistry tests in wild-type embryos showed decreasing amounts of Chd7 in the 
brain with increasing age (Figure 1). At E12.5 and E 14.5, Chd7 protein was present in all layers of 
the olfactory epithelium and olfactory bulb (Figure 1 A&B). At El 6.5, the expression became more 
restricted, but Chd7 was detected in the vomeronasal organ, olfactory epithelium, olfactory bulb, 
hypothalamus and pituitary (Figure 1 C-F). In the olfactory epithelium, Chd7 expression was highest 
in the inner basal layer, which contains horizontal and globose basal cells. Chd7 expression was also 
present in the nuclei of olfactory sensory neurons in the intermediate layer. The apical layer with 
supportive sustentacular cells showed the lowest expression of the Chd7 protein (Figure 1 D). 
Chd]whit+ mice performed worse than wild-type mice on olfaction test 
During the habituation-dishabituation test, we found that wild-type C3HeB/FeJ mice showed no 
interest in 129/55 urine, but did respond to BALB/c urine from 10 -3 concentration onwards (data 
not shown). Therefore, BALB/c urine at 10-2concentration was used to assess any difference in smell 
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Figure 1. lmmunohistochemistry showed that Chd7 protein is present in olfactory epithelium and in areas of 
the brain involved in olfaction and reproduction in wild-type C3HeB/FeJ mice. (a) At E1 2.5 and (b) E1 4.S, Chd7 
is present in the olfactory epithel ium and olfactory bulb (sagittal sections). (c-f) At El 6.5, Chd7 is present in the 
vomeronasal organ and olfactory epithel ium, olfactory bulb, hypothalamus and pituitary (coronal sections). (d) 
Chd7 expression is most prominent in the basal cells and olfactory sensory neurons. Scale bars=S00 µm (a&b); 
1 00 µm (c, e&f); 50 µm (d). be, basal cells; hypo, hypothalamus; ns, nasal septum; ob, olfactory bulb; oe, olfactory 
epithel ium; osn, olfactory sensory neurons; pit, pituitary; rp, Rathke's pouch; ssc, supportive sustentacular cells; 
to, tongue; vno, vomeronasal organ. (see color image on page 236) 
behaviour between wild-type and Chdrvw+ mice. Wild-type mice (n=19) showed an increased 
response to urine compared to water (P<0.01; Wilcoxon test; Figure 2). ChdJWhit+ mice (n=21) also 
showed an increased response to urine compared to water (P<0.05 for number of sniff bouts and 
P<0.01 for the cumulative duration of sniff bouts; Figure 2), but the response was less than that seen 
in wild-type mice (P<0.01; Figure 2). In addition, the number of non-responders, defined as those 
mice that did not explore the urine,'5 was greater in ChdJWhlt+ mice (5/21 ) compared to wild-type 
mice (1/19). 
Chd1wh1t+ mice have mild olfactory bulb hypoplasia 
Macroscopic examination of the ChdJWhil+ and wild-type brains was carried out to analyse the 
olfactory bulb/brain length ratio (Figure 3A-C, F). Chdrvnv+ mice (n=23) displayed a slightly decreased 
olfactory bulb/brain length ratio compared to wild-type controls (n=1 6) (P<0.01; Student's t-test; 
Figure 3F). Abnormal olfactory bulbs were seen in two ChdJWhil+ mice; one olfactory bulb consisted 
of two parts (Figure 3B) and in one case, asymmetrical olfactory bulb hypoplasia was observed 
(Figure 3(). Microscopic analysis of olfactory bulbs in ChdJWhll+ mice showed no abnormalities in the 
layered organisation of the olfactory bulb (Figure 3D&E). 
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Figure 2. Olfaction test in wild-type and Chdl"""'• mice. (a) Mean number of sniff bouts on presentation of water 
a nd urine. (b) Mean cumulative duration of sniff bouts. Error bars are means ± SEM. * P<0.05. 
Figure 3, Macroscopic and microscopic analysis of olfactory bulbs from wild-type and Chd?Whv+ mice. (a-c) 
Macroscopic view of brains of adult wild-type and Chd?IVhv+ mice, with olfactory bulb/brain length ratio measured 
as mean olfactory bulb length divided by length of cerebral hemispheres (arrows in a). (b) Left olfactory bulb 
consisting of two parts, (c) asymmetrical olfactory bulb hypoplasia. (d&e) Nissl-stained coronal sections of adult 
wild-type and Chd?WhV+ olfactory bulbs, showing no abnormalities. (f) Scatter plot of olfactory bulb/brain length 
ratio of adult wild-type and Chd?W""• mice. Scale bars=S mm (a-c); 1 00 µm (d&e). gl, glomerular cell layer; ml, 
mitral cell layer; pgl, periglomerular layer. (see color image on page 236) 
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Abnormal reproductive system in Chdpthit+ mice 
Reproductive organs were examined at a macroscopic level (Figure 4). The mean testis weight of 
adult ChdJWhY+ males (n=l 2) was less than for adult wild-type males (n=l 1) (PS0.05; Mann-Whitney 
test; Table 1 ). However, as ChdJWhY+- mice had a lower body weight, they had a significantly raised 
testis weight/body weight ratio (gonadosomatic index, GSI, P<0.05; Mann-Whitney test; Table 1, 
Figure 4C). Of twelve ChdJWhV+ males, two had severely hypoplastic testes with a decreased GSI 
(Figure 4B&C). The combined weights of uteri and ovaries did not differ between wild-type and 
ChdJWhl
l+ mice (Table 1 ), but abnormalities were present in all ChdJWl!V• females (n=9) (Figure 4E&F). 
We identified a cyst in one uterine horn (data not shown), one unilateral hypoplastic uterine horn 
(Figure 4E), and all other uteri were shorter and wider than in wild-type mice (Figure 4F). 
Figure 4. Macroscopic view of male and female reproductive organs of adult wild-type and ChdJW"V• mice. (a) 
Normal testes in wild-type males. (b) Hypoplastic testes in some ChdJW"V• males. (c) Scatter plot of gonadosomatic 
index (GSI) of adult wild-type and ChdJWhY• males. (d) Normal uteri in wild-type females. (e-f) Abnormal uteri in 
all ChdJW"V• females, (e) unilateral hypoplastic uterine horn and (f) wider than normal uterine horns. Scale bars=S 
mm (a&b); 1 cm (d-f). (see color image on page 237) 
The reproductive performance of ChdJWhlt+ mice was slightly impaired. Maintaining the colony 
was not a major problem, but the number of days required to produce the first litter was significantly 
greater in both male and female ChdJWhY mice than in wild-type mice (P<0.05, Mann-Whitney or 
t-test, Table 1 ). The percentage of matings that did not lead to a litter two months after set-up was 
also counted (matings of mutant with wild-type compared to wild-type matings). In wild-type mice, 
the percentage of matings not producing a litter within two months after set-up was 6.1 %. The 
percentage of ChdJWI!"• X wild-type matings that did not produce a litter after two months was not 
significantly different to that of wild-type X wild-type matings. 
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Table 1 .  Reproductive and physical parameters of wild-type and ChdJWh�+ mice 
Females Males 
Wild-type Chd]Whll+ Wild-type ChdfWhll+ 
Testes weight (g) 0.1 7 ± 0.002 0.14  ± 0.01 1 *  
(n=l l )  (n=1 2) 
Body weight (g) 33.5 ± 2.3 21 ± 0.5* 37.2 ± 0.9 23.9 ± 0.6* 
(n=8) (n=9) (n= l l )  (n=1 2) 
Gonadosomatic index 0.46 ± 0.01 0.58 ± 0.04* 
(n=l l )  (n=1 2) 
Combined weight of uterus and 0.25 ± 0.Q1 9  0.20 ± 0.082 
ovaries (n=8) (n=9) 
Fertility (days/litter) 22.8 ± 0.3 27.4 ± 2.0* 22.8 ± 0.3 24.3 ± 0.6* 
(n,=46) (n,=7) (n,-=46) (n,=54) 
Values are expressed as mean ± 5EM. * Ps;0.05 compared to controls of the same sex. Gonadosomatic index: 
(testes weight in g/bodyweight in g) x 1 00. n = number of mice. n, = number of matings. 
GnRH1 neurons in developing and adult Chd7whu+ mice 
An immunoh istochemistry test w ith an anti-GnRHl ant ibody was carried out to detect GnRH 
neurons in the adult brain. GnRHl neurons were present in the organum vasculosum of the lamina 
terminalis and the ir fibres extended to the median em inence (ME) of adult w ild-type and ChdJWh1h 
mice ( Figure 5). Representat ive photomicrographs were taken to analyse the GnRH neuron dens ity, 
wh ich appeared to be reduced in the ME of adult ChdJNhll+ females compared to w ild-type females 
( Figure 5G&H). 
No morphological abnormal it ies were found in the olfactory ep ithel ia or olfactory bulbs of the 
ChdJNhll+ embryos at E16.5 (Supplementary Figure 51) .  GnRH l-pos itive cells were detected along 
the ir m igrat ion path, alongside the nasal septum, in the olfactory bulb and in the hypothalamus 
of the wild-type and ChdJN•V• embryos (Supplementary Figure S 1 A-F). No v is ible difference in 
the GnRH l neuron density between the w ild-type and ChdJNhll+ embryos could be detected 
(Supplementary Figure S 1 ) .  
Combining mutations in Fgfr1 and Chd7 is  lethal 
We collected offspr ing from mat ings between FgfrJH•Prl+ females and ChdJNIIII• males . No double 
heterozygous (Hspyl+;Whil+) animals were recovered at weaning (0/55), showing a s ign ificant 
dev iation from normal Mendel ian ratios (x2-test P<0.0 1) .  Subsequently, we collected embryos 
at E l  2 .5, E l  6.5 and PO  and found 8 out of 37 Hspyl+;Whil+ mice, w ith 2 at PO  (one dead) . This 
corresponds w ith the normal Mendel ian rat ios (x2-test P >0.9). Th is suggests that the comb inat ion 
of both heterozygous mutat ions results in per inatal or early postnatal death. No anatomical 
abnormalit ies were observed in E16.5 Hspy/+;Whil+ embryos (n=5), other than the anomal ies 
present in ChdJNhV+ mice w ith variable penetrance (cleft palate, choanal atres ia, heart defect; 
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data not shown). Furthermore, a normal distribution of the GnRH1 neurons was present in El 6.5 
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Figure S. Representative photomicrographs of coronal brain sections of adult wild-type and Chdl"hu+ mice 
showing GnRH1 -positive cells labelled by immunohistochemistry. (a-d) GnRH1 neurons in the organum 
vascutosum of the lamina terminalis (OVLT). (e-h) GnRH1 axon terminals in  the median eminence (ME). Scale 
bars=l 00 µm. (see color image on page 238} 
DISCUSSION 
The Chd7 protein distribution described here is similar to the Chdl mRNA distribution previously 
described5•9· ' 1 and corresponds to the B-galactosidase activity in mice carrying a ChdJG' allele." 
In the olfactory epithelium, the highest levels of Chd7 were found in the basal cells and olfactory 
sensory neurons, suggesting a role for Chd7 in the development of these cell types. We also detected 
Chd7 in the developing olfactory bulb and the hypothalamus, pointing to Chd7 having a role in the 
development of these organs. 
Sense of smell was evaluated with urine as an attractive odour, as previous studies had shown 
that mice are not interested in other odours.16 Urine contains pheromones as well as volatile 
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const ituents of ur inary odour types and is detected by both the vomeronasal organ and the 
olfactory ep ithelium.10·22 The smell test we used could therefore not dist ingu ish between actions 
of the vomeronasal organ and the olfactory epithel ium. As Chd7 is expressed in both organs, we 
expect that both could be affected by Chdl mutations. Overall, ChdJNhlJ+ mice performed worse 
than d id w ild-type mice, imply ing that they m ight have a smell defic it. However, with in the mutant 
group, some m ice performed well and seemed to have a normal sense of smell, whereas other m ice 
d id not explore the cotton bud d ipped in ur ine (non-responders). The non-responders could be 
anosm ic, but alternat ively severe balance d isturbances could also have contr ibuted to the ir poor 
performance on the smell test. Our study design d id not allow discr im inat ion between olfactory 
and balance/neuromotor dysfunct ion. However, a concurrent study by Layman eta/23 has confirmed 
the presence of a smell defic it in Chd7-defic ient mice ( ChdJG11• mice), w ith an odour-evoked electro­
olfactogram. 
Patholog ical examination of the brains of the ChdJNhil+ m ice showed m ild hypoplasia of 
the olfactory bulbs, w ith only two mice (out of 23) hav ing overt olfactory bulb anomalies. The 
organi sation of the layer s of the olfactory bulb was normal. These find ings are in concordance w ith 
a concurrent study.23 One could argue whether these mild olfactory bulb anomalies would have any 
effect on the abil ity to smell. It is al so possible that a dysfunction of the olfactory ep ithel ium causes 
the smell defic it, as was postulated by Layman et a/.23 The low inc idence of olfactory bulb anomal ies 
in ChdJNhll+ mice are in contrast to the previously descr ibed complete penetrance of olfactory bulb 
aplasia in humans.3 5 However, we know from our own observat ions that some patients w ith a CHDl 
mutat ion have normosm ia or sl ight hyposmia (5/24, Bergman JEH and van Ravenswaa ij-Arts CMA, 
unpubl ished result s). 
Defects of reproduct ive organs were seen in all ChdJNhlt+females and some ChdJNhll+ males. Of 
12 ChdJNhll+ males, 2 had severely hypoplast ic testes and all n ine ChdJN"'1• females had abnormal 
uterine horns. GnRH 1 neurons were present in the hypothalamus of ChdJN""+mice, but were mildly 
decreased in female ChdJN"11• mice. In contrast, no GnRH1 neuron abnormalities were observed in 
ChdJNh11• embryos, suggest ing that Chdl might have an ef fect on the GnRH 1 neuron surv ival in a 
sim ilar way to Fgfrl .24 The effect of the reproductive organ anomalies and assumed reduct ion in the 
GnRH1-posit ive neurons on reproduct ive performance seemed m in imal, a s  ma inta in ing the colony 
d id not present any major problems. Th is is to be expected, as there is a substant ial redundancy 
known to be present in the GnRH neuronal populat ion.25 However, on further analysis, ChdJNh11•mice 
were found to have a sl ightly lower reproduct ive performance (need ing more days to produce the 
first litter compared to w ild-type m ice). Reproduct ive fitness could be af fected by balance defects 
leading to abnormal head-bobb ing and c ircl ing behav iour, by reduced body we ight or by abnormal 
mat ing behav iour of ChdJNhit+ mice. Reduced body we ight was previously correlated with reduced 
reproduct ive fitness in mice. 26 The cause of reduced body we ight in ChdJNh11• mice is unknown, but 
could be caused by increased act iv ity, poor feed ing (ow ing to cranial nerve anomal ies or olfactory 
defic it) or growth hormone defic iency. Mat ing behaviour was not observed in this study, but it was 
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previously shown that a nosmic mice can mate and are fertile.27 However, other studiesR28 claim 
that anosmia could lead to reduced reproductive fitness in  mice. We were unable to differentiate 
between the d ifferent mechanisms that could influence reproductive fitness because some features 
that might affect reproductive fitness are fully penetrant in ChdJN°11+ mice (e.g. balance disturbance). 
The ability of ChdJN•U+ mice to reproduce corresponds with the situation in a minority of humans 
with CHARGE syndrome, in  which some mildly affected patients are seen to reproduce normally.29•30 
Anosmia and hypogonadotropic hypogonadism often occur together because of the interl inked 
migration process of olfactory neurons and GnRH neurons during embryonic development.31 
However, in our study, poor performance on the smell  test did not correlate with hypoplasia of 
reproductive organs in ChdJN""+ mice. Hypoplasia of reproductive organs was also not associated 
with a clearly reduced GnRHl neuronal population in the hypothalamus, implying that gonadal 
anomalies in ChdJNh11+ mice might be caused by a local effect of Chd7. 
The phenotypic overlap between CHARGE and Kallmann syndromes might be attributed 
to an interaction between the genes (or their encoded proteins) involved in both syndromes. 
lntercrosses between Fgfr1 11't>'11+ females and ChdJNh11• males showed that combining mutations 
in both Fgfr1 and Chdl leads to perinatal or early postnatal death. This is in contrast with the 
normal viability of Fgfr111'P'11' mice and 50% lethal ity of ChdlWh!i+ mice, suggesting that mutations 
in Fgfr1 and Chdl interact synergistical ly, showing more than simply an additive effect on viabi l ity. 
As Chd7 is a member of the .c_hromodomain helicase QNA-binding protein family,32•33 one can 
hypothesise that reduced levels of Chd7 may decrease Fgfr1  expression, leading to the Kallmann­
like phenotype in CHARGE syndrome patients. However, the Kallmann phenotype (olfactory bulb 
defects a nd hypogonadotropic hypogonadism) was not observed in  double heterozygote mice. 
This argues against genetic interaction between Fgfr1 and Chdlin olfactory bulb and hypothalamus 
development. 
CONCLUSIONS 
Whirligig mice show a reduced penetrance of features associated with anosmia and hypogonado­
tropic hypogonadism compared to humans with CHARGE syndrome. The observation of incomplete 
penetrance in mice that have the same Chdl mutation on an identical genetic background is in line 
with the variable expression and reduced penetrance observed in  humans with CHARGE syndrome. 
The reduced penetrance and variable expression in these mice may be attributed to purely 
stochastic events, or may be influenced by environmental differences between mice in their foetal 
microenvironment. In humans, the modifying effects of the varied genetic backgrounds of people 
with CHDl mutations is also l ikely to influence the penetrance and expression of each feature of the 
syndrome. The ChdJNhlt+ mice may be useful in investigating the potential influence of epigenetic 
alterations on different aspects of the phenotypic spectrum in these syndromes. 
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Supplementary information 
wild type Whi/+ 
Supplementary Figure S1 .  Representative photomicrographs of coronal brain sections of El 6.5 wild type and 
ChdJ""11• embryos showing GnRHl-positive cells labelled by immunohistochemistry. (a&b) GnRHl neurons 
alongside the nasal septum, (c&d) in the olfactory bulb and (e&f) in the hypothalamus. Scale bars=l OO µm. hypo, 
hypothalamus; ns, nasal septum; ob, olfactory bulb; oe, olfactory epithelium. (see color image on page 239) 
Material and methods 
Fgf,7Hspy/+ genotyping 
FgfrJH•PY1•mice were genotyped by a PCR with primer sets of Fw: 5'-GTGGTCTTTTGGAGTGCTCgG-3' 
and Rv: 5'-GCTTGCCAGTGGTGGATCCAA-3' with ReddyMix (Abgene), followed by Ddel (100 U/ml) 
restriction digest overnight at 37°C. A Ddel recognition site is introduced when the mutant sequence 
is combined with the single base pair (bp) mismatch in the forward primer. Digesting PCR products 
with Ddel followed by agarose gel electrophoresis generates a single band of 208 bp for wild type, 
two bands of 208 and 1 84 bp for Fgfr7HspyJ+ and one 184 bp band for FgfrJHspytHspy animals. 
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Objective To test the hypothesis that a smell test could predict the occurrence of hypogonadotropic 
hypogonadism (HH) in patients with CHARGE syndrome, which is a variable combination of ocular 
coloboma, heart defects, choanal atresia, retardation of growth/development, genital hypoplasia 
and ear anomalies or hearing loss caused by mutations in the CHDl (chromodomain helicase DNA­
binding protein 7) gene. 
Study design We performed endocrine studies and smell testing (University of Pennsylvania Smell 
Identification Test) in 35 adolescent patients with molecularly confirmed CHARGE syndrome. 
Results Complete data on smell and puberty were available for 15 patients; eleven patients had 
both anosmia and HH, whereas four patients had normosmia/hyposmia and spontaneous puberty. 
In addition, seven boys were highly suspected of having HH (they were too young for definite HH 
diagnosis, but all had cryptorchidism, micropenis, or both) and had anosmia. The type of CHDl 
mutation could not predict HH because a father and daughter with the same CHDl mutation were 
discordant for HH and anosmia. 
Conclusion Anosmia and HH were highly correlated in our cohort and therefore smell testing seems 
to be an attractive method to predict the occurrence of HH in patients with CHARGE syndrome. The 
use of this test could prevent delay of hormonal pubertal induction, resulting in an age-appropriate 
puberty. 
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INTRODUCTION 
CHARGE syndrome (OM IM #214800; 1/10,000 newborns 1 ) is an autosomal dominant disorder 
characterized by a variable occurrence of multiple congenital anomalies.1 Originally, ocular 
coloboma, heart defects, atresia of choanae, retardation of growth/development or both, genital 
hypoplasia and ear anomalies inc luding hearing loss, were identified as core features of the 
syndrome.3 More recently, semicircular canal anomalies, cranial nerve defects and arhinencephaly 
were found to be present in most patients.4 The diagnostic criteria for CHARGE syndrome have 
been revised several times. 1 •5 In 2 004, the chromodomain helicase DNA-binding protein 7 (CHD7) 
gene was identified as the major gene involved in CHARGE syndrome6 and CHDl mutations have 
been found in very mildly af fected patients who do not fulfil the diagnostic criteria .7 Olfactory bulb 
hypoplasia has long been recognized in CHARGE syndrome.3 Arhinencephaly was reported to be 
fully penetrant in patients with CHARGE syndrome and it was suggested that this feature might be 
a new diagnostic criterion.4•8•10 Impaired olfaction was found in most patients with smell testing.9·1 1  
Genital hypoplasia caused by hypogonadotropic hypogonadism (HH) is also frequently encountered 
in CHARGE syndrome. 12•14 In boys, micropenis and cryptorchidism can be early manifestations of 
HH. In girls, HH is often only diagnosed when puberty does not occur spontaneously. An earlier 
study found gonadotropin deficiency in approximately 85% of boys and 70% of girls with a CHDl 
mutation.15 The co-occurrence of anosmia and HH is not unique for CHARGE syndrome, but is also 
seen in Kallmann syndrome. It is speculated that the embryonic migration process of gonadotropin­
releasing hormone neurons (GnRH neurons) along the olfactory and vomeronasal nerve fibers is 
disturbed in Kallmann syndrome.16 The same defect might underlie anosmia, olfactory bulb defects 
and HH in CHARGE syndrome. A recent study in Chd7-deficient mice suggested that the smell deficit 
in CHARGE syndrome is caused by a dysfunctional olfactory epithelium.1 1  Our group identified 
smell deficits, genital anomalies and fewer GnRH neurons in a proportion of Chdl-mutated 
mice .17 Unfortunately, hormone levels and thus HH were not studied in both mouse models. From 
expression studies, we know that CHDl is present in the olfactory epithelium, olfactory bu lbs and 
pituitary gland during embryonic development .4 
Because anosmia and HH often occur in association, we hypothesized that a smell test might 
be a means of predicting the occurrence of HH in patients with CHARGE syndrome and thus offer 
the opportunity to start hormone replacement therapy at a more appropriate age. To investigate 
this hypothesis, we studied smell and pubertal development in a large cohort (n=35) of adolescent 
patients with CHARGE syndrome. 
METHODS 
Patients 
Patients with CHARGE syndrome (19 male, 16 female) aged � 10 years were recruited through the 
Dutch national multidisciplinary CHARGE clinic. Inclusion criteria were a proven CHDl mutation 




patients underwent standardized physical examination by a clinical geneticist (Ravenswaaij-Arts 
CMA) and paediatric endocrinologist (Bocca G). The Tanner stages were scored in all patients and 
stretched penile length (SPL) and testicular volume were measured in boys. Micropenis was defined 
as an SPL <-2.5 SD score for a given age in a Dutch cohort.1° Cryptorchidism was present when testes 
were not palpable in the scrotum at two consecutive examinations. Additional clinical information 
was obtained from retrospective chart review. Family history was taken for pubertal development, 
but none of the families showed evidence of constitutional delay of pubertal maturation. 
Informed consent was obtained from the patients or their parents for the collection of medical 
data, including re-analysis of magnetic resonance imaging (MRI) scans, the olfaction test and 
molecular and endocrine studies in a clinical setting according to the guidelines of the local ethical 
board. 
Molecular and endocrine studies 
Molecular analysis of the CHDl gene was performed as previously described.15 Multiplex ligation­
dependent probe amplification (MLPA) was performed when no CHDl mutation was found with 
routine analysis (method as described previously1 9). 
Baseline luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels were 
determined, as well as basal testosterone levels in boys and basal estradiol levels in girls. Because 
patients were recruited from all over the Netherlands, most of the hormone studies had already 
been done in different laboratories. FSH and LH were analyzed with Autodelfia (Perkin Elmer, 
Waltham, Massachusetts), Axsym (Abbott, Abbott Park, Illinois), DPC lmmulite 2000 (Block Scientific, 
Holbrook, New York), Elecsys (Roche, Basie, Switzerland) or Modular El 70 (Roche). Estradiol was 
measured with Autodelfia, Modular El 70 or radioimmunoassay. Testosterone levels were analyzed 
with Modular El 70 or radioimmunoassay. Growth hormone deficiency had been diagnosed in one 
of the patients (M 1 3) and four patients (M2, M4, M 14, M 17) had undergone baseline analysis of LH, 
FSH and testosterone levels in the neonatal period because of the presence of a micropenis. 
Olfaction test and magnetic resonance imaging brain scan evaluation 
The third edition of the University of Pennsylvania Smell Identification Test (UPSIT, Sensonics Inc, 
Haddon Heights, New Jersey; www.sensonics.com) was used to assess olfactory function.20 This test 
consists of 40 scratch-and-sniff odorants and is forced-choice (with four options for each odour). 
The UPSIT is suitable for children aged 2:5 years. UPSIT scores range between 0 and 40, with each 
correctly identified odorant scoring 1 point. Patients with CHARGE syndrome who had head colds 
were not tested because their sense of smell could be negatively affected. Patients with mental 
retardation (developmental age <5 years), uncorrected bilateral choanal atresia, or prolonged 
feeding difficulties necessitating tube feeding were excluded from the UPSIT. Patients with CHARGE 
syndrome who had communication difficulties were tested with a newly designed picture book for 
the Dutch population, with photographs representing the odour options (available on request). All 
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tests were conducted by one researcher (van Ravenswaaij-Arts CMA) in a separate room. Twelve 
healthy Dutch adults (six male, six female; age 20-26 years) took the same test to see whether 
the American UPSIT could be used for the Dutch population. The mean score of the male control 
subjects was 31.7 (range 29-35 or 73-88% correct answers; SD 2.7) and the mean score of the female 
control subjects was 32 (range 29-35 or 73-88%, SD 2.0). Five odours (fruit punch, cheddar cheese, 
turpentine, lime and lemon) were not correctly identified by at least half of the Dutch control 
subjects. When excluding these five odours, the mean percentage of correctly identified odours 
increased from 79% to 86% for male control subjects and from 80% to 89% for female control 
subjects. These five odours were also excluded in the test results of patients with CHARGE syndrome. 
Cerebral MRI scans were available for ten patients with CHARGE syndrome and were 
retrospectively analyzed for olfactory bulb anomalies by an experienced neuroradiologist (Meiners 
L). The MRI scans were performed in different hospitals with widely different techniques, making 
them less optimal for evaluating the olfactory bulbs. As a result, analysis of MRI scans was possible 
for only three patients. 
RESULTS 
Clinical data and the results of molecular and endocrine studies, olfaction test and cerebral MRI scan 
are summarized in the Table. CHDl analysis showed mutations in 34 patients. In one patient (MS), 
CHDl analysis was not performed, but this patient fulfilled both Blake's and Verloes's clinical criteria 
for CHARGE syndrome. 
Of nineteen male patients, two had no genital anomalies, one had a micropenis, seven had 
cryptorchidism and nine had both micropenis and cryptorchidism (Table). Only two of the eleven 
male patients aged �14 years had experienced spontaneous puberty. HH was diagnosed in the 
other nine patients on the basis of physical examination and prepubertal baseline levels of LH, FSH 
and testosterone. Six of these nine patients had started sex hormone replacement therapy (HRT). 
Four of the male patients (M2, M4, M 14, M 17) were treated with testosterone in the neonatal period. 
The eight boys between 1 0  and 1 4  years of age were too young for definite HH diagnosis, but none 
of them showed pubertal maturation yet and all eight had micropenis, cryptorchidism or both. 
None of the 1 6  female patients had genital abnormalities. Four of the twelve female patients 
aged � 1 3  years had experienced spontaneous puberty (Table). The other eight patients were 
prepubertal on physical examination and had prepubertal baseline levels of LH, FSH and estradiol. 
HH was diagnosed in all eight patients and six of them had started sex HRT. The four younger girls 
(aged 10-11 years) did not show any secondary sexual development. 
Olfactory evaluation and MRI brain scan evaluation 
The UPSIT was administered to 26 of 35 patients (12 male, 1 4  female). The scores were adapted 
for the Dutch population (see Methods section). There was a clear-cut difference between patients 




Table. Clinical data, results of molecular and endocrine studies, age at start of hormone replacement therapy, and olfaction test (University of Pennsylvania Smell Identification 
I f 00 Test) in 35 patients with CHARGE syndrome divided in 3 groups: hypogonadotropic hypogonadism (HH), normal puberty and too young for definite HH diagnosis 
Age• CHD7 Blake / Tanner Genitals• TV' LH• FSH• T or E• Age at UPSIT%1 UPSIT%1 I iv 
Mutation• Verloes' staged (ml) (U/L) (U/L) (nmol/L or start HRT" (uncorrected) (corrected) 
pmol/L) 
HH 
Ml 1 4;0 Missense - / a  G1P 1  C, M 2 0.1 0.6 <0.1 1 4;1 22.5 25.7 
M2 1 4;4 Missense - / a G1 P2 C, M 2 0.05 0.22 1 .6 1 4;5 1 0.0 8.6 
M3 1 4;8 Frameshift + I +  G1 P2 C u <0.2 0.2 u 1 4;9 u u 
M4 1 5;2 Frameshift - / +  G1 P1 C, M 2 0.03 0.29 1 .3 1 5;6 32.5 37.1 
MS 1 6;7 u + / +  G1 P2 M 2 u u u u u 
M6 1 8;9 Nonsense + / a* G1 P3 C, M u <1 0.4 2.4 1 8; 10 25.0 25.7 
M7 20;3 Frameshift + I +  G1P3 C, M 2 0.2 0.4 0.57 20;7 u u 
MB 20; 10  Frameshift + / +  G1P2 C u 0.01 0.1 6 2.7 u u 
M9 >40 Splice site + /  a* G 1P2 C, M u u u u u u 
Fl 1 3;1 Frameshift - / - B1 P1 0. 1 0  1 .36 30 1 3;6 1 5.0 1 7.1 
F2 1 4;9 Nonsense - / +  B1 P2 <1 .0 <1 .0 42 u u 
F3 1 6;1 Nonsense - / a* B 1 P3 O.D7 0.1 8  u 1 6;2 30.0" 34.3" 
F4 1 6;6 Nonsense + I +  B1P 1  <0.2 <0.2 24 1 9;1 30.0 34.3 
FS 1 6;8 Missense - I +  B 1P2 <0.2 0.4 37 1 6;1 1 35.0 37.1 
F6 1 7;1 Nonsense + / +  B 1P2 0.06 0.38 40 1 7;4 22.5 25.7 
F7 1 7;6 Frameshift + I +  B 1 P2 Low Low u 1 7;9 35.0 40.0 
FB 1 8;0 Selice site + I +  B 1 P2 < 1 .0 < 1 .0 52 25.0 22.9 
Normal puberty 
M10  1 4; 10  Frameshift - / -* G4PS 5 4.78 6.37 9.9 u u 
M1 1 >30 Frameshift - / -* u u u 0.76 2.33 6.5 72.5 80.0 
F9 1 4;8 Missense + / +  BSPS 5.98 3.52 380 60.0 62.9 
F 10  1 7;3 Missense - / - BS 8.49# 2.64# 1 40# 87.5 88.6 
F1 1 1 7;9 Nonsense - / +  BSPS 3.78 6.1 7 270 u u 
F12  20;7 Missense - / +  BSP4 u u u 62.5 68.6 
N 
IO 
Too young for definite HH diagnosis 
M 1 2  1 0;4 Frameshift + / +  G1P 1  C 1 0.03 0.39 1 .6 1 5.0 1 7.1 
M 1 3  1 0;1 1 Frameshift - I - G 1 P 1  C u <0. 1 5  0.38 0.2 30.0 3 1 .4 
M 1 4  1 1 ;3 Missense - / +  G 1 P2 C, M 1 0.04 0.1 9  1 .9 32.5 3 1 .4 
M l S  1 1 ;4 Frameshift - l a  G1P1  C 1 0.07 0.1 3  1 .8 7.5 8.6 
M 1 6  1 2;0 Splice site + I +  G 1 P1 C, M u 0.05 0.26 1 .4 U/\ U/\ 
M 1 7  1 2;5 Deletion - / a* G 1 P2 C, M, UTA 1 < 1 .0 0.2 0.6 1 2;6 25.0 25.7 
M 1 8  1 2;7 Splice site - / a  G 1 P1 C 1 0.05 0.1 6 1 .9 25.0 28.6 
M 1 9  1 3;3 Nonsense - / a  G1 P1 C u < 1  < 1  0.4 1 3;4 35.0 40.0 
F1 3 1 0;4 Missense - / p  B1 P1 u u u 57.5A 60.01\ 
F14  1 0;1 1 Missense + I +  B1 P1 0.04 0.29 30 20.0 22.9 
F 1 5  1 1 ;3 Missense + I +  B1 P1 0.09 0.44 20 27.5 28.6 
F 16  1 1 ;4 Splice site - /  a B1 P2 u u u 27.5 22.9 
---
F, female; M, male. U, unknown. 
• Age at evaluation {year;month). b CHD7 mutations: deletion, deletion of exon 1 3-38; frameshift, frameshift mutations {c.3053_3054insA, p.Phe101 9fs; c.5535-7G>A, 
p.Gly1 801 fs; c.5564dup, p.Glu1 856fs; c.5768_5769del, p.Ser1 923fs; c.601 8dup, p.Ser2007fs; c.683Sdel, p.Ala2279fs; c.7400del, p.Leu2467fs; c.7650_765 1 del, p.Glu2550fs; 
c.7769del, p.Asp2590fs; c.8267del, p.Thr2756fs); missense, missense mutations (c.3082A>G, p.lle1 028Val; c.3301T>C, p.Cysl 1 01 Arg; c.3302G>A, p.Cys1 1 01Tyr; c.3770T>G, 
p.Leul 257 Arg; c.3973T>G, p.Tyr1 325Asp; c.4406A>G, p.Tyrl 469Cys; c.4787 A>G, p.Aspl 596Gly; c.5222G>C, p.Argl 741 Pro; c.5402A>C, p.His 1 801 Pro; c.6322G>A, 
p.Gly21 08Arg); nonsense, nonsense mutations (c. 17 14(> T, p.Gln572X; c.1 940C>G, p.Ser647X; c.3655(> T, p.Argl 21 9X; c.401 SC> T, p.Argl 339X; c.41 57C>G, p.Ser1 386X; 
c.6070(> T, p.Arg2024X; c.7824T>A, p.Tyr2608X); splice site, splice site mutations {c.2238+ 1 G>A; c.2443+5G>C; c.3340A> T; c.3990-1 G>C; c.5405-1 7G>A, p.His1801 
Glyl 802insAspHisGlyThr). ' Score on Blake and Verloes criteria: +, positive; -, negative; a, atypical; p, partial; *, semicircular canal imaging not performed. d Tanner stage: B, 
breast development; G, genital development; P, pubic hair. •  Genitals: C, cryptorchidism; M, micropenis; UTA, unilateral testis agenesis. 'TV, testes volume. 9 Basal values of LH, 
FSH, T, testosterone and E, estradiol; #, endocrine studies done while using an oral anti-conceptive; low, documented as prepubertal. h HRT, hormone replacement therapy. ' 
UPSIT, University of Pennsylvania Smell Identification Test: uncorrected for the Dutch population (40 multiple choice questions); corrected for the Dutch population (5 odours 
that were not recognized by healthy Dutch controls were left out); /\, olfactory bulb anomalies on cerebral MRI scan (F3 and M 16 aplasia of olfactory bulbs, Fl 3 hypoplasia 

























scores, 9% -40%; Figure;Table). This difference was also seen without correction of the UPSIT for the 
Dutch population (Table). One patient (M 14) took the UPSIT twice at age 9 and 1 1  years, resulting in 
an UPSIT scores of 14/35 (40%) and 11 /35 (31%), respectively. We could not administer the U PSIT to 
nine patients because they had either a developmental age <5 years (M3, MS, M7, M8, M9, M 16, F2) 
or prolonged tube feeding (M 1 O) or uncorrected bilateral choanal atresia (F11 ). 
With cerebral MRI scans, ap!asia of the olfactory bulbs was shown in two of three patients. One 
of these patients could not perform the UPSIT because of developmental delay (M 16) and the other 
patient had anosmia (F3). The third cerebral MRI scan showed asymmetrical olfactory bulbs with 
aplasia of the right olfactory bulb and hypoplasia of the left olfactory bulb. This patient (Fl 3) had an 
UPSIT score of 21/35 (60%) showing that olfaction was not severely impaired by the olfactory bulb 
anomalies. 
Correlation between olfactory function and pubertal development 
Both smell and pubertal development could be evaluated in fifteen patients (five boys aged �14 
years and ten girls aged �13 years). Eleven of these patients had both anosmia (highest UPSIT 
score 14/35 or 40%) and HH, whereas four patients had spontaneous puberty and normosmia or 
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Figure. University of Pennsylvania Smell Identification Test (UPSIT) results corrected for the Dutch population 
(see Methods section) in 26 patients with CHARGE syndrome and 1 2  healthy Dutch controls. ( • )  Patients with 
proven hypogonadotropic hypogonadism (HH, n =1 1 )  or highly suspected of HH (boys aged 1 0-1 3  years with 
cryptorchidism/micropenis and no pubertal maturation, n=7); (•) girls aged 1 0-1 3  years with unknown HH 
status (n=4); (+) patients with normal pubertal development (n=4); and (-) Dutch control subjects (n=1 2). The 
mean is indicated by a dotted line ( . ..  ) for each subgroup. 
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were too young for definite HH diagnosis. However, all eight boys had cryptorc hidism and three 
boys also had a micropenis, suggesting HH. Seven of the boys (M 12, M 13, M 14, M 15, M 17, M 18, 
M l  9) had anosmia (U PS IT scores 3- 14/35; 9-40%). In the eig ht h boy (M 16), the UPSIT could not be 
performed, but the cerebral MRI scan showed olfactory bulb aplasia. 
DISCUSSION 
We show t hat the sense of smell is hig hly correlated wit h pubertal develop ment in our patients 
(n=l 5) and we propose t hat smell testing can be used as a method of predicting HH in patients wit h 
CHARGE syndrome. Knowing the HH status is beneficial because HRT can be started in time and 
reduce socio-emotional problems and t he risk of related osteoporosis and cardiovascular disease. 
Anosmia can be reliably diagnosed wit h the U P SIT in most patients with CHARGE syndrome. 
Anosmia was present in 81% of our patients (21/26), whereas 19% of our patients were a ble to 
smell (5/26). Ot her studies have reported a similar distribution of anosmia/normosmia in patients 
wit h CHARGE syndrome by using t he Biolfa test and t he B-SIT.9•11 There was a clear-cut difference 
between t he scores of patients w ho were able to smell and the anosmic test results (Figure). It is 
important to inform patients wit h anosmia (or their caregivers) t hat they are not able to detect 
warning odours (e.g., gas, rotten food, or smoke) or foul body odours. 
In this study, 15 patients showed 100% correlation between sense of smell and pubertal 
development. Eleven patients had anosmia wit h HH and four patients had both spontaneous 
pubertal develop ment and normosmia/hyposmia . Officially, delayed puberty cannot be diagnosed 
in boys before the age of 14 years. However, w hen we extend our results wit h our findings in t he 
seven boys aged 10 to 13 years w ho all had cryptorchidism, micropenis, or both, 22 patients wit h  
CHARGE syndrome showed concordance between the results on smell testing and HH or expected 
HH. In the four young girls no conclusion could be drawn about HH and a smell test could not be 
applied in t he nine remaining patients (from t he total cohort of 35). T his high concordance between 
smell and puberty corresponds to two earlier reports that together describe six fe male patients wit h 
CHARGE syndrome wit h both HH and either anosmia or olfactory bulb  anomalies. 10,21  
The combination of anosmia and pubertal delay is also seen in Kallmann syndrome. The clinical 
overlap between Kallmann and CHARGE syndrome might be explained by t he presumed function 
of CHD7 as a regulator of gene expression. CHD7 is a member of t he !;hromodomain helicase QNA 
binding protein family and is thought to regulate gene expression with its c hromatin re modeling 
activity. We do not yet know w hic h genes are regulated by CHD7,22 but we speculate that one or more 
of t he genes involved in Kallmann syndrome (KAL I, FGFR1, PROK2, PROKR2 and FGFB) are targets of 
CHD7. T he extremely high correlation between anosmia and HH in patients with CHDl mutations is 
in contrast with patients wit h FGFR1 mutations who can present with anosmia alone, HH alone, or 
both. T his suggests that the Kallmann phenotype in CHARGE syndrome is not caused by an effect of 
CHD7 on FGFR1 expression, but could point to an influence on the KAL 1 gene (which always leads 
to the combination of anosmia and HH in boys). T his is supported by t he over-representation of 
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HH in boys (9/11 ,  82%) compared with girls (8/12, 67%) in our study, although a larger study group 
is needed to confirm this observation. 
Two recent studies analyzed the CHDl gene in patients with Kallmann syndrome or normosmic 
HH. Jongmans et a/23 performed CHDl analysis in 36 patients and found three CHDl mutations in 
patients who had both anosmia and HH. Kim eta/24 analyzed CHDl in 197 patients and reported seven 
CHDl mutations: three in patients with both anosmia and HH, and four in patients with normosmic 
HH. This seems to contradict our observation that in CHARGE syndrome HH is always correlated 
with anosmia. There are two possible explanations: our patients were recruited from the CHARGE 
outpatient clinic so they might have a more complex phenotype, or there could be a difference in 
the clinical evaluation of the CHO7-positive patients in the different studies. In our study and that by 
Jong mans et al, the CHO7-positive patients were carefully examined (or re-examined) for CHARGE 
features and formal smell testing was performed. It is unclear whether Kim et al re-examined their 
CHO7-positive patients or used a formal smell test. In our experience, patients are often unaware of 
their smell deficit and smell testing therefore is crucial. 
The presence of HH in CHARGE syndrome cannot be predicted by the type of CHDl mutation. 
This is illustrated by a family included in our study: patient Fl is the daughter of patient M11 and they 
share the same mutation. Father has a proven fertility and normosmia, whereas his daughter has HH 
and anosmia. Earlier studies have also shown great intrafamilial variability in CHARGE syndrome 
and a lack of phenotype-genotype correlations.w Truncating CHDl mutations are most frequently 
found, but missense mutations are seen in as much as 12% of patients.2 In our cohort, missense 
mutations were over-represented (29%, 10/34). All ten missense mutations were considered to be 
pathogenic because all were de novo, located in a highly conserved region and predicted to be 
'not tolerated' with SIFT �orting intolerant from Tolerant). Five of the ten missense mutations were 
located in a functional domain of the CHD7 protein. 
Because this study was conducted in an as minimally invasive way as possible, it had some 
weaknesses. First, the endocrine studies were done in different laboratories with different assays. 
However, there were no marginal results and the presence of HH was easily recognized by low levels 
of gonadotropins and sex steroids in the different assays. Second, only three of ten MRI scans were of 
sufficient quality for olfactory bulb analysis (a high-resolution MRI with � 3 mm slices in the coronal 
plane is required). However, it has been shown that, apart from complete absence (bilateral aplasia), 
olfactory bulb anomalies do not correlate well with olfactory function926 and thus the information 
that can be obtained from such scans is limited, as illustrated by patient Fl 3. 
HH is a frequent feature in CHARGE syndrome, but is often only established at a relatively 
advanced age when puberty fails to occur spontaneously. Diagnosing HH in childhood is impossible 
because levels of LH, FSH and sex steroids are physiologically low. However, in boys and girls a peak 
of FSH, LH and sex steroids is present between age 2 weeks and 6 months.27When CHARGE syndrome 
is suspected, HH can be diagnosed during this period. In addition, micropenls, cryptorchidism, or 
both are easily recognizable in boys (present in 17 /19 male patients in our cohort) and suggest 
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the presence of HH. Only four male patients in our cohort were diagnosed with HH in the neonatal 
period, showing that HH is often overlooked in patients with CHARGE syndrome. In girls, there 
are no other features to suggest HH. Of the 17  patients with definite HH in this study, twelve were 
treated with sex HRT. Four patients aged <!: 1 6  years had not yet been treated (MS, MB, M9, FB). They 
all had developmental delay and severe behavioural problems and adverse effects from sex HRT 
were anticipated. In male patients, testosterone treatment increases muscle mass and can aggravate 
behavioural problems, especially aggressiveness, whereas in female patients menstruation can be 
a burden. Another reason for postponing treatment could be to achieve an increase in final adult 
height in patients with extremely short stature (as is done in Turner syndrome). Arguments in favour 
of early HRT are the decreased risk of osteoporosis13 and the possible lower risk of cardiovascular 
disease in men.2s In addition, early HRT can have a positive effect on psychological well-being, as 
was shown for girls with Turner syndrome and in boys with constitutional delay of puberty. 29.io 
In conclusion, we propose that smell testing can be used to predict the occurrence of HH in 
patients with CHARGE syndrome. Early diagnosis of HH can prevent a delay in inducing puberty with 
HRT and thus results in an age-appropriate puberty. This may lead to increased socio-emotional 
well-being and a lower risk of osteoporosis and cardiovascular disease. 
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CHARGE syndrome is a multiple congenital anomaly syndrome that can be life-threatening in the 
neonatal period. Complex heart defects, bi lateral choanal atresia, oesophageal atresia, severe T-cell 
deficiency, and brain anomalies can cause neonatal death. As little is known about the causes of 
death in childhood and adolescence, we studied post-neonatal death in patients with CHARGE 
syndrome. We collected medical data on three deceased children from a follow-up cohort of 48 
CHARGE patients and retrospectively on an additional four deceased patients (age at death 1 1  
months to 22 years). We analyzed the factors that had contributed to their death. I n  five patients 
respiratory aspiration had most l ikely contributed to premature death, one died of post-operative 
complications, and another choked during eating. From our findings and a literature review, we 
suggest that swallowing problems, gastro-oesophageal reflux disease, respiratory aspiration 
and post-operative airway events are important contributors to post-neonatal death in CHARGE 
syndrome. Cranial nerve dysfunction is proposed as the underlying pathogenic mechanism. We 
recommend every CHARGE patient with feeding difficulties to be assessed by a multidisciplinary 
team to evaluate cranial nerve function and swallowing. Timely treatment of swallowing problems 
and gastro-oesophageal reflux disease is important. Surgical procedures on these patients should 
be combined whenever possible because of their increased risk of post-operative complications and 
intubation problems. Final ly, we recommend performing autopsy in deceased CHARGE patients in 
order to gain more insight into causes of death. 
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INTRODUCTION 
CHARGE syndrome is a congenital malformat ion syndrome that occurs in approximately 1/ 10,000  
l ive b irths. '·2 CHARGE (OM IM  214800) is an acronym for i;;oloboma, heart defects, gtres ia o f  choanae, 
retardation of growth and development, gen ital abnormalit ies, and _gar anomal ies (including 
deafness).i Arhinencephaly, hypoplas ia of sem icircular canals, and cranial nerve (CN) palsies are 
also present in the major ity of pat ients.2.4-6 Occas ional features include oesophageal atres ia, cleft 
l ip/palate, renal abnormal it ies, and hypogonadotropic hypogonad ism.2 The genet ic aet iology of 
CHARGE syndrome was clar ified in 2004, when mutat ions in the bhromodomain .!:felicase .QNA 
bind ing protein 7 (CHD7) gene were descr ibed.7 
Some of the congen ital abnormalities present in CHARGE syndrome can lead to premature 
death. Abnormal it ies that can be l ife-threatening in the neonatal per iod are com plex heart defects, 
b ilateral choanal atres ia, oesophageal atres ia, severe T-cell deficiency and brain anomal ies. 1 •8·1 1 
However, from clin ical practice, we know that a s ign ificant percentage of ch ildren w ith CHARGE 
syndrome die after the neonatal per iod (with post-neonatal per iod defined as 28 days or older). Death 
is sometimes related to surgical procedures or major congenital abnormal ities, but occasionally it 
occ urs suddenly and unexpectedly. Prev ious stud ies have descr ibed the cl inical features in l arge 
ser ies of pat ients w ith CHARGE syndrome, but did not g ive details on causes of death. 1 •8•9•1 2• 13 We 
have, therefore, focused on causes of death in pat ients w ith CHARGE syndrome that died after the 
neonatal per iod . We collected med ical data on three deceased ch ildren from a follow-up cohort 
of 48 CHARGE patients and retrospectively on an additional four deceased patients. Based on our 
findings we propose recommendat ions to prevent premature death in patients with CHARGE 
syndrome. 
PATIENTS AND METHODS 
We studied a cohort of 48 pat ients with CHARGE syndrome who were seen at the mult id isc iplinary 
CHARGE outpatient cl in ic in the Netherlands between 2005 and 2009. The mean age at first 
admiss ion to the CHARGE outpat ient cl in ic was 11 years 8 months (range 4 months - 49 years). All 
48 patients (21 females, 27 males) had definite CHARGE syndrome, 46 had a CHD7 mutat ion (CHD7 
analys is as descr ibed in Jongmans et a/12 and the other two pat ients fulfilled the cl in ical cr iter ia 
descr ibed by Blake or Verloes. 14•15 Three of the pat ients in this cohort d ied at age 11.5 months, 8 years 
and 22 years. These data were used to produce a Kaplan-Meier actuarial surv ival curve. 
In addit ion, we collected the medical data of a further four pat ients w ith CHARGE syndrome 
who had d ied after 1 1  months of age. These pat ients were ident ified through the D utch pat ient 
organ isat ion (n=l ), through the database of the De partment of Genet ics, University Medical Centre 
Gron ingen (n=l ), and through the C anadian database of CHARGE pat ients ( Prof. K. Blake, n=2). All 
pat ients either fulfilled the cl in ical criter ia for CHARGE syndrome postulated by Blake or Verloes 14•1 5  
and/or had a pathogenic CHD7 mutat ion. The 22q l 1 delet ions were excluded in all patients by 




the Dutch patients gave informed consent to release the medical records and for publishing 
photographs. Ethical consent was granted by the IWK Health Centre for chart review of the Canadian 
patients. 
In the surviving patients of ten years and older from the CHARGE outpatient clinic (n=25), 
we scored the clinical features that were present in their first 1 0  years of life. We compared these 
features with the features of the six patients that died before 1 0  years of age (two patients from the 
CHARGE outpatient clinic and four patients from other centres). We tried to identify possible risk 
factors for premature death. One of the factors we scored was feeding difficulties, which we defined 
as feeding problems necessitating tube feeding (at present or in the past). Breathing difficulties 
were scored if patients had had a tracheotomy or needed extra oxygen. A x2-test was performed to 
Identify significant differences between the two groups (significance level 0.05). 
RESULTS 
The demographics, results of CHDl analysis, scores on Blake's and Verloes' criteria, and the clin ical 
details of the seven deceased patients with CHARGE syndrome are summarized in Table 1 .  A Kaplan­
Meier actuarial survival curve is presented in Figure 1, showing the incidence of premature death 
among patients with CHARGE syndrome, who were seen in the multidisciplinary CHARGE outpatient 
clinic in the Netherlands. Three of these patients died at the ages of 1 1 .5 months, 8 years and 22 
years, respectively, giving an actuarial post-neonatal survival of 98% at 1 year of age, 95% at 1 0  
years of age and 76% a t  2 5  years of age. We would l ike to stress that this survival curve only applies 
to patients, who survived the neonatal period, as that is the population of the CHARGE outpatient 
clinic. 
Patient A 
Patient A (Figure 2A) had oesophageal atresia, ventricular and atrial septal defects and brain 
anomalies (hypoplasia of cerebrum/cerebellum, smal l  pons). He received tube feeding until he was 
two years old and underwent fundoplication for gastro-oesophageal reflux disease (GERD). He had 
recurrent aspiration pneumonias. He ingested solid food rapidly but experienced problems with 
swallowing liquids. His parents described him as a voracious eater. A barium swallow was advised, 
but before this could take place he died unexpectedly while eating when he was 8 years old. His 
mother heard laboured breathing and saw he was choking. She was not able to free the airway; 
Heimlich manoeuvre and resuscitation were not successful. I ntubation by the emergency team 
failed. In the hospital (90 min later), secondary respiratory aspiration was seen. Because of the 
deteriorated respiratory and neurological condition, resuscitation was stopped. The cause of death 
was fatal choking on food. No autopsy was performed. 
Patient B 




Table 1 .  Clinical features of seven deceased patients with CHARGE syndrome 
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CHARGE features• Cranial nerve Features contributing to 
H, G, E 
C, R, G, E 
C, A, G, E  
C, H, R, G, E 
C, H, A, R, E 
C, H, A, R, G, E 
C, H, A, R, G, E 
dysfunction' premature death• 
1 1 1, VII, VIII, IX-X FD, GERD, RA, SGS, TE 
VII, VIII, IX-X CP, FD, GERD, RA 
VII, IX-X FD, GERD, LM 
VIII, IX-X FD, GERD, RA, TE 
IX-X FD, GERD 
V, VII, VIII, IX-X CLP, FD, GERD 
IX-X CP, FD, GERD, RA, SGS 
Cause of death 
Fatal choking on food 
Diagnosed with pneumonia: 
respiratory aspiration or circulatory 
arrest? 
Diagnosed with viral respiratory tract 
infection: 
respiratory aspiration or circulatory 
arrest? 





Cases were identified through the CHARGE outpatient clinic (cases A-C), through the database of the Department of Genetics, University Medical Centre Groningen (case D), 
through the Canadian database (cases E and F) and through the Dutch patient organisation (case G) . 
• F, female; M, male. b m, months; y, years. ' fs, frameshift mutation (c.1820_ 1 82 1  insTTGT, p.Ala608fs; c.4779del, p.Gln 1 S9Sfs; c.683Sdel, p.Ala2279fs); non, nonsense mutation 
(c.934C> T, p.Arg31 2X); U, unknown. d +, positive, or -, negative for clinical criteria; a, atypical CHARGE patient; * semicircular canal imaging not performed. • C, coloboma; 
H, heart defect; A, atresia or stenos is of choanae; R, retardation of growth and/or development; G, genital hypoplasia; E, ear anomalies or deafness. ' Ill, oculomotor nerve 
palsy; V, trigeminal nerve palsy; VII, facial nerve palsy; VIII, sensorineural hearing loss; IX-X, swallowing problems. 9 CLP, cleft lip and palate; CP, cleft soft palate; FD, feeding 




















and respiratory insufficiency, which necessitated a tracheotomy until he was ten years old. He was 
fed by a G-tube and fundoplication was performed because of GERD. The day before his death, at 
age 22 years, he was diagnosed with pneumonia and given antibiotic treatment. The next evening, 
his condition seemed to have improved, but he died unexpectedly while lying on his bed. Although 
some vomit was found, his parents did not have the impression that he had aspirated. Autopsy was 
not performed and cause of death is unknown. He may have died of respiratory aspiration or cardiac 
arrest. 
Patient C 
Patient C (Figure 2C) had neonatal convulsions and brain anomalies (enlarged ventricles, abnormal 
pons). For several days a Mayo tube was needed because of respiratory problems (unilateral 
choanal atresia and laryngomalacia). He was fed by a G-tube and had GERD. A barium swallow 
was performed a few days before his death, showing abnormal swallowing movements and nasal 
regurgitation. At age 11.5 months, a viral upper respiratory tract infection was diagnosed and within 
48 hours he died unexpectedly during the night. When his parents found him, he had a pink colour 
and was still warm; resuscitation was unsuccessful. No autopsy was performed and the cause of 
death is unknown. It was speculated that he died from respiratory aspiration or circulatory arrest 
(myocarditis or arrhythmia). 
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Figure 1 .  Kaplan-Meier curve. Kaplan-Meier post-neonatal actuarial survival of 48 patients with CHARGE 
syndrome. Along the curve is  the number of patients that were still being fol lowed up at the Dutch CHARGE 
outpatient clinic. 
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Patient D 
Patient D (Figure 2D) had oesophageal atresia, a congenital heart defect ( Fallot 's tetralogy, aberrant 
course of subclav ian artery and aorta  and a dysplastic pulmonary valve) and brain anomalies 
(polymicrogyr ia and abnor mal cerebellum). In addition, on ECG examination supraventr icular 
tachyc ardias were recorded. He suffered from recurrent aspiration pneumonias and rec eived tube 
feeding. Fundoplication was performed for GERO. When he was 13 months old, surgical correction 
of the Fal lot 's tetra logy was performed. The surgery and the post-operat ive stay in the hospital were  
uneventful and after four weeks he was discharged in good condition . A few days later, his parents 
found him dead in h is bed at n ight (age at death 1 4  months). No autopsy w as perfo rmed and the 
c ause of death is unknown. He may have had an arrhythmic event, but this remains s peculative 
w ithout monitoring. In general, supraventricular arrhythmias do not cause sudden death at this age. 
It is also possible he died from respiratory aspiration . 
Figure 2. Photographs of deceased patients with CHARGE syndrome. (A) Patient A at age 7 years 6 months, with 
strabismus, broad short neck and low set dysmorphic ears with triangular conchae and absent ear lobes. (B) 
Patient B at age 20 years 1 O months, with strabismus, left facial palsy, deviated nose and bilateral cup ears. (CJ 
Child C at 3 months of age, showing a square face with small chin and low set dysmorphic ears without lobes. (D) 
Child D at 1 month (left) and 6 months (right) of age showing strabismus and dysmorphic ears. (G) Child G at 3 





Patient E had Fallot's tetralogy and bilateral choanal atresia. She had a G-tube for severe feeding 
problems and GERD. She died at age 27 months. The cause of death is unknown, but it was thought 
that severe GERD led to respiratory aspiration and therefore played a major role in her death. No 
autopsy was performed. 
Patient F 
Patient F had seizures and a complex heart defect (double outlet right ventricle, sub-aortic stenosis 
and ventricular septa I defect). A G-tube was inserted at the age of 1 5  months because of feeding 
problems and withdrawn when he was 5 years old. The presence of GERD led to a fundoplication 
procedure. He suffered from recurrent bowel obstructions and sepsis, which was also the reason for 
his final admission to the hospital. After recovery from the bowel sepsis, he died suddenly during 
hospitalization at age 9 years. No autopsy was performed; as the bowel sepsis was no longer a 
problem at the time of death, other issues such as respiratory aspiration, were cited as contributing 
to his death. 
Patient G 
Patient G (Figure 2G) was born with bilateral choanal atresia, a complex heart defect (double outlet 
right ventricle, pulmonary valve stenosis and ventricular septal defect) and brain abnormalities 
(hypoplasia of the vermis, enlarged ventricles). Feeding difficulties and recurrent aspiration 
pneumonias required insertion of a G-tube. He underwent fundoplication surgery for GERD. At 
the age of 13 months, he had cardiovascular surgery complicated by post-operative respiratory 
problems, propofol intoxication, hypertriglyceridaemia, liver and kidney function disturbances, 
sepsis and hypotension. He developed a severe posthypoxic encephalopathy with cerebral atrophy. 
Contact was no longer possible and from then on he received only palliative treatment. He died at 
age 1 4  months. No autopsy was performed. 
We compared the features of the survivors aged 10 years and older (n=25) with the patients who 
died before they were 10 years old (n=6) (Table 2). The most striking difference was seen for GERD, 
which was present in all of the deceased patients, but only in 25% of survivors before the age of 10 
years (p=0.002, x2-test, univariate analysis). The combination of breathing and feeding difficulties 
with GERO was also significantly more often present in the deceased patients (p=0.029). Apart 
from congenital heart defects (p=0.022), none of the other clinical features was significantly over­
represented in the deceased patients. 
DISCUSSION 
Post-neonatal demise is an under-estimated complication in patients with CHARGE syndrome. In 
our prospective cohort of 48 patients with CHARGE syndrome, three patients died after 11 months 
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of age, resulting in an actuarial post-neonatal survival of 95% and 76% at the ages of 1 0  and 25 
years, respectively (Figure 1 ). This percentage is in line with previous studies that reported mortality 
rates between 7.5% and 30% in CHARGE patients older than one year.8•1 1•16•17 It must be noted that 
our prospective cohort (from the Dutch CHARGE outpatient clinic) is biased. Very severely or very 
mildly affected patients are often under-represented in this kind of multidisciplinary clinics and 
some very severe cases may have already died at a young age. Therefore, this survival curve only 
applies to patients who survived the neonatal period. 
Table 2. Comparison of features of surviving and deceased patients with CHARGE syndrome 
Surviving Patients 
patients .!: 1 O years who died < 1 O years Comparison 
n=25 % 
Features 
n=6 % p-value * 
Male gender 1 2/25 48.0% 5/6 83.3% NS 
Bilateral choanal atresia 5/25 20.0% 1 /6 1 6.7% NS 
Congenital heart defect 7/25 28.0% 5/6 83.3% 0.022 
Trachea-oesophageal anomaly 1 /25 4.0% 2/6 33.3% NS 
Breathing difficulties• 8/24' 33.3% 4/6 66.7% NS 
Brain malformation 1 3/1 7d 76.5% 4/4d 1 00.0% NS 
GERD 6/24 2S.0% 6/6 1 00.0% 0.002 
Feeding difficultiesb 1 4/24 58.3% 6/6 1 00.0% NS 
Epilepsy 3/24 1 2.5% 1 /6 1 6.7% NS 
Breathing + feeding difficulties 4/24 1 6.7% 4/6 66.7% 0.029 
+ GERD 
Breathing + feeding difficulties 7/24 29.2% 4/6 66.7% NS 
• Breathing difficulties: patient had needed oxygen or tracheotomy. b Feeding difficulties: patient had required 
(short- or long-term) tube feeding. ' Information on this specific feature was unknown in one patient, who was 
therefore not included in the analysis. d Brain scans were performed in only 1 7  /25 surviving patients and in 4/6 
deceased patients. * p-value (x'-test, univariate analysis); NS, not significant. GERD, gastro-oesophageal reflux 
disease. 
In this study, we describe seven cases of post-neonatal death. In most of these, death occurred 
suddenly and unexpectedly. In five patients the cause of death was likely attributable to respiratory 
aspiration and/or circulatory arrest. One patient choked during eating and another patient died after 
post-operative complications. Our observations are in line with a previous study that reported the 
causes of death in five patients with CHARGE syndrome older than one year to be circulatory arrest 
(n=2), respiratory aspiration (n=2) and postoperative complications (n=l ).17 Two other studiesa.1 1  
proposed respiratory aspiration as a major cause of  mortality. Our study supports this theory, with 
respiratory aspiration likely contributing to early death in 5/7 patients (Table 1 ). However, due to 
the predominantly retrospective nature of our study and the lack of autopsy data, the cause of 




death, like congenital heart defects (present in 3/5 patients), brain abnormalities (present in the two 
patients who had a cerebral magnetic resonance imaging (MRI) scan of these five patients), epilepsy 
(1 /5), or oesophageal atresia (1 /5). 
Unlike respiratory aspiration, choking has not been reported before as a cause of premature 
death in CHARGE syndrome. We presented the tragic history of patient A, who choked during eating 
when he was 8 years old. A major risk factor for choking is status post-repair of oesophageal atresia, 
but subglottic stenosis, swal lowing difficulties and voracious eating behaviour could also have 
contributed to his death.10-21 
Peri-operative complications are another important cause of death in post-neonatal CHARGE 
syndrome patients. Post-operative mortality rates are higher in patients with CHARGE syndrome than 
in the general population. Since patients with CHARGE syndrome generally have to undergo several 
surgical procedures, this risk should not be underestimated.8 Patients with airway malformations, 
severe feeding difficulties and GERD have a high risk of post-operative complications. Cardiovascular 
surgery in particular seems to pose the highest risk. Post-operative airway events occur after 35% 
of anaesthetic procedures in  CHARGE syndrome.2' It has been hypothesized that CN defects might 
underlie post-operative airway problems, since these nerves play an important role in the proper 
handling of oral secretions (which are increased after anaesthesia).11 Problems can also occur pre­
operatively, since intubation problems are often seen in patients with CHARGE syndrome. This is 
main ly due to congenital airway malformations (choanal atresia, cleft l ip/palate, micrognathia in 
combination with an anterior larynx, subglottic stenosis and laryngeal clefts).22•23 
GERD, feeding/breathing difficulties and congenital heart defects were identified as risk factors 
for early death in our outpatient clinic population. On comparing the features of the surviving 
patients of ten years and older (n=25) to the patients who died before ten years of age (n=6), we 
saw an overrepresentation of congenital heart defects and GERD in the deceased patients (Table 
2). I n  a previous study, these features were found in 4/5 and 2/5 deceased patients, respectivelyY 
Congenital heart defects can lead to post-neonatal death due to rhythm disturbances and 
circulatory stand-still. However, in patients with no prior history of rhythm disturbances, this is not 
a common cause of death. The other risk factors, feeding difficulties and GERD, both predispose 
to respiratory aspiration, which can lead to premature death. Both are seen in the majority of 
CHARGE patients.8•1 7•22-14 Respiratory aspiration is also common in CHARGE syndrome (prevalence 
47-74%).1 7•22•25 This explains why the combination of feeding/breathing problems and GERD have 
been determined as risk factors for premature death in our study group. 
CN dysfunction is prevalent in CHARGE syndrome and is l ikely to be the underlying common 
risk factor, as it can cause both swallowing/breathing problems and GERD. CN V, VII, IX, X and XII 
play an important role in the swallowing process, as they coordinate muscle movements and supply 
sensory information from the oral, pharyngeal and laryngeal region (Table 3).24•26 Blake et al reported 
dysfunction of at least one CN in 92% of patients with CHARGE syndrome and described multiple 
CN involvement in 72%.5The underlying cause of CN dysfunction in  CHARGE syndrome is unknown, 
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but abnormalities of the brainstem or CN nuclei could play a role. Unfortunately, hardly any research 
has been performed by MRI brain imaging or by post-mortem brain examination, to unravel the 
anatomical substrates underlying the CN anomalies in CHARGE syndrome. Detailed clinical 
assessment of CN function in CHARGE syndrome patients may also shed light upon the precise role 
of CN dysfunction in swallowing, aspiration, GERO and other possibly fatal complications. 
Table 3. Overview of cranial nerve involvement in phases of normal swallowing 
Swallowing phase Action 
Oral phase Mastication of the food and mixing it with saliva 
for passage into the oropharynx 
Swallow reflex: soft palate moves upward, larynx 
Pharyngeal phase and hyoid bone move forward and upward, 
epiglottis folds back, tongue pushes food bolus 
into the hypopharynx 
Downward movement of food bolus by a 
Oesophageal phase peristaltic wave from the upper to the lower 
oesophageal sphincter, entrance of food bolus 





V3, Vll, X I I  




V, Vll, IX 
IX, X 
X 
• 1, involuntary; V, voluntary. b V3, mandibular branch of trigeminal nerve; VII, facial nerve; IX, glossopharyngeal 
nerve; X, vagus nerve; XII, hypoglossal nerve 
In order to prevent premature death in patients with CHARGE syndrome, we recommend that 
every CHARGE patient with feeding difficulties (at present or in the past) should be thoroughly 
assessed by a multidisciplinary team (preferably consisting of an ear-nose-throat (ENT) surgeon, 
gastroenterologist, physiotherapist, occupational therapist, speech therapist and nutritionist). CN 
function should be investigated and should include analysis of chewing/biting (V), facial muscles 
(VII), velum function (IX), larynx mobility and closure of glottis (X), gag and cough reflexes (IX/X), 
tongue movement (XII), and the assessment of sensibility of the oropharynx (V, VII), pharynx (IX) 
and larynx (X). Swallowing studies, laryngopharyngoscopy, oesophageal pH studies, oesophageal 
manometry, and polysomnography may also be appropriate.27 In order to prevent respiratory 
aspiration, swallowing problems and GERO should be treated without delay. Possible treatments 
include gastrostomy, anti-reflux medication and fundoplication. Respiratory problems can 
necessitate tracheotomy, but sometimes injection of botulinum toxin (botox) into the salivary 
glands can avert this.5•28 In patients with a high risk of choking (as evaluated by the multidisciplinary 
team), we advise training the family or home carers in cardiopulmonary resuscitation and the 
Heimlich manoeuvre. For all patients with CHARGE syndrome, careful pre-operative assessment 




a paediatric anaesthesiologist and/or laryngologist should be present in the operating room to 
anticipate possible intubation problems. Patients with CHARGE syndrome should be monitored for 
longer after surgery in order to identify and treat post-operative airway events. Finally, we strongly 
advise to perform autopsy in deceased CHARGE patients in order to gain more insight into causes 
of death. 
In conclusion, post-neonatal death is not a rare event in patients with CHARGE syndrome and 
it often occurs unexpectedly. Gastro-oesophageal reflux and poor coordination of swallowing and 
breathing due to CN dysfunction seem to be the major risk factors. 
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ABSTRACT 
Kallmann syndrome (KS) is the combination of hypogonadotropic hypogonadism and anosmia or 
hyposmia, two features that are also frequently present in CHARGE syndrome. CHARGE syndrome 
is caused by mutations in the CHDl gene. We performed analysis of CHDl in 36 patients with KS 
and 20 patients with normosmic idiopathic hypogonadotropic hypogonadism (nlHH) in whom 
mutations in KAL 1, FGFR1, PROK2 and PROKR2 genes were excluded. Three of 56 KS/nlHH patients 
had de novo mutations in CH07. In retrospect, these three CH07-positive patients showed additional 
features that are seen in CHARGE syndrome. CH07 mutations can be present in KS patients who have 
additional features that are part of the CHARGE syndrome phenotype. We did not find mutations 
in patients with isolated KS. These findings imply that patients diagnosed with hypogonadotropic 
hypogonadism and anosmia should be screened for clinical features consistent with CHARGE 
syndrome. If such features are present, particularly deafness, dysmorphic ears and/or hypoplasia or 
aplasia of the semicircular canals, CHDl sequencing is recommended. 
1 52 
CHD7 mutations in patients initially diagnosed with Kallmann syndrome 
I NTRODUCTION 
Kallmann syndrome (KS) is a congenital disorder that combines hypogonadotropic hypogonadism 
and anosmia.1 Three modes of inheritance have been described: X-linked recessive, autosomal 
dominant and more rarely autosomal recessive. To date, several genes have been identified to c ause 
KS, either alone or in combination . Mutations in these genes together account for approximately 
30% of all c ases. KAL 1 encodes the protein anosmin and is involved in the X-linked form of KS 
(KA L  1, OM IM #308700).2•3 Loss-of-function mutations in the fibroblast growth factor receptor- 1 
gene (FGFR7) c ause a form of KS (KAL2, OM IM #147950) that is generally inherited in an autosomal 
dominant way.•.s Dode et al reported in a further 1 0% of patients mutations in the prokineticin 
receptor-2 (PROKR2, KA L3, OM IM #607123) and prokineticin-2 (PROK2, KA L4, OM IM #607002) genes, 
encoding a cell surface receptor and one of its ligands, respectively.6 Mutations of the ligand, 
PROK2, c an c ause KS as well as normosmic idiopathic hypogonadotropic hypogonadism (nlHH) 
within the same family.6.,The same intrafamilial phenotypic variability is seen in patients with FGFR1 
mutations.• Thus, KS is a phenotypically and genotypically heterogeneous disorder. Not only the 
degree of hypogonadism and anosmia may v ary significantly, but also other symptoms including 
bimanual synkinesia and dental agenesis (KAL1 and FGFR1), renal anomalies (KAL1) and cleft lip/ 
p alate (FGFR7) occur with variable frequency.a 
CHARGE syndrome (OMIM #2 14800) is an autosomal dominant condition characterized by a 
v ariety of congenital anomalies including £Oloboma, heart defects, choanal _atresia, retarded growth 
and development, genital hypoplasia, _gar anomalies and deafness. Other commonly observed 
congenital defects are semicircular canal hypoplasia, facial nerve palsy, cleft lip/palate and tracheo ­
oesophageal fistula.9 Our group has discovered CHDl as the c ausative gene in CHARGE syndrome.10 
Since this discovery, several authors have reported on the phenotypic spectrum of CHO7-positive 
p atients, including patients without typical CHARGE syndrome. 1 1-1 3 Therefore, we presume that the 
mild end of the phenotypic spectrum of CHDl mutations is not yet completely explored. 
Recent studies revealed that anosmia and abnormal olfactory bulb development, as well as 
hypogonadotropic hypogonadism, are almost consistent findings in CHARGE syndrome, indicating 
that the key features of KS are also present in CHARGE syndrome. 1•·16  For this reason, it has been 
suggested by others that CHDl may be considered a candidate locus in suspected KS cases without 
known mutations.a This hypothesis is worthwhile exploring, also because mutations in CHDl can 
result in a much milder phenotype than the classical CHARGE syndrome phenotype. Therefore, we 
sequenced CHDl in a l arge group of patients diagnosed as KS or nlHH but without mutations in 
KAL 1, FGFR 1, PROK2 and PROKR2. 
MATERIALS AND METHODS 
Patients 
A cohort of seven Japanese patients with a clinic al diagnosis of KS, without mutations in KAL 1, 
FGFR1, PROK2 and PROKR2, was screened for CHDl mutations.17 The diagnosis KS in this cohort was 
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based on an underdevelopment of secondary sexual characteristics in combination with anosmia or 
hyposmia. Subsequently, the cohort was enlarged by 49 KAL 1, FGFR1, PROK2 and PROKR2 negative 
North American patients with KS or nlHH. GnRH deficiency in this cohort was defined by (a) absent/ 
incomplete puberty by age 1 8  yr; (b) serum testosterone < 1 00 ng/dL in men or estradiol <20 pg/ml 
in women in association with low or normal levels of serum gonadotropins; (c) otherwise normal 
pituitary function; (d) normal serum ferritin concentrations; and (e) normal magnetic resonance 
imaging (MRI) of the hypothalamic-pituitary region.5 
The patients in whom CHDl mutations were identified were careful ly evaluated for clinical 
features of CHARGE syndrome. The CHDl gene was analyzed in the parents. The patients or their 
legal representatives gave informed consent for the DNA studies and the col lection of clinical data. 
The studies were approved by the institutional review boards. 
Mutation screening 
DNA was isolated according to standard procedures. The 37 coding exons of the CHDl gene (exon 
2-38, accession number NM_0l 7780, NCBI) and their flanking intron sequences were amplified by 
polymerase chain reaction (PCR). Subsequently, sequence analysis was performed using a 3730 
automated sequencer (Applied Biosystems, Foster City, CA). Primer information and PCR conditions 
are given in a previous report of our group." 
The DNA samples of eleven mutation-negative patients were subsequently screened for 
exon deletions and/or duplications of the CHDl gene by multiplex ligation-dependent probe 
amplification (MLPA) analysis (Table 1 ). We used a commercially available set of probes, the SALSA 
P201 kit (MRC-Hol land, Amsterdam, The Netherlands; http://www.mrc-holland.com). Further details 
are described in our recent report on MLPA analysis of the CHDl gene.18 
RESULTS 
The CHDl gene was first screened in a cohort of seven KAL 1, FGFR1, PROK2 and PROKR2 negative 
patients of Japanese descent (five males, two females). All had hypogonadotropic hypogonadism 
and anosmia, whereas some had additional symptoms. Their cl inical features are summarized in 
Table 1 and patient 2 is shown in Figure 1 .  
I n  two of the seven patients a heterozygous mutation i n  CHDl was identified: one nonsense 
mutation (c.8803G> T; p.Glu293SX) and one missense mutation (c.6347T>A; p.lle21 1 6Asn). The 
mutations were proven to be de nova in  both patients and were not present in  600 a l leles of healthy 
controls. 
The study cohort was extended by 49 North American patients (28 males, 21 females), including 
29 patients with KS and 20 with n lHH of whom three had a positive family history for KS. Some of 
these patients had additional phenotypic features (Table 1 ). I n  one of the patients (patient 8), a de 
nova pathogenic nonsense mutation in  CHDl was found (c.6070C> T; p.Arg2935X). 
As whole exon deletions or duplications will be missed by sequence analysis, we performed 
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Table 1 .  Clinical characteristics of all patients and results of CHDl analysis 
No. Sex Diagnosis Additional Features Family Mutation Parents MLPA 
CHD7 performed 
M KS Dental agenesis, Sp c.8803G>T; De novo 
high-arched palate, p.Glu293SX; 
unilateral perceptive exon 38 
deafness and short 
stature 
2 M KS Cleft palate, auricular Sp c.6347T>A; De novo 
dysplasia, nystagmus, p.lle21 1 6Asn;exon 
bilateral perceptive 31 
deafness, hypoplasia 
of semi-circular canals 
3 F KS Sp 
4 F KS Sp 
s M KS High-arched palate Sp 
6 M KS Ptosis Sp 
7 M KS Sp 
8 F KS Facial nerve palsy, Sp c.6070C>T; De novo 
bilateral colobomas, p.Arg293SX; 
cleft lip/palate, exon 30 
deafness, short stature 
and developmental 
delay 
9 F KS Fam 
+ 
1 0  M KS Fam 
1 1  F KS Crohn's disease and Fam 
syndactyly 
1 2  M KS Fam 
1 3  M KS Sp 
1 4  F KS Sp 
1 5  F KS, Choanal atresia Fam + 
1 6  M KS Fam 
1 7  M KS Congenital deafness Sp 
and Hirschsprung's 
disease 
1 8  F KS Fam 
1 9  M KS Fam 
20 F KS Fam + 
21 F KS Hearing impairment Fam 
22 M KS Deafness Sp 
23 F KS Multiple cranial nerve Sp + 
abnormalities 
24 F KS Fam 
25 F KS Sp + 
26 M KS Fam 
27 M KS Hearing impairment Sp 
28 M KS Fam 
29 M KS Fam 
30 M KS Cryptorchidism Fam 
31 M KS Fam 
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32 F KS Narrow palate Fam 
33 F KS High-arched palate Fam 
and hyperlaxity of 
hand joints 
34 M KS Macrocepha ly, u 
hypertelorism, 
high arched palate, 
ataxia, Dandy Walker 
malformation and 
developmental delay 
35 M KS Fam 
36 M Partial KS Spinal muscular Sp 
atrophy 
37 M IHH, KS in  Cardiac septum defect Fam 
family 
38 M IHH, KS in  Hearing impairment Fam 
family 
39 M IHH, KS in  Fam 
family 
40 F IHH Fam 
41 M IHH Sp 
42 F IHH Cardiac septum defect Sp 
43 M IHH Cryptorchidism Fam 
44 M IHH Growth hormone Fam 
deficient 
45 F IHH Fam 
46 F IHH Fam 
47 M IHH Cryptorchidism, blind, Sp 
seizures, mental 
retardation and short 
stature 
48 F IHH Fam 
49 M IHH Ataxia Sp 
so F IHH Fam 
51 F IHH Fam 
52 M IHH Fam 
53 M IHH Fam 
54 M IHH Developmental delay Fam 
and high arched 
palate 
55 M IHH Fam 
56 F IHH Fam 






F, female; Fam, familial; IHH, idiopathic hypogonadotropic hypogonadlsm; KS, Kallmann syndrome (IHH + 
anosmia); M, male; MLPA, multiplex ligation-dependent probe amplification; partial KS, patient with IHH and 
anosmia, with some degree of spontaneous pubertal development; Sp, sporadic; U, unknown. 
MLPA analysis. Due to a limited amount of available DNA, we were only able to finish this analysis in 
eleven patients. Two patients with a relatively high suspicion for CHARGE syndrome based on the 
features choanal atresia and multiple cranial nerve anomalies (respectively, patient 15 and 23; Table 
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Figure 1. Lateral view of patient 2. Note the dysmorphic ears with absence of the earlobe and the lower helical 
fold, and a triangular concha. These dysmorphisms are typical for CHARGE syndrome. 
1) were among those eleven patients. No exon copy number alterations were found. 
The main features of the three patients carrying a mutation in CHDl are given in Table 1 .  All three 
patients were proven to be anosmic by formal smell tests. Audiometry revealed a left-sided hearing 
impairment of 70 dB in patient 1, a bilateral hearing impairment of 60-90 dB in patient 2, and left­
sided complete sensorineural deafness and right-sided partial conductive hearing impairment in 
patient 8. Patient 1 had agenesis of four permanent teeth, the first upper and lower molars. No 
choanal atresia or heart defects were present in patients 1, 2 and 8. Colobomas were present in 
patient 8 but excluded by fundoscopy in patients 1 and 2. Patient 2 experienced feeding difficulties 
during infancy, but these were ascribed to the cleft palate. The dysmorphisms of the ears of patient 
2 are very characteristic for CHARGE syndrome with absence of the earlobe and the lower helical 
fold, and a typical triangular concha (Figure 1 ). After identification of the CHDl mutation, a CT 
scan of the os petrosum showed bilateral hypoplasia of the semicircular canals. In patients 1 and 
8, imaging studies of the temporal bones were not possible. Upon re-evaluation, patient 8 has not 
only deafness and bilateral colobomas but also left-sided facial nerve palsy, cleft lip and palate, 
short stature and developmental delay. 
In retrospect, patients 2 and 8 have typical CHARGE syndrome according to the commonly used 
clinical criteria9 while patient 1 has only some features of this syndrome. 
DISCUSSION 
Hypogonadotropic hypogonadism is a frequent feature in CHARGE syndrome. Chalouhi et al tested 
the olfactory function of 1 4  children with CHARGE syndrome and showed that all children had some 
degree of olfactory deficiency.14 Pinto et al showed that olfactory deficiency and abnormal olfactory 
bulbs were present in all 18 CHARGE syndrome patients in their cohort.15 
These observations prompted us to analyze the CHDl gene in 36 patients with KS and 20 patients 
with nlHH lacking mutations in KAL 1, FGFR1, PROK2 and PROKR2. CHDl mutations were identified by 
sequence analysis in two of seven Japanese KS patients and in one of 49 KS/nlHH North American 
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patients. By routine sequencing of the CHDl gene, we may have missed mutations located deep in 
intrans or in the promoter region. Furthermore, MLPA analysis could not be performed in  al l  patients. 
Hypogonadism in KS is caused by GnRH deficiency. GnRH neurons of the forebrain are thought 
to originate from the nasal placode. During embryonic development, they migrate alongside the 
olfactory axons towards the hypothalamus. Mutations in KAL I, FGFR I, PROK2 and PROKR2 can 
result in hypogonadotropic hypogonadism and anosmia. Therefore, the protein products of these 
genes are thought to be involved in this combined migration process.8·19 Since hypogonadotropic 
hypogonadism and anosmia are frequently present in CHARGE syndrome as well, it is possible 
that the same embryonic migration process is disturbed in CHARGE syndrome. CHDl encodes a 
protein of the chromodomain (mromatin Qrganisation modifier) fami ly. This family shares a unique 
combination of functional domains consisting of two N-terminal chromodomains, followed by 
a SWl2/SNF2-like ATPase/-helicase domain and a DNA-binding domain. It is assumed that CHD 
protein complexes affect chromatin structure and gene expression and thereby play important roles 
in regulating embryonic development.20 Therefore, one might speculate that CHD7 has a possible 
influence on the expression or actions of KAL 1, FGFR I, PROK2 and/or PROKR2 during development. 
However, because mutations in these genes account for only 30% of all KS cases, it is possible that 
CHD7 impacts on other, yet undiscovered, KS genes. 
We identified a de novo CHDl mutation in three patients initially diagnosed with KS. The two 
nonsense mutations are known to be pathogenic. The missense mutation p.lle21 1 6Asn is not 
located in one of the known protein domains of the CHD7 protein, but it concerns a drastic amino 
acid change that has not been detected in over 600 control al leles. Furthermore, the p.Gly21 08Arg 
mutation has been shown to be associated with CHARGE syndrome in two families with a variable 
phenotype, indicating that this part of the protein probably has an important function.12 This 
indicates that the p.lle21 1 6Asn mutation is possibly pathogenic. 
In retrospect two of the three CHDl positive patients (Patients 2 and 8) had typical CHARGE 
syndrome with the presence of at least three major features.9 Patient 1 presented with only two 
additional CHARGE features (short stature and uni lateral hearing impairment), although one should 
notice that vestibular function was not tested in this patient. 
From this study, we conclude that it is important to eva luate patients with hypogonadotropic 
hypogonadism and anosmia for clinical features characteristic of CHARGE syndrome. All three 
patients were proven to be anosmic. Therefore, the chance to find a CHDl mutation seems higher 
in anosmic patients although the study group is too smal l  to conclude that CHDl mutations cannot 
occur in patients with normosmic IHH. Indeed some patients with CHARGE syndrome are able to 
smell (personal observations). Because al l  three patients suffered from hearing impairment, it is 
tempting to regard this feature as discriminating. However, sensorineural hearing impairment is also 
an associated feature in  males with KAL 1 mutations. Thus, hearing abnormalities may be a sensitive 
but not very specific symptom of CHDl mutations. Hypoplasia or aplasia of the semicircular canals is 
a much more consistent feature in  CHARGE syndrome, even in  mildly affected patients.9·12 Therefore, 
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h istory taking regarding balance disturbances and gross motor development might reveal indicative 
information for the presence of a CHDl mutation. Abadie et al have described a specific pattern of 
postural behaviour related to vestibular anomalies in CHARGE syndrome. They noticed a frequent 
inabi lity to crawl on all fours without resting the head on the floor (5-point crawl), a prolonged 
duration of standing with support stage and an inability to ride a bike without stabilizers.21 After 
the first years of life, balance disturbances may not be unequivocally present as a result of visual 
compensation. In these patients, disequilibrium in  the dark is a helpful indication of vestibular 
deficit. If there is doubt about the vestibular function, screening for vestibular areflexia or imaging 
of the semicircular canals will be helpful. In the newborn, agenesis of the semicircular canals can be 
visualized on plain profile X-ray of the sku ll.9 In older patients, computerized tomography or MRI is 
necessary. 
Final ly, di lated fundus examination can be performed to reveal an optic disc coloboma. A less 
i nvasive, but of course also less accurate method, would be to ask for the presence of an optic field 
defect. 
CHDl screening in the large North-American cohort revealed only one mutation. In general, 
these patients underwent a more extensive clinical work-up.5 From this cohort, we learned that it is 
not useful to screen the CHDl gene in each patient diagnosed with KS or nlHH; additional CHARGE 
features should be present. Such additional features do not imply that a CHDl mutation wil l be 
present as has been demonstrated by patient 1 5  who has choanal atresia but no CHDl mutation. 
The patients carrying a mutation in CHDl in this cohort and the mild CHO7-positive patients 
reported by us in a previous study 1 2  show that the current diagnostic criteria can not a lways 
d iscriminate between patients with and without a mutation in CHO7.9•12 
We conclude that it is useful to screen patients with hypogonadotropic hypogonadism and 
anosmia for clinical features consistent with CHARGE syndrome, particularly hearing impairment, 
vestibular dysfunction and dysmorphisms of the ears. If additional features of CHARGE syndrome 
a re present, CHDl sequencing is recommended. 
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ABSTRACT 
Context Kallmann syndrome (KS) and CHARGE syndrome are rare heritable disorders in which 
anosmia and hypogonadotropic hypogonadism co-occur. KS is genetically heterogeneous and 
there are at least eight genes involved in its pathogenesis, whereas CHARGE syndrome is caused by 
autosomal dominant mutations in only one gene, the CHDl gene. Two i ndependent studies showed 
that CHDl mutations can also be found in a small minority of KS patients. 
Objective We aimed to investigate whether CHDl mutations can give rise to isolated KS or whether 
additional features of CHARGE syndrome always occur. 
Design We performed CHDl analysis in a cohort of 36 clinically well-characterised Dutch patients 
with KS but without mutations in KAL1. The KS genes with known incomplete penetrance, FGFR1, 
PROK2, PROKR2 and FGFB, were also studied. 
Results We identified six heterozygous PROKR2 mutations, one heterozygous FGFB mutation and 
three heterozygous CHDl mutations. The CHD7-positive patients were carefully re-examined and 
were all found to have additional features of CHARGE syndrome. 
Conclusions The yield of CHDl ana lysis in patients with isolated KS seems very low, but increases 
when additional CHARGE features are present. Therefore, we recommend performing CHDl analysis 
in KS patients who have at least two additional CHARGE features or semicircular canal a nomalies. 
Identifying a CHDl mutation has important clinical implications for the surveillance and genetic 
counsel l ing of patients. 
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INTRODUCTION 
Kallmann syndrome (KS) is characterised by the combination of anosmia and hypogonadotropic 
hypogonadism (HH).1 Anosmia, or the inability to smell, is the result of olfactory bulb defects,2.3 while 
HH presents as absent or impaired pubertal maturation and is caused by gonadotropin-releasing 
hormone (GnRH) deficiency.4 Besides anosmia and HH, other features are occasionally present in 
KS, e.g. bimanual synkinesia, unilateral renal agenesis, cleft lip/palate, hypodontia, hearing loss 
and, rarely, hand or feet anomalies.5•6 KS is very heterogeneous, both clinically and genetically. At 
present, eight genes are known to be involved in KS, but mutations in these genes are found in only 
25-35% of cases.7 12 Inheritance patterns are variable in KS: X-linked recessive (KAL 7 13• 14), autosomal 
dominant (FGFR1, 1 5  FGFB, 16 WDR11 1 1  and CHOl9·10), autosomal recessive ( PROK2, PROKR2 11 and 
NELF12) and digenic inheritance have been described.16-21 Mutations in KAL1 are always associated 
with HH and a smell deficit in males, whereas mutations in FGFR1, PROK2, PROKR2 and FGFB show 
variable expression and incomplete penetrance, indicating that patients can be asymptomatic, can 
have solely anosmia, solely HH, or KS.22 Heterozygous loss-of-function mutations in the CHDl gene 
were identified in patients with normosmic idiopathic HH (nlHH), KS and CHARGE syndrome.9·10 
CHARGE syndrome is a highly variable disorder in which congenital anomalies, multi-sensory 
impairment and variable mental retardation can occur.23 CHARGE is an acronym for ocular �oloboma, 
heart defects, �tresia of choanae, retardation of growth and/or development,genital hypoplasia and 
gar anomalies combined with deafness.24 The phenotypic spectrum of CHARGE syndrome is very 
broad, with some patients having few or mild features and other patients being severely affected.25 
HH and anosmia are present in the majority of patients with CHARGE syndrome,26 Recently, we 
showed that HH and anosmia always co-occur in CHARGE syndrome,27 which means that KS is part 
of the phenotypic spectrum of CHARGE syndrome, The CHDl gene is the major gene involved in 
CHARGE syndrome, with a CHDl mutation being present in more than 90% of the patients who fulfil 
the clinical criteria for CHARGE syndrome.26•28•30 
Conversely, CHDl mutations are not a major cause of KS, as only 3-5% of patients with nlHH or 
KS were found to have a CHDl mutation in two independent studies.9•10 The first study identified 
seven CHDl mutations in a cohort of 1 97 patients with nlHH or KS (7/1 97 = 3.6%). 10 Four of the 
CH07-positive patients were reported to have nlHH, while three patients had anosmia and thus 
KS. In the CH07-positive patients, no other features of CHARGE syndrome were present, except for 
cleft lip/palate and hearing loss, which can occur in both CHARGE and Kallmann syndromes. The 
authors concluded that CHDl mutations can give rise to isolated nlHH and KS. Unfortunately, it is 
not clear whether formal smell tests were used in this study or whether all the patients with a CHDl 
mutation were carefully re-evaluated for CHARGE features, e.g. fundoscopy to screen for retinal 
coloboma. The second study was performed by our group and found three CHDl mutations in a 
cohort of 56 nlHH/KS patients from Japan and North America in whom mutations in KAL1, FGFR1, 
PROK2 and PROKR2 had been excluded (3/56 = 5 .4%).9 The three CH07-positive patients were all 




of CHARGE syndrome. It was concluded that CHDl mutations in KS patients represent the mild end 
of the CHARGE spectrum and that it is only useful to perform CHDl analysis in  KS patients who have 
additional features of CHARGE syndrome. 
Because of the confl icting data from these two studies, we decided to investigate whether CHDl 
mutations can give rise to isolated KS in an independent cohort. We therefore analysed the CHDl 
gene in 36 clinically well-characterised Dutch patients with KS but without mutations in KAL 1. The 
KS genes with known incomplete penetrance, FGFR 1, PROK2, PROKR2, and FGFB, were also studied. 
The patients found to have a CHDl mutation were carefully re-evaluated for features of CHARGE 
syndrome. 
PATIENTS AND METHODS 
Patients 
A cohort of 36 Dutch KS patients (7 women, 29 men), without a hemizygous mutation in KAL 1 (KAL 1 
analysis was only performed in male patients), was informed about this study via their paediatric 
endocrinologist, endocrinologist, gynaecologist or clinical geneticist. The patients gave their 
informed consent for sequence analysis of FGFR 1, PROK2, PROKR2, FGFB and CHDl and for collection 
of their medical data via a questionnaire and/or retrospective chart review. The KS diagnosis was 
based on the presence of HH in combination with a smell deficit. HH was defined as no pubertal 
maturation in combination with low serum gonadotropins and sex steroids. The smell deficit 
was identified from the patient's history and/or forma l smell testing. The CHD7-positive patients 
who were identified in this study, were carefully re-evaluated for features of CHARGE syndrome 
and underwent formal smell testing (University of Pennsylvania Smell Identification test, UPSIT, 
Sensonics Inc, Haddon Heights, New Jersey, USA; www.sensonics.com3'). This study was approved 
by the ethical review board of the University Medical Centre Groningen (UMCG). 
DNA analysis 
DNA was extracted from peripheral blood lymphocytes using standard procedures. All individual 
exons of the respective genes were amplified by polymerase chain reaction (PCR, primers and 
PCR conditions are available upon request) and direct sequencing was performed on an ABI 3730 
automated DNA sequencer (Applied Biosystems, Foster City, CA, USA). The following GenBank 
accession numbers were used as reference sequences for the KAL 1, FGFR 1, PROK2, PROKR2, FGFB and 
CHD7 genes, respectively: NM_00021 6.2, NM 0231 1 0.2, NM 021 935.3, NM 1 44773.2, NM 0331 63.3 
and NM_0l 7780.2. In a l l  cases, the A of ATG was designated number 1 .  The intron sequences of the 
KALI, FGFR 1, PROK2, PROKR2, FGFB and CHD7 genes can be found in NG_007088.l ,  NG_007729.l ,  
NG_008275. l ,  NG_0081 32. l ,  NG_007 15 1 . 1 and NG_007009.l ,  respectively. 
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RESULTS 
The clinical features of the 36 Dutch KS patients and the results of DNA analysis are summarised 
in Table 1 .  A heterozygous CHDl mutation was identified in three patients: two patients had a 
nonsense mutation (c.401 5C> T; p.Arg1 339X and c.531 6G>A; p.Trp1 772X) and one patient had a 
missense mutation (c.6322G>A; p.Gly21 08Arg). The missense mutation had occurred de novo and 
was previously identified in three other index patients with CHARGE syndrome (Janssen et al, 
submitted, see also the locus-specific CHDl mutation database available at www.CHD7.org). 
The three CHD7-positive patients were carefully re-examined for additional features of CHARGE 
syndrome. Patient 1 had been diagnosed with KS at the age of 16 and was then started on hormone 
replacement therapy (HRT). She had a bilateral cleft lip and palate and bilateral mixed hearing 
loss. She was 20 years old when she was re-evaluated at the UMCG's multidisciplinary CHARGE 
outpatient clinic. Her history revealed delayed motor development (independent walking at age 
2.5 years) and feeding difficulties that had been attributed to the cleft lip and palate. She a lso had 
balance disturbance (but a CT scan of the temporal bone had not been performed), mild scoliosis, 
and impaired vision. We referred her for ophthalmological examination, which revealed bilateral 
retinal colobomas. Her external ears were normal and ultrasound of the heart and kidneys showed 
no abnormal ities. Anosmia was confirmed by formal smell testing (UPSIT score 1 2/40) and re­
evaluation of an earlier MRI brain scan showed olfactory bulb aplasia. In retrospect, she has typical 
CHARGE syndrome. 
Patient 2 had been diagnosed with KS when he was 1 6  years old and was started on HRT. He also 
had severe bilateral hearing loss. He was re-examined at the age of 31  at the Department of Human 
Genetics, Radboud University Nijmegen Medical Centre. His case history revealed mild ly delayed 
motor development and surgery for a cleft palate. Physical examination showed that he had short 
stature (length -2.5 SD), synkinesia and abnormal external ears with smal l  earlobes. An u ltrasound 
of the heart and kidneys was performed after identification of the CHDl mutation and revealed a 
bicuspid aortic valve and normal kidneys. Formal smell testing showed that he had anosmia (UPSIT 
score 7 /40). 
Patient 3 had been diagnosed with KS at the age of 1 4  years and started on HRT. He also had 
severe bilateral sensorineural hearing loss. His clinical data were recently published.25 He was re­
evaluated at the age of 1 7  years at the UMCG's CHARGE outpatient clinic. His case history revealed 
delayed motor development (independent walking at 22 months) and balance disturbance. He had 
a normal intelligence and normal external ears, eyes, kidneys and heart. Anosmia was confirmed 
with the UPSIT (score 9/40). A CT scan of the temporal bone showed hypoplasia of the cochlea and 
semicircular canals. This patient did not fulfil the clinical criteria for CHARGE syndrome.a,3o 
On analysis of FGFR1, PROK2, PROKR2 and FGFB, seven additional mutations were found in our 
Dutch KS cohort. Six patients harboured a heterozygous missense variant in  the PROKR2 gene 
(c.254G>A; p.Arg85His (4x), c.254G> T; p.Arg85Leu and c.791 G>A; p.Arg264His) and in one patient 
a heterozygous FGFB variant (c.86_1 03dup; p.Gly29_Arg34dup) was identified. The FGFB variant is 
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Table 1 .  Dutch patients with Kallmann syndrome who did not have a mutation in the KAL 1 gene: results of FGFRI ,  PROK2, PROKR2, FGFB and CHD7 analysis and an overview 
1
9 
a, of the clinical characteristics and family history 
Patient Sex• FGFR1, PROK2, CHD7 Clinical characteristics Family history< 1 t  
no. PROKR2 and FGFS results' besides HH and anosmiad 
(n=36) resultsb 
1 F c.401 5C>T; Cleft l ip and palate, mixed hearing loss, retinal 
p.Arg1 339X coloboma, balance disturbance, mild scoliosis, 
olfactory bulb aplasia 
2 M c.531 6G>A; Hearing loss, cleft palate, short stature, bicuspid aortic 
p.Trp1 772X valve, abnormal external ears, synkinesia 
3 M c.6322G>A; 5ensorineural hearing loss, hypoplasia of cochlea and 
p.Gly21 08Arg semicircular canals 
de novo 
4 M PROKR2: c.254G>A; Obesity (BMI 35 kg/m') ? 
p.Arg85His 
5 M PROKR2: c.254G>A; 
p.Arg85His 
6 M PROKR2: c.254G>A; Hypospadia 
p.Arg85His 
7 F PROKR2: c.254G>A; Myopia (-1 0 dioptres) Grandmother anosmia, uncle cleft lip/palate 
p.Arg85His 
8 M PROKR2: c.254G> T; Myopia (-5 dioptres) 
p.Arg85Leu 
9 F PROKR2: c.791 G>A; Unilateral renal agenesis, synkinesia Father uni lateral renal agenesis 
p.Arg264His 
1 0  F FGFB: c.86_1 03dup; 
p.Gly29_Arg34dup 
1 1  F Mother and sister anosmia 
1 2  F Myopia (-1 O dioptres) 
1 3  F 
1 4  M Obesity 
1 5  M Mother primary amenorrhea and anosmia 
1 6  M Two sisters smell deficit 
°' ..., 
1 7  M 
1 8  M 


















• F, female; M, male 
" -, normal results of FGFR/, PROK2, PROKR2 and FGFB analysis 
' -, normal result of CHDl analysis 
Obesity 
Myopia (-9.5 dioptres) 









Mother Kallmann syndrome 
Sister and aunt decreased fertility 
7 family members with HH, anosmia and/ 
or cleft lip/palate 
d -, no additional features of CHARGE and/or Kallmann syndromes; BMI, body mass index; HH, hypogonadotropic hypogonadism 




















located in the differentially spliced exon 1 C  of the FGFB gene and only affects FGF8e and FGF8f 
isoforms (and not FGF8a and FGF8b isoforms). 
DISCUSSION 
We have identified three CHDl mutations in 36 Dutch KS patients who had no mutation in the 
KAL 1 gene (3/36 = 8.3%). Here, we only studied KS patients and did not include patients with nlHH, 
because we have previously shown that HH is always associated with anosmia in  patients with a 
CHDl mutation.27 The three CHD7-positive patients that we identified all proved to have additional 
features of CHARGE syndrome on careful re-examination, which is in  agreement with our previous 
study.9 Two of the CHD7-positive patients had typical CHARGE syndrome (patients 1 and 2), but the 
third patient had only a few features of CHARGE syndrome. However, he did have semicircular canal 
anomalies, which are typical for CHARGE syndrome_30.3i,ll Hearing loss was the most frequent feature 
seen in the CHD7-positive KS patients in our study (Table 1 )  and in other published studies9•10; it was 
found in 7 /1 3 CHD7-positive KS patients. However, hearing loss is not specific for the presence of 
a CHDl mutation, because it can also occur in patients with a mutation in the KAL 1, FGFR1 or FGFB 
gene.6·16 Other features that were repeatedly found in CHD7-positive KS patients were a cleft lip and/ 
or palate (5/1 3), short stature (3/1 3 )  and balance disturbance (3/1 3) (Table 1, 9•10).  
We did not identify a CHDl mutation in 30 KS patients without additional CHARGE features 
(Table 1 ), which suggests that CHDl mutations are not a frequent cause of isolated KS. Recently, 
CHDl analysis was also performed in a cohort of 30 Finnish KS patients.34 Although three KS 
patients displayed additional CHARGE features, no CHDl mutations were identified in this cohort. 
Further studies in large cohorts of clin ically well-characterised KS patients are needed to estimate 
the frequency of CHDl mutations in KS patients more reliably. In addition, it would be useful to 
know whether the CHD7-positive patients in the study by Kim et a/10 underwent formal smell 
testing and were carefully re-evaluated after the CHDl mutation was identified. Without extensive 
clin ical examination, it is possible that subtle features of CHARGE syndrome were missed in their 
CHD7-positive patients, thereby undermining their claim that CHDl mutations can give rise to 
isolated nlHH and KS. This is well i l lustrated by our patients 1 and 3 in whom retinal colobomas and 
semicircular canal hypoplasia were only detected by fundoscopy and CT imaging, respectively, after 
the CHDl mutation was identified. Another limitation of the study by Kim et a/10 is that it is unclear 
whether CHDl analysis was performed in the parents of the patients with a CHDl missense variant. 
Segregation analysis is helpful to predict whether CHDl missense variants are pathogenic or benign 
(Bergman et al, submitted). Only one of the five missense mutations that Kim et a/10 identified, 
p.Ser834Phe, has been previously reported and it is probably pathogenic. The other four missense 
mutations were not identified in 1 80 healthy controls, but they may still be rare benign variants. The 
CHD7missense mutation (p.Gly21 08Arg) identified in our patient 3 is probably pathogenic, because 
it occurred de nova and had previously been identified in three other index patients with CHARGE 
syndrome (Jansen et al, submitted and www.CHD7.org). In addition, the glycine at position 2 108 is 
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highly conserved and the amino acid substitution is predicted to be pathogenic by SIFT �orting 
intolerant from Jolerant35·36), PolyPhen-2 (&ili'.morphism Phenotyping program-237·.>B) and Align­
GVGD.39,40 
Based on the results of this study and the literature, our advice is to evaluate KS patients carefully 
for features of CHARGE syndrome by taking a detailed case history and physical examination. 
Balance disturbance is almost always present in patients with CHARGE syndrome, but it often 
goes unnoticed because balance problems decrease after the first few years of life due to visual 
compensation. However, if the case history reveals that walking without support was delayed, that 
the patient was unable to crawl without resting the head on the floor (5-point crawling) and that 
the patient was unable to ride a bicycle without side-stabilisers, the patient probably suffered from 
balance disturbance.41 Imaging of the semicircular canals (preferably by a CT scan of the temporal 
bones) is indicated in all KS patients who are suspected of balance disturbance. Our advice is to 
perform CHDl analysis in KS patients who have at least two of the following features of CHARGE 
syndrome: ocular coloboma, choanal atresia or stenosis, characteristic external ear anomaly, cranial 
nerve dysfunction (facial palsy, sensorineural hearing loss or hypoplasia of cranial nerves on imaging) 
or balance disturbance. In addition, CHD7 analysis is recommended in KS patients with semicircular 
canal anomalies, but who do not show other evident CHARGE features. These recommendations 
are in line with our 201 1 guideline for CHDl analysis in patients suspected of CHARGE syndrome.25 
Identifying a CHO7mutation has important clinical implications. Firstly, the CHO7-positive patient 
should be screened for additional CHARGE features, because subtle features can remain undetected 
but can have therapeutic consequences, e.g. unilateral renal agenesis. For recommendations 
on screening, we refer to the clinical surveillance schedule in Bergman et a/.25 Secondly, genetic 
counselling is indicated, because the patient has a 50% chance of transmitting the CHDl mutation 
to his or her offspring. The offspring may develop a more severe manifestation of CHARGE syndrome, 
because the syndrome is highly variable, even within families.25·42"'5 The possibility of prenatal 
diagnosis and pre-implantation genetic diagnosis should therefore be discussed with the patient 
and his or her partner. 
Six patients in our Dutch KS cohort harboured a heterozygous missense mutation in the 
PROKR2 gene, which alone is thought to be insufficient for the development of HH or KS. One of 
the PROKR2 mutations that we identified, p.Arg85His, was previously found in a heterozygous state 
in patients with HH, KS, functional amenorrhea, or isolated anosmia, but also in unaffected family 
members.17•20•46 It was also identified in a homozygous state in a KS patient. 1 7  Functional assays 
showed that the p.Arg85His mutation results in a mild loss-of-receptor function.47 The other PROKR2 
missense mutations that we identified, p.Arg85Leu and p.Arg264His, have not been reported 
previously. However, since both mutations affect an amino acid that is conserved in bovine, murine 
and rat orthologous sequences, 17 they are thought to have a deleterious effect. 
The heterozygous FGFB mutation that we identified in patient 10 is also expected to be in­
sufficient alone for the development of KS. Evidence comes from a previous study in which 
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heterozygous FGFB missense variants (p.Pro26Leu and p.Arg209Leu) were identified in unaffected 
controls.21 The FGFB variant that we identified in patient 1 0  (p.Gly29_Arg34dup) has not been 
reported previously, but two other variants in exon 1 C of the FGFB gene have been described. 1• One 
FGFB variant was found in a heterozygous state (p.Pro26lle) in a father with anosmia and in his son 
with Kallmann syndrome. The other FGFB variant was found in a homozygous state (p.Phe40Leu) in 
combination with a double heterozygous FGFR I mutation (p.Gln764His/p.Asp768Tyr) in a sporadic 
male patient with nlHH. Functional assays showed that these two FGFB mutations reduce the 
FGFRl c activity levels and both were therefore classified as loss-of-function mutations.16 
KS is both genetically and clinically very heterogeneous. New genes implicated in KS will 
probably be identified in the near future, which will further increase the complexity of the 
inheritance patterns. KS is expected to follow oligogenic inheritance in most patients, with 
mutations in the KAL 1 gene as a possible exception (X-linked recessive inheritance, fully penetrant 
in males). Modifier genes and environmental factors will probably further increase the phenotypic 
variability of KS.48.49This hypothesis is supported by the identification of heterozygous mutations in 
several KS genes in unaffected persons, implying that heterozygous KS mutations are insufficient for 
the development of GnRH deficiency and anosmia.21 In our cohort, oligogenic inheritance was not 
identified. However, we expect most of our KS patients will carry other mutations in genes yet to be 
associated with KS. In our CHO7-positive patients, however, we do not expect oligogenic inheritance 
to be responsible for their observed phenotypes. In the literature, mutations in CHDl have never 
been described in combination with mutations in other KS genes. In theory, digenic inheritance 
may occur by coincidence, but CHDl mutations are, on their own, sufficient for the development 
of HH and anosmia. Moreover, we question whether CHD7 should be labelled as a KS gene because 
most, if not all, CHO7-positive KS patients have been shown to have additional features of CHARGE 
syndrome and therefore the diagnosis of KS could be revised to CHARGE syndrome, which is known 
to follow pure autosomal dominant inheritance. 
There is still much to learn about the underlying pathogenesis of HH and anosmia, but at present 
it is thought these features are the result of a failed embryonic migration process in patients with 
KS and CHARGE syndrome.48·50 During normal embryogenesis, the GnRH neurons migrate alongside 
the olfactory axons from the nasal placode into the brain.48 Pathological examination of two male 
foetuses with KS due to a KAL 1 mutation revealed that the migration of both GnRH and olfactory 
neurons was disturbed, as evidenced by the presence of entangled nerve fibres on the dorsal side 
of the cribriform plate and the absence of GnRH neurons in the hypothalamus.so.s, Comparable 
migration defects were also present in a foetus with CHARGE syndrome due to a frameshift 
mutation in the CHDl gene.so Studies in Chd;'G"• mice, however, suggested that GnRH deficiency in 
mice with Chdl haploinsufficiency is not caused by GnRH migration defects, but rather by reduced 
GnRH cellular proliferation in the embryonic olfactory placode.52 The olfactory bulb defects of these 
mice were possibly caused by reduced basal cell proliferation in the adult olfactory epithelium.53 
CHD7 is a member of the �hromodomain helicase QNA-binding protein family. This family 
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consists of adenosine triphosphate (ATP)-dependent chromatin remodelers. Recent studies have 
indicated that CHD7 regulates the transcription of m ultiple genes during embryonic development 
in a tissue- and time -dependent manner.54·56 It is therefore hypothesized that CHD7 reduces the 
expression of one or more KS genes, which would explain the co-occurrence of anosmia and HH 
in CHARGE and Kallmann syndromes. In ChdJG"+ mice, Chdl haploinsufficiency was found to be 
associated with reduced expression of Fgfr1, Bmp4 and Otx2, but not FgfB in the embryonic olfactory 
placode and reduced expression of Otx2 and GnRH1 in the adult hypothalam us.52 These data 
suggest that Chd7 regulates GnRH neurogenesis and signalling through transcription regulation of 
key target genes in mice. Future research in human foetal tissues is needed to investigate whether 
CHD7 also regulates the transcription of KS genes in humans. 
In concl usion, this st udy shows that CHDl mutations can be identified in a proportion of KS 
patients. The yield of CHDl analysis in patients with isolated KS seems very low, but increases when 
additional CHARGE feat ures are present. We recommend evaluating all KS patients for additional 
CHARGE feat ures by ta king a detailed case history and physical examination. CHDl analysis is 
indicated when at least two additional CHARGE feat ures or semicirc ular canal anomalies are present. 
Identifying a CHDl m utation has important clinical implications for the surveillance and genetic 
counselling of the patient. 
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ABSTRACT 
Background CHARGE syndrome is a highly variable, multiple congenital anomaly syndrome, of 
which the complete phenotypic spectrum was only revealed after identification of the causative 
gene in 2004. CHARGE is an acronym for ocular !;Oloboma, congenital heart defects, choanal gtresia, 
retardation of growth and development, genital hypoplasia and _ear anomalies associated with 
deafness. This typical combination of clinical features is caused by autosomal dominant mutations 
in the CHDl gene. 
Objective To explore the emerging phenotypic spectrum of CHDl mutations, with a special focus 
on the mild end of the spectrum. 
Methods We evaluated the clinical characteristics in  our own cohort of 280 CH07-positive patients 
and in previously reported patients with CHDl mutations and compared these with previously 
reported patients with CHARGE syndrome but an unknown CHDl status. We then further explored 
the mild end of the phenotypic spectrum of CHDl mutations. 
Results We discuss that CHARGE syndrome is primarily a clinical diagnosis. In addition, we propose 
guidelines for CHDl analysis and indicate when evaluation of the semicircular  canals is helpful in the 
diagnostic process. Finally, we give updated recommendations for clinical surveillance of patients 
with a CHDl mutation, based on our exploration of the phenotypic spectrum and on our experience 
in a multidisciplinary outpatient clinic for CHARGE syndrome. 
Conclusion CHARGE syndrome is an extremely variable clinical syndrome. CHDl analysis can be 
helpful in the diagnostic process, but the phenotype cannot be predicted from the genotype. 
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INTRODUCTION 
The first patients with what later became known as CHARGE syndrome (OM IM *2 1 4800) were 
described in 1961.1-2 In 1979, two independent clinicians recognised that coloboma, choanal 
atresia and congenital heart defects clustered together in several patients.3 •4 The acronym CHARGE 
dates from 198 1 and summarises some of the cardinal features : ocular �oloboma, congenital heart 
defects, choanal .i!_tresia, retardation of growth and/or development, genital anomalies, and !:ar 
anomalies associated with deafness.5 In 2004, mutations in the CHDl gene were identified as the 
major cause and 'CHARGE association' was changed to 'CHARGE syndrome'.6 CHARGE syndrome 
occurs in approximately 1 in 1 0, 000  newborns.7 The inheritance pattern is autosomal dominant 
with variable expressivity. Almost all mutations occur de novo, but parent-to-child transmission has 
occasionally been reported.8 In this review, we explore the phenotypic spectrum of CHDl mutations 
with special focus on the mild end of the spectrum. In the light of this expanding phenotype, we 
discuss whether CHARGE syndrome is a clinical or a molecular diagnosis, we propose guidelines for 




Before discovery of the causative gene, CHARGE syndrome was a clinical diagnosis (clinical features 
summarised in Figure 1 ). Pagon was the first to introduce diagnostic criteria for CHARGE syndrome 
in 198 1  ,S but these criteria are no longer in use. At present, the clinical criteria by Blake et al and 
Verloes are used in conjunction (Table 1).9• 10 
The Blake criteria9 were slightly adjusted by a consortium and last updated in 2009.11  These 
criteria encompass four major and seven minor criteria. The four major criteria are coloboma, 
choanal atresia, cranial nerve dysfunction, and abnormalities of the inner, middle, or external ear. 
At least four major, or three major and three minor, criteria must be present in order to diagnose 
CHARGE syndrome. In 2005, Verloes proposed renewed criteria. 10 He included semicircular canal 
defects as a major criterion, as these defects were shown to be a very specific and consistent feature 
in CHARGE syndrome.12 Verloes also anticipated broadening of the phenotypic spectrum and 
reduced the number of features necessary for a diagnosis of CHARGE (to only three major, or two 
major and two minor, criteria) and he made his criteria less age- and sex-dependent . A common 
feature of both sets of criteria is that either coloboma or choanal atresia (which can sometimes be 
replaced by cleft palate, Table 1 1 3) must be present in order to diagnose CHARG E syndrome. 
Molecular diagnosis 
Nowadays, CHARGE syndrome can also be diagnosed by a molecular genetic test. The CHDl gene, 
mutated in the majority of patients with CHARGE syndrome, consists of 37 coding exons and 
one non-coding exon.6 The gene encodes for a 2997 amino acid long protein that belongs to the 
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Figure 1. Overview of features occurring in CHARGE syndrome (frequencies are shown in Table 2). 
Major features Coloboma the of iris (A) and/or retina, with or without microphthalmia, often only visible by 
fundoscopy. Choanal atresia (B, uni lateral) or stenosis. Characteristic ear anomaly (C): cup shaped ear with 
triangular conchae and small/absent ear lobes. Middle or inner ear malformations may be present as well. 
Semicircular canal hypoplasia or aplasia (D arrow, semicircular canal aplasia of the left ear on a coronal CT scan). 
Cranial nerve dysfunction: oculomotor dysfunction (IIINI), less powerful chewing (V), facial palsy (VII) (E, right­
sided), hearing loss/vestibular problems (VIII), swallowing and feeding problems (IX/X). 
Minor features/occasional findings Hypothalamo-hypophyseal dysfunction: gonadotropin deficiency 
(hypogonadotroplc hypogonadlsm), growth hormone deficiency. Other congenital anomalies: cleft lip/palate, 
congenital heart defects, tracheo-oesophageal anomalies, kidney anomalies, brain anomalies (including 
olfactory bulb hypoplasia), lacrimal duct atresia. Developmental delay: delayed motor development and/or 
cognitive delay. Characteristic face: broad forehead, square face, facial asymmetry. Other features: behavioural 
problems, sleep disturbance, scoliosis, respiratory aspiration, gastro-oesophageal reflux, postoperative 
complications, sudden death, obstructive sleep apnoea, enuresis nocturna, hockey stick palmar crease, webbed 
neck/sloping shoulders. 
Rare features Immune deficiency, limb anomalies, epilepsy, oligodontia, anal atresia. 
Informed consent was obtained for publication of the photographs. 
bhromodomain tlelicase QNA binding (CHD) family. •• CHD7 can form complexes with different 
proteins, thereby ensuring specific binding to different enhancer regions leading to time and 
tissue specific regulation of gene expression.15 One example is the association of CHD7 with PBAF 
(Qolybromo- and .B_RG 1-gssociated factor containing complex) that is essential for neural crest gene 
expression and cell migration.16This is in line with previous assumptions that many of the congenital 
defects seen in CHARGE syndrome may be neural crest related.17 CHD7 was also shown to associate 
with rDNA and was therefore suggested to play a role as positive regulator of rRNA synthesis.18 
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CHD7 mutations and CHARGE syndrome 
Haploinsufficiency of the CHDl gene leads to CHARGE syndrome and, as expected, most patients 
are found to have truncating CH07 mutations. 19 24 Missense mutations occur in a minority of patients 
and partial or full deletions of the CHD l gene are rare events.6•1 9•23•25,31 Most CHDl mutations occur 
de novo. There are no mutational hotspots and recurrent mutations are rare.20 No clear genotype­
phenotype correlation exists, although it seems that missense mutations in general are associated 
with a milder phenotype.20 
Table 1 .  Clinical criteria for CHARGE syndrome 
Major criteria Minor criteria Inclusion rule 
Blake19 1 .  Coloboma, 1 .  Cardiovascular malformations Typical CHARGE: 
microphthalmia 2. Trachea-oesophageal defects 4 major or 
2. Choanal atresia or 3. Genital hypoplasia or delayed 3 major + 3 minor 
stenos is* pubertal development 
3. Characteristic 4. Cleft lip and/or palate 
external ear anomaly, 5. Developmental delay 
middle/inner ear 6. Growth retardation 
malformations, mixed 7. Characteristic face 
deafness 
4. Cranial nerve 
dysfunction 
Verloes10  1 .  Ocular coloboma 1 .  Heart or oesophagus Typical CHARGE: 
2. Choanal atresia malformation 3 major or 
3. Hypoplastic 2. Malformation of the middle 2 major + 2 minor 
semicircular canals or external ear 
3. Rhombencephalic Partial CHARGE: 
dysfunction including 2 major + 1 minor 
sensorineural deafness 
4. Hypothalamo-hypophyseal Atypical CHARGE: 
dysfunction (gonadotropin or 2 major + 0 minor or 
growth hormone deficiency) 1 major + 3 minor 
5. Mental retardation 
• Updated by a consortium in 2006 and 2009. 1 1  
* Cleft palate can be  substituted for  choanal atresia, since these anomalies rarely occur together.13 
CHDl analysis detects mutations in more than 90% of patients fulfilling the clinical criteria for 
CHARGE syndrome. The lack of mutation detection in the remaining 5-1 0% of patients suggests 
genetic heterogeneity. The SEMA3E gene was proposed as a candidate gene, but it seems to 
play a minor role as only two SEMA3E alterations have been described in patients with CHARGE 
syndrome.32 Besides genetic heterogeneity, it is also possible that mutations in intronic regions, 
5' or 3' untranslated regions, or in regulatory elements of CHDl underlie the CH07-negative 
cases. Phenocopies of CHARGE or CHARGE-like syndrome can be due to teratogen exposure (e.g. 
thalidomide, retinoic acid, maternal diabetes) or chromosomal aberrations.8 
PHENOTYPIC SPECTRUM OF PATIENTS WITH A MUTATION IN THE CHD7 GENE 
Phenotypic spectrum in our CHD7-positive cohort compared to two other cohorts 
Our CH07-positive cohort consists of patients who had CHDl analysis done in Nijmegen, the 
1 79 
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Netherlands. In N ijmegen, CHDl a nalysis was performed in 863 patients suspected of CHARGE 
syndrome and 360 CHDl mutations were found (360/863 = 42%). The mutations were scattered 
throughout the entire coding region and spl ice sites of the CHDl gene. One third of the mutations 
were found in exons 2, 3, 30, and 31 (34% of mutations, 33% of genomic size). However, exons 8, 1 2, 
26, 30, and 36 showed a remarkably high number of mutations relative to their genomic size ( 1 9% 
of mutations, 9% of genomic size). No mutations were found in exons 6, 7, 20, and 28, but these 
comprise only 3% of the coding genome of CHD l. Apart from the high number of mutations in 
exon 2 (the largest exon), our results do not agree with a previous report (n=91 ).33 Most mutations 
were nonsense (38%) or frameshift m utations (32%). Missense mutations and splice site mutations 
occurred in 1 3% and 1 7%, respectively, and deletions were rarely present (<1 %). The phenotypic 
spectrum of the missense mutations was more variable and on average milder when compared to 
the truncating mutations. 
In Table 2 we present an overview of the clinical features of 280 of our CHO7-positive patients, 
the CHO7-positive cohort reported in the literature (reviewed by Zentner eta/, n=25424) and a cohort 
of patients cl inically diagnosed with CHARGE syndrome, but of whom the CHD l  status is unknown 
(n=l 24'.34). We only included 280 of our 360 CHO7-positive patients, because cl inical data were 
lacking in the other 80 patients. The phenotypes of 64 of the 280 patients have been published 
previously (Table 2).20·26•35-4°35 
The clinical features of the CHO7-positive patients, previously reported or presented here, are 
rarely completely known. When calculating the percentage of patients who exhibit a certain feature, 
the incompleteness of the clinical data will have a major effect on the accuracy of the percentage. 
In order to compensate for this inaccuracy, we also calculated the frequency range. The minimum 
frequency is defined as the number of patients with a particular feature divided by the total number 
of patients in the cohort. The maximum frequency is defined as the number of patients with a 
particular feature plus patients for whom it is unknown whether they have the feature, divided by 
the total number of patients in the cohort. 
Four features are almost always present in patients with a CHD l  mutation: external ear 
anomalies, cran ia l  nerve dysfunction, semicircular canal hypoplasia, and delayed attainment of 
motor milestones (Table 2). The characteristic externa l  ear anomaly consists of triangular conchae 
or cup-shaped ears (Figure 1 )  and occurs in more than 90% of patients with a CHOl mutation. The 
second feature, cranial nerve dysfunction, is present in more than 95% of patients. The seventh 
and eighth cranial  nerves are most often affected, leading to facial palsy and sensorineural hearing 
loss, respectively. Dysfunction of other cranial nerves can also occur. The third feature, semicircular 
canal hypoplasia, is not always assessed, but when investigated it is found to be present in over 
90% of patients. The high frequency of semicircular canal hypoplasia is reflected in the delayed 
attainment of motor mi lestones (often scored as developmental delay in previous papers), that is 
almost universally present in  patients with CHARGE syndrome. A delay in speech development is 
also common in these patients who suffer from multiple sensory impairment (e.g. blindness and/or 
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Table 2. Clinical features of patients with a CHD7 mutation compared to clinically diagnosed patients with 
CHARGE syndrome 
Feature Our CHD7-positive CHD7-positive cohort CHARGE patients 
cohort (n=280) from the literature before CHD7 discovery 
(n=254)' (n=1 24)" 
External ear anomaly 224/231 ' 21 4/235 74/77 
97% (80-98%)' 91% 96% 
Cranial nerve dysfunction 1 73/1 74 1 07/124 
(VII, VI II and others) 99% (62-1 00%) 86% 
Semicircular canal anomaly 1 1 0/1 1 7  94/96 1 2/12  
94% (39-98%) 98% 100% 
Coloboma 1 89/234 1 90/253 96/124 
81 o/o (68-84%) 75% 77% 
Choanal atresia 99/ 1 79 95/247 76/124 
55% (35-71%) 38% 61% 
Cleft lip and/or palate 79/163 79/242 22/124 
48% (28-70%) 33% 1 8%" 
Feeding difficulties 90/1 1 0  40/47 
necessitating tube feeding 82% (32-93%) 85% 
Facial palsy 80/1 21  72/1 87 1 7/47 
66% (29-85%) 39% 36% 
Anosmia on formal smell 24/30 ? 
testing 80% 
Genital hypoplasia 1 1 8/145 1 1 6/1 87 45/1 24 
81% (42-90%) 62% 36%· 
Congenital heart defect 1 9 1 /252 1 93/250 1 05/124 
76% (68-78%) 77% 85%' 
Tracheo-oesophageal 42/146 35/1 85 22/124 
anomaly 29% (1 5-63%) 1 9% 18% 
Developmental delay Delayed motor Developmental delay Developmental delay 
milestones 1 07/141 47/47 




74% (39-91 %) 
Growth retardation 35/94 1 0 1 /141 80/1 24 
37% (1 3-79%) 72% 65% 
• CHO7-positive cohort from the literature as reviewed by Zentner et al in 201 0.24 This cohort partially overlaps 
with our CHO7-positive cohort because the phenotypes of 64 of our patients were published previously.'0·26•35 .. 0 
* Cohort of patients with clinically diagnosed CHARGE syndrome reported by Tellier et al in 1 998 and lssekutz et 
a/ in 2005, before CHO7analysis was possible.7 34 
A Frequencies are represented as the number of patients with a particular feature/the total number of patients 
that were tested for that particular feature 
' The range of percentages presented between brackets was calculated as: (positive/total)x1 00% - (positive 
+unknown/tota l)xl 00% (for further explanation see text) 
• Outside the frequency range of patients with a CHD7 mutation 
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deafness)_41.42 In our cohort, approximately 75% of patients had intellectual disability, indicating that 
one quarter had a normal intelligence. 
Two features seem to occur more frequently since CHDl analysis has become available as 
a diagnostic tool in CHARGE syndrome (Table 2). These are cleft lip and/or palate and genital 
hypoplasia; in  the study by Tellier et a/,14 the percentages of these two features were below our 
frequency range. The most l ikely explanation is that in the past, patients with cleft palate, and 
thus often without choanal atresia, were not recognised as having CHARGE syndrome. Mutation 
analysis enables a diagnosis in these clinically less typical patients. The higher prevalence of genital 
hypoplasia in  patients with a CHDl mutation can be explained by a higher mean age in the patients 
for whom molecular studies have been performed, but it may also be due to an increased awareness 
that genital hypoplasia is a frequent feature in patients with a CHDl mutation. 
One feature seems to occur less frequently since CHDl analysis became available: congenital 
heart defects were present in 76% of CHD7-positive patients and in 85% of patients with a clinical 
diagnosis of CHARGE syndrome. The most likely explanation is that the clinical diagnosis was more 
readily made in hospitalised chi ldren with a heart defect and that, l ike children with cleft palate, 
children without a heart defect were more l ikely to remain unrecognised as having CHARGE 
syndrome before CHDl analysis. 
Exploration of the mild end of the phenotypic spectrum of CHD7 mutations 
Patients with a typical presentation of CHARGE syndrome are easily clinically recognised, but those 
who are mildly affected can be missed, as the mild end of the CHARGE spectrum is only recently 
starting to emerge. Several studies have shown that an increasing number of patients with a CHDl 
mutation do not fulfil the clin ical criteria, as they do not have coloboma or choanal atresia or cleft 
palate.10 Exploration of the mild end of the CHARGE spectrum can be undertaken in four ways: by 
studying familial CHARGE syndrome, by evaluating very mildly affected patients who are picked 
up with CHD7 analysis, by performing CHDl analysis in cohorts of patients with only one CHARGE 
feature, and finally by studying syndromes that show clinical overlap with CHARGE syndrome (e.g. 
22q l 1 deletion syndrome and Kal lmann syndrome). 
Familial CHARGE syndrome 
Very mildly affected patients with CHARGE syndrome can be identified by studying familial CHARGE 
syndrome. In the literature, only 1 6 famil ies have been described with recurrence of molecularly 
confirmed CHARGE syndrome.20•21 •23•37.4345 These families include seven sib-pairs, three monozygotic 
twin-pairs, and six two-generation families. In this review, we describe another two-generation 
fami ly from our CHD7-positive cohort, making a total of 1 7  famil ies (Table 3). 
Of the 39 CHO7-positive individuals, only 24 (62%) fulfilled the clinical criteria for CHARGE 
syndrome as defined by either Blake eta/9 orVerloes.10 Atypical CHARGE patients are most frequently 
seen in the two-generation families. Often, the mildly affected individuals were recognised only 
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Table 3. Familial CHARGE syndrome 
Reference CHDl Fulfilling clinical criteria Segregation 
mutation 
Sib-pairs Sib 1 Sib 2 
1 .  Wincent c.401 SC> T; + (case 1 l a) + (case 1 l b) Father no 
200823 p.R1 339X mutation 
2. Pauli 200944 c.7302dupA + (girl) + (boy) Germline 
mosaicism in 
father 
3. Lalani 200621 p.W2332X + (died) - (case CHA76) Parents no 
mutation 
4. Jongmans c.2442+5G>C - (case 1 )  + (case 2) Mother no 
200837 mutation 
5. Jongmans c.2520G>A; + (case 3) + (case 4) Somatic 
200837 p.W840X mosaicism in 
father 
6. Jongmans c.1 61 0G>A; + (case 5) + (case 6) Parents no 
200837 p.W537X mutation 
7. Jongmans c.5982G>A; + (case 29) + (case 30) Somatic 
200620 p.W1 994X mosaicism in 
mother 
Monozygotic Twin 1 Twin 2 
twins 
1 .  Wincent c.5428C>T; + (case 1 3a) + (case 1 3 b) De novo 
200823 p.R1 8 1 0X 
2. Lalani 200621 p.E1271X + (case A) + (case Bl Unknown 
3. Jongmans c.5752_5753 + (case 26) - (case 27) Parents were 
200620 dupA; not tested 
p.T191 8fs 
Parent - child Child 1 Child 2 Parent 
1 .  Vuorela c.4795C>T; + (case 1 )  + (case 2) - (case 3) De novo in 
200845 p.Q 1 599X father* 
2. Delahaye c.2501 C> T; + (case A 11 1-2) + (case A 11 1-3) - (case A 11-2) De novo in 
200743 p.5834F mother 
3. Delahaye c.469> T; + (B 111- 1 )  + ( B  111-3) - (B 11-2) De novo in 
200743 p.R157X father 
4. Lalani 200621 p.R231 95 - (case CHA 1 66) Unknown 
5. Jongmans c.6322G>A; - (case 7) - (case 8) De novo in 
200837 p.G21 08R mother* 
6. Jongmans c.6322G>A; - (case 9) + (case 1 0) - (case 1 1 )  De novo in 
200837 p.G21 08R mother 
7. This study c.7769del Unknown 
Total clinical criteria positive Children 24/32 Parents 0/7 
* Somatic mosaicism was excluded (the CHDl mutation was present in both peripheral blood lymphocytes and 
buccal cells). +, fulfilling the criteria, -, not fu lfilling the clinical criteria of Blake and/or Verloes.9· '0 
after a CHDl mutation was found in a more severely affected family member. The most mildly 
affected patients described in the literature had dysmorphic ears and balance disturbance as the 
only manifestations of CHARGE syndrome. Somatic mosaicism was considered unlikely in two of 
the very mildly affected parents, because the CHDl mutation was found in different tissues.37-45 
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The monozygotic twin-pairs showed strik ingly discordant features and underscore the great intra­
familial variabi lity seen i n  CHARGE syndrome.10·2u1This variability might be explained by differential 
epigenetic regulation or fluctuating embryonic CHD7 levels in relation to a time and tissue 
dependent critical threshold during embryonic development. 
Mildly affected patients from our CH07-positive cohort 
The most widely used criteria are those of Blake et a/9 and La lani et a/1 1  Interestingly, 1 8  out of the 
1 3 1  ( 1 4%) CHO7-positive patients that could be scored for these criteria had only one or two major 
Blake features and thus could not be clin ically diagnosed as having CHARGE syndrome. Based on 
the presence of none, or only one major Verloes feature, as many as 1 7% (22/1 24 patients) could not 
be clinically diagnosed with CHARGE syndrome using the Verloes criteria. The phenotypes of the 
three most mildly affected (previously unpublished) patients are presented below. 
The first patient had abnormal external ears and a congenital heart defect, but no other features 
of CHARGE syndrome. She had normal semicircular canals, no cranial nerve dysfunction, and a 
normal pubertal development. She had a de novo pathogenic missense mutation in the CHDl gene 
that had not been described before (c.4406A>G; p.Tyrl 469Cys in  exon 1 9). 
The second patient had mild semicircular canal anomalies and a mild hearing loss. His external 
ears were normal. He was only recognised as having CHARGE syndrome after a CHDl splice site 
mutation was found in his more severely affected children (Table 3, two-generation family from this 
study). 
The third patient was diagnosed with Kallmann syndrome and had sensorineural hearing loss. 
After a de novo pathogenic missense mutation in the CHDl gene (c.6322G>A; p.Gly21 08Arg in  
exon 31 )  was identified, a CT scan of h is  temporal bone was re-evaluated and semicircular canal 
hypoplasia was seen. He had normal external ears. 
CHD7 analysis in cohorts of patients with only one CHARGE feature 
Some authors have undertaken CHDl screening in patients with only one CHARGE syndrome 
feature - e.g. cleft lip and/or palate,46 congenital heart disease,47 or scoliosis.48 These studies did not 
identify pathogenic CHDl mutations. The general impression is that in the absence of other CHARGE 
features, the chance of finding a CHDl mutation is very low. 
Studies in syndromes that overlap with CHARGE syndrome 
Thus far, two clinically overlapping syndromes have been studied in relation to CHDl mutations: 
velocardiofacial syndrome (VCFS) and Kallmann syndrome. 
Velocardiofacial or 22ql 1 deletion syndrome, shares many features with CHARGE syndrome, 
including congenital heart defects, cleft palate, developmental delay, renal anomalies, growth 
retardation, ear anomal ies, hearing loss, hypoglycaemia and lymphopenia.49 In particular, thymus 
aplasia and hypoparathyroidism are increasingly recognised in CHARGE syndrome and mark the 
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clinical overlap with the DiGeorge phenotype of 22ql 1 deletions.50•1' In approximately 85% of 
VCFS patients, a common 3 Mb heterozygous deletion of 22ql 1 .2 is present, resulting in TBX1 
haploinsufficiency. Mutations in the TBX1 gene are present in a minority of VCFS patients. Array 
comparative genomic hybridisation (CGH) in a cohort of VCFS patients without 22ql 1 deletion or 
TBX1 mutation revealed one heterozygous deletion encompassing the CHDl gene in a patient with 
features typical of VCFS.52 This patient had a learning difficulty with speech delay, severe feeding 
difficulties, a congenital heart defect (interruption of the aortic arch, coarctation of the aorta, 
bicuspid aortic valve, ventricular and atrial septal defect), long slender fingers and low set, over­
folded ear helices. The patient did not have coloboma, choanal atresia or cleft palate, but did have 
typical CHARGE ears with triangular conchae. To our knowledge, CHDl sequence analysis has not 
yet been performed in a cohort ofVCFS patients without deletion or mutation of TBX1.  In Figure 2 
we il lustrate how difficult it can be to distinguish between CHARGE syndrome and 22ql 1 deletion 
syndrome. The phenotypic similarity between VCFS and CHARGE syndrome is also apparent in mice 
with haploinsufficiency of Tbx l and Chdl.52 Both genes are required in pharyngeal ectoderm for 
fourth pharyngeal artery development. In addition, both genes are important in the development 
of the thymus and semicircular canals. The Tbx l and Chdl genes were shown to interact in mice, but 
a direct regulatory effect of Chd7 on Tbx l expression could not been demonstrated.51 
Kallmann syndrome usually presents as the combination of hypogonadotropic hypogonadism 
(HH) and anosmia. Both features also occur in the majority of patients with CHARGE syndrome.5) 56 
Figure 2. Patient with typical CHARGE syndrome and a 22q1 1 deletion. 
This 3½-year-old girl presented with retinal and iris coloboma, unilateral choanal stenosis, abnormal semicircular 
canals, mixed hearing loss, pulmonary valve stenosis and simple ears. Clinically she has typical CHARGE 
syndrome, but neither a CHDl mutation nor a deletion could be detected by sequence analysis and multiplex 
l igation-dependent probe amplification {MLPA).26 Subsequently, array comparative genomic hybridisation (CGH) 
was performed {Agilent 1 80K custom HD-DGH microarray) and revealed a de novo 3 Mb 22q1 1 .2 loss, suggestive 
for the typical DiGeorge/velocardiofacial syndrome deletion. 
Informed consent was obtained for publication of the photographs. 
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Other features that can be present in both syndromes are hearing loss, cleft lip/palate and renal 
malformations. Two studies have been performed in which patients with normosmic HH or 
Kallmann syndrome were screened for CHDl mutations. CHDl mutations were reported in seven 
out of 197 patients with normosmic HH or Kallmann syndrome,57 in three out of 36 patients with 
Kallmann syndrome (confirmed by a smell test), but in none of 20 patients with normosmic HH.5" 
The second study showed that after thorough clinical examination of the CHD7-positive Kallmann 
patients, other CHARGE features were universally present. The authors concluded that these 
patients represent the mild end of the CHARGE phenotypic spectrum, as we also demonstrated in 
our patient who was referred with Kallmann syndrome (see the section "Mildly affected patients 
from our CHD7-positive cohort"). 
CHDl AND CHARGE SYNDROME: THE CLINICAL IMPLICATIONS 
Based on the studies conducted after the identification of CHDl and summarised above, we discuss 
whether CHARGE syndrome is a clinical or molecular diagnosis, propose a new guideline for CHDl 
analysis and give recommendations for clinical surveillance of CHD7-positive patients. 
CHARGE syndrome, a clinical or molecular diagnosis? 
In our opinion, CHARGE syndrome is primarily a clinical diagnosis. If patients fulfil the clinical criteria 
of Blake or Verloes and chromosomal aberrations and teratogenic exposure effects fully explaining 
the clinical features have been ruled out, then they have CHARGE syndrome, irrespective of the 
results of CHDl analysis. On the other hand, patients who do not completely fulfil the clinical criteria 
should not be excluded from CHDl analysis. If a mutation is found in these patients, clinical follow­
up and genetic counselling should be performed as in clinically diagnosed patients with CHARGE 
syndrome. 
Guideline for CHDl analysis 
Considering the broad phenotypic spectrum, it is evident that CHDl analysis should not be restricted 
to patients fulfilling the clinical criteria for CHARGE syndrome. Coloboma and choanal atresia (or 
cleft palate) are not always present in CHARGE syndrome. Therefore, patients with other CHARGE 
features, but without those cardinal features, should not be excluded from CHDl analysis. When a 
patient is suspected of CHARGE syndrome, the external ears, cranial nerve function and semicircular 
canals should be thoroughly examined, as these features occur in the great majority of patients with 
a CHDl mutation (Table 2). 
We propose a guideline for CHDl analysis in Figure 3. In our experience, imaging of the 
semicircular canals is not an easy routine in daily clinical practice, especially in children in whom 
sedation can be complicated (see "Clinical surveillance" and Table 4). Therefore, in our guideline we 
have indicated when imaging of the semicircular canals is needed to support the decision for CHDl 
analysis. We based our guideline on the clinical features that were present in our CHD7-positive 
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patients (n=280). When applying our guideline, CHD7 analysis would not have been recommended 
in one of our patients. This patient is the first one described in the section "Mildly affected patients 
from our CHO7-positive cohort" and is extremely mildly affected. A prospective study is needed to 
evaluate the usefulness of this guideline in clinical practice. 
Figure 3. Guideline for CHDl ana lysis in patients suspected of CHARGE syndrome. 
Cardinal features 
Coloboma 
Choanal atresia or stenosis 
Characteristic external ear anomaly 
(triangular conchae or cup ear) 
Cranial nerve dysfunction (facial palsy or 
sensorineural hearing loss or hypoplasia 
of cranial nerves on imaging) 
Vestibular phenotype• 
3 cardinal or 2 cardinal + 1 supportive 
Supportive features 
Cleft lip/pa late 
Hypogonadotropic hypogonadism or anosmia 
Congenital heart defect or tracheo-oesophageal 
malformation 
Mental retardation (IQ < 70) 
Growth retardation (length <-2.5 SD) 
Family member with 1 cardinal or 2 supportive 
features 
2 cardinal or 1 cardinal + 1 supportive 
+ Temporal bone CT scan: typical semicircular canal abnormalities 
CHDl analysis including M.PA* Array CGH 
CGH, comparative genomic hybridisation; MLPA, multiplex ligation-dependent probe amplification. 
' A convincing h istory of vestibular problems (e.g. five-point crawl) or abnormal vestibular test or semicircular 
canal hypoplasia. " If clinical presentation is very atypical, it is recommended to perform array CGH first. 
Patients with velocardiofacial syndrome, but without a mutation or deletion of the TBXI gene, are also good 
candidates for CHDl a nalysis 
Clinical surveillance of patients with a CHD7 mutation or typical CHARGE syndrome 
Ideal ly, follow-up of patients with a CHD7 mutation or typical CHARGE syndrome should be done 
by an expert multidisciplinary team, because this approach will ensure optimal treatment of this 
very complex patient group. I n  the Netherlands, several specialities are involved in the CHARGE out­
patient clinic of the University Medical Centre Groningen: clin ical genetics, paediatric endocrinology, 
ear nose throat (ENT), speech and occupational therapy, ophthalmology, child and youth psychiatry, 
social paediatrics, gynaecology, endocrinology, paediatric cardiology, neuroradiology and dentistry. 
I n  Table 4, we show updated recommendations for clinical surveillance of patients with a CHD7 
mutation based on the experiences of our CHARGE outpatient clinic, on the clinical features in our 

















Full ophthalmological examination including 
fundoscopy 
Multidisciplinary evaluation: 
Assess patency of choanae (CT scan or nasal 
endoscopy) 
Evaluation for cleft palate and tracheo-oesophageal 
anomalies 
Audiometry (BAER), tympanometry 
Temporal bone CT scan (pathology of middle ear, inner 
ear, cranial nerves, semicircular canals, aberrant course 
of blood vessels or cranial nerves) 
Cranial nerve function tests 
Swallowing studies, pH monitoring, reflux scan in case 
of feeding/swallowing difficulties 
University of Pennsylvania Smell Identification Test 
Renal ultrasound, voiding cysto-urethrogram in case of 
urinary infections 
Immunological studies in case of recurrent infections 
or suspected hypocalcaemia 
Follow-up of growth and development (growth 
hormone stimulation test if indicated) 
Monitor cryptorchidism 
Gonadotropin levels (age 6-8 weeks) and follow-up of 
pubertal development 
DEXA scan (when suspected for osteoporosis) 
Monitor for scoliosis 
Cardiac evaluation including ultrasound 
Extensive preoperative assessment 
Treatment/advice 
Tinted spectacles for photophobia (iris 
coloboma) 
Artificial tears in case of facial palsy 
Correction of refraction errors 
Surgical correction of choanal atresia 
Hearing aids, ventilation tubes 
Sign language and speech training 
GERD: Nissen fundoplication, 
antispasmodics 
Gastrostomy/tracheotomy in case of severe 
swallowing problems 
Surgery of tracheo-oesophageal 
abnormalities 
Advice concerning anosmia 
Early treatment of bladder infections 
(especially in case of unilateral renal 
agenesis or vesico-urethral reflux) 
Growth hormone treatment if growth 
hormone deficiency is present 
Orchidopexy when indicated 
Gonadotropin treatment in case of 
hypogonadotropic hypogonadism 
Corset or surgery when severe progressive 
scoliosis is present 
Cardiac surgery and/or antibiotic 
prophylaxis 
Combine surgical procedures whenever 
possible 
Longer surveillance after surgery 
Be aware of 
Retinal detachment (in case of retinal 
coloboma) 
Respiratory aspiration (recurrent 
pneumonias) 
Aberrant course of blood vessels 
or cranial nerves when surgery for 
cochlear implants 
Obstructive sleep apnoea 
Postoperative complications (due to 
aspiration/cranial nerve dysfunction) 














Cerebral MRI scan (including visualisation of olfactory 
bulbs, and inner ear if no temporal bone CT scan has 
been performed) 
EEG (only when clinically seizures are observed) 
Extensive multidisciplinary evaluation of 
developmental and sensory impairments and 
behavioural problems 
Use formal tests in order to screen for autism 
spectrum, obsessive compulsive disorders and ADHD 
Perform IQ tests regularly 
Assessment of balance problems, motor delay, 
visiospatial coordination and hypotonia 
CHD7 analysis (when no CHD7 mutation or deletion is 
found, perform array CGH) 
Anticonvulsants if overt epilepsy seen 
Integrated individualised therapy 
with special attention for optimising 
communication 
Therapy for hypotonia and devices to 
overcome balance impairment 
Genetic counselling, options for prenatal 
diagnosis 
Intra-familial variability in CHARGE 
syndrome 
ADHD, attention deficit hyperactivity disorder; BAER, brain stem auditory evoked response; array CGH, array comparative genomic hybridisation; DEXA, dual energy x-ray 
absorptiometry; EEG, electroencephalogram; ENT, ear nose throat; GERD, gastro-oesophageal reflux disease. 
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An ultrasound of the heart and kidneys should be done in a l l  patients, because mild congenital 
anomalies can remain undetected until adulthood, but may have therapeutic consequences (e.g. 
early treatment of urinary tract infections in case of renal anomalies). 
Cranial nerve investigation is important. Dysfunction of the seventh, n inth and tenth cranial 
nerve can lead to severe feeding and swallowing problems, can result in respiratory aspiration and 
postoperative compl ications and might be involved in sudden death.59-62 
HH should be diagnosed at an early stage, because patients are at risk for osteoporosis if 
hormone replacement therapy is not started in time. We recently demonstrated that anosmia and 
HH are 1 00% correlated in CHARGE syndrome and we proposed smell testing as a predictive test 
for HH.63 
Last, but not least, an  Individualised educational program is needed in order to stimulate fully the 
intellectual potential of a child with CHARGE syndrome and to manage behavioural problems.64-68 
Clinicians should be aware that semicircular canal hypoplasia, a very frequent feature in CHARGE 
syndrome, causes balance problems and therefore a delay in motor development. This motor 
retardation may erroneously lead to the suspicion of intellectual disability, although approximately 
25% of patients have a normal intelligence. 
In addition, identifying a CHDl mutation gives further tools for genetic counselling of both the 
parents and the patients themselves. When the CHDl mutation has occurred de novo in the index 
patient, the recurrence risk for the parents is 2-3% because both germline and somatic mosaicism 
have been described in CHARGE syndrome.20-37.44 Patients themselves, when fertile with or without 
appropriate hormone replacement therapy, have a 50% chance of transmitting the CHDl mutation 
to their offspring. The severity of CHARGE syndrome in offspring cannot be predicted, because intra­
familial variabil ity is large. Prenatal diagnosis, either by molecular analysis or ultrasound, and pre­
implantation genetic diagnosis, when appropriate, should be discussed with parents and patients. 
CONCLUSIONS 
CHARGE syndrome is extremely variable, an observation that has been strongly underscored 
since the discovery of the CHDl gene. The phenotype cannot be predicted from the genotype, as 
exemplified by intra-familial variability. CHARGE syndrome remains primarily a clinical diagnosis, but 
molecular testing can confirm the diagnosis in mildly affected patients. Guidelines for CHDl analysis 
in individuals suspected of having CHARGE syndrome are proposed in Figure 3. In addition, updated 
guidelines for the surveillance of patients with a CHDl mutation or typical CHARGE syndrome are 
presented in Table 4. 
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THE CHD7 GENE IN CHARGE SYNDROME 
CHD7 mutation database 
The CHDl gene is the major gene involved in CHARGE syndrome.U A CHDl mutation can be 
identified in more than 90% of patients who fulfil the clinical diagnostic criteria. H In chapter 2.1 , a 
comprehensive CHDl mutation database was presented which contained 531 different pathogenic 
CHDl mutations (June 1 5th 201 1 ). The database contains all the CHDl mutations reported in the 
l iterature, in addition to mutations identified by the molecular genetic laboratories of the Radboud 
University Nijmegen Medical Centre, N ijmegen, the Netherlands and the Department of Cel lular 
and Molecular Medicine, the Panum Institute, University of Copenhagen, Copenhagen, Denmark. 
Nonsense and frameshift mutations were identified in the majority of patients (77%), while splice 
site mutations were found in 1 1  %, missense mutations in 9% and deletions/duplications and 
genomic rearrangements occurred only rarely (3%). Several recurrent mutations (n=96) were found, 
but most mutations were unique. The database will be helpful for clinicians as well as scientists, as 
it gives a complete and readily available overview of all CHDl mutations in combination with any 
relevant clinical information on them. We will continue to add new CHDl mutations to the database 
and we hope that other laboratories will submit their CHDl mutations to the database, because 
any additional information, including new patients with a recurrent mutation, can be valuable. For 
example, it might become clear that a particular mutation infers a high risk for a specific congenital 
anomaly. At present, however, no clear genotype-phenotype correlations have been identified and 
the database cannot therefore be used for individual predictions. The current lack of genotype­
phenotype correlations is underscored by observations in famil ial CHARGE syndrome, where family 
members with the same CHDl mutation can be affected in a very variable manner, and where 
monozygotic twins with a CHDl mutation have been shown to have different congenital anomalies 
(see also chapter S.1 ) . 
Pathogenicity of CHD7 missense variants 
Assessing the pathogenlcity of missense variants is difficult, especially when the variant has not 
been published in the literature or recorded in our database. Computational algorithms (e.g. SIFT,6 7  
PolyPhen8·9 and Align GVGD10- 1 1 ) can give an indication of pathogenicity, but often show conflicting 
results. Since correct interpretation of the pathogenicity of missense variants is essential for genetic 
counselling, we developed a novel classification system for CHDl missense variants (described in 
chapter 2.2). The classification is based on the output of SIFT, PolyPhen and Align GVGD combined 
with data from segregation analysis and it assigns a score to each missense variant that reflects 
the likelihood that the variant is pathogenic. Structural modelling of the CHO? protein was used 
for further confirmation of our prediction. With our system, we classified 30% (43/1 45) as 'probably 
pathogenic; 23% (33/145) as 'probably benign; and 48% (69/1 45) as 'unclassified variant; due to 
lacking segregation or phenotypic data. Our classification was frequently in agreement with previous 
predictions from the literature. Unfortunately, we cannot test the validity of our classifications, 
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because there is no a gold standard for the classification of CHD7 missense variants. We had to 
classify many variants as 'unknown; mainly because of a lack of segregation and phenotypic data . 
Segregation analysis can be helpful in classifying CHD7 variants, but should be done with care. If 
a parent is found to carry the missense variant of interest, a detailed cl inical examination of this 
parent should be performed. If the carrier parent has subtle features of CHARGE syndrome, the 
chance that the missense variant is pathogenic will increase. However, it is still possible that the 
variant is not pathogenic, but that it is in linkage disequilibrium with an unidentified pathogenic 
mutation . It would also be worthwhile to determine how many CHD7 variants are present in the 
healthy population, because such data can help to calculate the prior chance that a certain CHD7 
variant is pathogenic. The 1000 Genomes Project and the Genome of the Netherlands could supply 
useful data. The ongoing submission of our own data and that from other laboratories to the CHD7 
mutation database will contribute to a better classification of CHD7 missense variants. This will 
improve the molecular diagnosis of CHARGE syndrome and facilitate genotype-phenotype studies. 
Both aspects are important for the genetic counselling and surveillance of patients with CHARGE 
syndrome. The classification system that we developed for CHD7 missense variants may also be 
applicable to other predominantly sporadic, autosomal dominant disorders. Future studies could 
explore this. 
In addition to the classification system described in chapter 2.2, it would be helpful to 
develop a functional assay to assess the effects of missense variants on CHD7 function. The first 
requirement for developing such functional assay is to determine the precise function of the protein 
of interest . For CHD7, it is generally accepted that the protein has an important role in controlling 
the expression of multiple genes in a cell type- and embryonic stage-dependent manner.12•13 Many 
binding partners of CHD7 have been identified, but the underlying molecular pathways have not 
yet been elucidated.1rn One study identified CHDB as a binding partner of CHD7 through a yeast 
two-hybrid library screen and also investigated the effect of four different missense variants of the 
CHD7 gene on the binding affinity to CHDB.14 Three of the four missense variants showed disrupted 
binding of CHD7 to CHDB in the yeast two-hybrid system, but not in the co-immunoprecipitation 
studies, indicating that CHD7 and CHD8 might be components of a larger protein complex. If the 
binding of CHD7 to CHD8 is an essential step in the development of CHARGE syndrome, then 
three of the four missense mutations would be considered pathogenic . This prediction agrees 
with the results of our classification system, which predicted that the three missense variants 
that disrupted binding to CHD8 were pathogenic, whereas the fourth variant was predicted to be 
benign. Other potential means of investigating functional effects of CHD7 missense variants are the 
in vivo migration assay of cephalic neural crest cells, phenotypic analysis of mutant mRNA injected 
tadpoles, and investigating the binding affinity of CHD7 to other partners (e .g. PBAF components, 
N LK, SETDBl, PPAR-gamma and specific D NA regions) .12 At present, however, too little is known 
about the interacting partners of CHD7 that are functionally important, or about the pathways that 




Phenotypic spectrum of CHD7 missense mutations 
In chapter 2.2, we compared the clinical features of patients with missense mutations with those 
of patients with truncating mutations (nonsense and frameshift mutations and deletions). The 
patients with missense mutations showed a highly variable phenotype and were, on average, 
less severely affected than those with a truncating mutation in the CHDl gene. It is therefore not 
possible to predict the disease severity in an individual patient with a CHDl missense mutation, but 
there is a chance that the patient will only be mildly affected. Our observations are in line with data 
from studies of famil ial CHARGE syndrome, in which missense and splice site mutations are often 
present.1 9•21 However, the same mutation can lead to an extremely variable phenotype among family 
members (see also chapter 5.1 ). Based on our clinical observations, I hypothesise that complete 
haploinsufficiency (due to truncating mutations) has more severe effects on CHD7 function than 
missense mutations that lead to an altered, but possibly partly functional protein. 
Cause of CHARGE syndrome in patients without a CHD7 mutation 
In some patients highly suspected of having CHARGE syndrome, no CHDl mutation can be found. 
The initial discoveryofthe genewas based on a microdeletion in 8ql 2, including the CH07gene,1 and 
thus the CHDl haploinsufficiency may be due to a deletion in a subset of patients. However, partial 
or complete deletions of the gene wil l  not be detected by routine Sanger sequencing. In chapter 
2.3, I described the results of multiplex l igation-dependent probe amplification (MLPA) in a cohort of 
54 patients with features of CHARGE syndrome but who did not have a CH07mutation on sequence 
analysis. Eighteen of these 54 patients fulfilled the cl inical criteria of Blake and/or Verloes3•5 a nd 
therefore presented with typical CHARGE syndrome. The other 36 patients had features of CHARGE 
syndrome, but did not fulfil the clinical criteria and therefore had atypical CHARGE syndrome. We 
identified a deletion of exons 1 3  to 38 in one patient with typical CHARGE syndrome { 1  /54 = 1 .9%). 
Because C HDl deletions were not found in the atypical patients of our cohort, the yield of MLPA in 
atypical patients was assumed to be very low. In a subsequent Swedish study, however, the yield 
of MLPA was much higher. Four CHDl deletions were identified in eighteen Swedish patients with 
features of CHARGE syndrome, but without a CHDl mutation upon sequencing.m3 In two patients 
a deletion of the entire CHDl gene was found, one patient had a de novo deletion of exon 1 ,  and the 
other patient had a de novo deletion of exon 4. Three of the four patients did not fulfil the clin ical 
criteria and it was therefore advised to perform MLPA in all patients who are suspected of CHARGE 
syndrome.2i I agree with Wincent et al's advice, but want to warn about the possibility of obtaining 
false-positive results in MLPA. If a single nucleotide polymorphism (SNP) is located underneath an 
MLPA probe, the MLPA wi l l  detect a deletion that is not actually present. If a single exon deletion 
is detected by MLPA, it is advisable to confirm the deletion with another molecular technique. 
Another possibility is to sequence the region of the MLPA probe that is found to be deleted, in order 
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to exclude SNPs that prohibit binding of the probe. 
CHDl sequence analysis and MLPA should be performed in all patients who are suspected of 
CHARGE syndrome. However, after sequence analysis and MLPA, 5-10% of the patients with typical 
CHARGE syndrome and a substantial number of patients with atypical CHARGE syndrome still have 
no molecular diagnosis. The cause of CHARGE syndrome might differ in the typical and atypical 
cases. Particularly in patients with typical CHARGE syndrome, it is possible that they do have a 
CHDl mutation, but that the mutation cannot be identified with current molecular techniques. For 
example, mutations in the deep intronic regions, 5' or 3' untranslated regions, or critical regulatory 
elements of the CHDl gene will currently not be identified. To investigate this possibility, RNA 
analysis could be performed. However, it is difficult to find a cell type that expresses a gene like 
CHDl, which is mainly active during embryogenesis. One report showed that CHDl is expressed 
in adult retina, cornea, brain, skeletal muscle, heart, kidney and lung,1 but these cells are difficult 
to ascertain for RNA analysis in patients. We therefore examined whether CHDl was expressed in 
a control EBV cell line, but unfortunately found no CHDl expression. Further studies are needed to 
identify a suitable cell type for CHDl RNA analysis. 
A second possibility is that the CHDl-negative patients have a mutation in another, as yet 
unidentified, gene for CHARGE syndrome. Several candidate genes, e.g. PAX2, PITX2 and CHDB, have 
been analysed in patients, but no mutations were identified.14•24•25 In 2004, alterations of the SEMA3E 
gene were found in two patients with CHARGE syndrome,26 but no additional SEMA3E mutations 
have been reported since then. In searching for a new gene for CHARGE or CHARGE-like syndromes, 
our group will perform exome sequencing in a selected group of CHDl-negative patients with 
features of CHARGE syndrome. 
CHARGE SYNDROME: STUDIES IN MICE AND MEN 
Studies in Chd7whit+ and Chd7"11+ mice 
Mouse models can be helpful in gaining insight into the pathogenesis of human disease. Two mouse 
models are commonly used to study CHARGE syndrome; the Whirligig mouse (ChdJWW+), which 
carries a heterozygous nonsense mutation in the Chdl gene,27 and a mouse that is heterozygous for 
a gene-trapped /acZ allele (ChdJG11+).28 The ChdJWhll• mice have been most extensively studied and 
have many features in common with human CHARGE syndrome, e.g. ful ly penetrant semicircular 
canal anomalies and occasional congenital heart defects, cleft palate, choanal atresia and reduced 
body weight.27 However, sense of smell and reproductive organ anatomy had not been studied in 
detail in Chdlwhii+ mice. Since we were interested in anosmia and hypogonadotropic hypogonadism 
(HH), which are the main features of Kallmann syndrome and which also occur in the majority of 
patients with CHARGE syndrome, we studied olfaction and aspects of the reproductive system 
in ChdJWhll+ mice (in chapter 3.1 ). We found that Chd7 is expressed in brain regions involved in 
olfaction and reproduction during embryonic development, which is in concordance with previous 
studies.21- 30 We showed that ChdJWhlt+ mice maintained on a C3HeB/FeJ background performed 
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less well on a smell test than wild-type mice. Unfortunately, our study design did not allow us to 
discriminate between an olfactory deficit and severe balance disturbance, and we were therefore 
uncertain whether hyposmia was present in ChdJWhll+ mice. A concurrent study, however, confirmed 
the presence of hyposmia in adult ChdJG"• mice maintained on a 1 295I/SvlmJ background, by using 
odour-evoked electro-olfactograms.31 In our study, we observed olfactory bulb hypoplasia and 
reproductive organ anomal ies (uterine abnormalities in females and testes hypoplasia in males) 
in some of the ChdJWIW+ mice. The reproductive performance of both male and female ChdJWhll+ 
mice was slightly impaired compared to wi ld-type mice. In addition, the gonadotropin-releasing 
hormone (GnRH) neuron density appeared to be lower in adult female ChdJWW• mice, suggesting 
that GnRH deficiency could underlie their reproductive defects. A subsequent study also identified 
reproductive defects in Chdl'"'''+ mice maintained on a 1 295I/SvlmJ background. These mice had 
delayed puberty, erratic oestrus cycles, decreased levels of circulating LH and FSH, and a reduced 
GnRH neuron count in the hypothalamus.12 It was suggested that the reduced GnRH neuron count 
was caused by reduced GnRH cellular proliferation in  the embryonic olfactory placode rather than 
by GnRH migration defects or increased cell death of GnRH neurons. In addition, Layman et al found 
that Chdl haploinsufficiency was associated with a decreased expression of Fgfr1, Bmp4 and Otx2, 
but not FgfB, in  the embryonic olfactory placode and Otx2 and GnRH1 in the adult hypothalamusP 
Combined with the results from their previous study,31 the authors suggested that the reproductive 
and olfactory defects in Chd7-deficient mice were caused by a decreased proliferation of GnRH 
neurons i n  the embryonic olfactory placode, together with a decreased proliferation of basal cells 
in the adult olfactory epithelium. Chd7 could possibly affect GnRH neurogenesis and signall ing by 
influencing transcriptional regulation of target genes involved in the BMP and FGF pathway.32 
I n  our study, we crossed ChdJWM• mice with Fgfr1Hw1• mice, and showed that a mutation in  
both Chdl and Fgfr7 was associated with perinatal or early postnatal death. This is in contrast to 
the normal viability of Fgfr7H,pyJ+ mice and the 50% lethality of ChdJW"'1+ mice and suggests that 
mutations in Fgfr1 and Chdl interact synergistically. Both Chd7 and Fgfr1 are expressed in  multiple 
tissues throughout embryogenesis and will probably Interact in an unidentified pathway that is 
essential for survival. Olfactory bulbs and GnRH neuron distribution were, however, normal in the 
double heterozygous embryos, arguing against a genetic interaction between Chdl and Fgfr1 in  the 
development of the olfactory bulb and hypothalamus in mice. 
Extrapolating the results from mouse studies to human CHARGE syndrome could prove difficult 
because of species-specific differences. The Chd7-deficient mice did not have complete aplasia 
of olfactory bulbs, nor were they infertile. Neither did the Fgfr7H,pyl+ mice have overt features of 
Kal lmann syndrome.ll The phenotypic discrepancies between humans and mice might be due to 
species-specific differences in  the developmental requirements for CHD7 and FGFR1 . It is interesting 
that the KAL 1 gene (which is implicated in X-linked Kallmann syndrome in humans) has not been 
identified in mice, but it is  hypothesised to have a pseudo-autosomal location.34•35 The KAL 1 gene 
product, anosmin-1 , is expected to interact with FGFR1 and FGF8. Theoretically, a higher Kall 
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expression level in mice could make Fgfr7Hspyt+ mice less susceptible for HH. The genetic background 
of the mice could also play a major role, with modifier genes having an effect on the penetrance 
and expressivity of different phenotypic features. This was already shown for the olfactory and ear 
phenotype, with ChdJG11• mice maintained on a 1295I/SvlmJ background having a more severe 
olfactory phenotype, and mice on a C57BU6J background having a more severe ear phenotype 
compared to mice maintained on a mixed background.1 The difference in genetic background of 
the ChdJWW+ mice (C3HeB/FeJ) and the ChdJG'1• mice (12951 /Svl mJ) could also have an effect on the 
severity of the olfactory and reproductive phenotype. 
In our study, we were surprised to find that even the genetically identical ChdJWl!II• mice 
maintained on a homogeneous C3HeB/FeJ background showed incomplete penetrance of 
congenital anomalies. This observation supports the theory that the extreme variability of the 
CHARGE phenotype in both humans and mice is due to variants in the foetal micro-environment, 
leading to small fluctuations of the local Chd7 level or of the downstream gene products. Congenital 
anomalies will only occur if the Chd7 level is below a critical threshold that is tissue- and embryonic· 
stage-dependent. Some tissues, for example the inner ear, appear to be highly sensitive to Chd7 
dosage, and are frequently affected in CHARGE syndrome. Other tissues, for example choanae, 
palate, eye and kidney, seem less sensitive to Chd7 dosage and are less frequently affected in 
CHARGE syndrome.2•36 
In the future our group would like to study the pathogenesis of congenital heart defects in 
ChdJGti• mice. We hypothesise that Chdl haploinsufficiency in neural-crest-derived cardiac cells 
will alter the transcription of cardiogenic genes and that this will result in cardiac outflow tract 
defects. Candidate genes for outflow tract defects can possibly be identified by comparing the 
gene expression patterns of ChdJGtl• mice with those of their wild-type litter mates during different 
embryonic stages in neural-crest-derived cardiac cells. Such a study could provide insight into the 
pathogenetic mechanisms underlying CHO7-related heart defects. If novel genes for cardiac defects 
are discovered, more aetiological diagnoses can be made in patients with congenital heart defects 
and this would lead to a more accurate determination of the recurrence risk and would improve 
genetic counselling. 
Study of anosmia and HH in patients with CHARGE syndrome 
After studying the occurrence of anosmia and HH in ChdJWhV• mice, we investigated the prevalence 
of these two features in human CHARGE syndrome. We hypothesised that HH and anosmia might co­
occur in CHARGE syndrome, as is the case in Kallmann syndrome. The results, presented in chapter 
3.2, showed that anosmia and HH were indeed 100% correlated in our cohort of 35 adolescent 
patients with CHARGE syndrome. The co-occurrence of anosmia and HH had previously been 
reported for six female patients with CHARGE syndrome37•38 In addition, a recent study reported 
arrhinencephaly and defective migration of GnRH neurons in a foetus with CHARGE syndrome, 
offering further support of the link between anosmia and HH.39 In the foetus with CHARGE syndrome, 
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there were very few GnRH neurons in the hypothalamic region and entangled nerve fibres were 
found on the dorsal side of the cribriform plate, as was also the case in a foetus with Kallmann 
syndrome. These results are in contrast to data from mouse studies, where normal migration of 
GnRH neurons was observed in Chd7-deficient mice.12These observations shows that extrapolating 
results from mouse studies to the human situation is not always possible. It would therefore be 
interesting to investigate the effect of CHD7 haploinsufficiency on the expression of several genes 
(e.g. KAL 1, FGFR1, PROK2, PROKR2, FGFB, NELF, WDR11, OTX2, BMP4 and GnRH I) in human embryonic 
olfactory placode and hypothalamus. In this way, we could gain more insight into the underlying 
pathogenesis of HH and anosmia in human CHARGE syndrome. 
Our findings and the literature provide convincing evidence that anosmia and HH always co­
occur in CHARGE syndrome, which means that a smell test can be used to predict the occurrence 
of HH in patients with CHARGE syndrome. This gives the opportunity to start with hormone 
replacement therapy (HRT) at an age-appropriate time in anosmic children with CHARGE syndrome, 
thereby reducing socio-emotional problems and lowering the riskof osteoporosis and cardiovascular 
disease, which are related to low sex hormone levels. Although there are many advantages to early 
HRT, there are also some drawbacks. Testosterone treatment increases muscle mass in boys and 
may aggravate behavioural problems. In girls, menstruation can be a burden, but can be minimized 
to three menstrual bleeds a year. The advantages and disadvantages of HRT should be discussed 
with the patient and parents in order to provide optimal patient care. At our CHARGE outpatient 
clinic, we are following patients who have received HRT and will investigate whether these patients 
or their parents report negative side effects. At present, it is not known how many patients with 
CHARGE syndrome experience problems due to HRT or how severe these problems are. The results 
from this study will be used to counsel patients more accurately about the negative side-effects of 
HRT in CHARGE syndrome. 
Study of sudden death in patients with CHARGE syndrome 
CHARGE syndrome is a rare disease, which makes it difficult to ascertain a large enough cohort for 
clinical studies. Our group is fortunate to have approximately 70 patients in the CHARGE outpatient 
clinic to follow, which greatly facilitates our research. The phenotypic variability of CHARGE 
syndrome is impressive; some patients have no health issues and a normal intelligence, whereas 
others die shortly after birth due to bilateral choanal atresia or complex congenital heart defects. 
We had gained the impression that the life expectancy of patients with CHARGE syndrome who 
survived the neonatal period was not significantly decreased. We were therefore surprised to hear 
that three patients had died unexpectedly after the neonatal period. We collected their clinical data 
and that for four other patients who had died after the neonatal period to study the risk factors 
for premature demise. The results, presented in chapter 3.3, showed that gastro-oesophageal 
reflux disease (GERO) and poor coordination of swallowing and breathing, leading to respiratory 
aspiration and post-operative airway events, were risk factors for post-neonatal death in CHARGE 
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syndrome. These observations are in line with previous studies.4()-42 Cranial nerve dysfunction was 
proposed as the underlying mechanism. We advised multidisciplinary follow-up of patients with 
CHARGE syndrome who have feeding difficulties, in combination with assessing their swallowing 
function and cranial nerve function. Treatment of swallowing problems and GERD should not be 
delayed and surgical procedures should be combined whenever possible in such patients. Further 
research is needed to elucidate the underlying cause of cranial nerve dysfunction in CHARGE 
syndrome. Detailed MRI brain imaging or post-mortem brain examination might shed light on the 
anatomical substrates of cranial nerve dysfunction in CHARGE syndrome. In addition, it is worth 
studying cranial nerve function in relation to swallowing problems, respiratory aspiration, GERD, 
and post-operative complications. Autopsy data from patients with CHARGE syndrome who died 
unexpectedly could lead to more knowledge on causes of death. This could help to identify more 
accurately which patients are at high risk for sudden death and, ideally, preventive measures could 
be taken to reduce the risk. Another factor that might contribute to sudden death in CHARGE 
syndrome is central adrenal insufficiency during infection-related stress (as was postulated for 
patients with Prader Willi syndrome by De Lind van Wijngaarden et a/).4' Adrenal insufficiency has 
not been reported in CHARGE syndrome, but it is known that patients with CHARGE syndrome can 
have other hypothalamic insufficiencies, for example growth hormone deficiency (present in a small 
minority of patients) or GnRH deficiency (leading to HH).44 
Study of other aspects of CHARGE syndrome 
We have studied only three aspects of CHARGE syndrome (olfaction, pubertal development and 
sudden death), but many other aspects of this complex syndrome deserve further study. At our 
outpatient clinic we gain insight into the questions that are relevant for the patients and their 
parents. One question that is frequently voiced concerns nocturnal enuresis. Many parents report 
that the young patient is still wetting the bed long after the age that children normally stay dry at 
night (6 to 7 years of age). This aspect of CHARGE syndrome has, to our knowledge, never been 
studied. In the general population, at least three pathogenic mechanisms are known to contribute 
to nocturnal enuresis: nocturnal polyuria, nocturnal detrusor overactivity, and high arousal 
thresholds.45 Polyuria is often caused by nocturnal lack of vasopressin, an antidiuretic hormone that 
is produced in the pituitary gland. Brainstem disturbance is thought to be the underlying cause for 
all three mechanisms.46 50 It is tempting to speculate that brainstem pathology could also be the 
cause of nocturnal enuresis in CHARGE syndrome. Future research is needed to gain insight into the 
pathophysiological mechanisms of this problem. This could contribute to better treatment options 
for children with CHARGE syndrome with nocturnal enuresis. 
Another problem that is frequently reported by parents is disturbed sleep. A previous study 
investigated sleep disturbance in 87 children with CHARGE syndrome and found that the majority 
had a clinically significant disturbance as measured on the sleep disturbance scale for children.51 
Disorders of initiating and maintaining sleep, sleep breathing, and sleep-wake transition were most 
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commonly found, were associated with behavioural problems, and had negative effects on the 
parents' mental health. The cause of sleep disturbance in CHARGE syndrome is unknown, but could 
be related to pain (e.g. due to ear infections) or breathing problems caused by congenital anomalies 
(e.g. choanal atresia). Another possibil ity is that patients have a disturbed circadian rhythm. Support 
for this last possibility comes from mouse studies. The Wheels mouse, an ENU-generated mouse 
with a Chd7 mutation, was reported to have a disturbed circadian rhythm.27•52 The Wheels mouse has 
a lengthened circadian period and is more active in light conditions, which is aberrant behaviour for 
a nocturnal rodent. An altered melatonin secretion pattern is known to underlie sleep disturbance 
in other syndromes, for example in Smith Magenis syndrome,s3 Angelman syndrome,S4 and fragile 
X syndrome,55 but it has not been studied in CHARGE syndrome. Our group would therefore 
like to study melatonin secretion patterns in patients with CHARGE syndrome with severe sleep 
disturbance. If altered patterns are found in such patients, we will investigate whether melatonin 
supplementation can be used to improve sleeping patterns. 
Other aspects of CHARGE syndrome that need studying are hearing loss (and the benefit of 
cochlear implants), speech development, dental anomalies, adrenal gland function, and health 
problems in adult and elderly patients with CHARGE syndrome. Some of these studies are already 
being carried out in collaboration with the dentists and ear-nose-throat (ENT) special ists from 
the CHARGE outpatient clinic at the UMCG and the ENT department of the Radboud University 
Nijmegen Medical Centre. 
Eventual ly, we hope an evidence-based guideline can be developed for al l  aspects of CHARGE 
syndrome. Ideal ly, this guideline will be used by all doctors and support workers who are caring 
for patients with CHARGE syndrome. The implementation of a best clinical practice guideline will 
improve the qual ity of life of patients and may contribute to an increased l ife expectancy. 
THE CHD7 GENE IN KALLMANN SYNDROME 
CHD7 analysis in patients with Kallmann syndrome 
Because the key features of Kallmann syndrome, anosmia and hypogonadotropic hypogonadism 
(HH), are also frequently encountered in CHARGE syndrome, we hypothesised that the CHDl gene 
could be a candidate gene for Kallmann syndrome. In a pilot study, we therefore analysed the CHDl 
gene in 36 patients with Kallmann syndrome and in 20 patients with HH but a normal sense of smell 
from Japan and North America who did not have a mutation in KAL1, FGFR1, PROK2 and PROKR2. 
We presented the results of this study in chapter 4.1 .  Three de novo CHDl mutations were found in  
the patients with Kaltmann syndrome (3/36 = 8.3%), whereas none of the patients with on ly HH had 
a CHDl mutation. Thus, a close relationship between anosmia, HH, and CHDl mutations was again 
observed. Upon re-evaluation, it became evident that the CHO7-positive patients al t  had additional 
features of CHARGE syndrome. We concluded that Kallmann patients should be evaluated for any 
features consistent with CHARGE syndrome and advised performing CHDl analysis if additional 
features are found. 
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A concurrent study performed CHDl analysis in 50 patients with Kallmann syndrome and in 
5 1  patients with normosmic idiopathic HH (nlHH).29 They also screened exons 6-10 of the CHDl 
gene in 96 additional patients with Kallmann syndrome or nlHH. In total, they found seven CHDl 
mutations: two splice site mutations and five missense mutations. Three of the CHO7-positive 
patients had Kallmann syndrome, whereas four of the CHO7-positive patients had nlHH. Besides a 
cleft lip (present in two CHO7-positive patients) and hearing loss (in one CHO7-positive patient), no 
additional features of CHARGE syndrome were reported. Although this study confirms that CHDl 
mutations can be found in patients with Kallmann syndrome, CHDl mutations were also identified 
in patients with nlHH but no other features of CHARGE syndrome. Unfortunately, the authors do 
not report whether their CHO7-positive patients underwent formal smell testing or if they were 
later re-evaluated for other features of CHARGE syndrome (e.g. fundoscopy). It is therefore possible 
that subtle features of CHARGE syndrome could have been missed. Another limitation of this study 
is that CHDl analysis was not performed in the parents of the CHO7-positive patients. Segregation 
analysis can help to predict whether missense variants are pathogenic or benign (see chapter 2.2). 
Only one of the five missense mutations that the authors identified had been previously reported 
and was known to be pathogenic. The other four missense mutations are of uncertain pathogenicity 
according to our classification system (with summed scores ranging between 0 and 1 .5). We cannot 
therefore exclude the possibility that four of the seven CHDl mutations identified by Kim et a/29 are 
actually benign polymorphisms. 
Because of the conflicting results of the studies described above, we decided to perform CHDl 
analysis in a well-characterised cohort of Dutch patients with Kallmann syndrome without mutations 
in the KAL7 gene. Al l  the patients were screened for mutations in FGFR7, PROK2, PROKR2, FGFB and 
CHDl. We have included 36 patients with Kallmann syndrome in this study and have identified six 
heterozygous variants in PROKR2, one heterozygous variant in FGFB, and three pathogenic CHDl 
mutations (see chapter 4.2). Both the FGFB and PROKR2 variants are thought to contribute to the 
development of Kallmann syndrome in combination with one or more other mutations, but on their 
own they seem to be insufficient for the development of GnRH deficiency. Re-evaluation of the 
three CHO7-positive patients revealed that other CHARGE features were present (e.g. hearing loss, 
cleft lip and palate, balance disturbance, coloboma, short stature and scoliosis). Our results are in 
agreement with those from our pilot study (presented in chapter 4.1 ). 
We and others have shown that Kallmann syndrome can be part of the CHARGE spectrum. 
CHARGE syndrome can have a very mild presentation, but we believe that every CHO7-positive 
patient will display at least one other CHARGE feature upon detailed examination. We therefore 
recommend evaluating all KS patients for additional CHARGE features by history taking and physical 
examination. CHDl analysis is indicated when at least two additional major CHARGE features or 
semicircular canal anomalies are present. The major features are ocular coloboma, choanal atresia 
or stenosis, external ear anomalies, cranial nerve dysfunction (including sensorineural hearing loss) 
and balance disturbance. Identifying a CHDl mutation in a patient with Kallmann syndrome has 
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important impl ications for their clinical treatment. A CHO7-positive patient should be screened 
for other CHARGE features (e.g. heart defects and renal anomal ies; see our recommendations for 
survei llance of CHO7-positive patients in chapter 5.1 ) . In addition, genetic counsell ing is indicated, 
because the patient has a 50% chance of transmitting the CHDl mutation to his/her offspring. 
Because of the great intrafamilial variability of CHARGE syndrome, the offspring could suffer from 
severe CHARGE syndrome.19- 21 •56 Prenatal diagnosis and pre-implantation genetic diagnosis should 
be discussed. 
CHD7 analysis in other cohorts 
Considering the important implications of identifying a CHDl mutation, it is worth performing CHDl 
analysis in other cohorts of patients with one or a few features of CHARGE syndrome. At present, 
our group is collecting a cohort of patients with a congenital heart defect and one other CHARGE 
feature for analysis of the CHDl gene. It would also be interesting to perform CHDl analysis in a 
cohort of patients with semicircular canal anomalies and in a cohort of patients with veiocardiofacial 
syndrome who do not have a 22ql 1 deletion or TBX1 mutation. I would expect to find CHDl 
mutations in these cohorts and likely some other features of CHARGE syndrome upon detailed 
examination of CHO7-positive patients. In addition, it would be interesting to perform CHDl analysis 
in patients with Goldenhar syndrome (oculo-auriculo-vertebral spectrum) and patients with the 
VACTERL association (vertebral anomalies, anal atresia, cardiac defects, tracheo-oesophageal fistula, 
oesophageal atresia, renal anomal ies and l imb defects). These two conditions show some clinical 
overlap with CHARGE syndrome, but the underlying genetic defect is largely unknown (mutations 
in the ZIC3 gene are known to underlie some cases of X-l inked VACTERL-H57). By performing CHDl 
analysis in patients with other syndromes, we can further explore the full phenotypic spectrum of 
CHDl mutations and may shed light on the underlying pathogenesis. 
CONCLUSION 
Our research has provided new insights into the clinical effects of mutations in the CHDl gene in 
the context of CHARGE and Kallmann syndromes. We have shown that the phenotypic spectrum 
of CHDl mutations is even broader than was original ly anticipated. We have also constructed a 
comprehensive CHDl mutation database and presented a classification system for missense variants 
in the CHDl gene. We investigated olfaction and aspects of the reproductive system in patients 
and mice with heterozygous CHDl mutations. We found that anosmia and hypogonadotropic 
hypogonadism (HH) always co-occurred in patients with CHARGE syndrome and therefore proposed 
that a smell test could be used to predict the occurrence of HH in patients with CHARGE syndrome. 
We also showed that CHDl mutations are occasionally present in patients initially diagnosed with 
Kallmann syndrome. Our studies have further expanded the knowledge of CHARGE and Kallmann 
syndromes and our results have raised many new questions for further research in this field. 
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The aim of this thesis was to gain more insight into CHARGE syndrome and Kallmann syndrome, with 
a special focus on the CHDl gene. For this purpose, we collected all the CHDl mutations reported 
in the literature or identified by the DNA diagnostic laboratories in Nijmegen and Copenhagen. 
In addition, olfaction and aspects of the reproductive system were studied in a mouse model for 
CHARGE syndrome. Smell and pubertal development and causes of death were studied in patients 
with CHARGE syndrome. Finally, the CHDl gene was analysed in patients with Kallmann syndrome. 
Chapter 1 :  The background 
Detailed background information on CHDl, CHARGE syndrome and Kallmann syndrome can be 
found in chapter 1 .  In short, CHARGE syndrome is a complex and variable multi-system disorder 
with an incidence of approximately 1/1 0,000 newborns. CHARGE is an acronym for ocular 
!;oloboma (closure defect of the eye), heart defects, 2tresia of choanae (blockage of the nasal 
airway), retardation of growth and/or development, genital hypoplasia (micropenis in boys) and 
�ar anomalies. Other anomalies can also occur, for example, a decreased sense of balance (due to 
anomalies of the semicircular canals), cranial nerve dysfunction (which can result in hearing loss, 
facial palsy or swallowing problems) and a smell deficit. In addition, the majority of patients have 
hypogonadotropic hypogonadism (HH), which manifests as a lack of pubertal maturation and 
Infertility. CHARGE syndrome is caused by autosomal dominant mutations in the CHDl gene; these 
are mostly de novo mutations. 
CHARGE syndrome has considerable clinical overlap with another rare heritable disorder, 
Kallmann syndrome. The main features of Kallmann syndrome are HH and a smell deficit. Additional 
features may also occur, for example, hearing loss, kidney anomalies and missing teeth. A mutation 
can be identified in only 25-35% of patients, in genes displaying different modes of inheritance: 
X-linked recessive (caused by mutations in KAL 7), autosomal dominant (caused by mutations in 
FGFR1, FGFB and CHD7), and autosomal recessive (caused by mutations in PROK2 and PROKR2). 
However, it has been postulated that many patients with Kallmann syndrome may have mutations 
in several different genes (oligogenic inheritance). 
Chapter 2: The CHD7 gene 
In chapter 2.1, a complete overview is given of all pathogenic CHDl mutations reported in the 
literature or identified by the DNA diagnostic laboratories in Nijmegen and Copenhagen (in total, 531 
different mutations per June 15th 201 1 ). The CHDl mutations were found to be equally distributed 
along the coding region of the CHDl gene. Most mutations were unique, but 96 recurrent mutations 
were identified (predominantly arginine to stop mutations). Nonsense and frameshift mutations 
were the main mutations found, with splice site mutations, missense mutations and deletions being 
present only in a minority of patients. We built a locus-specific database that contains all the CHDl 
mutations and relevant clinical data (available at www.CHD7.org). This database is a valuable source 
of information for clinicians as well as researchers. In addition, we summarize the latest data on 
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expression studies, animal models and functional studies. 
In chapter 2.2, we present a novel classification system that can help to predict whether a certain 
missense variant in the CHDl gene is either pathogenic (disease-causing) or benign (not associated 
with the disease). Correct classification of missense variants is essential for genetic counselling of 
patients and their families. Our classification system combines the outcome of three computational 
algorithms (SIFT, PolyPhen and align-GVGD) with information about the segregation of the variant 
of interest (de novo versus inherited). This combination of different variables is expected to lead to a 
more confident prediction of pathogenicity than was previously possible. We have used our system 
to classify 145 CHDl missense variants and have stored the data in the locus-specific database 
presented in chapter 2.1. Our classification of missense variants was confirmed by studies in a 
structural model of the CHD7 chroma- and helicase domains, which showed that the variants that 
we classified as 'probably pathogenic' were predicted to reduce the stability of the CHD7 protein 
and were frequently located in the protein core. Furthermore, the pathogenic missense mutations 
were mainly located in the middle of the CHDl gene, whereas the benign missense variants were 
predominantly clustered in the 5' and 3' regions. Finally, we showed that missense mutations are, in 
general, associated with a milder phenotype than mutations that lead to a truncated protein. 
In chapter 2.3, we describe our investigations into how often partial deletions of the CHDl gene 
are present in patients with features of CHARGE syndrome. Partial deletions cannot be detected by 
routine DNA analysis of the CHDl gene (sequence analysis), but can be identified with multiplex 
ligation-dependent probe amplification (MLPA). We therefore performed MLPA in 54 patients with 
features of CHARGE syndrome, who did not show a CHDl mutation upon sequence analysis. Only 
one partial deletion of the CHDl gene was identified in a patient with a clinical diagnosis of CHARGE 
syndrome. We concluded that partial deletions of the CHDl gene are rarely found in patients with 
features of CHARGE syndrome. 
Chapter 3: CHARGE syndrome 
In chapter 3.1, we present the results of our studies in a mouse model for CHARGE syndrome, the 
Whirligig mouse, which harbours a nonsense mutation in the Chdl gene. We set out to investigate 
whether these mice have a smell deficit and genital anomalies, in analogy to patients with CHARGE 
syndrome. We designed a smell test and showed that the Whirligig mice performed less well than the 
wild-type mice. Their poor performance could be the result of a smell deficit, but could also be due 
to a severe balance disturbance. Next, we studied the area of the brain that is involved in olfaction 
and found that some mice had abnormal olfactory bulbs. We also identified abnormalities of the 
reproductive organs in some of the mice (testes hypoplasia in males and uterine abnormalities in 
females). The fertility of the Whirligig mice was also mildly decreased. It was remarkable that the 
Whirligig mice showed a very variable phenotype, with genital anomalies, heart defects, cleft palate 
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and choanal anomalies being present in only some of the mice, even though they were genetically 
identical. This may indicate that slight local modulations in the reduced CHD7 level, rather than 
variants in modifier genes, underlie the wide variations in the phenotypes seen between individuals. 
In chapter 3.2, smell and pubertal development were studied in 35 adolescent patients with 
CHARGE syndrome. Anosmia (completely absent sense of smell) was present in 81 % of patients 
and HH was seen in 67% of girls and 89% of boys with CHARGE syndrome. In our cohort, anosmia 
was always correlated with HH, whereas patients with a normal sense of smell always had a normal 
pubertal development. We therefore proposed using a smell test to predict the occurrence of HH in 
patients with CHARGE syndrome. This provides the opportunity to start with hormone replacement 
therapy at an early age in affected patients, leading to age-appropriate puberty. This will in turn 
reduce socio-emotional problems and also lower the risk of osteoporosis and cardiovascular 
disease, which are related to low sex hormone levels. 
In chapter 3.3, the clinical data are presented of seven patients with CHARGE syndrome who died 
unexpectedly after the neonatal period. Respiratory aspiration (food or stomach acid entering the 
lungs) probably contributed to death in five patients, one patient choked while eating, and another 
died of post-operative airway complications. Unfortunately, no autopsies were performed on these 
patients. Based on our findings and a literature review, we suggested that gastro-oesophageal reflux 
disease, poor coordination of swallowing and breathing, respiratory aspiration, and post-operative 
airway events are important contributors to early death in CHARGE syndrome. We proposed cranial 
nerve dysfunction as the underlying mechanism and advised examining patients with CHARGE 
syndrome at a multidisciplinary specialist clinic. Assessment of swallowing and cranial nerve 
function is important and timely treatment of swallowing problems and gastro-oesophageal reflux 
disease is required. In order to prevent post-operative airway events, we advised combining surgical 
procedures whenever possible and monitoring patients with CHARGE syndrome for a longer period 
after surgery. 
Chapter 4: Kallmann syndrome 
In chapter 4.1 , we studied the overlap between CHARGE and Kallmann syndromes by performing 
CHD7 analysis in 36 patients with Kallmann syndrome and 20 patients with solely HH and a normal 
sense of smel l. The patients were from Japan and North America. Three CHD7 mutations were 
identified in the patients with Kallmann syndrome, whereas none of the patients with solely HH had 
a CHD7 mutation. Thorough re-evaluation of the CH07-positive patients with Kallmann syndrome 
revealed that they all had additional features of CHARGE syndrome. We concluded that patients 
with Kallmann syndrome should be carefully screened for features of CHARGE syndrome and 
recommended performing CHD7 analysis in patients who have any additional CHARGE features. 
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In chapter 4.2, we descr ibe the results of CHD7 analysis in a cohort of Dutch Kallmann patients. 
We conducted th is study because another group presented data that conflicted with the previous 
study (chapter 4.1 ). The other group had ident ified CHD7 mutations in pat ients w ith HH or Kallmann 
syndrome who d id not have add it ional features of CHARGE syndrome. We therefore dec ided to 
repeat our study in an independent cohort of cl in ica lly well character ised patients w ith Ka llmann 
syndrome. We have identified three CHD7 mutations in 36 Dutch patients. Upon re -evaluat ion, the 
CH07-posit ive patients all had addit iona l CHARGE features, wh ich is in agreement w ith findings in 
our previous study. We conclude that the yield of CHD7 analysis in patients w ith iso lated Kallmann 
syndrome seems very low, but increases when addit ional CHARGE features are present . Our current 
adv ice is to eva luate all pat ients w ith Ka l lmann syndrome and to perform CHD7 ana lysis if two 
or more addit ional CHARGE features, or semic ircular canal anoma lies, are present. Identificat ion 
of a CHD7 mutat ion has important c linical imp licat ions regarding the surve i l lance and genetic 
counselling of the patient. 
Chapter 5: Implications and general discussion 
In chapter 5.1, the expand ing phenotyp ic spectrum of CHARGE syndrome is descr ibed and we show 
that some molecularly diagnosed pat ients have very few features of CHARGE syndrome. We present 
the c lin ica l features of 280 CH07-posit ive patients and show that four features are almost universally 
present :  external ear anomalies, cran ial nerve dysfunct ion, semic ircular cana l hypoplasia, and 
delayed motor deve lopment. CHARGE syndrome is primarily a cl inical d iagnosis, but CHD7 analysis 
can help to establ ish the diagnosis in patients who do not fulfil the cl in ical cr iter ia. We propose 
a gu ideline for conducting CHD7 analysis, wh ich also indicates when imaging  of the sem ic ircular 
cana ls is helpful in the d iagnost ic process. Fina lly, we present updated recommendat ions for the 
clinical surve illance of patients w ith a CHD7 mutation. 
In chapter 5.2, the results of the work presented in th is thesis  are discussed in re lation to the 
literature and we h igh light the cl in ical implications of our research. In add ition, we present plans 
for future research. For example, our group will perform exome sequencing in a group of pat ients 
w ith some features of CHARGE syndrome who do not have a mutat ion or delet ion in the CHD7 gene. 
The major accompl ishments of the research presented in this thesis are as follows: 
We bu ilt a locus-specific database that contains all the CHD7 mutat ions (www.CHD7.org) 
We created a c la ssificat ion system that leads to more confident predict ion of the pathogenic ity 
of CHD7 missense variants 
We ga ined more insight into the pathogenesis of anosmia and hypogonadotropic 
hypogonad ism in CHARGE syndrome 
We presented recommendat ions to improve the c l in ica l surveillance on pubertal development 
and to prevent sudden death in patients with CHARGE syndrome 
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Dit promotieonderzoek was erop gericht meer inzichtte verkrijgen in CHARGE syndroom en Kallmann 
syndroom met een focus op het CHDl gen. Hiertoe hebben we al le CHDl mutaties verzameld die 
eerder in de literatuur waren beschreven of die ge"identificeerd waren in de moleculair genetische 
laboratoria van N ijmegen en Kopenhagen. Daarnaast hebben we het reukvermogen en aspecten 
van het voortplantingssysteem in een muismodel voor CHARGE syndroom bestudeerd. Vervolgens 
hebben we bij patienten met CHARGE syndroom het reukvermogen, de puberteitsontwikkeling en 
mogelijke oorzaken van overlijden onderzocht. Ten slotte is het CHDl gen geanalyseerd in patienten 
met Kal lmann syndroom. 
Hoofdstuk 1: Achtergrondinformatie 
Gedetail leerde achtergrondinformatie over het CHDl gen, over CHARGE syndroom en over Kallmann 
syndroom is te vinden in hoofdstuk 1.  Kort samengevat is CHARGE syndroom een complexe en 
variabele multisysteem aandoening d ie voorkomt bij ongeveer 1 op de 1 0.000 pasgeborenen. 
CHARGE is een Engels acroniem, waarbij de zes letters staan voor zes kenmerken: colobomen 
(aangeboren oogafwijkingen), aangeboren hartafwijkingen, atresie van de choanen (blokkade van 
de opening tussen neus en mond), retardatie van groei en/of ontwikkeling, onderontwikkeling van 
de genitalien (micropenis bij jongens) en oorafwijkingen. Daarnaast kunnen ook andere problemen 
optreden, zoals een verminderd evenwicht (ten gevolge van afwijkingen aan het evenwichtsorgaan), 
hersenzenuwdisfunctie (wat kan leiden totgehoorverlies, aangezichtsverlamming of slikproblemen) 
en een afwezig reukvermogen. Verd er heeftde meerderheid van de patienten een hypogonadotroop 
hypogonadisme (HH), wat het uitblijven van de puberteit en onvruchtbaarheid tot gevolg heeft. 
CHARGE syndroom wordt veroorzaakt door autosomaal dominante mutaties in het CHDl gen. 
Oat wil zeggen dat CHARGE syndroom even vaak voorkomt bij jongens als bij meisjes (autosomaal) 
en dat de kans dat iemand met CHARGE syndroom dit doorgeeft aan zijn of haar kind 50% is 
(dominant). Het kind met CHARGE syndroom is echter vaak de eerste in de fa mi lie, omdat de CHDl 
mutatie meestal nieuw (de nova) ontstaat. 
CHARGE syndroom lijkt klinisch gezien op een andere zeldzame ziekte, Kallmann syndroom. 
Bij beide syndromen komen HH en een verminderd reukvermogen voor. Deze twee kenmerken 
zijn de hoofdkenmerken van Kallmann syndroom en zijn dus, per definitie, altijd aanwezig bij 
patienten met Kallmann syndroom. Patienten met Kal lmann syndroom hebben soms ook nog 
andere verschijnselen, zoals gehoorverlies, n ierafwijkingen en missende tanden. Slechts bij 25 tot 
30% van de patienten met Kallmann syndroom kan een mutatie warden aangetoond, in genen 
met verschil lende overervingpatronen: X-gebonden recessief (veroorzaakt door mutaties in het 
KAL 7-gen), autosomaal dominant (veroorzaakt door mutaties in het FGFR7-, FGFB- en CH07-gen) en 
autosomaal recessief (veroorzaakt door mutaties in het PROK2- en PROKR2-gen). Het meest recente 
inzicht is echter dat in het merendeel van de patienten met Kallmann syndroom meerdere genen 
gemuteerd zijn (oligogene overerving). 
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Hoofdstuk 2: Het CHD7 gen 
In hoofdstuk 2.1 wordt een volledig overzicht gegeven van alle pathogene CHDl mutaties die zijn 
beschreven in de literatuur of die zijn ge"identificeerd door de moleculair geneti sche laboratoria 
in Nijmegen en Kopenhagen (in totaal 531 verschillende mutaties op 15 juni 2011 ). D e  CHD7 
mutaties bleken gelijkmatig te zijn verdeeld over de coderende regio van het CHDl gen. D e  meeste 
mutaties waren uniek, maar 96 mutaties zijn meer dan eens gevonden (met name arginine naar 
stop mutaties). We hebben vooral nonsense en frameshift mutaties gevonden, terwijl splice site 
mutaties, missense mutaties en deleties slechts in een minderheid van de patienten voorkwamen. 
We hebben een database gemaakt, die alle CHDl mutaties bevat met relevante klini sche gegevens 
(beschikbaar op www.CHD7.org). Deze database i s  een waardevolle informatiebron voor artsen en 
onderzoekers. Daarnaast hebben we in dit hoofdstuk een up-to-date overzicht gegeven van alle 
expressiestudies, diermodellen en functionele studies betreffende CHD7. 
In hoofdstuk 2.2 presenteren we een nieuw classificatiesysteem dat kan he Ipen bij de voorspelling 
of een bepaalde missense variant in het CHDl gen pathogeen (ziekteverwekkend) of benigne (geen 
v erband houdend met de ziekte) i s. Een correcte classificatie van missense varianten is  essentieel 
voor de erfelijkheidsvoorlichting aan patienten en hun families. Ons classificatiesysteem combineert 
de output van drie algoritmes (S IF T, Poly Phen en Align-GVGD) met informatie over de oorsprong van 
een bepaalde missense variant (de novo versus overgeerfd). De  combinatie van deze ver schillende 
variabelen zal waarschijnlijk leiden tot een meer betrouwbare voorspelling van pathogeniteit dan 
voorheen mogelijk was. Met ons systeem hebben we 145 CHDl missense varianten geclassificeerd 
en we hebben deze data opgeslagen in de database die we hebben gepresenteerd in hoofdstuk 2.1. 
Onze classificatie van de missense varianten kwam overeen met de voorspelling gebaseerd  op een 
structuur model van de chromo- en helicasedomeinen van het CHD7 eiwit. Dit model voorspelde 
dat de var ianten die wij hebben geclassificeerd als 'waarschijnlijk pathogeen' de stabiliteit van 
het CHD7 eiwit verminderen en veelal in de kern van het eiwit liggen. Op DNA niveau bleken de 
pathogene missense varianten voornamelijk in het midden van het CHDl gen te liggen, terwijl de 
b enigne missense varianten vooral aan het begin of aan het einde van het gen gelegen waren. Tot 
slot hebben we laten zien dat patienten met een missense mutatie in het algemeen minder ernstige 
v erschijnselen hebben dan patienten met een mutatie die leidt tot een getrunceerd (verkort )  eiwit. 
In hoofdstuk 2.3 hebben we onderzocht hoe vaak deleties van een gedeelte van het CHDl gen 
aanwezig zijn in patienten met kenmerken van CHARGE syndroom. Gedeeltelijke deleties kunnen 
niet worden gedetecteerd met standaard DNA onderzoek van het CHDl gen (sequentieanalyse), 
maar kunnen wel worden gevonden met 'multiplex ligation-dependent probe amplification'(MLPA). 
Daarom hebben we MLPA analyse verricht in 54 patienten met ken merken van CHARGE syndroom, 
bij wie geen CHDl mutatie was gevonden met sequentieanalyse. Hierbij hebben we slechts een 
gedeeltelijke deletie van het CHDl gen gevonden in een patient met de klinische diagnose CHARGE 
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syndroom. Hieruit hebben we geconcludeerd dat gedeeltelijke deleties van het CHDl gen slechts 
zelden voorkomen bij patienten met kenmerken van CHARGE syndroom. 
Hoofdstuk 3: CHARGE syndroom 
In hoofdstuk 3.1 beschrijven we de resultaten van ans onderzoek in een muismodel voor CHARGE 
syndroom, de Whirligig muis, die een nonsense mutatie in het CHDl gen heeft. Ons doel was 
om te onderzoeken of deze muizen een reukstoornis en afwijkende genitalien hebben, net als 
patienten met CHARGE syndroom. De Whirligig muizen presteerden slechter bij de reuktest dan 
wi ldtype muizen. De slechte prestatie zou kunnen warden veroorzaakt door een reukstoornis, maar 
zou oak het gevolg kunnen zijn van ernstige evenwichtsstoornissen. Nader onderzoek wees uit 
dat enkele muizen afwijkende reukhersenen hadden. Sommige muizen hadden oak afwijkende 
geslachtsorganen (onderontwikkelde zaadballen bij mannetjes en baarmoederafwijkingen bij 
vrouwtjes). Whirligig muizen waren oak enigszins verminderd vruchtbaar. Erg opvallend was het 
sterk variabele fenotype van Whirligig muizen die genetisch identiek zijn. Deze grate variatie in  
fenotype wordt mogelijk veroorzaakt wordt door kleine lo kale veranderingen in het door de mutatie 
toch al verminderde CHO? niveau, en niet door variaties in modificerende genen. 
In hoofdstuk 3.2 staan de resultaten van ans onderzoek naar reukvermogen en puberteits­
ontwikkeling bij 35 adolescenten met CHARGE syndroom beschreven. Anosmie (volledig afwezig 
reukvermogen) was aanwezig bij 81 % van de patienten en HH (u itblijvende puberteit) werd 
gezien bij 67% van de meisjes en 89% van de jongens met CHARGE syndroom. Anosmie kwam 
a ltijd samen met HH voor, terwijl patienten met een normaal reukvermogen oak altijd een 
normale puberteitsontwikkeling hadden doorgemaakt. We hebben daarom voorgesteld om een 
reuktest te gebruiken om te kunnen voorspellen bij welke patienten met CHARGE syndroom de 
puberteitsontwikkeling niet spontaan op gang komt. Een hormoonbehandeling kan er vervolgens 
voor zorgen dat zij wel op de juiste leeftijd in de puberteit komen. Hierdoor zul len minder socio­
emotionele problemen voorkomen en oak het risico op botontkalking en hart- en vaatziekten zal 
afnemen, omdat deze gerelateerd zijn aan lage hormoonspiegels. 
In hoofdstuk 3.3 warden de medische gegevens gepresenteerd van zeven patienten met CHARGE 
syndroom die plotseling zijn overleden na de neonatale periode. Bij vijf patienten heeft respiratoire 
aspiratie (voedsel of maagzuur dat in de longen terecht komt) waarschijnlijk bijgedragen aan 
het overlijden, een patient is gestikt tijdens het eten en een andere patient is overleden aan 
postoperatieve luchtwegproblemen. Helaas was bij geen van deze patienten obductie verricht. 
Gebaseerd op onze bevindingen en een literatuuronderzoek, denken wij dat gastro-oesophageale 
reflux, verstoorde coordinatie van slikken en ademhalen, respiratoire aspiratie en postoperatieve 
luchtwegproblemen een belangrijke rol spelen bij vroegtijdig overlijden van patienten met CHARGE 
syndroom. Hersenzenuwdisfunctie zou aan deze problemen ten grondslag kunnen liggen. Gezien 
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bovengenoemde risicofactoren adviseren we om patienten met CHARGE syndroom te controleren 
op een multidisciplinaire polikliniek. Daarbij is controle van de slikfunctie en hersenzenuwfunctie 
belangrijk en snelle behandeling van slikproblemen en gastro-oesophageale reflux is raadzaam. 
Postoperatieve luchtwegproblemen zijn deels te voorkomen door operaties waarvoor narcose 
noodzakelijk is, indien mogelijk, te combineren en door patienten met CHARGE syndroom na een 
operatie langer dan normaal op de uitslaapkamer te laten blijven. 
Hoofdstuk 4: Kallmann syndroom 
In hoofdstuk 4.1 onderzoeken we de overlap tussen CHARGE syndroom en Kallmann syndroom 
door het CHDl gen te analyseren bij 36 patienten met Kallmann syndroom en 20 patienten met HH 
(uitblijvende puberteit en onvruchtbaarheid) en een normaal reukvermogen. Deze patienten waren 
afkomstig uit Japan en Noord Amerika. We vonden drie CHDl mutaties bij patienten met Kallmann 
syndroom, terwijl geen van de patienten met alleen HH een CHDl mutatie had. De drie patienten 
bij wie we een CHDl mutatie hadden gevonden, bleken bij herbeoordeling alledrie additionele 
CHARGE kenmerken te hebben. We concluderen dat patienten met Kallmann syndroom goed 
moeten worden onderzocht op kenmerken van CHARGE syndroom en adviseren CHDl analyse als 
additionele CHARGE kenmerken aanwezig zijn. 
I n  hoofdstuk 4.2 beschrijven we de resultaten van CHDl analyse in een cohort Nederlandse 
patienten met Kallmann syndroom. We hebben dit onderzoek verricht, omdat een andere 
onderzoeksgroep data had gepubliceerd die in strijd was met onze eerdere studie (hoofdstuk 4.1 ). 
Deze onderzoeksgroep had CHDl mutaties gevonden bij patienten met HH of Kallmann syndroom 
die geen andere kenmerken van CHARGE syndroom hadden. Wij hebben daarom besloten om onze 
studie te herhalen in een onafhankelijk cohort van patienten met Kallmann syndroom die klinisch 
goed onderzocht waren. We vonden drie CHDl mutaties bij 36 Nederlandse patienten. Ook nu bleek 
dat alledrie patienten additionele CHARGE kenmerken hadden, hetgeen in overeenstemming is met 
de resultaten van onze eerdere studie (hoofdstuk 4.1 ). We concluderen dat de opbrengst van CHDl 
analyse bij patienten met Kallmann syndroom zonder andere CHARGE kenmerken erg laag is, maar 
dat deze analyse wel zinvol is bij patienten met additionele CHARGE kenmerken. Ons huidige advies 
is om alle patienten met Kallmann syndroom te evalueren en om CHDl analyse te verrichten als 
twee of meer additionele CHARGE kenmerken, of afwijkingen aan het evenwichtsorgaan, aanwezig 
zijn. ldentificatie van een CHDl mutatie heeft belangrijke klinische consequenties voor de verdere 
controle van de patient en de erfelijkheidsvoorlichting aan de patient en zijn/haar familie. 
Hoofdstuk 5: lmplicaties en discussie 
In hoofdstuk 5.1 laten we zien dat sommige patienten met een CHDl mutatie erg weinig kenmerken 
van CHARGE syndroom hebben, terwijl andere patienten juist veel of ernstige afwijkingen hebben. 
We presenteren de klinische kenmerken van 280 patienten met een CHDl mutatie en laten zien 
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dat vier kenmerken bijna altijd aanwezig zijn: een afwijkende oorschelp, hersenzenuwdisfunctie, 
een afwijkend evenwichtsorgaan en een vertraagde motorische ontwikkeling. CHARGE syndroom is 
voornamelijk een klinische diagnose, maar CHDl analyse kan helpen bij het stellen van de diagnose 
bij patienten die niet aan de klinische criteria voldoen. We hebben een richtlijn opgesteld die, al dan 
niet na het verrichten van een scan van het evenwichtsorgaan, aangeeft bij welke patienten CHDl 
analyse zinvol is. Tot slot presenteren we nieuwe adviezen voor de verdere controle van patienten 
met een CHDl mutatie. 
In hoofdstuk 5.2 bediscussieren we de resultaten van ons onderzoek in relatie tot de literatuur 
en we geven aan wat de klinische implicaties van ons onderzoek zijn. Daarnaast presenteren 
we onze plannen voor toekomstig onderzoek. Onze groep zal bijvoorbeeld exome sequencing 
(sequentieanalyse van het gehele coderende genoom) gaan verrichten in een groep patienten met 
enkele kenmerken van CHARGE syndroom, bij wie geen mutatie of deletie van het CHDl gen is 
gevonden. 
De belangrijkste resultaten van ons onderzoek zijn als volgt: 
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We hebben een database gecreeerd die 531 CHDl mutaties bevatte op 15 juni 2011 (www. 
CHD7.org) 
We hebben een classificatiesysteem gemaakt waarmee de pathogeniteit van CHDl missense 
variaties beter kan worden voorspeld 
We hebben meer inzicht gekregen in de onderliggende mechanismen van anosmie en 
hypogonadotroop hypogonadisme in CHARGE syndroom 
We hebben adviezen gegeven voor de verdere controle van patienten met CHARGE syndroom, 
met name gericht op puberteitsontwikkeling en op het voorkomen van plotse dood 
We hebben een richtlijn opgesteld die aangeeft wanneer CHDl analyse zinvol is bij patienten 
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